diabetes, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, diabetes

Aarnisalo J, Treszl A, Svec P, Marttila J, Oling V, Simell O, Knip M, Korner A, Madacsy L, Vasarhelyi B, Ilonen J, Hermann R. Reduced CD4(+)T cell activation in children with type 1 diabetes carrying the PTPN22/Lyp 620Trp variant. J. Autoimmun. 31: 13-21 (2008).
Aarnisalo J, Veijola R, Vainionpaa R, Simell O, Knip M, Ilonen J. Cytomegalovirus infection in early infancy: risk of induction and progression of autoimmunity associated with type 1 diabetes. Diabetologia 51: 769-772 (2008). *
Aarsetoey H, Ponitz V, Grundt H, Staines H, Harris WS, Nilsen DW. (n-3) Fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome. J. Nutr. 139: 507-513 (2009). *
Abahusain MA, Al-Nahedh NN. The biochemical status of vitamin A and alpha-tocopherol during different stages of renal disease and its relationship to diabetes. Saudi J. Kidney Dis. Transpl. 13: 18-23 (2002).
Abate N, Chandalia M, Di Paola R, Foster DW, Grundy SM, Trischitta V. Mechanisms of disease: ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat. Clin. Pract. Endocrinol. Metab. 2: 694-701 (2006). *
Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, Sandeep S, Radha V, Deepa R, Mohan V. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. Diabetes 54: 1207-1213 (2005). *
Abbas Z, Jafri W, Rasool S, Abid S, Hameed I. Mucormycosis in patients with complicated cirrhosis. Singapore Med. J. 48: 69-73 (2007). *
Abbatecola AM, Evans W, Paolisso G. PUFA supplements and type 2 diabetes in the elderly. Curr. Pharm. Des. 15: 4126-4134 (2009).
Abbott J, Hart A, Morton AM, Dey P, Conway SP, Webb AK. Can health-related quality of life predict survival in adults with cystic fibrosis? Am. J. Respir. Crit. Care Med. 179: 54-58 (2009). *
Abdel Aziz AM, Lehman GA. Current treatment options for chronic pancreatitis. Curr. Treat. Options Gastroenterol. 10: 355-368 (2007).
Abdelmalek M, Ludwig J, Lindor KD. Two cases from the spectrum of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 20: 127-130 (1995).
Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 4: 1162-1169 (2006).
Abderrahmani A, Chevre JC, Otabe S, Chikri M, Hani EH, Vaxillaire M, Hinokio Y, Horikawa Y, Bell GI, Froguel P. Genetic variation in the hepatocyte nuclear factor-3beta gene (HNF3B) does not contribute to maturity-onset diabetes of the young in French Caucasians. Diabetes 49: 306-308 (2000). *
Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman SE. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy. J. Diabetes Complications Jun 22 [Epub ahead of print] (2009).
Abdul-Hai A, Hershkoviz R, Weiss L, Lider O, Slavin S. Effect of linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion. Int. Immunopharmacol. 5: 231-239 (2005).
Abdullah MA. Epidemiology of type I diabetes mellitus among Arab children. Saudi Med. J. 26: 911-917 (2005).
Abe T, Iinuma Y, Ando M, Yokoyama T, Yamamoto T, Nakashima K, Takagi N, Baba H, Hasegawa Y, Shimokata K. NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis. J. Infect. 46: 215-220 (2003).
Abe T, Takino H, Yamasaki H, Ozaki M, Sera Y, Kondo H, Sakamaki H, Kawasaki E, Awata T, Yamaguchi Y, Eguchi K. CTLA4 gene polymorphism correlates with the mode of onset and presence of ICA512 Ab in Japanese type 1 diabetes. Diabetes Res. Clin. Pract. 46: 169-175 (1999).
Abebe F, Mustafa T, Nerland AH, Bjune GA. Cytokine profile during latent and slowly progressive primary tuberculosis: a possible role for interleukin-15 in mediating clinical disease. Clin. Exp. Immunol. 143: 180-192 (2006). *
Abiru N, Kawasaki E, Eguch K. Current knowledge of Japanese type 1 diabetic syndrome. Diabetes Metab. Res. Rev. 18: 357-366 (2002). *
Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann. N. Y. Acad. Sci. 1150: 234-238 (2008). *
Abraham RS, Wen L, Marietta EV, David CS. Type 1 diabetes-predisposing MHC alleles influence the selection of glutamic acid decarboxylase (GAD) 65-specific T cells in a transgenic model. J. Immunol. 166: 1370-1379 (2001). *
Abrahamian H, Endler G, Exner M, Mauler H, Raith M, Endler L, Rumpold H, Gerdov M, Mannhalter C, Prager R, Irsigler K, Wagner OF. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp. Clin. Endocrinol. Diabetes 115: 38-41 (2007).
Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology 40: 475-483 (2004). *
Abreu MT, Yang H. Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318 (2004). *
Abu-Zekry M, Kryszak D, Diab M, Catassi C, Fasano A. Prevalence of celiac disease in Egyptian children disputes the East-West agriculture-dependent spread of the disease. J. Pediatr. Gastroenterol. Nutr. 47: 136-140 (2008). *
Accardo-Palumbo A, Triolo G, Giardina E, Carbone MC, Ferrante A, Triolo G. Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus. Acta Diabetol. 33: 103-107 (1996).
Acevedo-Suarez CA, Hulbert C, Woodward EJ, Thomas JW. Uncoupling of anergy from developmental arrest in anti-insulin B cells supports the development of autoimmune diabetes. J. Immunol. 174: 827-833 (2005). *
Acha-Orbea H. Limited heterogeneity of autoantigens and T cells in autoimmune diseases? Res. Immunol. 142: 487-490 (1991).
Achenbach P, Fuchtenbusch M. Modulating the autoimmune response in type 1 diabetes: a report on the 64th Scientific Sessions of the ADA, June 2004, Orlando, FL, USA. Rev. Diabet. Stud. 1: 137-140 (2004). *
Achenbach P, Lampasona V, Landherr U, Koczwara K, Krause S, Grallert H, Winkler C, Pfluger M, Illig T, Bonifacio E, Ziegler AG. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia 52: 1881-1888 (2009). *
Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr. Opin. Gastroenterol. 24: 429-434 (2008). *
Ackerman NB, Kronmueller J. The importance of candida as an infectious agent. Surg. Gynecol. Obstet. 140: 65-68 (1975).
Adam SJ, Counter CM. A method to generate genetically defined tumors in pigs. Methods Enzymol. 439: 39-51 (2008). *
Adamiec J, Oficjalska-Mlynczak J. Contribution of selected cellular adhesion molecules and proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy. Przegl. Lek. 64: 389-392 (2007).
Adamiec R, Gacka M, Dobosz T, Szymaniec S, Bednarska-Chabowska D, Sadakierska-Chudy A. Stimulation of the peroxisome proliferator-activated receptor gamma (PPARgamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy. Atherosclerosis 194: e108-e115 (2007).
Adamiec-Mroczek J, Oficjalska-Mlynczak J. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes - role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes. Arch. Clin. Exp. Ophthalmol. 246: 1665-1670 (2008). *
Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39: 909-914 (2004). *
Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. Feb 9 [Epub ahead of print] (2010). *
Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am. J. Gastroenterol. 104: 861-867 (2009). *
Adams M, Williams A, Fell J. Exercise in the fight against thrombosis: friend or foe? Semin. Thromb. Hemost. 35: 261-268 (2009).
Adams PC. Nonexpressing homozygotes for C282Y hemochromatosis: minority or majority of cases? Mol. Genet. Metab. 71: 81-86 (2000). *
Adamson KA, Cheetham TD, Kendall-Taylor P, Seckl JR, Pearce SH. The role of the IDDM2 locus in the susceptibility of UK APS1 subjects to type 1 diabetes mellitus. Int. J. Immunogenet. 34: 17-21 (2007). *
Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L. Understanding and treating patients with alcoholic cirrhosis: an update. Alcohol Clin. Exp. Res. 33: 1136-1144 (2009).
Addous A, Mohamed AS, Ismail G, Al-Hashemy A. Post-transplant diabetes mellitus in kidney transplant recipients with special reference to association with HLA antigens. Saudi J. Kidney Dis. Transpl. 11: 559-562 (2000).
Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G779-G788 (2003). *
Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49: 755-765 (2006). *
Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet. Med. 24: 1143-1148 (2007). *
Adler AI, Shine BS, Chamnan P, Haworth CS, Bilton D. Genetic determinants and epidemiology of cystic fibrosis-related diabetes - results from a British cohort of children and adults. Diabetes Care 31: 1789-1794 (2008). *
Adorini L. New trends in clinical and experimental immunosuppression - fourth international conference. IDrugs 3: 496-498 (2000).
Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4: 404-412 (2008).
Agalliu I, Suuriniemi M, Prokunina-Olsson L, Johanneson B, Collins FS, Stanford JL, Ostrander EA. Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate 68: 740-747 (2008).
Aganna E, Aksentijevich I, Hitman GA, Kastner DL, Hoepelman AI, Posma FD, Zweers EJ, McDermott MF. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance. Eur. J. Hum. Genet. 9: 63-66 (2001). *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293 (2004). *
Agardh D. Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease. Clin. Gastroenterol. Hepatol. 5: 1276-1281 (2007).
Agardh D, Bjorck S, Agardh CD, Lidfeldt J. Coeliac disease-specific tissue transglutaminase autoantibodies are associated with osteoporosis and related fractures in middle-aged women. Scand. J. Gastroenterol. 44: 571-578 (2009). *
Agardh D, Lynch K, Brundin C, Ivarsson SA, Lernmark A, Cilio CM. Reduction of tissue transglutaminase autoantibody levels by gluten-free diet is associated with changes in subsets of peripheral blood lymphocytes in children with newly diagnosed coeliac disease. Clin. Exp. Immunol. 144: 67-75 (2006). *
Agarwal K, Jones DE, Daly AK, James OF, Vaidya B, Pearce S, Bassendine MF. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol. 32: 538-541 (2000). *
Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol. Res. 33: 92-96 (2005).
Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756 (2003). *
Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441 (2004). *
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72: 1605-1621 (2006). *
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186 (2006).
Aggarwal PK, Jain V, Srinivasan R, Jha V. Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. J. Hypertens. 27: 2044-2050 (2009).
Agostoni C, Decsi T, Fewtrell M, Goulet O, Kolacek S, Koletzko B, Michaelsen KF, Moreno L, Puntis J, Rigo J, Shamir R, Szajewska H, Turck D, van Goudoever J; ESPGHAN Committee on Nutrition:. Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition. J. Pediatr. Gastroenterol. Nutr. 46: 99-110 (2008). *
Agostoni C, Shamir R. For debate: can a change in policy of complementary infant feeding reduce the risk for type 1 diabetes and celiac disease? Pediatr. Endocrinol. Rev. 6: 2-4 (2008).
Agrawal RP, Rathore A, Joshi A, Changal H, Kochar DK. Prevalence of celiac disease in type 1 diabetes mellitus in North West Rajasthan, India. Diabetes Res. Clin. Pract. 79: e15-e16 (2008).
Agrawal S, Dimitrova N, Prasthani N, Udayakumar K, Sailakshmi S, Sriram S, Manjusha N, Sengupta U. T2D-Db: an integrated platform to study the molecular basis of type 2 diabetes. BMC Genomics 9: 320 (2008). *
Agte VV, Tarwadi KV. Combination of diabetes and cataract worsens the oxidative stress and micronutrient status in Indians. Nutrition 24: 617-624 (2008). *
Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 6: 139-148 (2010).
Aguirre AL, Center SA, Randolph JF, Yeager AE, Keegan AM, Harvey HJ, Erb HN. Gallbladder disease in Shetland sheepdogs: 38 cases (1995-2005). J. Am. Vet. Med. Assoc. 231: 79-88 (2007).
Agyei-Frempong MT, Titty FV, Owiredu WK, Eghan BA. The prevalence of autoimmune diabetes among diabetes mellitus patients in Kumasi, Ghana. Pak. J. Biol. Sci. 11: 2320-2325 (2008).
Ahima RS. The natural history of nonalcoholic fatty liver disease: insights from children and mice. Gastroenterology 135: 1860-1862 (2008). *
Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, Khullar M. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 28: 141-150 (2009).
Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, Bhansali A, Khullar M. Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Mol. Cell. Biochem. 314: 9-17 (2008). *
Ahmad R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol. Immunotoxicol. 31: 388-396 (2009).
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Am. J. Ther. 14: 49-62 (2007).
Ahmed I, Nasreen S, Bhatti R. Alopecia areata in children. J. Coll. Physicians Surg. Pak. 17: 587-590 (2007).
Ahmed RA, Murao K, Imachi H, Yu X, Li J, Wong NC, Ishida T. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes. Endocrine 35: 233-242 (2009).
Ahmed S, Ihara K, Bassuny WM, Kuromaru R, Kohno H, Miyako K, Matsuura N, Iwata I, Nagafuchi S, Hara T. Association study between CD30 and CD30 ligand genes and type 1 diabetes in the Japanese population. Genes Immun. 3: 96-101 (2002). *
Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J. Intern. Med. 262: 184-198 (2007). *
Ahn JH, Shin MS, Jung SH, Kang SK, Kim KR, Rhee SD, Jung WH, Yang SD, Kim SJ, Woo JR, Lee JH, Cheon HG, Kim SS. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. J. Med. Chem. 49: 4781-4784 (2006). *
Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056: 218-233 (2005). *
Ahrens ET, Morel PA. In vivo imaging of autoimmune disease in model systems. Curr. Top. Dev. Biol. 70C: 215-238 (2005).
Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul. Homeost. Agents 17: 29-45 (2003).
Airaghi L, Tedeschi A. Negative association between occurrence of type 1 diabetes and tuberculosis incidence at population level. Acta Diabetol. 43: 43-45 (2006). *
Aithal GP. Dangerous liaisons: drug, host and the environment. J. Hepatol. 46: 995-998 (2007). *
Aittoniemi J, Fotinou C, Craig TJ, de Wet H, Proks P, Ashcroft FM. Review. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 364: 257-267 (2009). *
Aittoniemi J, Turpeinen H, Tiittanen M, Knip M, Simell O, Ilonen J, Vaarala O. Relation among mannose-binding lectin 2 genotype, beta-cell autoantibodies, and risk for type 1 diabetes in Finnish children. Hum. Immunol. 69: 108-111 (2008).
Ajuebor MN, Aspinall AI, Zhou F, Le T, Yang Y, Urbanski SJ, Sidobre S, Kronenberg M, Hogaboam CM, Swain MG. Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells. J. Immunol. 174: 8027-8037 (2005). *
Ajuebor MN, Carey JA, Swain MG. CCR5 in T cell-mediated liver diseases: what's going on? J. Immunol. 177: 2039-2045 (2006). *
Akay BN, Bozkir M, Anadolu Y, Gullu S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J. Eur. Acad. Dermatol. Venereol. Feb 25 [Epub ahead of print] (2010).
Aker S, Bantis C, Reis P, Kuhr N, Schwandt C, Grabensee B, Heering P, Ivens K. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol. Dial. Transplant. 24: 2847-2851 (2009).
Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet. 115: 18-29 (2002).
Akesson K, Carlsson A, Ivarsson SA, Johansson C, Weidby BM, Ludvigsson J, Gustavsson B, Lernmark A, Kockum I. The non-inherited maternal HLA haplotype affects the risk for type 1 diabetes. Int. J. Immunogenet. 36: 1-8 (2009). *
Akesson L, Gelling RW, Jensen R, Ogimoto K, Fuller JM, Pefley R, Manavi S, Lernmark A, Schwartz MW. Increased lipid oxidation heralds diabetes onset in DR.lyp/lyp rats. Exp. Clin. Endocrinol. Diabetes 116: 475-480 (2008).
Akimoto T, Kobayashi S, Tamura N, Ohsawa T, Kawano T, Tanaka M, Hashimoto H. Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus. Angiology 56: 601-609 (2005).
Akinci A, Cetinkaya E, Aycan Z. Dry eye syndrome in diabetic children. Eur. J. Ophthalmol. 17: 873-878 (2007).
Akinci B, Comlekci A, Tankurt E. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis. Exp. Clin. Endocrinol. Diabetes 117: 142-145 (2009).
Akinmoladun VI, Akadiri OA, Adeleye JO, Lasisi OA. An unusual case of total maxillary sequestration in a diabetic patient. Afr. J. Med. Med. Sci. 37: 395-398 (2008).
Akirav E, Kushner JA, Herold KC. Beta-cell mass and type 1 diabetes: going, going, gone? Diabetes 57: 2883-2888 (2008). *
Akiyama S, Katsumata SI, Suzuki K, Nakaya Y, Ishimi Y, Uehara M. Hypoglycemic and hypolipidemic effects of hesperidin and cyclodextrin-clathrated hesperetin in Goto-Kakizaki rats with type 2 diabetes. Biosci. Biotechnol. Biochem. 73: 2779-2782 (2009). *
Aksoy DY, Agbaht K, Harmanci O, Karadag O, Aytemir K, Sungur A, Onat AM, Apras S, Yildiz BO, Bayraktar M. Autoimmune polyendocrine syndrome with atrial septal defect. Am. J. Med. Sci. 335: 157-159 (2008).
Al-Attas OS, Al-Daghri NM, Al-Rubeaan KA, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc. Diabetol. 8: 20 (2009).
Al-Daghri NM, Al-Attas OS, Al-Rubeaan K, Sallam R. Adipocytokine profile of type 2 diabetics in metabolic syndrome as defined by various criteria. Diabetes Metab. Res. Rev. 24: 52-58 (2008). *
Al-Harbi EM, Abbassi AJ, Tamim H, al-Jenaidi F, Kooheji M, Kamal M, al-Mahroos S, al-Nasir F, Motala AA, Almawi WY. Specific HLA-DRB and -DQB alleles and haplotypes confer disease susceptibility or resistance in Bahraini type 1 diabetes patients. Clin. Diagn. Lab. Immunol. 11: 292-296 (2004). *
Al-Jenaidi FA, Wakim-Ghorayeb SF, Al-Abbasi A, Arekat MR, Irani-Hakime N, Najm P, Al-Ola K, Motala AA, Almawi WY. Contribution of selective HLA-DRB1/DQB1 alleles and haplotypes to the genetic susceptibility of type 1 diabetes among Lebanese and Bahraini Arabs. J. Clin. Endocrinol. Metab. 90: 5104-5109 (2005). *
Al-Kateb H, Mirea L, Xie X, Sun L, Liu M, Chen H, Bull SB, Boright AP, Paterson AD. Multiple variants in vascular endothelial growth factor (VEGF) are risk factors for time to severe retinopathy in type 1 diabetes: the DCCT/EDIC genetics study. Diabetes 56: 2161-2168 (2007). *
Al-Mendalawi MD, Shiva S, Behbahan AG. Autoimmune thyroid disease in children and adolescents with type 1 diabetes mellitus in Northwest Iran. Saudi Med. J. 30: 1489-1490 (2009).
Al-Mujaini A, Ganesh A, Al-Zuhaibi S, Al-Dhuhli H, Al-Mashani A, Al-Kindi H, Al-Memari A, Al-Futaisi A, Al-Asmi A. Lymphocytic infundibulo-neurohypophysitis: an unusual cause of recurrent optic neuropathy in a child. J. AAPOS 13: 207-209 (2009).
Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with psoriasis: an experience from the Middle East. J. Dermatol. 37: 146-155 (2010).
Al-Ruhaily AD, Malabu UH. Short stature in Saudi Arabia: etiologic profile in adult endocrine clinic. Niger. J. Med. 18: 268-271 (2009).
Alam MA, Husain SA, Narang R, Chauhan SS, Kabra M, Vasisht S. Association of polymorphism in the thermolabile 5,10-methylene tetrahydrofolate reductase gene and hyperhomocysteinemia with coronary artery disease. Mol. Cell. Biochem. 310: 111-117 (2008).
Alam MU, Harken JA, Knorn AM, Elford AR, Wigmore K, Ohashi PS, Millar DG. Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune diabetes in response to beta cell damage. J. Immunol. 183: 5728-5737 (2009).
Alanentalo T, Loren CE, Larefalk A, Sharpe J, Holmberg D, Ahlgren U. High-resolution three-dimensional imaging of islet-infiltrate interactions based on optical projection tomography assessments of the intact adult mouse pancreas. J. Biomed. Opt. 13: 054070 (2008).
Alard P, Manirarora JN, Parnell SA, Hudkins JL, Clark SL, Kosiewicz MM. Deficiency in NOD antigen-presenting cell function may be responsible for suboptimal CD4+CD25+ T-cell-mediated regulation and type 1 diabetes development in NOD mice. Diabetes 55: 2098-2105 (2006). *
Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion 8: 329-337 (2008).
Alba A, Planas R, Clemente X, Carrillo J, Ampudia R, Puertas MC, Pastor X, Tolosa E, Pujol-Borrell R, Verdaguer J, Vives-Pi M. Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta. Clin. Exp. Immunol. 151: 467-475 (2008). *
Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 17: 977-986 (2003). *
Albahrani AI, Usher J, Marks E, Ranganath L, Shenkin A. Atypical presentation of a middle age male with severe hypertriglyceridaemia: a case report. J. Med. Case Reports 1: 51 (2007). *
Albala BC, Jimenez RB, Perez B F, Liberman GC. Fatty acid binding protein 2 (FABP-2) polymorphism, obesity and insulin resistance. Rev. Med. Chil. 134: 372-379 (2006).
Albala C, Villarroel A, Santos JL, Angel B, Lera L, Liberman C, Sanchez H, Perez-Bravo F. FABP2 Ala54Thr polymorphism and diabetes in Chilean elders. Diabetes Res. Clin. Pract. 77: 245-250 (2007).
Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54: 987-993 (2005). *
Albers HM, Kurreeman FA, Stoeken-Rijsbergen G, Brinkman DM, Kamphuis SS, van Rossum MA, Girschick HJ, Wouters C, Saurenmann RK, Hoppenreijs E, Slagboom P, Houwing-Duistermaat JJ, Verduijn W, Huizinga TW, Ten Cate R, Toes RE, Schilham MW. Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis. Arthritis Rheum. 60: 901-904 (2009). *
Albert MA, Pare G, Morris A, Rose L, Buring J, Ridker PM, Zee RY. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups. Am. Heart J. 157: 777-783.e1 (2009).
Alberti-Flor JJ, Jeffers L, Schiff ER. Primary sclerosing cholangitis occurring in a patient with systemic lupus erythematosus and diabetes mellitus. Am. J. Gastroenterol. 79: 889-891 (1984).
Alblowi J, Kayal RA, Siqueria M, McKenzie E, Krothapalli N, McLean J, Conn J, Nikolajczyk B, Einhorn TA, Gerstenfeld L, Graves DT. High levels of tumor necrosis factor-alpha contribute to accelerated loss of cartilage in diabetic fracture healing. Am. J. Pathol. 175: 1574-1585 (2009). *
Aldamiz-Echevarria L, Prieto JA, Andrade F, Elorz J, Sojo A, Lage S, Sanjurjo P, Vazquez C, Rodriguez-Soriano J. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy. Pediatr. Res. 66: 585-589 (2009).
Alemany-Rodriguez MJ, Aladro Y, Amela-Peris R, Perez-Vieitez MC, Reyes-Yanez MP, Deniz-Naranjo MC, Sanchez-Garcia F. Autoimmune diseases and multiple sclerosis. Rev. Neurol. 40: 594-597 (2005).
Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila J, Bucan M, Ahima RS, Kaestner KH, Lazar MA. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456: 997-1000 (2008). *
Alenghat T, Yu J, Lazar MA. The N-CoR complex enables chromatin remodeler SNF2H to enhance repression by thyroid hormone receptor. EMBO J. 25: 3966-3974 (2006). *
Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels. Mol. Pharmacol. 76: 414-424 (2009). *
Alexander E, Pinto J, Pal GS, Kamath N, Kuruvilla M. Disease concomitance in psoriasis: a clinical study of 61 cases. Indian J. Dermatol. Venereol. Leprol. 67: 66-68 (2001). *
Alexander JW, Goodman HR, Succop P, Light JA, Kuo PC, Moser AB, James JH, Woodle ES. Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant. Exp. Clin. Transplant. 6: 118-126 (2008).
Alexandru N, Jard�n I, Popov D, Simionescu M, Garc�a-Estan J, Salido GM, Rosado JA. Effect of homocysteine on calcium mobilization and platelet function in type 2 diabetes mellitus. J. Cell. Mol. Med. 12: 2015-2026 (2008).
Alfonso B, Liao E, Busta A, Poretsky L. Vitamin D in diabetes mellitus - a new field of knowledge poised for D-velopment. Diabetes Metab. Res. Rev. 25: 417-419 (2009).
Ali BR. Is cystic fibrosis-related diabetes an apoptotic consequence of ER stress in pancreatic cells? Med. Hypotheses 72: 55-57 (2009).
Ali SB, Yahia FB, Sediri Y, Kallel A, Ftouhi B, Feki M, Elasmi M, Haj-Taieb S, Souheil O, Sanhagi H, Slimane H, Jemaa R, Kaabachi N. Gender specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin. Biochem. 42: 1642-1647 (2009). *
Alibek K, Grechanyi L, Klimenko T, Pashkova A. Fifth revolution in medicine: on the role of infections in pathogenesis of aging and chronic diseases. Lik. Sprava. 1-2: 3-30 (2008).
Alisi A, Manco M, Panera N, Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. Ann. Hepatol. 8 Suppl. 1: S44-S50 (2009). *
Alison MR, Choong C, Lim S. Application of liver stem cells for cell therapy. Semin. Cell Dev. Biol. 18: 819-826 (2007). *
Alizadeh BZ, Eerligh P, van der Slik AR, Shastry A, Zhernakova A, Valdigem G, Bruining JG, Sanjeevi CB, Wijmenga C, Roep BO, Koeleman BP. MICA marks additional risk factors for type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. Mol. Immunol. 44: 2806-2812 (2007). *
Alizadeh BZ, Valdigem G, Coenen MJ, Zhernakova A, Franke B, Monsuur A, van Riel PL, Barrera P, Radstake TR, Roep BO, Wijmenga C, Koeleman BP. Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum. Mol. Genet. 16: 2552-2559 (2007). *
Aljada A, Shah KA, Mousa SA. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res. 2009: 460764 (2009). *
Allcock RJ, Christiansen FT, Price P. The central MHC gene IKBL carries a structural polymorphism that is associated with HLA-A3,B7,DR15. Immunogenetics 49: 660-665 (1999). *
Allcock RJ, Windsor L, Gut IG, Kucharzak R, Sobre L, Lechner D, Garnier JG, Baltic S, Christiansen FT, Price P. High-density SNP genotyping defines 17 distinct haplotypes of the TNF block in the Caucasian population: implications for haplotype tagging. Hum. Mutat. 24: 517-525 (2004).
Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Puccetti D, Hsu DA, Sondel P, Hetherington M, Goldman S, McClain KL. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr. Blood Cancer Nov 11 [Epub ahead of print] (2009).
Allen DB, MacDonald MJ, Gottschall JL, Hunter JB. Autoimmune thyroid phenomena are not evidence for human lymphocyte antigen-genetic heterogeneity in insulin-dependent diabetes. Am. J. Med. Genet. 33: 405-408 (1989).
Allen S, Huber J, Devendra D. Prevalence of organ-specific autoantibodies in childhood- and adult-onset type 1 diabetes. Ann. N. Y. Acad. Sci. 1150: 260-262 (2008). *
Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 55: 2523-2533 (2006). *
Allgayer H, Kruis W. PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer? Z. Gastroenterol. 41: 1035-1038 (2003).
Allotey RA, Mohan V, McDermott MF, Deepa R, Premalatha G, Hassan Z, Cassell PG, North BV, Vaxillaire M, Mein CA, Swan DC, O'Grady E, Ramachandran A, Snehalatha C, Sinnot PJ, Hemmatpour SK, Froguel P, Hitman GA. The EIF2AK3 gene region and type I diabetes in subjects from South India. Genes Immun. 5: 648-652 (2004). *
Alnajjar A, Chabane Sari D, Abuharfeil N, Hudaib M, Aburjai T. Effect of n-3 and n-6 polyunsaturated fatty acids on lymphocyte proliferation, interleukin production and phospholipid fatty acids composition in type 2 diabetic and healthy subjects in Jordan people. Prostaglandins Leukot. Essent. Fatty Acids 74: 347-356 (2006). *
Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *
Alonso N, Granada ML, Salinas I, Reverter JL, Flores L, Ojanguren I, Martinez-Caceres EM, Sanmarti A. Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis. Eur. J. Endocrinol. 157: 763-769 (2007). *
Alonso N, Soldevila B, Sanmarti A, Pujol-Borrell R, Martinez-Caceres E. Regulatory T cells in diabetes and gastritis. Autoimmun. Rev. 8: 659-662 (2009).
Alper CA, Husain Z, Larsen CE, Dubey DP, Stein R, Day C, Baker A, Beyan H, Hawa M, Ola TO, Leslie RD. Incomplete penetrance of susceptibility genes for MHC-determined immunoglobulin deficiencies in monozygotic twins discordant for type 1 diabetes. J. Autoimmun. 27: 89-95 (2006). *
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Implants Res. 19: 670-676 (2008).
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J. Clin. Periodontol. 34: 610-617 (2007).
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Alsmadi O, Al-Rubeaan K, Wakil SM, Imtiaz F, Mohamed G, Al-Saud H, Al-Saud NA, Aldaghri N, Mohammad S, Meyer BF. Genetic Study of Saudi Diabetes (GSSD): significant association of the KCNJ11 E23K polymorphism with type 2 diabetes. Diabetes Metab. Res. Rev. 24: 137-140 (2008).
Altinova AE, Engin D, Akbay E, Akturk M, Toruner F, Ersoy R, Yetkin I, Arslan M. Association of polymorphisms in the IL-18 and IL-12 genes with susceptibility to type 1 diabetes in Turkish patients. J. Endocrinol. Invest. Dec 22 [Epub ahead of print] (2009).
Altintas E, Senli MS, Sezgin O. Prevalence of celiac disease among dyspeptic patients: a community-based case-control study. Turk. J. Gastroenterol. 19: 81-84 (2008). *
Altobelli E, Maccarone M, Petrocelli R, Marziliano C, Giannetti A, Peris K, Chimenti S. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 7: 59 (2007). *
Altobelli E, Petrocelli R, Maccarone M, Altomare G, Argenziano G, Giannetti A, Peserico A, Vena GA, Tiberti S, Chimenti S, Peris K. Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur. J. Dermatol. 19: 252-256 (2009).
Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 6: 793-810 (2007). *
Alvaro A, Rosales R, Masana L, Vallve JC. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids. J. Nutr. Biochem. May 13 [Epub ahead of print] (2009). *
Alver A, Mentese A, Karahan SC, Erem C, Keha EE, Arikan MK, Eminagaoglu MS, Deger O. Increased serum anti-carbonic anhydrase II antibodies in patients with Graves' disease. Exp. Clin. Endocrinol. Diabetes 115: 287-291 (2007).
Alves C, Lima DS, Cardeal M, Santana A. Low prevalence of glucose intolerance in racially mixed children with cystic fibrosis. Pediatr. Diabetes Feb 8 [Epub ahead of print] (2010).
Alves C, Toralles MB, Carvalho GC. HLA class II polymorphism in patients with type 1 diabetes mellitus from a Brazilian racially admixtured population. Ethn. Dis. 19: 420-424 (2009).
Alves Cde A, Aguiar RA, Alves AC, Santana MA. Diabetes mellitus in patients with cystic fibrosis. J. Bras. Pneumol. 33: 213-221 (2007). *
Aly T, Devendra D, Eisenbarth GS. Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am. J. Ther. 12: 481-490 (2005).
Aly TA, Baschal EE, Jahromi MM, Fernando MS, Babu SR, Fingerlin TE, Kretowski A, Erlich HA, Fain PR, Rewers MJ, Eisenbarth GS. Analysis of single nucleotide polymorphisms identifies major type 1A diabetes locus telomeric of the major histocompatibility complex. Diabetes 57: 770-776 (2008). *
Aly TA, Eller E, Ide A, Gowan K, Babu SR, Erlich HA, Rewers MJ, Eisenbarth GS, Fain PR. Multi-SNP analysis of MHC region: remarkable conservation of HLA-A1-B8-DR3 haplotype. Diabetes 55: 1265-1269 (2006). *
Aly TA, Ide A, Humphrey K, Barker JM, Steck A, Erlich HA, Yu L, Miao D, Redondo MJ, McFann K, Roberts CM, Babu SR, Norris JM, Eisenbarth GS, Rewers MJ. Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes. J. Autoimmun. 25: S40-S45 (2005).
Aly TA, Ide A, Jahromi MM, Barker JM, Fernando MS, Babu SR, Yu L, Miao D, Erlich HA, Fain PR, Barriga KJ, Norris JM, Rewers MJ, Eisenbarth GS. Extreme genetic risk for type 1A diabetes. Proc. Natl. Acad. Sci. U.S.A. 103: 14074-14079 (2006). *
Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir. Med. 103: 407-413 (2009).
Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann. Hepatol. 5: 30-33 (2006). *
Amarapurkar A, Ghansar T. Fatty liver: experience from western India. Ann. Hepatol. 6: 37-40 (2007). *
Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Baijal R, Lala S, Chaudhary D, Deshpande A. Prevalence of non-alcoholic fatty liver disease: population based study. Ann. Hepatol. 6: 161-163 (2007). *
Amarapurkar DN, Patel ND. Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferase values. Trop. Gastroenterol. 25: 130-134 (2004).
Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann. Hepatol. 7: 148-151 (2008). *
Ambye L, Rasmussen S, Fenger M, Jorgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res. Clin. Pract. 67: 175-179 (2005).
Amerio P, Tracanna M, De Remigis P, Betterle C, Vianale L, Marra ME, Di Rollo D, Capizzi R, Feliciani C, Tulli A. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin. Exp. Dermatol. 31: 746-749 (2006). *
Aminkeng F, Van Autreve JE, Koeleman BP, Quartier E, Van Schravendijk C, Gorus FK, Van der Auwera BJ; Belgian Diabetes Registry. TNFa microsatellite polymorphism modulates the risk of type 1 diabetes in the Belgian population, independent of HLA-DQ. Hum. Immunol. 68: 690-697 (2007).
Amirshahrokhi K, Dehpour AR, Hadjati J, Sotoudeh M, Ghazi-Khansari M. Methadone ameliorates multiple-low-dose streptozotocin-induced type 1 diabetes in mice. Toxicol. Appl. Pharmacol. 232: 119-124 (2008). *
Ammann R. Diagnosis and management of chronic pancreatitis: current knowledge. Swiss Med. Wkly. 136: 166-174 (2006). *
Amrouche Ch, Jamoussi Kamoun H, Trabelsi N, Blouza Chabchoub S. Latent autoimmune diabetes in Tunisian adults (LADA): identification of autoimmune markers. Tunis. Med. 86: 316-318 (2008).
An P, Feitosa M, Ketkar S, Adelman A, Lin S, Borecki I, Province M. Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study. BMC Proc. 3 Suppl. 7: S71 (2009). *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818 (2007). *
Anaya JM, Castiblanco J, Tobon GJ, Garcia J, Abad V, Cuervo H, Velasquez A, Angel ID, Vega P, Arango A. Familial clustering of autoimmune diseases in patients with type 1 diabetes mellitus. J. Autoimmun. 26: 208-214 (2006).
Anaya JM, Gomez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases? Clin. Dev. Immunol. 13: 185-195 (2006). *
Andersen G, Burgdorf KS, Sparso T, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. AHSG tagSNPs associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 Danish whites. Diabetes 57: 1427-1432 (2008). *
Andersen G, Overgaard J, Albrechtsen A, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Studies of the association of the GNB3 825C>T polymorphism with components of the metabolic syndrome in white Danes. Diabetologia 49: 75-82 (2006). *
Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosis-related diabetes: the presence of microvascular diabetes complications. Diabetes Care 29: 2660-2663 (2006). *
Andersen JN, Jansen PG, Echwald SM, Mortensen OH, Fukada T, Del Vecchio R, Tonks NK, Moller NP. A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage. FASEB J. 18: 8-30 (2004). *
Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm. Metab. Res. 40: 635-639 (2008).
Anderson AC, Chandwaskar R, Lee DH, Kuchroo VK. Cutting edge: the Idd3 genetic interval determines regulatory T cell function through CD11b+CD11c- APC. J. Immunol. 181: 7449-7452 (2008). *
Anderson CC. On the sorting of the repertoire: an analysis of Cohn's challenge to integrity (Dembic), round 2. Scand. J. Immunol. 70: 321-325 (2009). *
Anderson CC. Placing regulatory T cells into global theories of immunity: an analysis of Cohn's challenge to integrity (Dembic). Scand. J. Immunol. 69: 306-309 (2009). *
Anderson DE. TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin. Ther. Targets 11: 1005-1009 (2007).
Anderson L, Joseph F, Goenka N, Patel V. Isolated thyroxine malabsorption treated with intramuscular thyroxine injections. Am. J. Med. Sci. 337: 150-152 (2009).
Anderson MS. Update in endocrine autoimmunity. J. Clin. Endocrinol. Metab. 93: 3663-3670 (2008). *
Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu. Rev. Immunol. 23: 447-485 (2005). *
Anderson MS, Venanzi ES, Chen Z, Berzins SP, Benoist C, Mathis D. The cellular mechanism of Aire control of T cell tolerance. Immunity 23: 227-239 (2005). *
Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C, Mathis D. Projection of an immunological self shadow within the thymus by the aire protein. Science 298: 1395-1401 (2002). *
Anderson RP. Coeliac disease: current approach and future prospects. Intern. Med. J. 38: 790-799 (2008). *
Anderson RP. Coeliac disease. Aust. Fam. Physician 34: 239-242 (2005). *
Andersson DE, Sjoholm A. Comment on "Spontaneous autoimmunity sufficiently potent to induce diabetes mellitus is insufficient to protect against insulinoma". J. Immunol. 183: 3559-3560 (2009).
Andersson G, Svensson AC, Setterblad N, Rask L. Retroelements in the human MHC class II region. Trends Genet. 14: 109-114 (1998). *
Andreasen CH, Andersen G. Gene-environment interactions and obesity - further aspects of genomewide association studies. Nutrition 25: 998-1003 (2009).
Andreeva-Gateva P. Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism. Ann. Biol. Clin. (Paris) 61: 295-303 (2003).
Andren-Sandberg A, Hardt PD. Second Second Giessen International Workshop on Interactions of Exocrine and Endocrine Pancreatic Diseases. Castle of Rauischholzhausen of the Justus-Liebig-University, Giessen (Rauischholzhausen), Germany. March 7-8, 2008. JOP 9: 541-575 (2008). *
Andres E, Dali-Youcef N, Vogel T, Serraj K, Zimmer J. Oral cobalamin (vitamin B) treatment. An update. Int. J. Lab. Hematol. 31: 1-8 (2009).
Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 56: 1181-1186 (2007). *
Andrulionyte L, Laukkanen O, Chiasson JL, Laakso M; STOP-NIDDM Study Group. Single nucleotide polymorphisms of the HNF4alpha gene are associated with the conversion to type 2 diabetes mellitus: the STOP-NIDDM trial. J. Mol. Med. 84: 701-708 (2006). *
Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 55: 2148-2152 (2006). *
Andrulionyte L, Zacharova J, Chiasson JL, Laakso M; for the STOP-NIDDM Study Group. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 47: 2176-2184 (2004). *
Ang DK, Brodnicki TC, Jordan MA, Wilson WE, Silveira P, Gliddon BL, Baxter AG, van Driel IR. Two genetic loci independently confer susceptibility to autoimmune gastritis. Int. Immunol. 19: 1135-1144 (2007). *
Ange-van Heugten KD, Burns R, Verstegen MW, Jansen WL, Ferket PR, van Heugten E. Evaluation of diabetes determinants in woolly monkeys (Lagothrix lagotricha). J. Anim. Physiol. Anim. Nutr. (Berl.) 91: 481-491 (2007). *
Angel B, Santos JL, Carrasco E, Albala C, Perez-Bravo F. Vitamin D receptor polymorphism and susceptibility to type 1 diabetes in Chilean subjects: a case-parent study. Eur. J. Epidemiol. 19: 1085-1087 (2004). *
Anghel SI, Wahli W. Fat poetry: a kingdom for PPARgamma. Cell Res. 17: 486-511 (2007). *
Angulo P. Treatment of nonalcoholic fatty liver disease. Ann. Hepatol. 1: 12-19 (2002). *
Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *
Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44 (2002).
Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 4: 611-623 (2003).
Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol. 41: 943-949 (2004). *
Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30: 1356-1362 (1999). *
Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin. Liver Dis. 21: 81-88 (2001).
Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 17: 186S-190S (2002). *
Angulo P, Lindor KD. Treatment of non-alcoholic steatohepatitis. Best Pract. Res. Clin. Gastroenterol. 16: 797-810 (2002). *
Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570 (1999). *
Anheim M, Degos B, Echaniz-Laguna A, Fleury M, Grucker M, Tranchant C. Ataxia associated with gluten sensitivity, myth or reality? Rev. Neurol. (Paris) 162: 214-221 (2006).
Anjos S, Polychronakos C. Mechanisms of genetic susceptibility to type I diabetes: beyond HLA. Mol. Genet. Metab. 81: 187-195 (2004). *
Anjos SM, Tessier MC, Polychronakos C. Association of the cytotoxic T lymphocyte-associated antigen 4 gene with type 1 diabetes: evidence for independent effects of two polymorphisms on the same haplotype block. J. Clin. Endocrinol. Metab. 89: 6257-6265 (2004). *
Ansari MJ, Sayegh MH. Costimulation couture: a designer approach to regulating autoimmunity. J. Clin. Invest. 116: 2080-2083 (2006). *
Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr. Pharm. Des. 15: 537-552 (2009).
Antal Z, Jarchum I, DiLorenzo TP. HLA class I supertypes in type 1 diabetic children in an urban children's hospital. Ann. N. Y. Acad. Sci. 1150: 86-89 (2008). *
Antinozzi PA, Garcia-Diaz A, Hu C, Rothman JE. Functional mapping of disease susceptibility loci using cell biology. Proc. Natl. Acad. Sci. U.S.A. 103: 3698-3703 (2006). *
Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil. Steril. 87: 862-869 (2007). *
Antolic B, Gersak K, Verdenik I, Novak-Antolic Z. Adverse effects of thyroid dysfunction on pregnancy and pregnancy outcome: epidemiologic study in Slovenia. J. Matern. Fetal Neonatal Med. 19: 651-654 (2006).
Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d'Annunzio G, Lorini R, Vanelli M, Ferrannini E. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet. Med. 25: 1349-1353 (2008). *
Antonelli A, Ferri C, Ferrari SM, Colaci M, Fallahi P. Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. Autoimmun. Rev. 8: 18-23 (2008).
Anuradha S, Radha V, Deepa R, Hansen T, Carstensen B, Pedersen O, Mohan V. A prevalent amino acid polymorphism at codon 98 (Ala98Val) of the hepatocyte nuclear factor-1alpha is associated with maturity-onset diabetes of the young and younger age at onset of type 2 diabetes in Asian Indians. Diabetes Care 28: 2430-2435 (2005). *
Aoki CA, Borchers AT, Ridgway WM, Keen CL, Ansari AA, Gershwin ME. NOD mice and autoimmunity. Autoimmun. Rev. 4: 373-379 (2005).
Aoki K, Taniyama M, Nagayama C, Oikawa Y, Shimada A. T cell immunity to glutamic acid decarboxylase in fulminant type 1 diabetes without significant elevation of serum amylase. Ann. N. Y. Acad. Sci. 1079: 181-185 (2006). *
Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, Ostroff GR, Czech MP. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458: 1180-1184 (2009). *
Appel SJ, Wadas TM, Rosenthal RS, Ovalle F. Latent autoimmune diabetes of adulthood (LADA): an often misdiagnosed type of diabetes mellitus. J. Am. Acad. Nurse Pract. 21: 156-159 (2009).
Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J. Immunol. 182: 340-346 (2009). *
Arababadi MK, Nosratabadi R, Hassanshahi G, Yaghini N, Pooladvand V, Shamsizadeh A, Hakimi H, Derakhshan R. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Res. Clin. Pract. Oct 27 [Epub ahead of print] (2009).
Arafat HA, Lada E, Katakam AK, Amin N. Osteopontin deficiency impacts the pancreatic TH1/TH2 cytokine profile following multiple low dose streptozotocin-induced diabetes. Exp. Clin. Endocrinol. Diabetes 114: 555-562 (2006).
Arafat Y, Fenalti G, Whisstock JC, Mackay IR, Garcia de la Banda M, Rowley MJ, Buckle AM. Structural determinants of GAD antigenicity. Mol. Immunol. 47: 493-505 (2009). *
Arakawa Y, Kobayashi H, Ozaki T, Ariga H, Matsuo Y, Honda T, Arai T, Kurosu Y, Morita K, Konuma H, et al. Serum determination of CA 19-9 in patients with digestive cancers and its diagnostic evaluation. Gan. To. Kagaku. Ryoho. 11: 917-925 (1984).
Araki E, Igata M, Motoshima H, Tsuruzoe K. Polymorphisms of PPARs and metabolic disorders. Nippon Rinsho 63: 617-622 (2005).
Araki M, Chung D, Liu S, Rainbow DB, Chamberlain G, Garner V, Hunter KM, Vijayakrishnan L, Peterson LB, Oukka M, Sharpe AH, Sobel R, Kuchroo VK, Wicker LS. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. J. Immunol. 183: 5146-5157 (2009).
Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Hirakawa M, Ikeda K, Kumada H. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49: 739-744 (2009). *
Arason GJ. The association of complement with common connective tissue diseases - a review. Laeknabladid. 94: 371-374 (2008).
Arason GJ, Kolka R, Hreidarsson AB, Gudjonsson H, Schneider PM, Fry L, Arnason A. Defective prevention of immune precipitation in autoimmune diseases is independent of C4A*Q0. Clin. Exp. Immunol. 140: 572-579 (2005). *
Araujo EP, De Souza CT, Ueno M, Cintra DE, Bertolo MB, Carvalheira JB, Saad MJ, Velloso LA. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 148: 5991-5997 (2007). *
Araujo J, Brandao LA, Guimaraes RL, Santos S, Falcao EA, Milanese M, Segat L, Souza PR, de Lima-Filho JL, Crovella S. Prevalence of autoimmune thyroid disease and thyroid dysfunction in young Brazilian patients with type 1 diabetes. Pediatr. Diabetes 9: 272-276 (2008).
Araujo J, Brandao LA, Guimaraes RL, Santos S, Falcao EA, Milanese M, Segat L, Souza PR, de Lima-Filho JL, Crovella S. Mannose binding lectin gene polymorphisms are associated with type 1 diabetes in Brazilian children and adolescents. Hum. Immunol. 68: 739-743 (2007).
Araujo J, da Silva GA, de Melo FM. Serum prevalence of celiac disease in children and adolescents with type 1 diabetes mellitus. J. Pediatr. (Rio J.) 82: 210-214 (2006). *
Araujo J, Segat L, Guimaraes RL, Brandao LA, Souza PE, Santos S, Soares TS, Falcao EA, Rodrigues F, Carvalho R Jr, de Lima-Filho JL, Arraes LC, Crovella S. Mannose binding lectin gene polymorphisms and associated auto-immune diseases in type 1 diabetes Brazilian patients. Clin. Immunol. 131: 254-259 (2009). *
Araujo J, Silva GA, Melo FM. Prevalence of celiac disease in children and adolescents with type 1 diabetes - authors' reply. J. Pediatr. (Rio J.) 82: 401 (2006).
Ardesjo B, Hansson CM, Bruder CE, Rorsman F, Betterle C, Dumanski JP, Kampe O, Ekwall O. Autoantibodies to glutathione S-transferase theta 1 in patients with primary sclerosing cholangitis and other autoimmune diseases. J. Autoimmun. 30: 273-282 (2008).
Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell. Transplant. 16: 787-798 (2007).
Arfa I, Abid A, Nouira S, Elloumi-Zghal H, Malouche D, Mannai I, Zorgati MM, Ben Alaya N, Rebai A, Zouari B, Ben Ammar S, Ben Rayana MC, Hmida S, Blousa-Chabchoub S, Abdelhak S. Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. J. Renin Angiotensin Aldosterone Syst. 9: 32-36 (2008).
Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51: 371-379 (2009).
Aribi M. Candidate genes implicated in type 1 diabetes susceptibility. Curr. Diabetes Rev. 4: 110-121 (2008).
Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur. J. Cancer 39: 2341-2348 (2003). *
Aridor M. Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases. Adv. Drug Deliv. Rev. 59: 759-781 (2007).
Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, Roep BO, Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451-463 (2004). *
Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11: 191-198 (2005). *
Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J. Rare Dis. 1: 14 (2006). *
Arkwright PD, Abinun M, Cant AJ. Autoimmunity in human primary immunodeficiency diseases. Blood 99: 2694-2702 (2002). *
Armagan O, Ekim A, Dinc A, Oner C. Ankylosing spondylitis in a patient with Turner syndrome: a case report. Rheumatol. Int. 27: 1177-1180 (2007). *
Arnaiz-Villena A, Martinez-Laso J, Corell A, Allende L, Rosal M, Gomez-Reino JJ, Vicario JL. Frequencies of HLA-A24 and HLA-DR4-DQ8 are increased and that of HLA-B blank is decreased in chronic toxic oil syndrome. Eur. J. Immunogenet. 23: 211-219 (1996).
Arnlov J, Zethelius B, Riserus U, Basu S, Berne C, Vessby B, Alfthan G, Helmersson J. Serum and dietary beta-carotene and alpha-tocopherol and incidence of type 2 diabetes mellitus in a community-based study of Swedish men: report from the Uppsala Longitudinal Study of Adult Men (ULSAM) study. Diabetologia 52: 97-105 (2009). *
Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann. Rheum. Dis. 66: 1137-1142 (2007). *
Arpiainen S, Jarvenpaa SM, Manninen A, Viitala P, Lang MA, Pelkonen O, Hakkola J. Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes. Toxicol. Appl. Pharmacol. 232: 135-141 (2008). *
Arredondo M, Jorquera D, Carrasco E, Albala C, Hertrampf E. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with iron status in persons with type 2 diabetes mellitus. Am. J. Clin. Nutr. 86: 1347-1353 (2007). *
Arroyo A, Perez-Vicente F, Serrano P, Candela F, Sanchez A, Teresa Perez-Vazquez M, Calpena R. Treatment of chronic anal fissure. Cir. Esp. 78: 68-74 (2005).
Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez-Peralto JL. Lupus-like reaction to interferon at the injection site: report of five cases. J. Cutan. Pathol. 34 Suppl. 1: 18-21 (2007).
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc. Natl. Acad. Sci. U.S.A. 106: 262-267 (2009). *
Artwohl M, Lindenmair A, Sexl V, Maier C, Rainer G, Freudenthaler A, Huttary N, Wolzt M, Nowotny P, Luger A, Baumgartner-Parzer SM. Different mechanisms of saturated versus polyunsaturated free fatty acid-induced apoptosis in human endothelial cells. J. Lipid Res. 49: 2627-2640 (2008). *
Artz E, Warren-Ulanch J, Becker D, Greenspan S, Freemark M. Seropositivity to celiac antigens in asymptomatic children with type 1 diabetes mellitus: association with weight, height, and bone mineralization. Pediatr. Diabetes 9: 277-284 (2008).
Asaf R, Blum S, Roguin A, Kalet-Litman S, Kheir J, Frisch A, Miller-Lotan R, Levy AP. Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice. Cardiovasc. Diabetol. 8: 29 (2009). *
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists. Bioorg. Med. Chem. 16: 981-994 (2008). *
Asano K, Ikegami H, Fujisawa T, Kawabata Y, Noso S, Hiromine Y, Ogihara T. The gene for human IL-21 and genetic susceptibility to type 1 diabetes in the Japanese. Ann. N. Y. Acad. Sci. 1079: 47-50 (2006). *
Asano K, Ikegami H, Fujisawa T, Nishino M, Nojima K, Kawabata Y, Noso S, Hiromine Y, Fukai A, Ogihara T. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum. Immunol. 68: 384-391 (2007).
Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am. J. Gastroenterol. 103: 2308-2313 (2008). *
Asleh R, Blum S, Kalet-Litman S, Alsheik J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 57: 2794-2800 (2008). *
Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92: 1193-1200 (2003). *
Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ. Res. 99: 1419-1425 (2006). *
Asnani S, Theuma P, Fonseca VA. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease. Metab. Syndr. Relat. Disord. 1: 23-32 (2003).
Aso Y, Matsuura H, Momobayashi A, Inukai Y, Sugawara N, Nakano T, Yamamoto R, Wakabayashi S, Takebayashi K, Inukai T. Profound reduction in T-helper (Th) 1 lymphocytes in peripheral blood from patients with concurrent type 1 diabetes and Graves' disease. Endocr. J. 53: 377-385 (2006). *
Assisi A, Banzi R, Buonocore C, Capasso F, Muzio VD, Michelacci F, Renzo D, Tafuri G, Trotta F, Vitocolonna M, Garattini S. Fish oil and mental health: the role of n-3 long-chain polyunsaturated fatty acids in cognitive development and neurological disorders. Int. Clin. Psychopharmacol. 21: 319-336 (2006).
Astapova I, Lee LJ, Morales C, Tauber S, Bilban M, Hollenberg AN. The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo. Proc. Natl. Acad. Sci. U.S.A. 105: 19544-19549 (2008). *
Asunis I, Marini MG, Porcu L, Meloni A, Cabriolu AL, Cao A, Moi P. A novel missense mutation (C84R) in a patient with type II vitamin D-dependent rickets. Exp. Clin. Endocrinol. Diabetes Feb 9 [Epub ahead of print] (2010).
Atar D, Dyrberg T, Michelsen B, Karlsen A, Kofod H, M�lvig J, Lernmark A. Site-specific antibodies distinguish single amino acid substitutions in position 57 in HLA-DQ beta-chain alleles associated with insulin-dependent diabetes. J. Immunol. 143: 533-538 (1989).
Atassi MZ, Casali P. Molecular mechanisms of autoimmunity. Autoimmunity 41: 123-132 (2008).
Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined 1H NMR spectroscopy and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome. Physiol. Genomics 27: 178-186 (2006). *
Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 200: 1-12 (2008).
Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin. Investig. Drugs 17: 969-972 (2008).
Atladottir HO, Pedersen MG, Thorsen P, Mortensen PB, Deleuran B, Eaton WW, Parner ET. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 124: 687-694 (2009). *
Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP. Dupuytren's contracture, alcohol consumption, and chronic liver disease. Arch. Intern. Med. 147: 1065-1067 (1987).
Attie AD, Flowers MT, Flowers JB, Groen AK, Kuipers F, Ntambi JM. Stearoyl-CoA desaturase deficiency, hypercholesterolaemia, cholestasis and diabetes. Novartis Found. Symp. 286: 47-53 (2007).
Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clin. Exp. Med. 3: 119-123 (2003). *
Augarten A, Kerem BS, Yahav Y, Noiman S, Rivlin Y, Tal A, Blau H, Ben-Tur L, Szeinberg A, Kerem E, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10 kb C-->T mutation. Lancet 342: 25-26 (1993).
Augarten A, Tov AB, Madgar I, Barak A, Akons H, Laufer J, Efrati O, Aviram M, Bentur L, Blau H, Paret G, Wilschanski M, Kerem BS, Yahav Y. The changing face of the exocrine pancreas in cystic fibrosis: the correlation between pancreatic status, pancreatitis and cystic fibrosis genotype. Eur. J. Gastroenterol. Hepatol. 20: 164-168 (2008).
Augstein P, Heinke P, Salzsieder E, Grimm R, Giebel J, Salzsieder C, Harrison LC. Dominance of cytokine- over FasL-induced impairment of the mitochondrial transmembrane potential (Deltapsim) in the pancreatic beta-cell line NIT-1. Diab. Vasc. Dis. Res. 5: 198-204 (2008).
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. Nov 18 [Epub ahead of print] (2009). *
Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease. Curr. Pharm. Des. 9: 1905-1917 (2003).
Aune TM, Maas K, Parker J, Moore JH, Olsen NJ. Profiles of gene expression in human autoimmune disease. Cell. Biochem. Biophys. 40: 81-96 (2004).
Autiero I, Costantini S, Colonna G. Human Sirt-1: molecular modeling and structure-function relationships of an unordered protein. PLoS One 4: e7350 (2009). *
Avagliano L, Grillo C, Prioli MA. Congenital heart disease: a retrospective study of their frequency. Minerva Ginecol. 57: 171-178 (2005).
Avila M, Prado C, Ventura MD, Mora C, Briones D, Valdez H, Hurtado ME, Lindholm B, Qureshi A, Castillo-Henkel C, Paniagua R. Vitamin D receptor gene, biochemical bone markers and bone mineral density in Mexican women on dialysis. Nephrol. Dial. Transplant. Feb 2 [Epub ahead of print] (2010).
Awadallah S, Hamad M. The prevalence of type II diabetes mellitus is haptoglobin phenotype-independent. Cytobios. 101: 145-150 (2000).
Awadallah S, Hamad M. A study of haptoglobin phenotypes in patients with chronic renal failure. Ann. Clin. Biochem. 40: 680-683 (2003).
Awadallah SM, Saleh SA, Abu Shaqra QM, Hilow H. Association of haptoglobin phenotypes with markers of diabetic nephropathy in type 2 diabetes mellitus. J. Diabetes Complications 22: 384-388 (2008).
Awais M, Sato M, Umezawa Y. A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells. Biosens. Bioelectron. 22: 2564-2569 (2007). *
Awara WM, El-Sisi AE, El-Refaei M, El-Naa MM, El-Desoky K. Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes. Rev. Diabet. Stud. 2: 146-156 (2005). *
Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28: 660-670 (2008). *
Awata T, Kanazawa Y. Genetic markers for insulin-dependent diabetes mellitus in Japanese. Diabetes Res. Clin. Pract. 24: S83-S87 (1994).
Awata T, Kawasaki E, Tanaka S, Ikegami H, Maruyama T, Shimada A, Nakanishi K, Kobayashi T, Iizuka H, Uga M, Kawabata Y, Kanazawa Y, Kurihara S, Osaki M, Katayama S; on behalf of the Japanese Study Group on Type 1 Diabetes Genetics. Association of type 1 diabetes with two loci on 12q13 and 16p13 and the influence coexisting thyroid autoimmunity in Japanese. J. Clin. Endocrinol. Metab. 94: 231-235 (2009).
Awata T, Kurihara S, Iitaka M, Takei S, Inoue I, Ishii C, Negishi K, Izumida T, Yoshida Y, Hagura R, Kuzuya N, Kanazawa Y, Katayama S. Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) in the Japanese population. Diabetes 47: 128-129 (1998).
Ayala F, Ayala F. Clinical aspects and comorbidities of psoriasis. J. Rheumatol. Suppl. 83: 19-20 (2009).
Ayanlowo O, Olumide YM, Akinkugbe A, Ahamneze N, Otike-Odibi BI, Ekpudu VI, Nnaji T, Akolawole NA. Characteristics of vitiligo in Lagos, Nigeria. West Afr. J. Med. 28: 118-121 (2009).
Aycan Z, Berberoglu M, Adiyaman P, Ergur AT, Ensari A, Evliyaoglu O, Siklar Z, Ocal G. Latent autoimmune diabetes mellitus in children (LADC) with autoimmune thyroiditis and celiac disease. J. Pediatr. Endocrinol. Metab. 17: 1565-1569 (2004).
Aydin E, Demir HD, Ozyurt H, Etikan I. Association of plasma homocysteine and macular edema in type 2 diabetes mellitus. Eur. J. Ophthalmol. 18: 226-232 (2008).
Ayela C, Roquet F, Valera L, Granier C, Nicu L, Pugniere M. Antibody-antigenic peptide interactions monitored by SPR and QCM-D A model for SPR detection of IA-2 autoantibodies in human serum. Biosens. Bioelectron. 22: 3113-3119 (2007).
Aygun C, Uraz S, Damci T, Osar Z, Yumuk V, Akdenizli E, Ilkova H. Celiac disease in an adult Turkish population with type 1 diabetes mellitus. Dig. Dis. Sci. 50: 1462-1466 (2005). *
Ayilavarapu S, Kantarci A, Fredman G, Turkoglu O, Omori K, Liu H, Iwata T, Yagi M, Hasturk H, Van Dyke TE. Diabetes-induced oxidative stress is mediated by Ca2+-independent phospholipase A2 in neutrophils. J. Immunol. Jan 6 [Epub ahead of print] (2010).
Ayse Selimoglu M, Ertekin V, Gursan N, Orbak Z, Esrefoglu M. Brunner's gland hyperplasia in a child with diabetes mellitus and coeliac disease. Acta Paediatr. 95: 508-510 (2006). *
Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr. Opin. Rheumatol. 20: 416-422 (2008). *
Azukizawa S, Kasai M, Takahashi K, Miike T, Kunishiro K, Kanda M, Mukai C, Shirahase H. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPARgamma agonists. Chem. Pharm. Bull. (Tokyo) 56: 335-345 (2008).
Azulay JP. The extent of the clinical manifestations of chronic polyradiculoneuropathy. Rev. Neurol. (Paris) 162: 518-521 (2006).
Babaya N, Nakayama M, Eisenbarth GS. The stages of type 1A diabetes. Ann. N. Y. Acad. Sci. 1051: 194-204 (2005). *
Babio N, Bullo M, Salas-Salvado J. Mediterranean diet and metabolic syndrome: the evidence. Public Health Nutr. 12: 1607-1617 (2009).
Baccala R, Theofilopoulos AN. The new paradigm of T-cell homeostatic proliferation-induced autoimmunity. Trends Immunol. 26: 5-8 (2005). *
Bach JF. A Toll-like trigger for autoimmune disease. Nat. Med. 11: 120-121 (2005). *
Bach JF. Infections and autoimmune diseases. J. Autoimmun. 25: S74-S80 (2005).
Bach JF. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease. C. R. Biol. 329: 260-262 (2006). *
Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu. Rev. Immunol. 19: 131-161 (2001). *
Bach JF, Koutouzov S, van Endert PM. Are there unique autoantigens triggering autoimmune diseases? Immunol. Rev. 164: 139-155 (1998).
Bach JM, Otto H, Nepom GT, Jung G, Cohen H, Timsit J, Boitard C, van Endert PM. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J. Autoimmun. 10: 375-386 (1997).
Bacher S, Schmitz ML. The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837 (2004).
Bachmann C, Lehr D, Janhsen E, Sambach H, Muehlan H, von Gontard A, Bachmann H. Health related quality of life of a tertiary referral center population with urinary incontinence using the DCGM-10 questionnaire. J. Urol. 182: S2000-S2006 (2009).
Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 27: 412-424 (2007).
Bacon BR. Iron overload states. Clin. Liver Dis. 2: 63-75, vi (1998).
Badenhoop K, Boehm BO. Genetic susceptibility and immunological synapse in type 1 diabetes and thyroid autoimmune disease. Exp. Clin. Endocrinol. Diabetes 112: 407-415 (2004).
Badenhoop K, Donner H, Pani M, Rau H, Siegmund T, Braun J. Genetic susceptibility to type 1 diabetes: clinical and molecular heterogeneity of IDDM1 and IDDM12 in a German population. Exp. Clin. Endocrinol. Diabetes 107 Suppl. 3: S89-S92 (1999).
Badenhoop K, Kahles H, Seidl C, Kordonouri O, Lopez ER, Walter M, Rosinger S, Ziegler A, Bohm BO; Diabetes Genetics Consortium. MHC-environment interactions leading to type 1 diabetes: feasibility of an analysis of HLA DR-DQ alleles in relation to manifestation periods and dates of birth. Diabetes Obes. Metab. 11 Suppl. 1: 88-91 (2009). *
Badenhoop K, Schwarz G, Trowsdale J, Lewis V, Usadel KH, Gale EA, Bottazzo GF. TNF-alpha gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 32: 445-448 (1989).
Badenhoop K, Tonjes RR, Rau H, Donner H, Rieker W, Braun J, Herwig J, Mytilineos J, Kurth R, Usadel KH. Endogenous retroviral long terminal repeats of the HLA-DQ region are associated with susceptibility to insulin-dependent diabetes mellitus. Hum. Immunol. 50: 103-110 (1996).
Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U, Schleusener H, Usadel KH. Susceptibility and resistance alleles of human leukocyte antigen (HLA) DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J. Clin. Endocrinol. Metab. 80: 2112-2117 (1995). *
Badii R, Bener A, Zirie M, Al-Rikabi A, Simsek M, Al-Hamaq AO, Ghoussaini M, Froguel P, Wareham NJ. Lack of association between the Pro(12)Ala polymorphism of the PPAR-gamma2 gene and type 2 diabetes mellitus in the Qatari consanguineous population. Acta Diabetol. 45: 15-21 (2008). *
Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 307: 1909-1914 (2005). *
Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150: 4931-4940 (2009). *
Baeke F, Etten EV, Gysemans C, Overbergh L, Mathieu C. Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol. Aspects Med. 29: 376-387 (2008).
Baev DV, Caielli S, Ronchi F, Coccia M, Facciotti F, Nichols KE, Falcone M. Impaired SLAM-SLAM homotypic interaction between invariant NKT cells and dendritic cells affects differentiation of IL-4/IL-10-secreting NKT2 cells in nonobese diabetic mice. J. Immunol. 181: 869-877 (2008). *
Baeyens L, Bonne S, Bos T, Rooman I, Peleman C, Lahoutte T, German M, Heimberg H, Bouwens L. Notch signaling as gatekeeper of rat acinar-to-beta cell conversion in vitro. Gastroenterology 136: 1750-1760.e13 (2009). *
Bagarolli RA, Saad MJ, Saad ST. Toll-like receptor 4 and inducible nitric oxide synthase gene polymorphisms are associated with Type 2 diabetes. J. Diabetes Complications Apr 21 [Epub ahead of print] (2009).
Bagley J, Paez-Cortez J, Tian C, Iacomini J. Gene therapy in type 1 diabetes. Crit. Rev. Immunol. 28: 301-324 (2008).
Bagley J, Tian C, Iacomini J. Prevention of type 1 diabetes in NOD mice by genetic engineering of hematopoietic stem cells. Methods Mol. Biol. 433: 277-286 (2008).
Baglietto MG, Mancardi MM, Giannattasio A, Minuto N, Rossi A, Capovilla G, Veneselli E, Lorini R, d'Annunzio G. Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep. Neurol. Sci. 30: 509-512 (2009).
Bahn RS. Graves' ophthalmopathy. N. Engl. J. Med. 362: 726-738 (2010). *
Bahr MJ, Ockenga J, Boker KH, Manns MP, Tietge UJ. Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance. Am. J. Physiol. Endocrinol. Metab. 291: E199-E206 (2006). *
Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr. Diab. Rep. 4: 194-198 (2004).
Bai JP, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors. Pharmacotherapy 30: 195-209 (2010).
Baier LJ, Permana PA, Traurig M, Dobberfuhl A, Wiedrich C, Sutherland J, Thuillez P, Luczy-Bachman G, Hara M, Horikawa Y, Hinokio Y, Hanson RL, Bogardus C. Mutations in the genes for hepatocyte nuclear factor (HNF)-1alpha, -4alpha, -1beta, and -3beta; the dimerization cofactor of HNF-1; and insulin promoter factor 1 are not common causes of early-onset type 2 diabetes in Pima Indians. Diabetes Care 23: 302-304 (2000). *
Bailey CJ. Drugs on the horizon for diabesity. Curr. Diab. Rep. 5: 353-359 (2005).
Bailey MM, Gorman EM, Munson EJ, Berkland C. Pure insulin nanoparticle agglomerates for pulmonary delivery. Langmuir. 24: 13614-13620 (2008).
Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, Hudson TJ, Bouchard C, Gaudet D, Perusse L, Vohl MC, Engert JC. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55: 2896-2902 (2006). *
Bailliard F, Anderson RH. Tetralogy of Fallot. Orphanet J. Rare Dis. 4: 2 (2009). *
Baisch JM, Capra JD. Linkage disequilibrium within the HLA complex does not extend into HLA-DP. Scand. J. Immunol. 37: 499-503 (1993).
Baisch JM, Weeks T, Giles R, Hoover M, Stastny P, Capra JD. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N. Engl. J. Med. 322: 1836-1841 (1990).
Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. J. Pak. Med. Assoc. 59: 512-515 (2009).
Bajaj JS, Zadvornova Y, Heuman DM, Hafeezullah M, Hoffmann RG, Sanyal AJ, Saeian K. Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites. Am. J. Gastroenterol. 104: 1130-1134 (2009). *
Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, Defronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50: 1723-1731 (2007). *
Bajwa PJ, Lee JW, Straus DS, Lytle C. Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 297: G82-G89 (2009). *
Bak H, Lee JW, Ahn HJ, Hwang SM, Choi EH, Lee SH, Ahn SK. An unusual case with membranous lipodystrophy in a hypertensive patient with transepidermal elimination. Yonsei. Med. J. 47: 428-431 (2006). *
Bakalov VK, Cheng C, Zhou J, Bondy CA. X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J. Clin. Endocrinol. Metab. 94: 3289-3296 (2009).
Baker C, Petrich de Marquesini LG, Bishop AJ, Hedges AJ, Dayan CM, Wong FS. Human CD8 responses to a complete epitope set from preproinsulin: implications for approaches to epitope discovery. J. Clin. Immunol. 28: 350-360 (2008). *
Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. Lipoxin a4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J. Immunol. 182: 3819-3826 (2009).
Bakhtadze E, Cervin C, Lindholm E, Borg H, Nilsson P, Arnqvist HJ, Bolinder J, Eriksson JW, Gudbjornsdottir S, Nystrom L, Agardh CD, Landin-Olsson M, Sundkvist G, Groop LC. Common variants in the TCF7L2 gene help to differentiate autoimmune from non-autoimmune diabetes in young (15-34 years) but not in middle-aged (40-59 years) diabetic patients. Diabetologia 51: 2224-2232 (2008). *
Bakke AC, Purtzer MZ, Wildin RS. Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). Clin. Exp. Immunol. 137: 373-378 (2004). *
Balakrishnan V, Unnikrishnan AG, Thomas V, Choudhuri G, Veeraraju P, Singh SP, Garg P, Pai CG, Devi RN, Bhasin D, Jayanthi V, Premalatha N, Chacko A, Kar P, Rai RR, Rajan R, Subhalal N, Mehta R, Mishra SP, Dwivedi M, Vinayakumar KR, Jain AK, et al. Chronic pancreatitis. A prospective nationwide study of 1,086 subjects from India. JOP 9: 593-600 (2008). *
Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's box? Pharmacol. Res. 56: 91-98 (2007). *
Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology 80: 1-10 (2007).
Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM, Wei YL, Rakela J, Schafer DF, Roberts JP, Everhart JE, Wiesner RH. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database. Hepatology 48: 878-888 (2008). *
Balasubramanian R, Azua IR, Wess J, Jacobson KA. Activation of distinct P2Y receptor subtypes stimulates insulin secretion in MIN6 mouse pancreatic beta cells. Biochem. Pharmacol. Jan 9 [Epub ahead of print] (2010). *
Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr. Rev. 29: 292-302 (2008). *
Balazs C, Feher J. Associations of autoimmune disorders in endocrine diseases. Orv. Hetil. 150: 1589-1597 (2009).
Balducci-Silano PL, Layrisse ZE. HLA-DP and susceptibility to insulin-dependent diabetes mellitus in an ethnically mixed population. Associations with other HLA-alleles. J. Autoimmun. 8: 425-437 (1995).
Balic I, Angel B, Codner E, Carrasco E, Perez-Bravo F. Association of CTLA-4 polymorphisms and clinical-immunologic characteristics at onset of type 1 diabetes mellitus in children. Hum. Immunol. 70: 116-120 (2009).
Balistreri WF. Celiac disease and type 1 diabetes: to screen or not to screen? J. Pediatr. 150: a1 (2007). *
Ballarini A, Lee-Kirsch MA. Genetic dissection of autoimmune polyendocrine syndrome type 2: common origin of a spectrum of phenotypes. Ann. N. Y. Acad. Sci. 1110: 159-165 (2007). *
Ballotti S, de Martino M. Rotavirus infections and development of type 1 diabetes: an evasive conundrum. J. Pediatr. Gastroenterol. Nutr. 45: 147-156 (2007). *
Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, Ducloux D. IL-6 promoter polymorphism -174 is associated with new-onset diabetes after transplantation. J. Am. Soc. Nephrol. 17: 2333-2340 (2006). *
Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. U.S.A. 105: 13644-13649 (2008). *
Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 375-380 (2000).
Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 475-480 (2000).
Ban Y, Concepcion ES, Villanueva R, Greenberg DA, Davies TF, Tomer Y. Analysis of immune regulatory genes in familial and sporadic Graves' disease. J. Clin. Endocrinol. Metab. 89: 4562-4568 (2004). *
Ban Y, Davies TF, Greenberg DA, Concepcion ES, Osman R, Oashi T, Tomer Y. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease. Genes Immun. 5: 203-208 (2004). *
Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Concepcion ES, Villanueva RB, Barbesino G, Ling V, Tomer Y. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun. 4: 586-593 (2003). *
Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc. Natl. Acad. Sci. U.S.A. 100: 15119-15124 (2003). *
Ban Y, Greenberg DA, Concepcion ES, Tomer Y. A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves' disease. Thyroid 12: 1079-1083 (2002).
Ban Y, Taniyama M, Ban Y. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J. Clin. Endocrinol. Metab. 85: 4639-4643 (2000). *
Ban Y, Taniyama M, Tozaki T, Yanagawa T, Yamada S, Maruyama T, Kasuga A, Tomita M, Ban Y. No association of type 1 diabetes with a microsatellite marker for CTLA-4 in a Japanese population. Autoimmunity 34: 39-43 (2001).
Ban Y, Tomer Y. The contribution of immune regulatory and thyroid specific genes to the etiology of Graves' and Hashimoto's diseases. Autoimmunity 36: 367-379 (2003).
Ban Y, Tomer Y. Susceptibility genes in thyroid autoimmunity. Clin. Dev. Immunol. 12: 47-58 (2005). *
Ban Y, Tomer Y. Genetic susceptibility in thyroid autoimmunity. Pediatr. Endocrinol. Rev. 3: 20-32 (2005).
Ban Y, Tozaki T, Taniyama M, Nakano Y, Ban Y, Hirano T. Genomic polymorphism in the interferon-induced helicase (IFIH1) gene does not confer susceptibility to autoimmune thyroid disease in the Japanese population. Horm. Metab. Res. 42: 70-72 (2010).
Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama KI, Ban Y, Hirano T. Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population. Autoimmunity 42: 126-130 (2009).
Bandaru SS, Lin K, Roming SL, Vellipuram R, Harney JP. Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior. Physiol. Behav. Nov 12 [Epub ahead of print] (2009). *
Bando H, Hashimoto N, Hirota Y, Sakaguchi K, Hisa I, Inoue Y, Imanishi Y, Seino S, Kaji H. Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis. Intern. Med. 48: 353-358 (2009). *
Banerjee S, Ghosh US, Dutta S. Clinicopathological profile of hepatic involvement in type-2 diabetes mellitus and its significance. J. Assoc. Physicians India 56: 593-599 (2008).
Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, Ranganathan G. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am. J. Physiol. Endocrinol. Metab. 296: E480-E489 (2009). *
Baniasadi V, Narain N, Goswami R, Das SN. Promoter region -318 C/ T and -1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Tissue Antigens 67: 383-389 (2006). *
Banos G, Perez-Torres I, El Hafidi M. Medicinal agents in the metabolic syndrome. Cardiovasc. Hematol. Agents Med. Chem. 6: 237-252 (2008).
Banwell B, Bar-Or A, Cheung R, Kennedy J, Krupp LB, Becker DJ, Dosch HM; Wadsworth Pediatric Multiple Sclerosis Study Group. Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. Ann. Neurol. 63: 98-111 (2008).
Bao F, Babu SR, Roberts CM, Martin AK, Gowan K, Eisenbarth GS, Fain PR. Single nucleotide polymorphism study of IDDM 17 in a Bedouin Arab family. Ann. N. Y. Acad. Sci. 1005: 348-351 (2003). *
Bao F, Yu L, Babu S, Wang T, Hoffenberg EJ, Rewers M, Eisenbarth GS. One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies. J. Autoimmun. 13: 143-148 (1999).
Bao S, Root C, Jagasia S. Type B insulin resistance syndrome associated with systemic lupus erythematosus. Endocr. Pract. 13: 51-55 (2007).
Bao Y, Spiegelman D, Li R, Giovannucci E, Fuchs CS, Michaud DS. History of peptic ulcer disease and pancreatic cancer risk in men. Gastroenterology 138: 541-549 (2010). *
Baptista ML, Koda YK, Mitsunori R, Nisihara, Ioshii SO. Prevalence of celiac disease in Brazilian children and adolescents with type 1 diabetes mellitus. J. Pediatr. Gastroenterol. Nutr. 41: 621-624 (2005). *
Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 59 Suppl. 7: 31-55 (2008). *
Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability. Arch. Biochem. Biophys. 477: 86-91 (2008). *
Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21: 596-605 (2009). *
Barbato M, Viola F, Miglietta MR, Argo G, Iulianella VR, Di Giuseppe S, Pippa G, Gentiloni Silverj F, Lo Russo L, Frediani T, Lucarelli S, Multari G, Cardi E. Association between insulin dependent diabetes mellitus and coeliac disease. A study on 175 diabetes patients. Minerva Gastroenterol. Dietol. 44: 1-5 (1998).
Barbe-Tuana FM, Klein D, Ichii H, Berman DM, Coffey L, Kenyon NS, Ricordi C, Pastori RL. CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes 55: 2437-2445 (2006). *
Barbeau WE, Bassaganya-Riera J, Hontecillas R. Putting the pieces of the puzzle together - a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med. Hypotheses 68: 607-619 (2007).
Barbieri M, Marfella R, Rizzo MR, Boccardi V, Siniscalchi M, Schiattarella C, Siciliano S, Lemme P, Paolisso G. The -8 UTR C/G polymorphism of PSMA6 gene is associated with susceptibility to myocardial infarction in type 2 diabetic patients. Atherosclerosis 201: 117-123 (2008).
Barker JM. Type 1 diabetes associated autoimmunity: natural history, genetic associations and screening. J. Clin. Endocrinol. Metab. 91: 1210-1217 (2006). *
Barker JM, Liu E. Celiac disease: pathophysiology, clinical manifestations, and associated autoimmune conditions. Adv. Pediatr. 55: 349-365 (2008).
Barker JM, Triolo TM, Aly TA, Baschal EE, Babu SR, Kretowski A, Rewers MJ, Eisenbarth GS. Two single nucleotide polymorphisms identify highest-risk diabetes human leukocyte antigen genotype: potential for rapid screening. Diabetes 57: 3152-3155 (2008). *
Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F, Hoffenberg E, Nelson JC, Gottlieb PA, Rewers M, Eisenbarth GS. Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care 28: 850-855 (2005). *
Barnard ND, Noble EP, Ritchie T, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green AA, Ferdowsian H. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition 25: 58-65 (2009). *
Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc. Health Risk Manag. 5: 141-151 (2009). *
Barnett M, Bermingham E, McNabb W, Bassett S, Armstrong K, Rounce J, Roy N. Investigating micronutrients and epigenetic mechanisms in relation to inflammatory bowel disease. Mutat. Res. Feb 24 [Epub ahead of print] (2010).
Baroudi Ouederni T, Sanchez-Corona J, Flores Martinez SE, Ben Maiz H, Aounallah Skhiri H, Kammoun Abid H, Benammar-Elgaaied A. The G1057D polymorphism of IRS-2 gene is not associated with type 2 diabetes and obese patients among ethnic groups in Tunisian population. Clin. Biochem. 42: 1169-1173 (2009). *
Baroudi T, Bouhaha R, Moran-Moguel C, Sanchez-Corona J, Ben Maiz H, Kammoun Abid H, Benammar-Elgaaied A. Association of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene with type 2 diabetes in two ethnic groups of Jerba Island in Tunisia. J. Renin Angiotensin Aldosterone Syst. 10: 35-40 (2009).
Barral AM, Thomas HE, Ling EM, Darwiche R, Rodrigo E, Christen U, Ejrnaes M, Wolfe T, Kay TW, von Herrath MG. SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J. Autoimmun. 27: 166-173 (2006).
Barre DE. The role of consumption of alpha-linolenic, eicosapentaenoic and docosahexaenoic acids in human metabolic syndrome and type 2 diabetes - a mini-review. J. Oleo. Sci. 56: 319-325 (2007). *
Barrett JC, Clayton DG, Concannon P, Akolkar B, Cooper JD, Erlich HA, Julier C, Morahan G, Nerup J, Nierras C, Plagnol V, Pociot F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS; The Type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41: 703-707 (2009). *
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962 (2008). *
Barritt AS 4th, Zacks SL, Rubinas TC, Herfarth HH. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature. Inflamm. Bowel Dis. 14: 1695-1700 (2008). *
Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O'Rahilly S, Wareham NJ. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia 49: 501-505 (2006). *
Barroso I, Luan J, Wheeler E, Whittaker P, Wasson J, Zeggini E, Weedon MN, Hunt S, Venkatesh R, Frayling TM, Delgado M, Neuman RJ, Zhao J, Sherva R, Glaser B, Walker M, Hitman G, McCarthy MI, Hattersley AT, Permutt MA, Wareham NJ, Deloukas P. Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. Diabetes 57: 3161-3165 (2008). *
Barter P. Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides. Atheroscler. Suppl. 7: 17-21 (2006).
Barth A, Rost M, Kindt A, Peiker G. Serum bile acid profile in women during pregnancy and childbed. Exp. Clin. Endocrinol. Diabetes 113: 372-375 (2005).
Bartholo RM, Zaltman C, Elia C, Cardoso AP, Flores V, Lago P, Cassabian L, Carvalho Dorileo F, Lapa-E-Silva JR. Bronchial hyperresponsiveness and analysis of induced sputum cells in Crohn's disease. Braz. J. Med. Biol. Res. 38: 197-203 (2005). *
Barton A, Eyre S, Ke X, Hinks A, Bowes J, Flynn E, Martin P; YEAR Consortium; BIRAC Consortium, Wilson AG, Morgan AW, Emery P, Steer S, Hocking LJ, Reid DM, Harrison P, Wordsworth P, Thomson W, Worthington J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum. Mol. Genet. 18: 2518-2522 (2009). *
Barton A, Jury F, Eyre S, Bowes J, Hinks A, Ward D, Worthington J. Haplotype analysis in simplex families and novel analytic approaches in a case-control cohort reveal no evidence of association of the CTLA-4 gene with rheumatoid arthritis. Arthritis Rheum. 50: 748-752 (2004). *
Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology (Oxford) 39: 63-66 (2000). *
Bartsch DK, Kress R, Sina-Frey M, Grutzmann R, Gerdes B, Pilarsky C, Heise JW, Schulte KM, Colombo-Benkmann M, Schleicher C, Witzigmann H, Pridohl O, Ghadimi MB, Horstmann O, von Bernstorff W, Jochimsen L, Schmidt J, Eisold S, Estevez-Schwarz L, et al. Prevalence of familial pancreatic cancer in Germany. Int. J. Cancer 110: 902-906 (2004). *
Bartsocas CS, Gerasimidi-Vazeou A. Genetics of type 1 diabetes mellitus. Pediatr. Endocrinol. Rev. 3 Suppl. 3: 508-513 (2006).
Bas F, Kabatas-Eryilmaz S, Gunoz H, Darendeliler F, Kucukemre B, Bundak R, Saka N. Type 1 diabetes mellitus associated with autoimmune thyroid disease, celiac disease and familial Mediterranean fever: case report. Turk. J. Pediatr. 51: 183-186 (2009).
Basarkar A, Singh J. Poly (lactide-co-glycolide)-polymethacrylate nanoparticles for intramuscular delivery of plasmid encoding interleukin-10 to prevent autoimmune diabetes in mice. Pharm. Res. 26: 72-81 (2009). *
Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J. Soc. Integr. Oncol. 5: 92-105 (2007).
Baschal EE, Aly TA, Jasinski JM, Steck AK, Johnson KN, Noble JA, Erlich HA, Eisenbarth GS; Diabetes Genetics Consortium. The frequent and conserved DR3-B8-A1 extended haplotype confers less diabetes risk than other DR3 haplotypes. Diabetes Obes. Metab. 11 Suppl. 1: 25-30 (2009). *
Baschal EE, Aly TA, Jasinski JM, Steck AK, Noble JA, Erlich HA, Eisenbarth GS; the Type 1 Diabetes Genetics Consortium. Defining multiple common "completely" conserved major histocompatibility complex SNP haplotypes. Clin. Immunol. 132: 203-214 (2009). *
Baschal EE, Eisenbarth GS. Extreme genetic risk for type 1A diabetes in the post-genome era. J. Autoimmun. 31: 1-6 (2008).
Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, Su Q, Allister E, Wheeler M, Adeli K. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 297: E462-E473 (2009). *
Bassaganya-Riera J, Skoneczka J, Kingston DG, Krishnan A, Misyak SA, Guri AJ, Pereira A, Carter AB, Minorsky P, Tumarkin R, Hontecillas R. Mechanisms of action and medicinal applications of abscisic acid. Curr. Med. Chem. Dec 17 [Epub ahead of print] (2009).
Bassols J, Botas P, Moreno-Navarrete JM, Delgado E, Ortega F, Ricart W, Fernandez-Real JM. Environmental and genetic factors influence the relationship between circulating IL-10 and obesity phenotypes. Obesity (Silver Spring) Oct 1 [Epub ahead of print] (2009). *
Bassols J, Moreno JM, Ortega F, Ricart W, Fernandez-Real JM. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity (Silver Spring) Aug 13 [Epub ahead of print] (2009). *
Bassols J, Moreno-Navarrete JM, Ortega F, Ricart W, Fernandez-Real JM. LIGHT is associated with hypertriglyceridemia in obese subjects and increased cytokine secretion from cultured human adipocytes. Int. J. Obes. (Lond.) Sep 29 [Epub ahead of print] (2009).
Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fernandez-Real JM. Study of the proinflammatory role of human differentiated omental adipocytes. J. Cell. Biochem. 107: 1107-1117 (2009). *
Bassuny WM, Ihara K, Matsuura N, Ahmed S, Kohno H, Kuromaru R, Miyako K, Hara T. Association study of the NRAMP1 gene promoter polymorphism and early-onset type 1 diabetes. Immunogenetics 54: 282-285 (2002). *
Bastian HM, Alarcon GS, Roseman JM, McGwin G Jr, Vila LM, Fessler BJ, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 46: 683-689 (2007). *
Basu A, Jensen MD, McCann F, Nandy D, Mukhopadhyay D, McConnell JP, Rizza RA. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr. Pract. 13: 147-152 (2007).
Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4: 301-317 (2004).
Batarelo V, Durinovic-Bello I. The sentinel role of CD8 T cells in regulating CD4 T cell responses to proinsulin in beta-islet cell autoimmunity. Ann. N. Y. Acad. Sci. 1150: 270-272 (2008). *
Battaglia M, Roncarolo MG. In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy. Nat. Rev. Immunol. 8: c2 (2008). *
Battaglia M, Roncarolo MG. The fate of human Treg cells. Immunity 30: 763-765 (2009). *
Battelino T, Ursic-Bratina N, Dolzan V, Stopar-Obreza M, Pozzilli P, Krzisnik C, Vidan-Jeras B. The HLA-DRB, -DQB polymorphism and anti-insulin antibody response in Slovenian patients with type 1 diabetes. Eur. J. Immunogenet. 30: 223-227 (2003). *
Battezzati A, Battezzati PM, Costantini D, Seia M, Zazzeron L, Russo MC, Dacco V, Bertoli S, Crosignani A, Colombo C. Spontaneous hypoglycemia in patients with cystic fibrosis. Eur. J. Endocrinol. 156: 369-376 (2007). *
Baum H, Staines NA. MHC-derived peptides and the CD4+ T-cell repertoire: implications for autoimmune disease. Cytokines Cell Mol. Ther. 3: 115-125 (1997).
Baxter A, Jordan M, Silveira P, Wilson W, Van Driel I. Genetic control of susceptibility to autoimmune gastritis. Int. Rev. Immunol. 24: 55-62 (2005).
Baxter AG. Immunogenetics and the cause of autoimmune disease. Autoimmunity 25: 177-189 (1997). *
Beasley RP. Diabetes and hepatocellular carcinoma. Hepatology 44: 1408-1410 (2006). *
Beauquis J, Homo-Delarche F, Revsin Y, De Nicola AF, Saravia F. Brain alterations in autoimmune and pharmacological models of diabetes mellitus: focus on hypothalamic-pituitary-adrenocortical axis disturbances. Neuroimmunomodulation 15: 61-67 (2008).
Beauquis J, Saravia F, Coulaud J, Roig P, Dardenne M, Homo-Delarche F, De Nicola A. Prominently decreased hippocampal neurogenesis in a spontaneous model of type 1 diabetes, the nonobese diabetic mouse. Exp. Neurol. 210: 359-367 (2008).
Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57: 313-329 (2006). *
Beckebaum S, Klein C, Varghese J, Sotiropoulos GC, Saner F, Schmitz K, Gerken G, Paul A, Cicinnati VR. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment. Pharmacol. Ther. 30: 834-842 (2009). *
Becker A, Smulders YM, van Guldener C, Stehouwer CD. Epidemiology of homocysteine as a risk factor in diabetes. Metab. Syndr. Relat. Disord. 1: 105-120 (2003).
Becker D, Enk A, Brauninger W, Knop J. Granuloma anulare disseminatum as a rare side effect of allopurinol. Hautarzt. 46: 343-345 (1995).
Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin. Immunol. Immunopathol. 56: 219-225 (1990).
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam. Clin. Pharmacol. 20: 429-447 (2006). *
Becker KG. The common variants/multiple disease hypothesis of common complex genetic disorders. Med. Hypotheses 62: 309-317 (2004).
Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease: common loci, common pathways? Diabetes 48: 1353-1358 (1999). *
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 95: 9979-9984 (1998). *
Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J. 9: 242-247 (2009).
Beeton C, Smith BJ, Sabo JK, Crossley G, Nugent D, Khaytin I, Chi V, Chandy KG, Pennington MW, Norton RS. The D-diastereomer of SHK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation. J. Biol. Chem. 283: 988-997 (2008). *
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, Leehealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 103: 17414-17419 (2006). *
Befeler AS. New developments in hepatocellular carcinoma. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75: 330-337 (2004). *
Begum S, Chen W, Herold KC, Papaioannou VE. Remission of type 1 diabetes following anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors. Endocrinology 150: 4512-4520 (2009). *
Behjati S, Frank MH. The effects of tamoxifen on immunity. Curr. Med. Chem. 16: 3076-3080 (2009).
Behl Y, Krothapalli P, Desta T, Roy S, Graves DT. FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats. Diabetes 58: 917-925 (2009).
Beildeck ME, Islam M, Shah S, Welsh J, Byers SW. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One 4: e7872 (2009). *
Beilhack GF, Landa RR, Masek MA, Shizuru JA. Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. Diabetes 54: 1770-1779 (2005). *
Bekris LM, Shephard C, Janer M, Graham J, McNeney B, Shin J, Zarghami M, Griffith W, Farin F, Kavanagh TJ, Lernmark A. Glutamate cysteine ligase catalytic subunit promoter polymorphisms and associations with type 1 diabetes age-at-onset and GAD65 autoantibody levels. Exp. Clin. Endocrinol. Diabetes 115: 221-228 (2007).
Bekris LM, Shephard C, Peterson M, Hoehna J, Yserloo BV, Rutledge E, Farin F, Kavanagh TJ, Lernmark A. Glutathione-S-transferase M1 and T1 polymorphisms and associations with type 1 diabetes age-at-onset. Autoimmunity 38: 567-575 (2005).
Belalcazar LM, Reboussin DM, Haffner SM, Reeves RS, Schwenke DC, Hoogeveen RC, Pi-Sunyer FX, Ballantyne CM; for the Look AHEAD (Action for Health in Diabetes) Obesity, Inflammation and Thrombosis Research Group. Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD Study. Diabetes Care Oct 19 [Epub ahead of print] (2009).
Belanger S, Tai LH, Anderson SK, Makrigiannis AP. Ly49 cluster sequence analysis in a mouse model of diabetes: an expanded repertoire of activating receptors in the NOD genome. Genes Immun. 9: 509-521 (2008). *
Belfiore A, Genua M, Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res. 2009: 830501 (2009). *
Belfort R, Berria R, Cornell J, Cusi K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J. Clin. Endocrinol. Metab. Jan 8 [Epub ahead of print] (2010). *
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355: 2297-2307 (2006). *
Bell DS, Allbright E. The multifaceted associations of hepatobiliary disease and diabetes. Endocr. Pract. 13: 300-312 (2007).
Bell H, Berg JP, Undlien DE, Distante S, Raknerud N, Heier HE, Try K, Thomassen Y, Haug E, Raha-Chowdhury R, Thorsby E. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand. J. Gastroenterol. 35: 1301-1307 (2000). *
Bell J, Rassenti L, Smoot S, Smith K, Newby C, Hohlfeld R, Toyka K, McDevitt H, Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet 1: 1058-1060 (1986).
Bell JI. The molecular genetics of HLA-related disorders. Ciba Found. Symp. 130: 197-214 (1987).
Bell JK, Askins J, Hall PR, Davies DR, Segal DM. The dsRNA binding site of human Toll-like receptor 3. Proc. Natl. Acad. Sci. U.S.A. 103: 8792-8797 (2006). *
Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Davies DR, Segal DM. The molecular structure of the TLR3 extracellular domain. J. Endotoxin Res. 12: 375-378 (2006). *
Bell JK, Botos I, Hall PR, Askins J, Shiloach J, Segal DM, Davies DR. The molecular structure of the Toll-like receptor 3 ligand-binding domain. Proc. Natl. Acad. Sci. U.S.A. 102: 10976-10980 (2005). *
Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 8 Suppl. 1: S4-S8 (2009). *
Bellisle F. Infrequently asked questions about the Mediterranean diet. Public Health Nutr. 12: 1644-1647 (2009).
Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases. Neurol. Neurochir. Pol. 41: 259-266 (2007).
Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol. 533: 101-109 (2006). *
Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur. J. Gastroenterol. Hepatol. 19: 615-617 (2007). *
Bending D, De La Pena H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, Cooke A. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119: 565-572 (2009). *
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2. Physiol. Res. 57 Suppl. 1: S77-S90 (2008). *
Benedek G, Brautbar C, Vardi P, Sharon N, Weintrob N, Zung A, Israel S. Effect of polymorphism in insulin locus and HLA on type 1 diabetes in four ethnic groups in Israel. Tissue Antigens 73: 33-38 (2009). *
Bengmark S. Curcumin, an atoxic antioxidant and natural NFkappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J. Parenter. Enteral Nutr. 30: 45-51 (2006). *
Bengmark S. Advanced glycation and lipoxidation end products amplifiers of inflammation: the role of food. JPEN J. Parenter. Enteral Nutr. 31: 430-440 (2007). *
Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr. Hosp. 24: 273-281 (2009). *
Bengtson MB, Ronning T, Vatn M, Harris J. Irritable bowel syndrome in twins: genes and environment. Gut 55: 1754-1759 (2006). *
Benn CS, Aaby P. Sex-differential responses to preventive health interventions. Maybe we treat boys and girls differently when we treat them equally? - Secondary publication. Dan. Med. Bull. 54: 153-154 (2007).
Bennett AJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Franks S, Elliott P, Jarvelin MR, McCarthy MI. No evidence that established type 2 diabetes susceptibility variants in the PPARG and KCNJ11 genes have pleiotropic effects on early growth. Diabetologia 51: 82-85 (2008). *
Bennett ST, Wilson AJ, Cucca F, Nerup J, Pociot F, McKinney PA, Barnett AH, Bain SC, Todd JA. IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. J. Autoimmun. 9: 415-421 (1996).
Benoist C, Germain RN, Mathis D. A plaidoyer for 'systems immunology'. Immunol. Rev. 210: 229-234 (2006). *
Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat. Immunol. 2: 797-801 (2001). *
Bensing S, Brandt L, Tabaroj F, Sjoberg O, Nilsson B, Ekbom A, Blomqvist P, Kampe O. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin. Endocrinol. (Oxf.) 69: 697-704 (2008). *
Benten D, Follenzi A, Bhargava KK, Kumaran V, Palestro CJ, Gupta S. Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice. Hepatology 42: 140-148 (2005). *
Bento JL, Palmer ND, Mychaleckyj JC, Lange LA, Langefeld CD, Rich SS, Freedman BI, Bowden DW. Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2 diabetes. Diabetes 53: 3007-3012 (2004). *
Bento JL, Palmer ND, Zhong M, Roh B, Lewis JP, Wing MR, Pandya H, Freedman BI, Langefeld CD, Rich SS, Bowden DW, Mychaleckyj JC. Heterogeneity in gene loci associated with type 2 diabetes on human chromosome 20q13.1. Genomics 92: 226-234 (2008). *
Beranek M, Kolar P, Tschoplova S, Kankova K, Vasku A. Genetic variation and plasma level of the basic fibroblast growth factor in proliferative diabetic retinopathy. Diabetes Res. Clin. Pract. 79: 362-367 (2008).
Berchtold LA, Larsen CM, Vaag A, Faulenbach M, Workman CT, Kruh�ffer M, Donath M, Mandrup-Poulsen T. IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur. Cytokine Netw. 20: 81-87 (2009).
Berends MA, Snoek J, DE Jong EM, VAN DE Kerkhof PC, VAN Oijen MG, VAN Krieken JH, Drenth JP. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment. Pharmacol. Ther. 24: 805-811 (2006). *
Bergamaschi L, Ban M, Leone MA, Sawcer SJ, D'Alfonso S. No evidence of association of the rare nsSNP rs35667974 in IFIH1 with multiple sclerosis. J. Neuroimmunol. Jan 29 [Epub ahead of print] (2010).
Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J. Am. Acad. Dermatol. 41: 431-434 (1999).
Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 27: 679-684 (1998). *
Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102: 544-549 (1992).
Bergasa NV, Vergalla J, Turner ML, Loh PY, Jones EA. Alpha-melanocyte-stimulating hormone in primary biliary cirrhosis. Ann. N. Y. Acad. Sci. 680: 454-458 (1993). *
Berger J, Moller DE. The mechanisms of action of PPARs. Annu. Rev. Med. 53: 409-435 (2002). *
Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol. Ther. 4: 163-174 (2002).
Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26: 244-251 (2005). *
Berger JR, Weaver A, Greenlee J, Wahlen GE. Neurologic consequences of autoimmune polyglandular syndrome type 1. Neurology 70: 2248-2251 (2008).
Berger K, Stogbauer F, Stoll M, Wellmann J, Huge A, Cheng S, Kessler C, John U, Assmann G, Ringelstein EB, Funke H. The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum. Genet. 121: 169-178 (2007). *
Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in ZDF rats: a comparison to PPARgamma agonism. Endocrinology 147: 4252-4262 (2006). *
Bergholdt R. Understanding type 1 diabetes genetics - approaches for identification of susceptibility genes in multi-factorial diseases. Dan. Med. Bull. 56: 1-39 (2009).
Bergholdt R, Brorsson C, Boehm B, Morahan G, Pociot F. No association of the IRS1 and PAX4 genes with type I diabetes. Genes Immun. 10: S49-S53 (2009).
Bergholdt R, Heding P, Nielsen K, Nolsoe R, Sparre T, Storling J, Nerup J, Pociot F, Mandrup-Poulsen T. Type 1 database mellitus: an inflammatory disease of the islet. Adv. Exp. Med. Biol. 552: 129-153 (2004).
Bergholdt R, Karlsen AE, Hagedorn PH, Aalund M, Nielsen JH, Kruhoffer M, Orntoft T, Wang H, Wollheim CB, Nerup J, Pociot F. Transcriptional profiling of type 1 diabetes genes on chromosome 21 in a rat beta-cell line and human pancreatic islets. Genes Immun. 8: 232-238 (2007). *
Bergholdt R, Larsen ZM, Andersen NA, Johannesen J, Kristiansen OP, Mandrup-Poulsen T, Nerup J, Pociot F; Danish Study Group of IDDM in Childhood; Danish IDDM Epidemiology and Genetics Group. Characterization of new polymorphisms in the 5' UTR of the human interleukin-1 receptor type 1 (IL1R1) gene: linkage to type 1 diabetes and correlation to IL-1RI plasma level. Genes Immun. 1: 495-500 (2000). *
Bergholdt R, Nerup J, Pociot F. Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes. J. Med. Genet. 42: 17-25 (2005). *
Bergholdt R, Taxvig C, Eising S, Nerup J, Pociot F. CBLB variants in type 1 diabetes and their genetic interaction with CTLA4. J. Leukoc. 77: 579-585 (2005). *
Bergman BC, Perreault L, Hunerdosse DM, Koehler MC, Samek AM, Eckel RH. Intramuscular lipid metabolism in the insulin resistance of smoking. Diabetes 58: 2220-2227 (2009). *
Bergman ML, Cilio CM, Penha-Goncalves C, Lamhamedi-Cherradi SE, Lofgren A, Colucci F, Lejon K, Garchon HJ, Holmberg D. CTLA-4-/- mice display T cell-apoptosis resistance resembling that ascribed to autoimmune-prone non-obese diabetic (NOD) mice. J. Autoimmun. 16: 105-113 (2001).
Bergmann A, Li J, Selisko T, Reimann M, Fischer S, Grassler J, Schulze J, Bornstein SR, Schwarz PE. The A98V single nucleotide polymorphism (SNP) in hepatic nuclear factor 1 alpha (HNF-1alpha) is associated with insulin sensitivity and beta-cell function. Exp. Clin. Endocrinol. Diabetes 116 Suppl. 1: S50-S55 (2008).
Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur. J. Epidemiol. 19: 411-416 (2004).
Bergstrom JP, Helander A. HPLC evaluation of clinical and pharmacological factors reported to cause false-positive carbohydrate-deficient transferrin (CDT) levels. Clin. Chim. Acta 389: 164-166 (2008). *
Bering B, Devendra D. Latent autoimmune diabetes in the young. Clin. Med. 9: 93 (2009).
Berka N, Bland GN, Erabhaoui el H, Dunston GM. Heat-shock protein gene is not associated with type-1 diabetes in African Americans. J. Natl. Med. Assoc. 99: 715-717 (2007). *
Berka N, Nunlee-Bland G, Erabhaoui E, Belmamoun M, Dunston GM. IDDM2 and the polymorphism of the human tyrosine hydroxylase (hTH) gene in African Americans with type-1 diabetes. J. Natl. Med. Assoc. 96: 1042-1046 (2004).
Berkovic M, Cacev T, Zjacic-Rotkvic V, Kapitanovic S. TNF-alpha promoter single nucleotide polymorphisms in gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 84: 346-352 (2006).
Bermudez Menendez de la Granda M, Sinclair AJ. Fatty acids and obesity. Curr. Pharm. Des. 15: 4117-4125 (2009).
Bernal-Reyes R, Escudero RB. Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Rev. Gastroenterol. Mex. 67: 70-75 (2002).
Bernardo A, Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists. PPAR Res. 2008: 864140 (2008). *
Berney T, Ferrari-Lacraz S, Buhler L, Oberholzer J, Marangon N, Philippe J, Villard J, Morel P. Long-term insulin-independence after allogeneic islet transplantation for type 1 diabetes: over the 10-year mark. Am. J. Transplant. 9: 419-423 (2009). *
Berr C, Akbaraly T, Arnaud J, Hininger I, Roussel AM, Barberger Gateau P. Increased selenium intake in elderly high fish consumers may account for health benefits previously ascribed to omega-3 fatty acids. J. Nutr. Health Aging 13: 14-18 (2009).
Bersot T, Haffner S, Harris WS, Kellick KA, Morris CM. Hypertriglyceridemia: management of atherogenic dyslipidemia. J. Fam. Pract. 55: S1-S8 (2006).
Berthold HK, Giannakidou E, Krone W, Mantzoros CS, Gouni-Berthold I. The Leu72Met polymorphism of the ghrelin gene is associated with a decreased risk for type 2 diabetes. Clin. Chim. Acta 399: 112-116 (2009). *
Berthold HK, Laaksonen R, Lehtimaki T, Gylling H, Krone W, Gouni-Berthold I. SREBP-1c gene polymorphism is associated with increased inhibition of cholesterol-absorption in response to ezetimibe treatment. Exp. Clin. Endocrinol. Diabetes 116: 262-267 (2008).
Bertrams J. The HLA association of insulin-dependent (type I) diabetes mellitus. Behring Inst. Mitt. 75: 89-99 (1984).
Bertuzzi F, Ricordi C. Beta-cell replacement in immunosuppressed recipients: old and new clinical indications. Acta Diabetol. 44: 171-176 (2007).
Besin G, Gaudreau S, Menard M, Guindi C, Dupuis G, Amrani A. Thymic stromal lymphopoietin and thymic stromal lymphopoietin-conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes 57: 2107-2117 (2008). *
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U. Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev. Cardiovasc. Ther. 6: 1071-1082 (2008).
Bessa SS, Hamdy SM, Ali EM. Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: an Egyptian study. Eur. J. Intern. Med. 18: 489-495 (2007).
Betteridge DJ. Lipid lowering in diabetes mellitus. Curr. Opin. Lipidol. 19: 579-584 (2008).
Betteridge DJ. Lipid-lowering trials in diabetes. Curr. Opin. Lipidol. 12: 619-623 (2001).
Betterle C, Dalpra C, Greggio N, Volpato M, Zanchetta R. Autoimmunity in isolated Addison's disease and in polyglandular autoimmune diseases type 1, 2 and 4. Ann. Endocrinol. (Paris) 62: 193-201 (2001).
Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome type 2: the tip of an iceberg? Clin. Exp. Immunol. 137: 225-233 (2004). *
Betterle C, Rossi A, Dalla Pria S, Artifoni A, Pedini B, Gavasso S, Caretto A. Premature ovarian failure: autoimmunity and natural history. Clin. Endocrinol. (Oxf.) 39: 35-43 (1993).
Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. Ateneo. Parmense. 74: 9-33 (2003).
Bettini M, Vignali DA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr. Opin. Immunol. 21: 612-618 (2009).
Betts P, Mulligan J, Ward P, Smith B, Wilkin T. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the 'accelerator hypothesis' (2). Diabet. Med. 22: 144-151 (2005). *
Beulens JW, Rimm EB, Hendriks HF, Hu FB, Manson JE, Hunter DJ, Mukamal KJ. Alcohol consumption and type 2 diabetes: influence of genetic variation in alcohol dehydrogenase. Diabetes 56: 2388-2394 (2007). *
Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab. Res. Rev. 19: 89-100 (2003).
Beyan H, Ola T, David R, Leslie G. Progression of autoimmune diabetes: slowly progressive insulin-dependent diabetes mellitus or latent autoimmune diabetes of adult. Ann. N. Y. Acad. Sci. 1079: 81-89 (2006). *
Beylot M. Regulation of in vivo ketogenesis: role of free fatty acids and control by epinephrine, thyroid hormones, insulin and glucagon. Diabetes Metab. 22: 299-304 (1996).
Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, Hellerstein MK, Boyle PJ. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J. Lipid Res. 49: 2657-2663 (2008). *
Bhadada SK, Udawat HP, Bhansali A, Rana SS, Sinha SK, Bhasin DK. Chronic pancreatitis in primary hyperparathyroidism: comparison with alcoholic and idiopathic chronic pancreatitis. J. Gastroenterol. Hepatol. 23: 959-964 (2008). *
Bhaskar S, Reddy DN, Mahurkar S, Rao GV, Singh L, Chandak GR. Lack of significant association of an insertion/deletion polymorphism in the angiotensin converting enzyme (ACE) gene with tropical calcific pancreatitis. BMC Gastroenterol. 6: 42 (2006). *
Bhat A, Koul A, Rai E, Sharma S, Dhar MK, Bamezai RN. PGC-1alpha Thr394Thr and Gly482Ser variants are significantly associated with T2DM in two North Indian populations: a replicate case-control study. Hum. Genet. 121: 609-614 (2007). *
Bhat M, Nguyen GC, Pare P, Lahaie R, Deslandres C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant S, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhart H, Griffiths AM, Elkadri A, Cho J, et al. Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository. Am. J. Gastroenterol. 104: 2233-2240 (2009). *
Bhatia E, Choudhuri G, Sikora SS, Landt O, Kage A, Becker M, Witt H. Tropical calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations. Gastroenterology 123: 1020-1025 (2002). *
Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers. Curr. Opin. Investig. Drugs 7: 891-897 (2006).
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, Almahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization - results of the PPAR study. Am. Heart J. 154: 137-143 (2007). *
Bhibhatbhan A, Kline G, Vincent A, Toth C. Anti-MuSK myasthenia gravis presenting with Epstein-Barr virus-associated mononucleosis and immune-mediated diabetes mellitus. Muscle Nerve 36: 264-266 (2007).
Bhoj EJ, Romeo S, Baroni MG, Bartov G, Schultz RA, Zinn AR. MODY-like diabetes associated with an apparently balanced translocation: possible involvement of MPP7 gene and cell polarity in the pathogenesis of diabetes. Mol. Cytogenet. 2:5 (2009). *
Bi EG, Shi W, Zou J, Hao ZH, Li ZH, Cai D, Zhang HQ, Sun B. IL-12p40 is not required for islet allograft rejection. Acta Pharmacol. Sin. 27: 1065-1070 (2006). *
Bi Y, Sun WP, Chen X, Li M, Liang H, Cai MY, Zhu YH, He XY, Xu F, Weng JP. Effect of early insulin therapy on nuclear factor kappaB and cytokine gene expressions in the liver and skeletal muscle of high-fat diet, streptozotocin-treated diabetic rats. Acta Diabetol. 45: 167-178 (2008).
Biagi F, Campanella J, Soriani A, Vailati A, Corazza GR. Prevalence of coeliac disease in Italian patients affected by Addison's disease. Scand. J. Gastroenterol. 41: 302-305 (2006). *
Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J. Clin. Invest. 116: 2571-2579 (2006). *
Biason-Lauber A, Boehm B, Lang-Muritano M, Gauthier BR, Brun T, Wollheim CB, Schoenle EJ. Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 48: 900-905 (2005). *
Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin. Nephrol. 28: 245-251 (2008).
Bid HK, Konwar R, Aggarwal CG, Gautam S, Saxena M, Nayak VL, Banerjee M. Vitamin D receptor (FokI, BsmI and TaqI) gene polymorphisms and type 2 diabetes mellitus: a North Indian study. Indian J. Med. Sci. 63: 187-194 (2009). *
Bid HK, Konwar R, Agrawal CG, Banerjee M. Association of IL-4 and IL-1RN (receptor antagonist) gene variants and the risk of type 2 diabetes mellitus: a study in the north Indian population. Indian J. Med. Sci. 62: 259-266 (2008). *
Bidel S, Silventoinen K, Hu G, Lee DH, Kaprio J, Tuomilehto J. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes. Eur. J. Clin. Nutr. 62: 178-185 (2008). *
Bieda K, Pani MA, van der Auwera B, Seidl C, Tonjes RR, Gorus F, Usadel KH, Badenhoop K. A retroviral long terminal repeat adjacent to the HLA DQB1 gene (DQ-LTR13) modifies type I diabetes susceptibility on high risk DQ haplotypes. Diabetologia 45: 443-447 (2002). *
Bielinski SJ, Pankow JS, Boerwinkle E, Bray MS, Kao WH, Folsom AR. Lack of association between uncoupling protein-2 Ala55Val polymorphism and incident diabetes in the atherosclerosis risk in communities study. Acta Diabetol. 45: 179-182 (2008).
Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83: 876-886 (2005). *
Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann. N. Y. Acad. Sci. 1043: 676-680 (2005). *
Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 52: 2251-2263 (2009). *
Biering H, Bohner G, Strasburger CJ. Autoimmune hypophysitis. Dtsch. Med. Wochenschr. 130: 2826-2828 (2005).
Biernacka JM, Cordell HJ. Exploring causality via identification of SNPs or haplotypes responsible for a linkage signal. Genet. Epidemiol. 31: 727-740 (2007).
Biernacka JM, Sun L, Bull SB. Simultaneous localization of two linked disease susceptibility genes. Genet. Epidemiol. 28: 33-47 (2004). *
Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, Benson J, Therneau T, Kremers W, Wiesner R, Kamath P, Klintmalm G. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130: 1652-1660 (2006). *
Bijl N, Sokolovic M, Vrins C, Langeveld M, Moerland PD, Ottenhoff R, van Roomen CP, Claessen N, Boot RG, Aten J, Groen AK, Aerts JM, van Eijk M. Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice. Hepatology 50: 1431-1441 (2009).
Bijl N, van Roomen CP, Triantis V, Sokolovic M, Ottenhoff R, Scheij S, van Eijk M, Boot RG, Aerts JM, Groen AK. Reduction of glycosphingolipid biosynthesis stimulates biliary lipid secretion in mice. Hepatology 49: 637-645 (2009). *
Bikle DD. What is new in vitamin D: 2006-2007. Curr. Opin. Rheumatol. 19: 383-388 (2007).
Bilbao JR, Calvo B, Aransay AM, Martin-Pagola A, Perez de Nanclares G, Aly TA, Rica I, Vitoria JC, Gaztambide S, Noble J, Fain PR, Awdeh ZL, Alper CA, Castano L. Conserved extended haplotypes discriminate HLA-DR3-homozygous Basque patients with type 1 diabetes mellitus and celiac disease. Genes Immun. 7: 550-554 (2006). *
Bilbao JR, Martin-Pagola A, Calvo B, Perez de Nanclares G, Gepv-N, Castano L. Contribution of MIC-A polymorphism to type 1 diabetes mellitus in Basques. Ann. N. Y. Acad. Sci. 958: 321-324 (2002). *
Bilbao JR, Martin-Pagola A, Perez De Nanclares G, Calvo B, Vitoria JC, Vazquez F, Castano L. HLA-DRB1 and MICA in autoimmunity: common associated alleles in autoimmune disorders. Ann. N. Y. Acad. Sci. 1005: 314-318 (2003). *
Bilbao JR, Martin-Pagola A, Vitoria JC, Zubillaga P, Ortiz L, Castano L. HLA-DRB1 and MHC class 1 chain-related A haplotypes in Basque families with celiac disease. Tissue Antigens 60: 71-76 (2002). *
Bilbao JR, Villoslada P, Martin-Pagola A, Castano L. No evidence of pancreatic autoimmunity among patients with multiple sclerosis. Ann. N. Y. Acad. Sci. 1037: 133-137 (2004). *
Bilgic S, Aktas E, Salman F, Ersahin G, Erten G, Yilmaz MT, Deniz G. Intracytoplasmic cytokine levels and neutrophil functions in early clinical stage of type 1 diabetes. Diabetes Res. Clin. Pract. 79: 31-36 (2008).
Billin AN. PPAR-beta/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home. Expert Opin. Investig. Drugs 17: 1465-1471 (2008).
Billotey C, Aspord C, Beuf O, Piaggio E, Gazeau F, Janier MF, Thivolet C. T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging. Radiology 236: 579-587 (2005). *
Bilz S, Samuel V, Morino K, Savage D, Choi CS, Shulman GI. Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters. Am. J. Physiol. Endocrinol. Metab. 290: E716-E722 (2006). *
Bingley PJ. Clinical applications of diabetes antibody testing. J. Clin. Endocrinol. Metab. Oct 29 [Epub ahead of print] (2009).
Binstadt BA, Hebert JL, Ortiz-Lopez A, Bronson R, Benoist C, Mathis D. The same systemic autoimmune disease provokes arthritis and endocarditis via distinct mechanisms. Proc. Natl. Acad. Sci. U.S.A. 106: 16758-16763 (2009). *
Binstadt BA, Patel PR, Alencar H, Nigrovic PA, Lee DM, Mahmood U, Weissleder R, Mathis D, Benoist C. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat. Immunol. 7: 284-292 (2006). *
Bircan R, Miehle K, Mladenova G, Ivanova R, Ivanova R, Sarafova A, Borissova AM, Lublinghoff J, Paschke R. Multiple relapses of hyperthyroidism after thyroid surgeries in a patient with long term follow-up of sporadic non-autoimmune hyperthyroidism. Exp. Clin. Endocrinol. Diabetes 116: 341-346 (2008).
Birlea S, Birlea M, Cimponeriu D, Apostol P, Cosgarea R, Gavrila L, Tigan S, Costin G, Das PK. Autoimmune diseases and vitamin D receptor Apa-I polymorphism are associated with vitiligo in a small inbred Romanian community. Acta Derm. Venereol. 86: 209-214 (2006). *
Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr. Drug Targets 9: 345-359 (2008).
Birlea SA, Fain PR, Spritz RA. A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch. Dermatol. 144: 310-316 (2008). *
Birlea SA, Gowan K, Fain PR, Spritz RA. Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. J. Invest. Dermatol. Nov 5 [Epub ahead of print] (2009). *
Biros E, Jordan MA, Baxter AG. Genes mediating environment interactions in type 1 diabetes. Rev. Diabet. Stud. 2: 192-207 (2005). *
Biscetti F, Gaetani E, Flex A, Tamar A, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57: 1394-1404 (2008). *
Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, De Angelis G, Iuliano L, Ghirlanda G, Flex A. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPAR-gamma stimulation. Cardiovasc. Diabetol. 8: 49 (2009).
Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis. Nutr. Metab. Cardiovasc. Dis. 19: 751-759 (2009).
Bishop-Bailey D. The platelet as a model system for the acute actions of nuclear receptors. Steroids Sep 21 [Epub ahead of print] (2009).
Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat. 71: 1-22 (2003).
Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, de Blic J, Lenoir G, Robert JJ. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J. Pediatr. 152: 540-545.e1 (2008). *
Bismuth M, Aguilar-Martinez P, Michel H. Hereditary haemochromatosis. Presse. Med. 32: 1716-1723 (2003).
Bister V, Kolho KL, Karikoski R, Westerholm-Ormio M, Savilahti E, Saarialho-Kere U. Metalloelastase (MMP-12) is upregulated in the gut of pediatric patients with potential celiac disease and in type 1 diabetes. Scand. J. Gastroenterol. 40: 1413-1422 (2005). *
Biswas A, Chittari K, Gey van Pittius D, Stephens M, Tan BB. Palisaded neutrophilic and granulomatous dermatitis in a child with type I diabetes mellitus and coeliac disease. Br. J. Dermatol. 159: 488-489 (2008). *
Bitan M, Weiss L, Zeira M, Reich S, Pappo O, Vlodavsky I, Slavin S. Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production. Diabetes Metab. Res. Rev. 24: 413-421 (2008).
Bizzaro N. The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin. Rev. Allergy Immunol. 34: 326-331 (2007).
Bjelakovic G, Beninati S, Pavlovic D, Kocic G, Jevtovic T, Kamenov B, Saranac LJ, Bjelakovic B, Stojanovic I, Banic J. Glucocorticoids and oxidative stress. J. Basic Clin. Physiol. Pharmacol. 18: 115-127 (2007).
Bjorck S, Brundin C, Lorinc E, Lynch KF, Agardh D. Screening detects a high proportion of celiac disease in young HLA-genotyped children. J. Pediatr. Gastroenterol. Nutr. 50: 49-53 (2010).
Bjorkbacka H, Lavant EH, Fredrikson GN, Melander O, Berglund G, Carlson JA, Nilsson J. Weak associations between human leucocyte antigen genotype and acute myocardial infarction. J. Intern. Med. Dec 14 [Epub ahead of print] (2009). *
Bjorksten B. The hygiene hypothesis: do we still believe in it? Nestle Nutr. Workshop Ser. Pediatr. Program 64: 11-22 (2009).
Bjorksten B. Disease outcomes as a consequence of environmental influences on the development of the immune system. Curr. Opin. Allergy Clin. Immunol. 9: 185-189 (2009).
Bjorksten B. Environmental influences on the development of the immune system: consequences for disease outcome. Nestle Nutr. Workshop Ser. Pediatr. Program. 61: 243-254 (2008).
Bjornvold M, Amundsen SS, Stene LC, Joner G, Dahl-Jorgensen K, Njolstad PR, Ek J, Ascher H, Gudjonsdottir AH, Lie BA, Skinningsrud B, Akselsen HE, Ronningen KS, Sollid LM, Undlien DE. FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J. Autoimmun. 27: 140-144 (2006).
Bjornvold M, Munthe-Kaas MC, Egeland T, Joner G, Dahl-Jorgensen K, Njolstad PR, Akselsen HE, Gervin K, Carlsen KC, Carlsen KH, Undlien DE. A TLR2 polymorphism is associated with type 1 diabetes and allergic asthma. Genes Immun. 10: 181-187 (2009).
Bjornvold M, Undlien DE, Joner G, Dahl-Jorgensen K, Njolstad PR, Akselsen HE, Gervin K, Ronningen KS, Stene LC. Joint effects of HLA, INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes. Diabetologia 51: 589-596 (2008). *
Black MH, Fingerlin TE, Allayee H, Zhang W, Xiang AH, Trigo E, Hartiala J, Lehtinen AB, Haffner SM, Bergman RN, McEachin RC, Kjos SL, Lawrence JM, Buchanan TA, Watanabe RM. Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 57: 1048-1056 (2008). *
Black PH. The inflammatory consequences of psychologic stress: relationship to insulin resistance, obesity, atherosclerosis and diabetes mellitus, type II. Med. Hypotheses 67: 879-891 (2006).
Blackman SM, Hsu S, Ritter SE, Naughton KM, Wright FA, Drumm ML, Knowles MR, Cutting GR. A susceptibility gene for type 2 diabetes confers substantial risk for diabetes complicating cystic fibrosis. Diabetologia 52: 1858-1865 (2009). *
Blackman SM, Hsu S, Vanscoy LL, Collaco JM, Ritter SE, Naughton K, Cutting GR. Genetic modifiers play a substantial role in diabetes complicating cystic fibrosis. J. Clin. Endocrinol. Metab. 94: 1302-1309 (2009). *
Blackwell JM, Searle S. Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). Immunol. Lett. 65: 73-80 (1999).
Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5: 2087-2102 (2006). *
Blaha V, Mistr�k E. Hypolipidemic drugs and diabetes mellitus. Vnitr. Lek. 55: 357-362 (2009).
Blanco Quiros A, Arranz Sanz E, Bernardo Ordiz D, Garrote Adrados JA. From autoimmune enteropathy to the IPEX (immune dysfunction, polyendocrinopathy, enteropathy, X-linked) syndrome. Allergol. Immunopathol. (Madr.) 37: 208-215 (2009). *
Blandino-Rosano M, Perez-Arana G, Mellado-Gil J, Segundo C, Aguilar-Diosdado M. Anti-proliferative effect of pro-inflammatory cytokines in cultured beta cells is associated with Erk1/2 pathway inhibition: protective role of GLP-1. J. Mol. Endocrinol. 41: 35-44 (2008). *
Blankenhorn EP, Cort L, Greiner DL, Guberski DL, Mordes JP. Virus-induced autoimmune diabetes in the LEW.1WR1 rat requires Iddm14 and a genetic locus proximal to the major histocompatibility complex. Diabetes 58: 2930-2938 (2009).
Blankenhorn EP, Descipio C, Rodemich L, Cort L, Leif JH, Greiner DL, Mordes JP. Refinement of the Iddm4 diabetes susceptibility locus reveals TCRVbeta4 as a candidate gene. Ann. N. Y. Acad. Sci. 1103: 128-131 (2007). *
Blankenhorn EP, Rodemich L, Martin-Fernandez C, Leif J, Greiner DL, Mordes JP. The rat diabetes susceptibility locus iddm4 and at least one additional gene are required for autoimmune diabetes induced by viral infection. Diabetes 54: 1233-1237 (2005). *
Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents. Cancer Ther. 6(A): 25-34 (2008).
Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol. Metab. Clin. North Am. 35: 561-574 (2006).
Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: new implications. Vascul. Pharmacol. 45: 3-18 (2006).
Blaschke F, Takata Y, Caglayan E, Collins A, Tontonoz P, Hsueh WA, Tangirala RK. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 99: e88-e99 (2006). *
Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26: 28-40 (2006). *
Blasi C. The autoimmune origin of atherosclerosis. Atherosclerosis 201: 17-32 (2008).
Blau H, Livne M, Mussaffi H. Cystic fibrosis in adults: a changing scene. Isr. Med. Assoc. J. 5: 491-495 (2003). *
Blazovics A. Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596 (2007).
Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J. Clin. Invest. 103: 1431-1436 (1999). *
Bletter N. A quantitative synthesis of the medicinal ethnobotany of the Malinke of Mali and the Ashaninka of Peru, with a new theoretical framework. J. Ethnobiol. Ethnomed. 3: 36 (2007). *
Blewett MM. Lipid autoreactivity in multiple sclerosis. Med. Hypotheses 74: 433-442 (2010).
Bloch AS. Low carbohydrate diets, pro: time to rethink our current strategies. Nutr. Clin. Pract. 20: 3-12 (2005).
Block G, Jensen CD, Norkus EP, Dalvi TB, Wong LG, McManus JF, Hudes ML. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr. J. 6: 30 (2007). *
Bloks VW, Bakker-Van Waarde WM, Verkade HJ, Kema IP, Wolters H, Vink E, Groen AK, Kuipers F. Down-regulation of hepatic and intestinal Abcg5 and Abcg8 expression associated with altered sterol fluxes in rats with streptozotocin-induced diabetes. Diabetologia 47: 104-112 (2004). *
Blomhoff A, Lie BA, Myhre AG, Kemp EH, Weetman AP, Akselsen HE, Huseby ES, Undlien DE. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J. Clin. Endocrinol. Metab. 89: 3474-3476 (2004). *
Bluestone JA. CTLA-4Ig is finally making it: a personal perspective. Am. J. Transplant. 5: 423-424 (2005). *
Bluestone JA. Opinion: regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5: 343-349 (2005). *
Bluestone JA. A balanced attack. The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s32/1/ ) (2007).
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257 (2003). *
Bluestone JA, Boehmer H. Regulatory T cells. Semin. Immunol. 18: 77 (2006). *
Bluestone JA, Mackay CR, O'Shea JJ, Stockinger B. The functional plasticity of T cell subsets. Nat. Rev. Immunol. 9: 811-816 (2009). *
Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24: 233-238 (2006). *
Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol. 17: 638-642 (2005).
Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 101: 14622-14626 (2004). *
Bluestone JA, Tang Q, Sedwick CE. T regulatory cells in autoimmune diabetes: past challenges, future prospects. J. Clin. Immunol. 28: 677-684 (2008). *
Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler. Thromb. Vasc. Biol. 28: e18-e20 (2008).
Blumberg RS, Li L, Nusrat A, Parkos CA, Rubin DC, Carrington JL. Recent insights into the integration of the intestinal epithelium within the mucosal environment in health and disease. Mucosal Immunol. 1: 330-334 (2008).
Blumenfeld Z. GnRH-agonists in fertility preservation. Curr. Opin. Endocrinol. Diabetes Obes. 15: 523-528 (2008).
Bochenski J, Placha G, Wanic K, Malecki M, Sieradzki J, Warram JH, Krolewski AS. New polymorphism of ENPP1 (PC-1) is associated with increased risk of type 2 diabetes among obese individuals. Diabetes 55: 2626-2630 (2006). *
Bochkis IM, Rubins NE, White P, Furth EE, Friedman JR, Kaestner KH. Hepatocyte-specific ablation of Foxa2 alters bile acid homeostasis and results in endoplasmic reticulum stress. Nat. Med. 14: 828-836 (2008). *
Bockenhauer D, Hug MJ, Kleta R. Cystic fibrosis, aminoglycoside treatment and acute renal failure: the not so gentle micin. Pediatr. Nephrol. 24: 925-928 (2009).
Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found. Symp. 252: 55-63 (2003).
Boden G. High or low carbohydrate diets: which is better for weight loss, insulin resistance and fatty livers? Gastroenterology 136: 1490-1492 (2009). *
Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin. Investig. Drugs 15: 243-250 (2006).
Bodhini D, Radha V, Deepa R, Ghosh S, Majumder PP, Rao MR, Mohan V. The G1057D polymorphism of IRS-2 gene and its relationship with obesity in conferring susceptibility to type 2 diabetes in Asian Indians. Int. J. Obes. (Lond.) 31: 97-102 (2007). *
Bodhini D, Radha V, Dhar M, Narayani N, Mohan V. The rs12255372(G/T) and rs7903146(C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. Metabolism 56: 1174-1178 (2007). *
Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf. 32: 539-547 (2009).
Bodolay E, Derfalvi B, Gergely P, Poor G. When does an autoimmune disease begin? Importance of the early diagnosis. Orv. Hetil. 148: S25-S30 (2007).
Boehm BO, Bluestone JA. Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev. Diabet. Stud. 1: 156-164 (2004). *
Boehm BO, Manfras B, Rosak C, Schoffling K, Trucco M. Aspartic acid at position 57 of the HLA-DQ beta chain is protective against future development of insulin-dependent (type 1) diabetes mellitus. Klin. Wochenschr. 69: 146-150 (1991).
Boehm BO, Manfras B, Seidl S, Holzberger G, Kuhnl P, Rosak C, Schoffling K, Trucco M. The HLA-DQ beta non-Asp-57 allele: a predictor of future insulin-dependent diabetes mellitus in patients with autoimmune Addison's disease. Tissue Antigens 37: 130-132 (1991).
Boehm BO, Rosinger S, Sauer G, Manfras BJ, Palesch D, Schiekofer S, Kalbacher H, Burster T. Protease-resistant human GAD-derived altered peptide ligands decrease TNF-alpha and IL-17 production in peripheral blood cells from patients with type 1 diabetes mellitus. Mol. Immunol. 46: 2576-2584 (2009). *
Boehm BO, Seissler J, Gluck M, Manfras BJ, Thomas H, Schmidt K, Rudert WA, Usadel KH, Trucco M, Scherbaum WA. The level and the persistence of islet cell antibodies in healthy schoolchildren are associated with polymorphic residues of the HLA-DQ beta chain. Dis. Markers 9: 273-280 (1991).
Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences. G. Ital. Dermatol. Venereol. 143: 307-313 (2008).
Boehncke WH, Boehncke S. Managing comorbidities in psoriasis. Actas. Dermosifiliogr. 100: S22-S27 (2009).
Boehncke WH, Boehncke S. Research in practice: the systemic aspects of psoriasis. J. Dtsch. Dermatol. Ges. 6: 622-625 (2008).
Boehncke WH, Boehncke S. Research in practice: the systemic aspects of psoriasis. J. Dtsch. Dermatol. Ges. Jun 16 [Epub ahead of print] (2008).
Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt. 60: 116-121 (2009).
Boesgaard TW, Zilinskaite J, Vanttinen M, Laakso M, Jansson PA, Hammarstedt A, Smith U, Stefan N, Fritsche A, H�ring H, Hribal M, Sesti G, Zobel DP, Pedersen O, Hansen T; for the EUGENE 2 Consortium. The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients-the EUGENE2 study. Diabetologia 51: 816-820 (2008). *
Boger CA, Stubanus M, Haak T, Gotz AK, Christ J, Hoffmann U, Riegger GA, Kramer BK. Effect of MTHFR C677T genotype on survival in type 2 diabetes patients with end-stage diabetic nephropathy. Nephrol. Dial. Transplant. 22: 154-162 (2007).
Bogoyevitch MA. The isoform-specific functions of the c-Jun N-terminal kinases (JNKs): differences revealed by gene targeting. Bioessays 28: 923-934 (2006). *
Bohme J, Carlsson B, Wallin J, Moller E, Persson B, Peterson PA, Rask L. Only one DQ-beta restriction fragment pattern of each DR specificity is associated with insulin-dependent diabetes. J. Immunol. 137: 941-947 (1986).
Bohmer AE, Souza DG, Hansel G, Brum LM, Portela LV, Souza DO. Long-term cyclosporine treatment in non transplanted rats and metabolic risk factors of vascular diseases. Chem. Biol. Interact. Feb 23 [Epub ahead of print] (2010).
Bohmova K, Hladikova Z, Cerny M, Flajsmanova K, Vrabelova Z, Skramlikova T, Spalova I, Cerna M, Chudoba D, Pithova P, Stadlerova G, Bartaskova D, Faresjo M, Stechova K. Cord blood cytokine profile detection in neonates with T1D parents - monitoring of cellular auto-reactivity using protein microarray. Scand. J. Immunol. 66: 563-571 (2007). *
Bohren KM, Gabbay KH, Owerbach D. Affinity chromatography of native SUMO proteins using His-tagged recombinant UBC9 bound to Co(2+)-charged talon resin. Protein Expr. Purif. 54: 289-294 (2007). *
Bohren KM, Nadkarni V, Song JH, Gabbay KH, Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279: 27233-27238 (2004). *
Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. Liver Transpl. 11: 61-67 (2005). *
Boitard C, Debray-Sachs M, Bach JF. Autoimmune disorders in diabetes. Adv. Nephrol. Necker Hosp. 15: 281-305 (1986).
Boj SF, Servitja JM, Martin D, Rios M, Talianidis I, Guigo R, Ferrer J. Functional targets of the monogenic diabetes transcription factors HNF-1alpha and HNF-4alpha are highly conserved between mice and humans. Diabetes 58: 1245-1253 (2009).
Bollyky PL, Bice JB, Sweet IR, Falk BA, Gebe JA, Clark AE, Gersuk VH, Aderem A, Hawn TR, Nepom GT. The Toll-like receptor signaling molecule Myd88 contributes to pancreatic beta-cell homeostasis in response to injury. PLoS ONE 4: e5063 (2009). *
Bolotin E, Liao H, Ta TC, Yang C, Hwang-Verslues W, Evans JR, Jiang T, Sladek FM. Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology 51: 642-653 (2010). *
Bongardt F, Schopfer-Wendels A, Huth C, Heid I, Rathmann W, Martin S, Vollmert C, Holle R, Thorand B, Wichmann HE, Koenig W, Kolb H, Herder C. Genetics of type 2 diabetes: impact of interleukin-6 gene variants. Gesundheitswesen 67 Suppl. 1: 122-126 (2005).
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44: 126-129 (2005). *
Bongiorno MR, Pistone G, de Giorgi V, Arico M. Clinical and immunohistochemical evaluation of the vulvar Langerhans cell histiocytosis. Dermatol. Ther. 21 Suppl. 3: S15-S20 (2008).
Bonifacio E, Achenbach P, Pan L, Ziegler AG. Mucosal insulin vaccination for type 1 diabetes prevention. Exp. Clin. Endocrinol. Diabetes 116 Suppl. 1: S26-S29 (2008).
Bonifacio E, Ziegler A, Achenbach P, Barker J, Eisenbarth G. Translating mucosal antigen based prevention of autoimmune diabetes to human. Novartis Found. Symp. 292: 187-199 (2008).
Bonkovsky HL. Hepatic manifestations of systemic disease. Clin. Liver Dis. 6: xiii-xiv (2002). *
Bonnet F, Patel S, Laville M, Balkau B, Favuzzi A, Monti LD, Lalic N, Walker M; on behalf of the EGIR-RISC Study group. Influence of the ACE gene I/D polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. Diabetes Care 31: 789-794 (2008). *
Bonnycastle LL, Willer CJ, Conneely KN, Jackson AU, Burrill CP, Watanabe RM, Chines PS, Narisu N, Scott LJ, Enloe ST, Swift AJ, Duren WL, Stringham HM, Erdos MR, Riebow NL, Buchanan TA, Valle TT, Tuomilehto J, Bergman RN, Mohlke KL, Boehnke M, Collins FS. Common variants in maturity-onset diabetes of the young genes contribute to risk of type 2 diabetes in Finns. Diabetes 55: 2534-2540 (2006). *
Bonora E. Protection of pancreatic beta-cells: is it feasible? Nutr. Metab. Cardiovasc. Dis. 18: 74-83 (2007).
Bookstaver PB, Norris L, Rudisill C, Dewitt T, Aziz S, Fant J. Multiple toxic effects of low-dose methotrexate in a patient treated for psoriasis. Am. J. Health Syst. Pharm. 65: 2117-2121 (2008). *
Boom A, Lybaert P, Pollet JF, Jacobs P, Jijakli H, Golstein PE, Sener A, Malaisse WJ, Beauwens R. Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas. Endocrine 32: 197-205 (2007).
Boomgaarden I, Bosy-Westphal A, Muller MJ, Doring F. Influence of a type 2 diabetes associated prostaglandin E synthase 2 polymorphism on blood prostaglandin E2 levels. Prostaglandins Leukot. Essent. Fatty Acids 80: 185-188 (2009). *
Boraska V, Skrabic V, Culic VC, Becic K, Kapitanovic S, Zemunik T. Association of TNF promoter polymorphisms with type 1 diabetes in the South Croatian population. Biol. Res. 41: 157-163 (2008). *
Boraska V, Skrabic V, Zeggini E, Groves CJ, Buljubalic M, Peruzovic M, Zemunik T. Family-based analysis of vitamin D receptor gene polymorphisms and type 1 diabetes in the population of South Croatia. J. Hum. Genet. 53: 210-214 (2008). *
Boraska V, Terzic J, Skrabic V, Cacev T, Bucevic-Popovic V, Peruzovic M, Markotic A, Zemunik T. NeuroD1 gene and interleukin-18 gene polymorphisms in type 1 diabetes in Dalmatian population of Southern Croatia. Croat. Med. J. 47: 571-578 (2006). *
Boraska V, Torlak V, Skrabic V, Kacic Z, Jaksic J, Stipancic G, Spehar A, Markotic A, Zemunik T. Glycosyltransferase B4GALNT1 and type 1 diabetes in Croatian population. Clin. Biochem. 42: 819-822 (2009). *
Boraska V, Zeggini E, Groves CJ, Rayner NW, Skrabic V, Diakite M, Rockett KA, Kwiatkowski D, McCarthy MI, Zemunik T. Family-based analysis of tumor necrosis factor and lymphotoxin-alpha tag polymorphisms with type 1 diabetes in the population of South Croatia. Hum. Immunol. 70: 195-199 (2009).
Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. J. Autoimmun. Dec 21 [Epub ahead of print] (2009).
Borchers AT, Uibo R, Gershwin ME. The geoepidemiology of type 1 diabetes. Autoimmun. Rev. Dec 4 [Epub ahead of print] (2009).
Borel V, Gallot D, Marceau G, Sapin V, Blanchon L. Placental implications of peroxisome proliferator-activated receptors in gestation and parturition. PPAR Res. 2008: 758562 (2008). *
Borgaonkar MR, Morgan DG. Primary biliary cirrhosis and type II autoimmune polyglandular syndrome. Can. J. Gastroenterol. 13: 767-770 (1999). *
Boris M, Kaiser C, Golblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J. Neuroinflammation 4: 3 (2007). *
Borlak J, Niehof M. HNF4alpha and HNF1alpha dysfunction as a molecular rational for cyclosporine induced posttransplantation diabetes mellitus. PLoS One 4: e4662 (2009). *
Bornstein SR, Schumann RR, Rettori V, McCann SM, Zacharowski K. Toll-like receptor 2 and Toll-like receptor 4 expression in human adrenals. Horm. Metab. Res. 36: 470-473 (2004).
Bortell R, Pino SC, Greiner DL, Zipris D, Rossini AA. Closing the circle between the bedside and the bench: Toll-like receptors in models of virally induced diabetes. Ann. N. Y. Acad. Sci. 1150: 112-122 (2008). *
Boscolo S, Sarich A, Lorenzon A, Passoni M, Rui V, Stebel M, Sblattero D, Marzari R, Hadjivassiliou M, Tongiorgi E. Gluten ataxia: passive transfer in a mouse model. Ann. N. Y. Acad. Sci. 1107: 319-328 (2007). *
Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49: 2824-2827 (2006). *
Bosnjak AP, Grguric J. Long-term health effects of breastfeeding. Lijec. Vjesn. 129: 293-298 (2007).
Botella Romero F, Alfaro Martinez JJ. Nutritional repercussions and management of chronic pancreatitis. Nutr. Hosp. 23 Suppl. 2: 59-63 (2008).
Botes L, van der Westhuizen FH, Loots du T. Phytochemical contents and antioxidant capacities of two Aloe greatheadii var. davyana extracts. Molecules 13: 2169-2180 (2008).
Botta S, Roveto S, Rimoldi D. Seric 21-hydroxilase antibodies in patients with anti-microsomal fraction antibodies. Autoimmune polyendocrine syndrome. Medicina (B. Aires) 67: 143-146 (2007).
Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellecchia M, Eisenbarth GS, Comings D, Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36: 337-338 (2004). *
Bottini N, Vang T, Cucca F, Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18: 207-213 (2006). *
Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. U.S.A. 104: 20878-20883 (2007). *
Bouillon R, Carmeliet G, Verlinden L, van Etten E, Verstuyf A, Luderer HF, Lieben L, Mathieu C, Demay M. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29: 726-776 (2008). *
Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford) 46: 178-179 (2007). *
Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J, Comas D. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 4: 132-137 (2003). *
Bour-Jordan H, Bluestone JA. B cell depletion: a novel therapy for autoimmune diabetes? J. Clin. Invest. 117: 3642-3645 (2007). *
Bour-Jordan H, Bluestone JA. How suppressor cells led to anergy, costimulation, and beyond. J. Immunol. 183: 4147-4149 (2009).
Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229: 41-66 (2009). *
Bour-Jordan H, Bluestone JA. Sensory neurons link the nervous system and autoimmune diabetes. Cell 127: 1097-1099 (2006). *
Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat. Immunol. 4: 182-188 (2003). *
Bour-Jordan H, Salomon BL, Thompson HL, Santos R, Abbas AK, Bluestone JA. Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J. Immunol. 179: 1004-1012 (2007). *
Bour-Jordan H, Thompson HL, Bluestone JA. Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice. J. Immunol. 175: 5649-5655 (2005). *
Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 2: macronutrients. J. Nutr. Health Aging 10: 386-399 (2006).
Bourre JM. Dietary omega-3 fatty acids for women. Biomed. Pharmacother. 61: 105-112 (2007).
Bouwhuis MG, Gast A, Figl A, Eggermont AM, Hemminki K, Schadendorf D, Kumar R. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? Cancer Immunol. Immunother. Aug 12 [Epub ahead of print] (2009). *
Bouwman JJ, Visseren FL, Bouter KP, Diepersloot RJ. Infection-induced inflammatory response of adipocytes in vitro. Int. J. Obes. (Lond.) 32: 892-901 (2008). *
Bouwman LH, Eerligh P, Terpstra OT, Daha MR, de Knijff P, Ballieux BE, Bruining GJ, van der Slik AR, Roos A, Roep BO. Elevated levels of mannose-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes 54: 3002-3006 (2005). *
Bouwman LH, Ling Z, Duinkerken G, Pipeleers DG, Roep BO. HLA incompatibility and immunogenicity of human pancreatic islet preparations cocultured with blood cells of healthy donors. Hum. Immunol. 66: 494-500 (2005).
Bouzakri K, Ribaux P, Halban PA. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta-cells from TNF-alpha induced decrease of IRS2 and inhibition of glucose-stimulated insulin secretion. J. Biol. Chem. 284: 27892-27898 (2009). *
Bouzat P, Broux C, Soriano E, Pavese P, Croize J, Stahl JP, Jacquot C. Streptococcus pneumoniae cellulitis in a diabetic patient. Med. Mal. Infect. 37: 290-292 (2007).
Bowden DW, Rudock M, Ziegler J, Lehtinen AB, Xu J, Wagenknecht LE, Herrington D, Rich SS, Freedman BI, Carr JJ, Langefeld CD. Coincident linkage of type 2 diabetes, metabolic syndrome, and measures of cardiovascular disease in a genome scan of the diabetes heart study. Diabetes 55: 1985-1994 (2006). *
Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am. J. Med. 120: S12-S17 (2007). *
Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 28: 51-57 (2007). *
Bozkurt O, de Boer A, Grobbee DE, Kroon AA, Schiffers P, de Leeuw P, Klungel OH. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. J. Renin Angiotensin Aldosterone Syst. 10: 101-108 (2009).
Bozkurt O, Verschuren WM, van Wieren-de Wijer BM, Knol MJ, de Boer A, Grobbee DE, Geerlings MI, Heerdink ER, Klungel OH. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J. Hum. Hypertens. 22: 774-780 (2008).
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, Umpleby AM, Russell-Jones D. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes and normal lipids. Diabet. Med. 26: 532-539 (2009).
Bradbury RA, Shirkhedkar D, Glanville AR, Campbell LV. Prior diabetes mellitus is associated with increased morbidity in cystic fibrosis patients undergoing bilateral lung transplantation: an "orphan" area? Intern. Med. J. 39: 384-388 (2009). *
Bradley R, Oberg EB, Calabrese C, Standish LJ. Algorithm for complementary and alternative medicine practice and research in type 2 diabetes. J. Altern. Complement. Med. 13: 159-176 (2007).
Bradna P. Gout and diabetes. Vnitr. Lek. 52: 488-492 (2006).
Bradshaw EM, Raddassi K, Elyaman W, Orban T, Gottlieb PA, Kent SC, Hafler DA. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J. Immunol. 183: 4432-4439 (2009).
Braga-Neto UM, Marques ET. From functional genomics to functional immunomics: new challenges, old problems, big rewards. PLoS Comput. Biol. 2: e81 (2006). *
Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome. Physiol. Behav. 94: 187-197 (2008). *
Braier J, Chantada G, Rosso D, Bernaldez P, Amaral D, Latella A, Balancini B, Masautis A, Goldberg J. Langerhans cell histiocytosis: retrospective evaluation of 123 patients at a single institution. Pediatr. Hematol. Oncol. 16: 377-385 (1999).
Brand OJ, Lowe CE, Heward JM, Franklyn JA, Cooper JD, Todd JA, Gough SC. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. (Oxf.) 66: 508-512 (2007). *
Brandao LC, Vatta S, Guimaraes R, Segat L, Araujo J, de Lima FJ, Arraes LC, Not T, Crovella S. Rapid genetic screening for major HLA risk haplotypes in patients with type 1 diabetes from North East Brazil. Hum. Immunol. Dec 22 [Epub ahead of print] (2009).
Brandimarte G, Tursi A, Giorgetti GM. Changing trends in clinical form of celiac disease. Which is now the main form of celiac disease in clinical practice? Minerva Gastroenterol. Dietol. 48: 121-130 (2002).
Brant SR. Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease. Gastroenterology 136: 396-399 (2009). *
Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br. J. Dermatol. 159: 1331-1337 (2008). *
Braun J, Arnemann J, Lohrey M, Donner H, Siegmund T, Usadel KH, Badenhoop K. No association between the deltaF508 cystic fibrosis mutation and type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 107: 568-569 (1999).
Braun WE. HLA molecules in autoimmune diseases. Clin. Biochem. 25: 187-191 (1992). *
Brauner H, Elemans M, Lemos S, Broberger C, Holmberg D, Flodstrom-Tullberg M, Karre K, Hoglund P. Distinct phenotype and function of NK cells in the pancreas of nonobese diabetic mice. J. Immunol. Feb 3 [Epub ahead of print] (2010).
Brazionis L, Rowley K, Itsiopoulos C, O'Dea K. Plasma carotenoids and diabetic retinopathy. Br. J. Nutr. 101: 270-277 (2009). *
Brazova J, Sismova K, Vavrova V, Bartosova J, Macek M Jr, Lauschman H, Sediva A. Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin. Immunol. 121: 350-357 (2006). *
Breant B, Gesina E, Blondeau B. Nutrition, glucocorticoids and pancreas development. Horm. Res. 65 Suppl. 3: 98-104 (2006).
Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 53-56 (2006). *
Bregenzer N, Schaffler A, Gelbmann CM, Steinkamp M, Reinshagen M, Scholmerich J, Andus T. Lack of correlation between the vitamin D receptor Fokl start codon polymorphism and bone mineral density in patients with Crohn's disease. Exp. Clin. Endocrinol. Diabetes 114: 1-5 (2006).
Breidert M, Zimmermann TF, Schneider R, Ehninger G, Brabant G. Ghrelin/leptin-imbalance in patients with primary biliary cirrhosis. Exp. Clin. Endocrinol. Diabetes 112: 123-126 (2004).
Brenol CV, Monticielo OA, Xavier RM, Brenol JC. Rheumatoid arthritis and atherosclerosis. Rev. Assoc. Med. Bras. 53: 465-470 (2007).
Brenzovich J, Macey M, Fernando J, Chong HJ, Barnstein B, Mirmonsef P, Morales JK, Kimura A, Cruz TD, Ryan JJ. IgE signaling suppresses FcvarepsilonRIbeta expression. J. Leukoc. Biol. 86: 1351-1358 (2009). *
Bresson D, Togher L, Rodrigo E, Chen Y, Bluestone JA, Herold KC, von Herrath M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116: 1371-1381 (2006). *
Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J. Inorg. Biochem. 100: 927-930 (2006). *
Briani C, Doria A, Ruggero S, Toffanin E, Luca M, Albergoni MP, D'Odorico A, Grassivaro F, Lucchetta M, De Lazzari F, Balzani I, Battistin L, Vernino S. Antibodies to muscle and ganglionic acetylcholine receptors (AchR) in celiac disease. Autoimmunity 41: 100-104 (2008).
Bridoux F, Kyndt X, Abou-Ayache R, Mougenot B, Baillet S, Bauwens M, Lemaitre V, Goujon JM, Touchard G, Vanhille P. Proximal tubular dysfunction in primary Sjogren's syndrome: a clinicopathological study of 2 cases. Clin. Nephrol. 61: 434-439 (2004).
Briede J, Stivrina M, Stoldere D, Vigante B, Duburs G. Effect of cerebrocrast, a new long-acting compound on blood glucose and insulin levels in rats when administered before and after STZ-induced diabetes mellitus. Cell. Biochem. Funct. 25: 673-680 (2007). *
Bright JJ. Curcumin and autoimmune disease. Adv. Exp. Med. Biol. 595: 425-451 (2007).
Brilot F, Geenen V. Role of viral infections in the pathogenesis of type 1 diabetes. Rev. Med. Liege. 60: 297-302 (2005).
Brims DR, Qian J, Jarchum I, Mikesh L, Palmieri E, Ramagopal UA, Malashkevich VN, Chaparro RJ, Lund T, Hattori M, Shabanowitz J, Hunt DF, Nathenson SG, Almo SC, Dilorenzo TP. Predominant occupation of the class I MHC molecule H-2Kwm7 with a single self-peptide suggests a mechanism for its diabetes-protective effect. Int. Immunol. Jan 21 [Epub ahead of print] (2010).
Brinar VV, Petelin Z, Brinar M, Djakovic V, Zadro I, Vranjes D. CNS demyelination in autoimmune diseases. Clin. Neurol. Neurosurg. 108: 318-326 (2006).
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213 (2003).
Briscoe CP, Looper D, Tran P, Herrera J, McDonnell SR, Bhat BG. LPS-induced biomarkers in mice: a potential model for identifying insulin sensitizers. Biochem. Biophys. Res. Commun. 361: 140-145 (2007). *
Brittan M, Alison MR, Schier S, Wright NA. Bone marrow stem cell-mediated regeneration in IBD: where do we go from here? Gastroenterology 132: 1171-1173 (2007). *
Britten AC, Mijovic CH, Barnett AH, Kelly MA. Differential expression of HLA-DQ alleles in peripheral blood mononuclear cells: alleles associated with susceptibility to and protection from autoimmune type 1 diabetes. Int. J. Immunogenet. 36: 47-57 (2009). *
Britto MT, Jimison HB, Munafo JK, Wissman J, Rogers ML, Hersh W. Usability testing finds new problems for novice users of pediatric portals. J. Am. Med. Inform. Assoc. 16: 660-669 (2009).
Broady R, Levings MK. Graft-versus-host disease: suppression by statins. Nat. Med. 14: 1155-1156 (2008). *
Brock JW, Jenkins AJ, Lyons TJ, Klein RL, Yim E, Lopes-Virella M, Carter RE, Thorpe SR, Baynes JW. Increased methionine sulfoxide content of ApoAI in type 1 diabetes. J. Lipid Res. 49: 847-855 (2008). *
Brod SA, Hood Z. Ingested (oral) SIRS peptide 1-21 suppresses type 1 diabetes in NOD mice. J. Interferon Cytokine Res. 28: 25-30 (2008).
Brode S, Raine T, Zaccone P, Cooke A. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177: 6603-6612 (2006). *
Brody F, Hill S, Celenski S, Kar R, Kluk B, Pinzone J, Fu S. Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients. Surg. Endosc. 21: 941-944 (2007). *
Bromberg JS, LeRoith D. Diabetes cure - is the glass half full? N. Engl. J. Med. 355: 1372-1374 (2006). *
Bronson PG, Ramsay PP, Thomson G, Barcellos LF; Diabetes Genetics Consortium. Analysis of maternal-offspring HLA compatibility, parent-of-origin and non-inherited maternal effects for the classical HLA loci in type 1 diabetes. Diabetes Obes. Metab. 11 Suppl. 1: 74-83 (2009). *
Brooks-Worrell B, Warsen A, Palmer JP. Improved T cell assay for identification of type 1 diabetes patients. J. Immunol. Methods 344: 79-83 (2009).
Brophy S, Davies H, Bain S, Stephens JW, Cheung WY, Richards K, Wareham K, Beaverstock C, Lloyd J, Page D, Williams M, Russell I, Williams R. Randomized, controlled, parallel-group prospective study to investigate the clinical effectiveness of early insulin treatment in patients with latent autoimmune diabetes in adults. BMC Endocr. Disord. 8: 8 (2008). *
Brophy S, Yderstr�de K, Mauricio D, Hunter S, Hawa M, Pozzilli P, Schernthaner G, Schloot N, Buzzetti R, Davies H, Leslie R, Williams DR; on behalf of the Action LADA Group. Time to insulin initiation can not be used in defining latent autoimmune diabetes in adults. Diabetes Care 31: 439-441 (2008). *
Brorsson C, Hansen NT, Lage K, Bergholdt R, Brunak S, Pociot F; Diabetes Genetics Consortium. Identification of T1D susceptibility genes within the MHC region by combining protein interaction networks and SNP genotyping data. Diabetes Obes. Metab. 11 Suppl. 1: 60-66 (2009). *
Brosi H, Reiser M, Rajasalu T, Spyrantis A, Oswald F, Boehm BO, Schirmbeck R. Processing in the endoplasmic reticulum generates an epitope on the insulin A chain that stimulates diabetogenic CD8 T cell responses. J. Immunol. 183: 7187-7195 (2009).
Brousseau ME. Statins, super-statins and cholesterol absorption inhibitors. IDrugs 6: 458-463 (2003).
Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515 (2004). *
Brown EM. Anti-parathyroid and anti-calcium sensing receptor antibodies in autoimmune hypoparathyroidism. Endocrinol. Metab. Clin. North Am. 38: 437-445 (2009).
Brown J, Onyango D, Ramanjaneya M, Conner A, Patel S, Dunmore S, Randeva H. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes related genes in mouse pancreatic beta-cells. J. Mol. Endocrinol. Nov 11 [Epub ahead of print] (2009). *
Brown JE, Conner AC, Digby JE, Ward KL, Ramanjaneya M, Randeva HS, Dunmore SJ. Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides Feb 12 [Epub ahead of print] (2010). *
Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res. Ther. 10: 212 (2008). *
Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48: 1415-1424 (1999). *
Brown LC, Majumdar SR, Newman SC, Johnson JA. Type 2 diabetes does not increase risk of depression. CMAJ 175: 42-46 (2006). *
Brown RJ, Rother KI, Artman H, Mercurio MG, Wang R, Looney RJ, Cowen EW. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch. Dermatol. 145: 63-66 (2009). *
Brown WM. Anti-CD3 antibody MacroGenics Inc. Curr. Opin. Investig. Drugs 7: 381-388 (2006).
Brown WM, Pierce J, Hilner JE, Perdue LH, Lohman K, Li L, Venkatesh RB, Hunt S, Mychaleckyj JC, Deloukas P; Diabetes Genetics Consortium. Overview of the MHC fine mapping data. Diabetes Obes. Metab. 11 Suppl. 1: 2-7 (2009). *
Brown WM, Pierce JJ, Hilner JE, Perdue LH, Lohman K, Lu L, de Bakker PI, Irenze K, Ziaugra L, Mirel DB. Overview of the Rapid Response data. Genes Immun. 10: S5-S15 (2009).
Brown WV. Expert commentary: the safety of fibrates in lipid-lowering therapy. Am. J. Cardiol. 99: S19-S21 (2007). *
Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol. 99: 292-298 (2004). *
Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes. Metab. 9: 70-80 (2007). *
Browning SR, Briley JD, Briley LP, Chandra G, Charnecki JH, Ehm MG, Johansson KA, Jones BJ, Karter AJ, Yarnall DP, Wagner MJ. Case-control single-marker and haplotypic association analysis of pedigree data. Genet. Epidemiol. 28: 110-122 (2005). *
Bruck P, Bartsch W, Penna-Martinez M, Kahles H, Seidl C, Bohme A, Badenhoop K, Ramos-Lopez E. Polymorphisms of CXCR3-binding chemokines in type 1 diabetes. Hum. Immunol. 70: 552-555 (2009).
Bruck P, Ramos-Lopez E, Bartsch W, Bohme A, Badenhoop K. TIM-3 polymorphisms in type 1 diabetes families. J. Hum. Genet. 53: 559-564 (2008). *
Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y, von Boehmer H, Mahnke K, Buer J. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 54: 3395-3401 (2005). *
Brugman S, Visser JT, Hillebrands JL, Bos NA, Rozing J. Prolonged exclusive breastfeeding reduces autoimmune diabetes incidence and increases regulatory T-cell frequency in bio-breeding diabetes-prone rats. Diabetes Metab. Res. Rev. 25: 380-387 (2009).
Brumeanu TD, Bona CA, Casares S. T-cell tolerance and autoimmune diabetes. Int. Rev. Immunol. 20: 301-331 (2001).
Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin. Immunol. 119: 1-12 (2006). *
Brun T, Gauthier BR. A focus on the role of Pax4 in mature pancreatic islet beta-cell expansion and survival in health and disease. J. Mol. Endocrinol. 40: 37-45 (2008). *
Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, Marsh BJ, Rodrigues B, Johnson JD, Parks JS, Verchere CB, Hayden MR. beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat. Med. 13: 340-347 (2007). *
Brunner W. Pruritus - also a challenge in internal medicine. Schweiz. Med. Wochenschr. 125: 2244-2250 (1995).
Bruno S, Cattaneo D, Perico N, Remuzzi G. Emerging drugs for diabetic nephropathy. Expert Opin. Emerg. Drugs 10: 747-771 (2005).
Brunt EM. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24: 3-20 (2004).
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94: 2467-2474 (1999). *
Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research Network. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 809-820 (2009). *
Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 16: 49-56 (2003). *
Brusko T, Wasserfall C, McGrail K, Schatz R, Viener HL, Schatz D, Haller M, Rockell J, Gottlieb P, Clare-Salzler M, Atkinson M. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612 (2007). *
Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Rev. 223: 371-390 (2008). *
Bryan J, Munoz A, Zhang X, Dufer M, Drews G, Krippeit-Drews P, Aguilar-Bryan L. ABCC8 and ABCC9: ABC transporters that regulate K(+) channels. Pflugers Arch. 453: 703-718 (2007). *
Buc M, Bucova M, Javor J, Krivosikova M, Stuchlikova M, Shawkatova I, Michalkova D, Barak L, Jancova E, Petrek M. Associations between HLA class II alleles and type 1 diabetes mellitus in the Slovak population. Endocr. Regul. 40: 1-6 (2006). *
Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. Drug News Perspect. 18: 417-426 (2005).
Bucan K, Ivanisevic M, Zemunik T, Boraska V, Skrabic V, Vatavuk Z, Galetovic D, Znaor L. Retinopathy and nephropathy in type 1 diabetic patients - association with polymorphysms of vitamin D-receptor, TNF, neuro-D and IL-1 receptor 1 genes. Coll. Antropol. 33 Suppl. 2: 99-105 (2009).
Buchwald P, Margolles-Clark E, Kenyon NS, Ricordi C. Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction. J. Mol. Recognit. 23: 65-73 (2010). *
Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170 (2005).
Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing "D"ecline? Mol. Aspects Med. 29: 415-422 (2008).
Buettner C, Phillips RS, Davis RB, Gardiner P, Mittleman MA. Use of dietary supplements among United States adults with coronary artery disease and atherosclerotic risks. Am. J. Cardiol. 99: 661-666 (2007). *
Bugawan TL, Klitz W, Alejandrino M, Ching J, Panelo A, Solfelix CM, Petrone A, Buzzetti R, Pozzilli P, Erlich HA. The association of specific HLA class I and II alleles with type 1 diabetes among Filipinos. Tissue Antigens 59: 452-469 (2002). *
Bugawan TL, Mirel DB, Valdes AM, Panelo A, Pozzilli P, Erlich HA. Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am. J. Hum. Genet. 72: 1505-1514 (2003). *
Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis.11: 191-207 (2007).
Buhler MM, Craig M, Donaghue KC, Badhwar P, Willis J, Manolios N, Tait BD, Silink M, Bennetts BH, Stewart GJ. CCR5 genotyping in an Australian and New Zealand type 1 diabetes cohort. Autoimmunity 35: 457-461 (2002).
Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garcia-Urkia N, Sarasqueta C, Cosme A, Irastorza B, Gonzalez A, Arenas J Jr. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 8: 40 (2008). *
Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway. Am. J. Physiol. Heart Circ. Physiol. 296: H719-H727 (2009). *
Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch. Pathol. Lab. Med. 127: 1121-1123 (2003). *
Buraczynska M, Baranowicz-Gaszczyk I, Borowicz E, Ksiazek A. TGF-beta1 and TSC-22 gene polymorphisms and susceptibility to microvascular complications in type 2 diabetes. Nephron. Physiol. 106: 69-75 (2007).
Buraczynska M, Baranowicz-Gaszczyk I, Tarach J, Ksiazek A. Toll-like receptor 4 gene polymorphism and early onset of diabetic retinopathy in patients with type 2 diabetes. Hum. Immunol. 70: 121-124 (2009).
Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol. Dial. Transplant. 22: 827-832 (2007). *
Buraczynska M, Swatowski A, Buraczynska K, Dragan M, Ksiazek A. Heat-shock protein gene polymorphisms and the risk of nephropathy in type 2 diabetes patients. Clin. Sci. (Lond.) 116: 81-86 (2009). *
Burch LR, Donnelly LA, Doney AS, Brady J, Tommasi AM, Whitley AL, Goddard C, Morris AD, Hansen MK, Palmer CN. Peroxisome proliferator-sctivated receptor-delta genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: a genetics of diabetes audit and research Tayside study. J. Clin. Endocrinol. Metab. Mar 3 [Epub ahead of print] (2010). *
Burch LR, Zhou K, Donnelly LA, Doney AS, Brady J, Goddard C, Morris AD, Hansen MK, Palmer CN. A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children. J. Clin. Endocrinol. Metab. 94: 2587-2593 (2009). *
Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Marki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1 alpha (PGC1alpha), prevents triglyceride accumulation and potentiates insulin signaling in vitro. Mol. Endocrinol. 20: 809-830 (2006). *
Burguete-Garcia AI, Cruz-Lopez M, Madrid-Marina V, Lopez-Ridaura R, Hernandez-Avila M, Cortina B, Gomez RE, Velasco-Mondragon E. Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a candidate gene study. Metabolism 59: 38-45 (2010). *
Buriak VN, Shaban NI. Clinical and pathogenetic mechanisms of the formation of complicated course of I type diabetes mellitus in children. Lik. Sprava. 3: 24-29 (2007).
Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am. J. Transplant. 4: 686-693 (2004). *
Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ. Res. 102: 164-176 (2008). *
Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771: 952-960 (2007). *
Burster T, Marin-Esteban V, Boehm BO, Dunn S, Rotzschke O, Falk K, Weber E, Verhelst SH, Kalbacher H, Driessen C. Design of protease-resistant myelin basic protein-derived peptides by cleavage site directed amino acid substitutions. Biochem. Pharmacol. 74: 1514-1523 (2007). *
Burt RA, Watkins L, Tan IK, Wang N, Quirk F, Mackin L, Morgan P, Zhang JG, Berzins SP, Morahan G, Brodnicki TC. An NZW-derived interval on chromosome 7 moderates sialadenitis, but not insulitis in congenic nonobese diabetic mice. J. Immunol. 184: 859-868 (2010).
Burtea C, Laurent S, Lancelot E, Ballet S, Murariu O, Rousseaux O, Port M, Elst LV, Corot C, Muller RN. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol. Pharm. 6: 1903-1919 (2009). *
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin. Ther. 27: 1181-1195 (2005). *
Bussone G, Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmun. Rev. 8: 332-336 (2009).
Butler MG, Hodes ME, Conneally PM, Biegel AA, Wright JC. Linkage analysis in a large kindred with autosomal dominant transmission of polyglandular autoimmune disease type II (Schmidt syndrome). Am. J. Med. Genet. 18: 61-65 (1984).
Butt C, Peddle L, Greenwood C, Hamilton S, Gladman D, Rahman P. Association of functional variants of PTPN22 and tp53 in psoriatic arthritis: a case-control study. Arthritis Res. Ther. 8: R27-R30 (2006). *
Butt MS, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS. Oat: unique among the cereals. Eur. J. Nutr. 47: 68-79 (2008). *
Butty V, Campbell C, Mathis D, Benoist C; the Diabetes Prevention Trial-Type 1 Study Group. Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1). Diabetes 57: 2348-2359 (2008). *
Butty V, Roy M, Sabeti P, Besse W, Benoist C, Mathis D. Signatures of strong population differentiation shape extended haplotypes across the human CD28, CTLA4, and ICOS costimulatory genes. Proc. Natl. Acad. Sci. U.S.A. 104: 570-575 (2007). *
Buyse I, Sandkuyl LA, Zamani Ghabanbasani M, Gu XX, Bouillon R, Bex M, Dooms L, Emonds MP, Duhamel M, Marynen P, et al. Association of particular HLA class II alleles, haplotypes and genotypes with susceptibility to IDDM in the Belgian population. Diabetologia 37: 808-817 (1994).
Buysschaert M, Tomasi JP, Hermans MP. Prospective screening for biopsy proven coeliac disease, autoimmunity and malabsorption markers in Belgian subjects with type 1 diabetes. Diabet. Med. 22: 889-892 (2005). *
Buzi F, Badolato R, Mazza C, Giliani S, Notarangelo LD, Radetti G, Plebani A, Notarangelo LD. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria? J. Clin. Endocrinol. Metab. 88: 3146-3148 (2003). *
Buzzetti R, Petrone A, Capizzi M, Bosi E; for the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes: response to Kobayashi et al. Diabetes Care 30: e127 (2007).
Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Mario UD. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur. J. Hum. Genet. 12: 1050-1054 (2004). *
Cabral VL, Patr�cio FR, Gabbay MA, Dib SA, Miszputen SJ. Intraepithelial lymphocytes in duodenum from Brazilian adolescents with type 1 diabetes. Influence of Helicobacter pylori. Pediatr. Diabetes 10: 316-320 (2009). *
Cabrera R, Nelson DR. Review article: management of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31: 461-476 (2010). *
Cabrera-Rode E, Sarmiento L, Molina G, Perez C, Arranz C, Galvan JA, Prieto M, Barrios J, Palomera R, Fonseca M, Mas P, Diaz-Diaz O, Diaz-Horta O. Islet cell related antibodies and type 1 diabetes associated with echovirus 30 epidemic: a case report. J. Med. Virol. 76: 373-377 (2005). *
Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC, Vazquez M. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes. Diabetes 50: 1883-1890 (2001). *
Cadahia V, Rodrigo L, Fuentes D, Riestra S, De Francisco R, Fernandez M. Celiac disease (CD), ulcerative colitis (UC), and primary sclerosing cholangitis (PSC) in one patient: a family study. Rev. Esp. Enferm. Dig. 97: 907-913 (2005). *
Cadden IS, Partovi N, Yoshida EM. Review article: possible beneficial effects of coffee on liver disease and function. Aliment. Pharmacol. Ther. 26: 1-8 (2007). *
Caffrey C, Hitman GA, Niven MJ, Cassell PG, Kumar P, Fry L, Mackintosh P, Gallagher R, Feighery C, Weir D, et al. HLA-DP and coeliac disease: family and population studies. Gut 31: 663-667 (1990). *
Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, Rosenkranz S, Erdmann E, Peterson LE, Ross RS, Tangirala RK, Hsueh WA. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Diabetes 57: 2470-2479 (2008). *
Cai C, Hahn BH, Matarese G, La Cava A. Leptin in non-autoimmune inflammation. Inflamm. Allergy Drug Targets 8: 285-291 (2009).
Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11: 183-190 (2005). *
Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic. Biol. Med. 41: 851-861 (2006).
Caicedo RA, Li N, DES Robert C, Scumpia PO, Hubsher CP, Wasserfall CH, Schatz DA, Atkinson MA, Neu J. Neonatal formula feeding leads to immunological alterations in an animal model of type 1 diabetes. Pediatr. Res. 63: 303-307 (2008). *
Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens 73: 1-8 (2009). *
Caillat-Zucman S, Daniel S, Djilali-Saiah I, Timsit J, Garchon HJ, Boitard C, Bach JF. Family study of linkage disequilibrium between TAP2 transporter and HLA class II genes. Absence of TAP2 contribution to association with insulin-dependent diabetes mellitus. Hum. Immunol. 44: 80-87 (1995).
Cakir M, Akcay S, Karakas T, Gedik Y, Okten A, Orhan F. Prevalence of atopy in children with type 1 diabetes mellitus, hepatitis B virus carriers, and healthy children: role of T helper 1 (Th1)-type immune response. Allergy Asthma Proc. 29: 166-170 (2008).
Calcinaro F, Dionisi S, Marinaro M, Candeloro P, Bonato V, Marzotti S, Corneli RB, Ferretti E, Gulino A, Grasso F, De Simone C, Di Mario U, Falorni A, Boirivant M, Dotta F. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48: 1565-1575 (2005). *
Calderon B, Suri A, Miller MJ, Unanue ER. Dendritic cells in islets of Langerhans constitutively present beta cell-derived peptides bound to their class II MHC molecules. Proc. Natl. Acad. Sci. U.S.A. 105: 6121-6126 (2008). *
Calderon B, Suri A, Pan XO, Mills JC, Unanue ER. IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J. Immunol. 181: 6964-6974 (2008). *
Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S97-S103 (2004). *
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 519-525 (2001). *
Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29: 664-669 (1999). *
Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol. Dial. Transplant. 21: 2399-2405 (2006). *
Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, Tikellis C. PPARs and diabetes-associated atherosclerosis. Curr. Pharm. Des. 13: 2736-2741 (2007).
Calkin AC, Thomas MC. PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008: 245410 (2008). *
Calsolari MR, Rosario PW, Reis JS, Silva SC, Purisch S. Latent autoimmune diabetes of adult or slim type 2 diabetes mellitus? Arq. Bras. Endocrinol. Metabol. 52: 315-321 (2008).
Calverley DC, Baldermann LV, Moran K, Chen NN, McFann K. Platelet FcgammaRIIA expression is associated with the alpha(2) integrin C807T gene polymorphism in type 2 diabetes. Platelets 17: 78-83 (2006).
Calvisi DF, Evert M, Dombrowski F. Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats. Arch. Physiol. Biochem. 115: 97-104 (2009). *
Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. J. Nutr. 135: 310-316 (2005). *
Calzascia T, Pellegrini M, Lin A, Garza KM, Elford AR, Shahinian A, Ohashi PS, Mak TW. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 105: 2999-3004 (2008). *
Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat. Rev. Immunol. 7: 633-643 (2007). *
Cambon-Thomsen A, Roth MP. Genetics of autoimmune diseases. Rev. Prat. 44: 43-52 (1994).
Cameron EA, Martinez-Marignac VL, Chan A, Valladares A, Simmonds LV, Wacher N, Kumate J, McKeigue P, Shriver MD, Kittles R, Cruz M, Parra EJ. MGEA5-14 polymorphism and type 2 diabetes in Mexico City. Am. J. Hum. Biol. 19: 593-596 (2007).
Cameron NE, Cotter MA. The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes. Exp. Neurol. 207: 23-29 (2007).
Campbell AK, Waud JP, Matthews SB. The molecular basis of lactose intolerance. Sci. Prog. 88: 157-202 (2005).
Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 52: 77-92 (2006). *
Campbell MS, Kotlyar DS, Brensinger CM, Lewis JD, Shetty K, Bloom RD, Markmann JF, Olthoff KM, Shaked A, Reddy KR. Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl. 11: 1048-1055 (2005). *
Campbell PD, Estella E, Dudek NL, Jhala G, Thomas HE, Kay TW, Mannering SI. Cytotoxic T-lymphocyte-mediated killing of human pancreatic islet cells in vitro. Hum. Immunol. 69: 543-551 (2008).
Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D, Crawford JM, Atkinson MA. Pancreatic adenocarcinoma patients with localised chronic severe pancreatitis show an increased number of single beta cells, without alterations in fractional insulin area. Diabetologia 52: 262-270 (2009). *
Campese AF, Grazioli P, Colantoni S, Anastasi E, Mecarozzi M, Checquolo S, De Luca G, Bellavia D, Frati L, Gulino A, Screpanti I. Notch3 and pTalpha/pre-TCR sustain the in vivo function of naturally occurring regulatory T cells. Int. Immunol. 21: 727-743 (2009).
Campise M. Post-transplant diabetes mellitus: diagnosis and treatment. G. Ital. Nefrol. 24: 547-557 (2007).
Campos GM, Bambha K, Vittinghoff E, Rabl C, Posselt AM, Ciovica R, Tiwari U, Ferrel L, Pabst M, Bass NM, Merriman RB. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 47: 1916-1923 (2008). *
Canani LH, Capp C, Ng DP, Choo SG, Maia AL, Nabinger GB, Santos K, Crispim D, Roisemberg I, Krolewski AS, Gross JL. The fatty acid-binding protein-2 A54T polymorphism is associated with renal disease in patients with type 2 diabetes. Diabetes 54: 3326-3330 (2005). *
Candeloro P, Voltattorni CB, Perniola R, Bertoldi M, Betterle C, Mannelli M, Giordano R, De Bellis A, Tiberti C, Laureti S, Santeusanio F, Falorni A. Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. J. Clin. Endocrinol. Metab. 92: 1096-1105 (2007). *
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck AM, Lambert DM, Muccioli GG, Delzenne NM. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58: 1091-1103 (2009). *
Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern. Med. Rev. 13: 6-20 (2008). *
Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J. Intern. Med. 263: 353-365 (2008). *
Cannon JL, Collins A, Mody PD, Balachandran D, Henriksen KJ, Smith CE, Tong J, Clay BS, Miller SD, Sperling AI. CD43 regulates Th2 differentiation and inflammation. J. Immunol. 180: 7385-7393 (2008). *
Cannons JL, Chamberlain G, Howson J, Smink LJ, Todd JA, Peterson LB, Wicker LS, Watts TH. Genetic and functional association of the immune signaling molecule 4-1BB (CD137/TNFRSF9) with type 1 diabetes. J. Autoimmun. 25: 13-20 (2005).
Cano DA, Hebrok M, Zenker M. Pancreatic development and disease. Gastroenterology 132: 745-762 (2007). *
Cano DA, Sekine S, Hebrok M. Primary cilia deletion in pancreatic epithelial cells results in cyst formation and pancreatitis. Gastroenterology 131: 1856-1869 (2006). *
Cantor J, Haskins K. Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1. J. Immunol. 179: 5760-5767 (2007). *
Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc. Soc. Exp. Biol. Med. 223: 230-233 (2000). *
Cantorna MT, Mahon BD. D-hormone and the immune system. J. Rheumatol. Suppl. 76: 11-20 (2005). *
Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. (Maywood) 229: 1136-1142 (2004). *
Cao L, Xu X, Cao LL, Wang RH, Coumoul X, Kim SS, Deng CX. Absence of full-length Brca1 sensitizes mice to oxidative stress, and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis 28: 1401-1407 (2007). *
Cap J. Hypothyroidism substitution and adrenal insufficiency in diabetic patients. Vnitr. Lek. 55: 371-374 (2009).
Capeau J. The story of adiponectin and its receptors AdipoR1 and R2: to follow. J. Hepatol. 47: 736-738 (2007).
Capell WH, Eckel RH. Severe hypertriglyceridemia with a history of treatment failure. Nat. Clin. Pract. Endocrinol. Metab. 1: 53-58 (2005). *
Capitani G, De Biase D, Gut H, Ahmed S, Grutter MG. Structural model of human GAD65: prediction and interpretation of biochemical and immunogenic features. Proteins 59: 7-14 (2005). *
Capitano ML, Ertel BR, Repasky EA, Ostberg JR. Winner of the 2007 Society for Thermal Medicine Young Investigator Award. Fever-range whole body hyperthermia prevents the onset of type 1 diabetes in non-obese diabetic mice. Int. J. Hyperthermia 24: 141-149 (2008).
Capittini C, Pasi A, Bergamaschi P, Tinelli C, De Silvestri A, Mercati MP, Badulli C, Garlaschelli F, Sbarsi I, Guarene M, Martinetti M, Salvaneschi L, Cuccia M. HLA haplotypes and birth weight variation: is your future going to be light or heavy? Tissue Antigens 74: 156-163 (2009). *
Capobianco E, Mart�nez N, Higa R, White V, Jawerbaum A. The effects of maternal dietary treatments with natural PPAR ligands on lipid metabolism in fetuses from control and diabetic rats. Prostaglandins Leukot. Essent. Fatty Acids 79: 191-199 (2008). *
Capoluongo E, Pitocco D, Santonocito C, Concolino P, Santini SA, Manto A, Lulli P, Ghirlanda G, Zuppi C, Ameglio F. Association between serum free IGF-I and IGFBP-3 levels in type-I diabetes patients affected with associated autoimmune diseases or diabetic complications. Eur. Cytokine Netw. 17: 167-174 (2006).
Cappello F, Conway de Macario E, Di Felice V, Zummo G, Macario AJ. Chlamydia trachomatis infection and anti-Hsp60 immunity: the two sides of the coin. PLoS Pathog. 5: e1000552 (2009). *
Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, Corleto V, Borgia P, Pederzoli P, Scarpa A, Fave GD. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am. J. Gastroenterol. 104: 3034-3041 (2009). *
Caputo M, Cerrone GE, Lopez AP, Villalba A, Krochik GA, Cedola FN, Targovnik HM, Frechtel GD. Cytotoxic T lymphocyte antigen 4 heterozygous codon 49 A/G dimorphism is associated to latent autoimmune diabetes in adults (LADA). Autoimmunity 38: 277-281 (2005).
Caputo M, Cerrone GE, Mazza C, Cedola N, Targovnik HM, Gustavo DF. No evidence of association of CTLA-4 -318 C/T, 159 C/T, 3' STR and SUMO4 163 AG polymorphism with autoimmune diabetes. Immunol. Invest. 36: 259-270 (2007). *
Carbone J, Sarmiento E, Rodriguez-Molina J, Fernandez-Cruz E. Atypical presentation of common variable immunodeficiency without infections. Allergol. Immunopathol. (Madr.) 32: 218-222 (2004).
Carbone V, Zhao HT, Chung R, Endo S, Hara A, El-Kabbani O. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg. Med. Chem. 17: 1244-1250 (2009). *
Cardell SL. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice. Clin. Exp. Immunol. 143: 194-202 (2006). *
Cardenas A, Kelly CP. Celiac sprue. Semin. Gastrointest. Dis. 13: 232-244 (2002).
Carella AM, Conte M. Therapeutic options for metabolic syndrome in obese patients. Clin. Ter. 158: 457-464 (2007).
Carey AL, Petersen EW, Bruce CR, Southgate RJ, Pilegaard H, Hawley JA, Pedersen BK, Febbraio MA. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 49: 1000-1007 (2006). *
Cariou B. The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis. Diabetes Metab. 34: 685-691 (2008).
Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, Kuipers F, Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 281: 11039-11049 (2006). *
Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr. 16: 1-22 (2006).
Carless M. Investigation of genomic methylation status using methylation-specific and bisulfite sequencing polymerase chain reaction. Methods Mol. Biol. 523: 1-18 (2009).
Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, Hanrahan JW, Thomas DY. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem. 8: 1012-1020 (2007).
Carlsen M, Cilio CM. Normal T cell development in the absence of thymic insulin expression. Ann. N. Y. Acad. Sci. 1079: 205-212 (2006). *
Carlson CS, Eberle MA, Kruglyak L, Nickerson DA. Mapping complex disease loci in whole-genome association studies. Nature 429: 446-452 (2004). *
Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am. Heart J. 150: 859-870 (2005). *
Carmena R, Betteridge DJ. Statins and diabetes. Semin. Vasc. Med. 4: 321-332 (2004).
Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Penicaud L. S 26948, a new specific PPARgamma modulator (SPPARM) with potent antidiabetic and antiatherogenic effects. Diabetes 56: 2797-2808 (2007). *
Carneiro M, Dumont C. Pernicious anemia in an adolescent with type 1 diabetes mellitus. Arch. Pediatr. 16: 357-359 (2009).
Carpenter DO. Polychlorinated biphenyls (PCBs): routes of exposure and effects on human health. Rev. Environ. Health 21: 1-23 (2006).
Carpentier YA, Portois L, Malaisse WJ. n-3 Fatty acids and the metabolic syndrome. Am. J. Clin. Nutr. 83: 1499S-1504S (2006). *
Carpinteri R, Patelli I, Casanueva FF, Giustina A. Inflammatory and granulomatous expansive lesions of the pituitary. Best Pract. Res. Clin. Endocrinol. Metab. 23: 639-650 (2009).
Carpo M, Scarlato M, Bardella M, Terrani C, Peracchi M, Allaria S, Nobile-Orazio E, Bresolin N. Painful sensory neuropathy and dysimmunity: is there a relation? J. Peripher. Nerv. Syst. 9: 121 (2004).
Carr EJ, Clatworthy MR, Lowe CE, Todd JA, Wong A, Vyse TJ, Kamesh L, Watts RA, Lyons PA, Smith KG. Contrasting genetic association of IL2RA with SLE and ANCA - associated vasculitis. BMC Med. Genet. 10: 22 (2009). *
Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, Smith KG. Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med. Genet. 10: 121 (2009). *
Carrier CM, Mollen N, Rothman WC, Rodriguez de Cordoba S, Rey-Campos J, Ginsberg-Fellner F, Carpenter C, Rubinstein P. Definition of IDDM-associated HLA DQ and DX RFLPs by segregation analysis of multiplex sibships. Hum. Immunol. 24: 51-63 (1989).
Carroccio A, Di Prima L, Scalici C, Soresi M, Cefalu AB, Noto D, Averna MR, Montalto G, Iacono G. Unexplained elevated serum pancreatic enzymes: a reason to suspect celiac disease. Clin. Gastroenterol. Hepatol. 4: 455-459 (2006).
Carson KL, Hunt CM. Medical problems occurring after orthotopic liver transplantation. Dig. Dis. Sci. 42: 1666-1674 (1997). *
Carter JD, Chen M, Ellett JD, Smith KM, Nadler JL, Yang Z. Impact of donor immune cells in pancreatic islet transplantation. Transplant. Proc. 36: 2866-2868 (2004). *
Carvajal K, Hernandez-Esquivel Mde L, Moreno-Sanchez R. PPARs, metabolic syndrome and cardiac diseases. Arch. Cardiol. Mex. 77 Suppl. 4: S4-S66-S76 (2007).
Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 27: 246-256 (2007). *
Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism. Int. J. Obes. (Lond.) 32 Suppl. 6: S53-S61 (2008). *
Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries S, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 164: 921-935 (2006). *
Casas L, Berry DR, Logan K, Copeland KC, Royall JA. Cystic fibrosis related diabetes in an extremely young patient. J. Cyst. Fibros. 6: 247-249 (2007).
Cases Amenos A, Goicoechea Diezhandino M, de Alvaro Moreno F. Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment. Nefrologia 28 Suppl. 3: 39-48 (2008).
Casey WM, Brodie T, Yoon L, Ni H, Jordan HL, Cariello NF. Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X. Biomarkers 13: 364-376 (2008).
Cashman KD. Vitamin D in childhood and adolescence. Postgrad. Med. J. 83: 230-235 (2007). *
Casper RC. Nutrients, neurodevelopment, and mood. Curr. Psychiatry Rep. 6: 425-429 (2004).
Cassuto H, Kochan K, Chakravarty K, Cohen H, Blum B, Olswang Y, Hakimi P, Xu C, Massillon D, Hanson RW, Reshef L. Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver via an extended glucocorticoid regulatory unit. J. Biol. Chem. 280: 33873-33884 (2005). *
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).
Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genet. Test. 5: 249-254 (2001).
Castellanos-Rubio A, Martin-Pagola A, Santin I, Hualde I, Aransay AM, Castano L, Vitoria JC, Bilbao JR. Combined functional and positional gene information for the identification of susceptibility variants in celiac disease. Gastroenterology 134: 738-746 (2008). *
Castellanos-Rubio A, Santin I, Irastorza I, Castano L, Carlos Vitoria J, Ramon Bilbao J. TH17 (and TH1) signatures of intestinal biopsies of CD patients in response to gliadin. Autoimmunity 42: 69-73 (2009).
Castera L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Ledinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51: 828-835 (2010). *
Castiblanco J, Varela DC, Castano-Rodriguez N, Rojas-Villarraga A, Hincapie ME, Anaya JM. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect. Genet. Evol. 8: 541-544 (2008).
Castriota G, Thompson GM, Lin Y, Scherer PE, Moller DE, Berger JP. Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein. Cell Biol. Int. 31: 586-591 (2007). *
Castro CN, Barcala Tabarrozi AE, Noguerol MA, Liberman AC, Dewey RA, Arzt E, Morelli AE, Perone MJ. Disease-modifying immunotherapy for the management of autoimmune diabetes. Neuroimmunomodulation 17: 173-176 (2010).
Casu A, Trucco M, Pietropaolo M. A look to the future: prediction, prevention, and cure including islet transplantation and stem cell therapy. Pediatr. Clin. North Am. 52: 1779-1804 (2005).
Catalan V, Gomez-Ambrosi J, Ramirez B, Rotellar F, Pastor C, Silva C, Rodriguez A, Gil MJ, Cienfuegos JA, Fruhbeck G. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes. Surg. 17: 1464-1474 (2007).
Catanzaro OL, Dziubecki D, Obregon P, Rodriguez RR, Sirois P. Antidiabetic efficacy of bradykinin antagonist R-954 on glucose tolerance test in diabetic type 1 mice. Neuropeptides Jan 20 [Epub ahead of print] (2010).
Catnach SM, Ballinger AB, Stevens M, Fairclough PD, Trembath RC, Drury PL, Watkins PJ. Erythromycin induces supranormal gall bladder contraction in diabetic autonomic neuropathy. Gut 34: 1123-1127 (1993). *
Cauchi S, El Achhab Y, Choquet H, Dina C, Krempler F, Weitgasser R, Nejjari C, Patsch W, Chikri M, Meyre D, Froguel P. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. J. Mol. Med. 85: 777-782 (2007). *
Cauchi S, Nead KT, Choquet H, Horber F, Potoczna N, Balkau B, Marre M, Charpentier G, Froguel P, Meyre D. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies. BMC Med. Genet. 9: 45 (2008). *
Cavalier E, Delanaye P, Chapelle JP, Souberbielle JC. Vitamin D: current status and perspectives. Clin. Chem. Lab. Med. 47: 120-127 (2009). *
Cavallini M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen. 15: 35-38 (2007).
Cavan DA, Jacobs KH, Penny MA, Kelly MA, Mijovic C, Jenkins D, Fletcher JA, Barnett AH. Both DQA1 and DQB1 genes are implicated in HLA-associated protection from type 1 (insulin-dependent) diabetes mellitus in a British Caucasian population. Diabetologia 36: 252-257 (1993).
Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett. 582: 117-131 (2008). *
Cebeci AN, Nuhoglu Y, Arslanoglu I, Erguven M, Agachan N. The role of IL-18 in Th1/Th2 balance in children. Allergy Asthma Proc. 27: 365-370 (2006).
Cejkova P, Fojtikova M, Cerna M. Immunomodulatory role of prolactin in diabetes development. Autoimmun. Rev. 9: 23-27 (2009).
Cejkova P, Novota P, Cerna M, Kololtova K, Novakova D, Kucera P, Novak J, Andel M, Weber P, Zdarsky E. KCNJ11 E23K polymorphism and diabetes mellitus with adult onset in Czech patients. Folia Biol. (Praha) 53: 173-175 (2007).
Cejkova P, Novota P, Cerna M, Kolostova K, Novakova D, Kucera P, Novak J, Andel M, Weber P, Zdarsky E. HLA DRB1, DQB1 and insulin promoter VNTR polymorphisms: interactions and the association with adult-onset diabetes mellitus in Czech patients. Int. J. Immunogenet. 35: 133-140 (2008). *
Celik S, Doesch A, Erbel C, Blessing E, Ammon K, Koch A, Katus HA, Dengler TJ. Beneficial effect of omega-3 fatty acids on sirolimus- or everolimus-induced hypertriglyceridemia in heart transplant recipients. Transplantation 86: 245-250 (2008).
Cemlyn-Jones J, Gamboa F. Proteinuria in cystic fibrosis: a possible correlation between genotype and renal phenotype. J. Bras. Pneumol. 35: 669-675 (2009).
Ceperuelo-Mallafre V, Miranda M, Chacon MR, Vilarrasa N, Megia A, Gutierrez C, Fernandez-Real JM, Gomez JM, Caubet E, Fruhbeck G, Vendrell J. Adipose tissue expression of the glycerol channel aquaporin-7 gene is altered in severe obesity but not in type 2 diabetes. J. Clin. Endocrinol. Metab. 92: 3640-3645 (2007). *
Cerna M. Genetics of autoimmune diabetes mellitus. Wien. Med. Wochenschr. 158: 2-12 (2008). *
Cerna M, Kolostova K, Novota P, Romzova M, Cejkova P, Pinterova D, Pruhova S, Treslova L, Andel M. Autoimmune diabetes mellitus with adult onset and type 1 diabetes mellitus in children have different genetic predispositions. Ann. N. Y. Acad. Sci. 1110: 140-150 (2007). *
Cernea S, Buzzetti R, Pozzilli P. beta-Cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care 32 Suppl. 2: S246-S252 (2009).
Cernea S, Herold KC. Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies. Clin. Immunol. Oct 15 [Epub ahead of print] (2009). *
Cernea S, Pozzilli P. New potential treatments for protection of pancreatic B-cell function in type 1 diabetes. Diabet. Med. 25: 1259-1267 (2008). *
Cerrone GE, Caputo M, Lopez AP, Gonzalez C, Massa C, Cedola N, Targovnik HM, Frechtel GD. Variable number of tandem repeats of the insulin gene determines susceptibility to latent autoimmune diabetes in adults. Mol. Diagn. 8: 43-49 (2004).
Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, Cilio CM, Groop L. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 57: 1433-1437 (2008). *
Cetin I, Alvino G, Cardellicchio M. Long chain fatty acids and dietary fats in fetal nutrition. J. Physiol. 587: 3441-3451 (2009). *
Ch'ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin. Med. Res. 5: 184-192 (2007). *
Cha DR, Zhang X, Zhang Y, Wu J, Su DM, Han JY, Fang X, Yu B, Breyer MD, Guan Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 56: 2036-2045 (2007). *
Chabchoub G, Mnif M, Maalej A, Charfi N, Ayadi H, Abid M. Epidemiologic study of autoimmune thyroid disease in south Tunisia. Ann. Endocrinol. (Paris) 67: 591-595 (2006).
Chaillous L, Bouhanick B, Kerlan V, Mathieu E, Lecomte P, Ducluzeau PH, Delamaire M, Sonnet E, Maugendre D, Marechaud R, Rohmer V, Sai P, Charbonnel B. Clinical and metabolic characteristics of patients with latent autoimmune diabetes in adults (LADA): absence of rapid beta-cell loss in patients with tight metabolic control. Diabetes Metab. Jan 7 [Epub ahead of print] (2010).
Chakravarthy MV, Semenkovich CF. The ABCs of beta-cell dysfunction in type 2 diabetes. Nat. Med. 13: 241-242 (2007). *
Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 899-907 (2006). *
Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes. Am. J. Gastroenterol. 100: 1317-1321 (2005). *
Chamberlain G, Wallberg M, Rainbow D, Hunter K, Wicker LS, Green EA. A 20-Mb region of chromosome 4 controls TNF-alpha-mediated CD8+ T cell aggression toward beta cells in type 1 diabetes. J. Immunol. 177: 5105-5114 (2006). *
Chamberland D, Weight C, Rasmussen M, Abraham D. Thyroxine malabsorption in a patient with type 1 diabetes and celiac disease. Endocr. Pract. 11: 203-204 (2005).
Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care Nov 16 [Epub ahead of print] (2009).
Chan AW, Butzner JD, McKenna R, Fritzler MJ. Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients. Pediatrics 107: e8 (2001). *
Chan EY, Larson AM, Gernsheimer TB, Kowdley KV, Carithers RL Jr, Reyes JD, Perkins JD. Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. Liver Transpl. 13: 516-522 (2007). *
Chan J, Clements W, Field J, Nasa Z, Lock P, Yap F, Toh BH, Alderuccio F. Transplantation of bone marrow genetically engineered to express proinsulin II protects against autoimmune insulitis in NOD mice. J. Gene Med. 8: 1281-1290 (2006).
Chan JL, Matarese G, Shetty GK, Raciti P, Kelesidis I, Aufiero D, De Rosa V, Perna F, Fontana S, Mantzoros CS. Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans. Proc. Natl. Acad. Sci. U.S.A. 103: 8481-8486 (2006). *
Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr. Pract. Jan 9 [Epub ahead of print] (2010). *
Chan KH, Song Y, Hsu YH, You NC, F Tinker L, Liu S. Common genetic variants in fatty acid-binding protein-4 (FABP4) and clinical diabetes risk in the Women's Health Initiative Observational Study. Obesity (Silver Spring) Jan 28 [Epub ahead of print] (2010). *
Chan KM, Raikwar SP, Zavazava N. Strategies for differentiating embryonic stem cells (ESC) into insulin-producing cells and development of non-invasive imaging techniques using bioluminescence. Immunol. Res. 39: 261-270 (2007).
Chan PS, Kanwar M, Kowluru RA. Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. J. Diabetes Complications 24: 55-63 (2010).
Chandak GR, Idris MM, Reddy DN, Mani KR, Bhaskar S, Rao GV, Singh L. Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis. Gut 53: 723-728 (2004). *
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41: 973-983 (2007).
Chang KY, Unanue ER. Prediction of HLA-DQ8 beta cell peptidome using a computational program and its relationship to autoreactive T cells. Int. Immunol. 21: 705-713 (2009).
Chang LT, Sun CK, Wang CY, Youssef AA, Wu CJ, Chua S, Yip HK. Downregulation of peroxisme proliferator activated receptor gamma co-activator 1alpha in diabetic rats. Int. Heart J. 47: 901-910 (2006).
Chang Y, Yap S, Ge X, Piganelli J, Bertera S, Giannokakis N, Mathews C, Prud'homme G, Trucco M. DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther. 12: 1679-1685 (2005). *
Chang YH, Huang CN, Wu CY, Shiau MY. Association of Interleukin-10 A-592C and T-819C polymorphisms with type 2 diabetes mellitus. Hum. Immunol. 66: 1258-1263 (2005).
Chang YT, Chen TJ, Liu PC, Chen YC, Chen YJ, Huang YL, Jih JS, Chen CC, Lee DD, Wang WJ, Lin MW, Liu HN. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta Derm. Venereol. 89: 262-266 (2009).
Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol. Ther. 22: 61-73 (2009).
Chao C, Hellmich MR. Gastrin, inflammation, and carcinogenesis. Curr. Opin. Endocrinol. Diabetes Obes. 17: 33-39 (2010).
Chaparro RJ, Burton AR, Serreze DV, Vignali DA, Dilorenzo TP. Rapid identification of MHC class I-restricted antigens relevant to autoimmune diabetes using retrogenic T cells. J. Immunol. Methods 335: 106-115 (2008). *
Chaparro RJ, Konigshofer Y, Beilhack GF, Shizuru JA, McDevitt HO, Chien Yh. Nonobese diabetic mice express aspects of both type 1 and type 2 diabetes. Proc. Natl. Acad. Sci. U.S.A. 103: 12475-12480 (2006). *
Charalabopoulos K, Mittari E, Peschos D, Golias C, Charalabopoulos A, Tsanou E, Batistatou A. Rare association of chronic lymphocytic thyroiditis with dermatomyositis. Arch. Med. Res. 37: 563-565 (2006).
Charbonnel B. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. Lancet 374: 96-88 (2009). *
Charbonnel B. What a psychiatrist needs to know about diabetes. Eur. Psychiatry 20 Suppl. 4: S330-S334 (2005).
Charlton M. Obesity, hyperlipidemia, and metabolic syndrome. Liver Transpl. 15: S83-S89 (2009).
Charriere S, Bernard S, Aqallal M, Merlin M, Billon S, Perrot L, Le Coquil E, Sassolas A, Moulin P, Marcais C. Association of APOA5 -1131T>C and S19W gene polymorphisms with both mild hypertriglyceridemia and hyperchylomicronemia in type 2 diabetic patients. Clin. Chim. Acta 394: 99-103 (2008). *
Chatenoud L. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic. Handb. Exp. Pharmacol. 181: 221-236 (2008).
Chatenoud L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr. Opin. Organ Transplant. 14: 351-356 (2009).
Chatenoud L. Immune therapy for type 1 diabetes mellitus - what is unique about anti-CD3 antibodies? Nat. Rev. Endocrinol. 6: 149-157 (2010).
Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3: 123-132 (2003).
Chatenoud L. One step towards restoration of self-tolerance in human autoimmune diseases. Med. Sci. (Paris) 23: 167-172 (2007).
Chatenoud L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr. Opin. Immunol. 17: 632-637 (2005).
Chatenoud L, Bach JF. Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance. Expert Opin. Biol. Ther. 5 Suppl. 1: S73-S81 (2005).
Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern. Med. J. 37: 377-382 (2007). *
Chattopadhyay N. Effects of calcium-sensing receptor on the secretion of parathyroid hormone-related peptide and its impact on humoral hypercalcemia of malignancy. Am. J. Physiol. Endocrinol. Metab. 290: E761-E770 (2006). *
Chatzi L, Bitsios P, Solidaki E, Christou I, Kyrlaki E, Sfakianaki M, Kogevinas M, Kefalogiannis N, Pappas A. Type 1 diabetes is associated with alexithymia in nondepressed, non-mentally ill diabetic patients: a case-control study. J. Psychosom. Res. 67: 307-313 (2009).
Chatzigeorgiou AE, Lembessis PE, Mylona-Karagianni CF, Tsouvalas EA, Diamanti-Kandarakis E, Kamper EF. CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells. Exp. Clin. Endocrinol. Diabetes Oct 15 [Epub ahead of print] (2009).
Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 12: 431-437 (2009).
Chauffert M, Cisse A, Chevenne D, Parfait B, Michel S, Trivin F. HLA-DQ beta 1 typing and non-Asp57 alleles in the aborigine population of Senegal. Diabetes Care 18: 677-680 (1995).
Chavey C, Fajas L. CXCL5 drives obesity to diabetes, and further. Aging (Albany NY) 1: 674-677 (2009).
Chavez ML. Herbal-drug interactions. InetCE 9: 2-30 (www.InetCE.com; 221-999-05-056-H01) (2005). *
Chawla PS, Kochar MS. What's new in clinical pharmacology and therapeutics. WMJ 105: 24-29 (2006).
Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience. Am. J. Clin. Nutr. 91: 262S-266S (2010). *
Cheepsattayakorn A, Cheepsattayakorn R. Human genetic influence on susceptibility of tuberculosis: from infection to disease. J. Med. Assoc. Thai. 92: 136-141 (2009).
Chelala C, Duchatelet S, Joffret ML, Bergholdt R, Dubois-Laforgue D, Ghandil P, Pociot F, Caillat-Zucman S, Timsit J, Julier C. PTPN22 R620W functional variant in type 1 diabetes and autoimmunity related traits. Diabetes 56: 522-526 (2007). *
Chello M, Spadaccio C, Lusini M, Covino E, Blarzino C, De Marco F, Di Domenico F, Coccia R. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure. Diabetes Metab. Res. Rev. 25: 420-426 (2009).
Chemli J, Abid I, Yacoub M, Guedira I, Korbi S, Sahloul Essoussi A, Harbi A. Paediatric celiac disease in the region of Sousse: epidemiological and evolutive study of 80 cases. Tunis. Med. 86: 636-642 (2008).
Chen B, Zhang Y, Liu G, Guan GJ, Hou XH, Li XG, Liu JL. Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats. Zhonghua Yi Xue Za Zhi 88: 540-545 (2008).
Chen C, Lee WH, Zhong L, Liu CP. Regulatory T cells can mediate their function through the stimulation of APCs to produce immunosuppressive nitric oxide. J. Immunol. 176: 3449-3460 (2006). *
Chen C, Liu CP. Regulatory function of a novel population of mouse autoantigen-specific Foxp3 regulatory T cells depends on IFN-gamma, NO, and contact with target cells. PLoS One 4: e7863 (2009). *
Chen FJ, Yu H, Fan F, Lu JX. Mitochondrial D-loop gene polymorphisms in the patients with type 2 diabetes mellitus. Yi Chuan 31: 265-272 (2009).
Chen G, Brunt EM. Diabetic hepatosclerosis: a 10-year autopsy series. Liver Int. 29: 1044-1050 (2009). *
Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635 (2002). *
Chen G, Han G, Feng J, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Glutamic acid decarboxylase-derived epitopes with specific domains expand CD4CD25 regulatory T cells. PLoS One 4: e7034 (2009). *
Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J. Leukoc. Biol. 83: 280-287 (2008). *
Chen G, Han G, Wang J, Wang R, Xu R, Shen B, Qian J, Li Y. Induction of active tolerance and involvement of CD1d-restricted natural killer T cells in anti-CD3 F(ab')2 treatment-reversed new-onset diabetes in nonobese diabetic mice. Am. J. Pathol. 172: 972-979 (2008). *
Chen G, Zhang Y, Lu D, Li NQ, Ross AC. Retinoids synergize with insulin to induce hepatic Gck Expression. Biochem. J. 419: 645-653 (2009). *
Chen H, Hewison M, Adams JS. Functional characterization of heterogeneous nuclear ribonuclear protein C1/C2 in vitamin D resistance: a novel response element binding protein. J. Biol. Chem. 281: 39114-39120 (2006). *
Chen J, Gusdon AM, Thayer TC, Mathews CE. Role of increased ROS dissipation in prevention of T1D. Ann. N. Y. Acad. Sci. 1150: 157-166 (2008). *
Chen J, Liu X. The role of interferon gamma in regulation of CD4(+) T-cells and its clinical implications. Cell. Immunol. 254: 85-90 (2009). *
Chen J, Lu Y, Lee CH, Li R, Leiter EH, Mathews CE. Commonalities of genetic resistance to spontaneous autoimmune and free radical-mediated diabetes. Free Radic. Biol. Med. 45: 1263-1270 (2008).
Chen L, Wei B, Li J, Liu F, Xuan D, Xie B, Zhang J. Association of periodontal parameters with metabolic level and systemic inflammatory markers in patients with type 2 diabetes. J. Periodontol. 81: 364-371 (2010).
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. ENPP1 K121Q polymorphism is not related to type 2 diabetes mellitus, features of metabolic syndrome, and diabetic cardiovascular complications in a Chinese population. Rev. Diabet. Stud. 3: 21-30 (2006). *
Chen NX, Moe SM. Arterial calcification in diabetes. Curr. Diab. Rep. 3: 28-32 (2003).
Chen RT, Pless R, Destefano F. Epidemiology of autoimmune reactions induced by vaccination. J. Autoimmun. 16: 309-318 (2001).
Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M, Law CS, Gardner DG. Expression of the vitamin D receptor is increased in the hypertrophic heart. Hypertension 52: 1106-1112 (2008).
Chen S, Olsen K, Grigsby C, Gardner DG. Vitamin D activates type A natriuretic peptide receptor gene transcription in inner medullary collecting duct cells. Kidney Int. 72: 300-306 (2007). *
Chen SF, Lu XF, Yan WL, Huang JF, Gu DF. Variations in the calpain-10 gene are associated with the risk of type 2 diabetes and hypertension in northern Han Chinese population. Chin. Med. J. (Engl.) 120: 2218-2223 (2007).
Chen W, Herold KC, Bluestone JA. Achieving antigen-specific tolerance in diabetes: regulating specifically. Int. Rev. Immunol. 24: 287-305 (2005).
Chen W, Li YM, Yu MH. Astragalus polysaccharides: an effective treatment for diabetes prevention in NOD mice. Exp. Clin. Endocrinol. Diabetes 116: 468-474 (2008).
Chen X, Makala LH, Jin Y, Hopkins D, Muir A, Garge N, Podolsky RH, She JX. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood. Clin. Immunol. 129: 413-418 (2008). *
Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM, Rothlein R, Schmidt AM, Clynes R, Herold KC. RAGE ligation affects T cell activation and controls T cell differentiation. J. Immunol. 181: 4272-4278 (2008). *
Chen YG, Scheuplein F, Osborne MA, Tsaih SW, Chapman HD, Serreze DV. The Idd9/11 genetic locus regulates diabetogenic activity of CD4 T-cells in non-obese diabetic (NOD) mice. Diabetes 57: 3273-3280 (2008). *
Chen YG, Silveira PA, Osborne MA, Chapman HD, Serreze DV. Cellular expression requirements for inhibition of type 1 diabetes by a dominantly protective major histocompatibility complex haplotype. Diabetes 56: 424-430 (2007). *
Chen YJ, Shen JL, Wu CY, Chang YT, Chen CM, Lee FY. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J. Am. Acad. Dermatol. 60: 225-230 (2009).
Chen YJ, Wu CY, Shen JL, Chu SY, Chen CK, Chang YT, Chen CM. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch. Dermatol. 144: 1571-1575 (2008). *
Chen Z, Stockton J, Mathis D, Benoist C. Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc. Natl. Acad. Sci. U.S.A. 103: 16400-16405 (2006). *
Chen ZY, Istfan NW. Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells. Prostaglandins Leukot. Essent. Fatty Acids 63: 301-308 (2000). *
Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol. 21: 400-404 (2006).
Cheng AY, Leiter LA. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. Diabetes Obes. Metab. 10: 691-698 (2008).
Cheng K, Benten D, Bhargava K, Inada M, Joseph B, Palestro C, Gupta S. Hepatic targeting and biodistribution of human fetal liver stem/progenitor cells and adult hepatocytes in mice. Hepatology 50: 1194-1203 (2009).
Cheng MH, Fan U, Grewal N, Barnes M, Mehta A, Taylor S, Husebye ES, Murphy EJ, Anderson MS. Acquired autoimmune polyglandular syndrome, thymoma, and an AIRE defect. N. Engl. J. Med. 362: 764-766 (2010). *
Cheng MH, Shum AK, Anderson MS. What's new in the Aire? Trends Immunol. 28: 321-327 (2007). *
Cheng PT, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases. Mini. Rev. Med. Chem. 5: 741-753 (2005).
Chentoufi AA, Binder NR, Berka N, Abunadi T, Polychronakos C. Advances in type I diabetes associated tolerance mechanisms. Scand. J. Immunol. 68: 1-11 (2008). *
Cheong KY, Allcock RJ, Eerligh P, Witt CS, Christiansen FT, McCann V, Price P. Localization of central MHC genes influencing type I diabetes. Hum. Immunol. 62: 1363-1370 (2001).
Chernajovsky Y, Gould DJ, Podhajcer OL. Gene therapy for autoimmune diseases: quo vadis? Nat. Rev. Immunol. 4: 800-811 (2004). *
Cheung AT, Smith Tomic MM, Chen PC, Miguelino E, Li CS, Devaraj S. Correlation of microvascular abnormalities and endothelial dysfunction in type-1 diabetes mellitus (T1DM): a real-time intravital microscopy study. Clin. Hemorheol. Microcirc. 42: 285-295 (2009).
Cheung C, Akiyama TE, Kudo G, Gonzalez FJ. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol. 66: 2011-2020 (2003). *
Cheung D, Bryer-Ash M. Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J. Am. Acad. Dermatol. 60: 1032-1036 (2009).
Cheung MS, Bridges NA, Prasad SA, Francis J, Carr SB, Suri R, Balfour-Lynn IM. Growth in children with cystic fibrosis-related diabetes. Pediatr. Pulmonol. 44: 1223-1225 (2009).
Cheunsuk S, Hsu T, Gershwin ME, Bowlus CL. Analysis of the IDDM candidate gene Prss16 in NOD and NON mice. Dev. Immunol. 9: 183-186 (2002). *
Cheunsuk S, Lian ZX, Yang GX, Gershwin ME, Gruen JR, Bowlus CL. Prss16 is not required for T-cell development. Mol. Cell. Biol. 25: 789-796 (2005). *
Chew P, Yuen DY, Koh P, Stefanovic N, Febbraio MA, Kola I, Cooper ME, de Haan JB. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 29: 823-830 (2009).
Chi XZ, Kim J, Lee YH, Lee JW, Lee KS, Wee H, Kim WJ, Park WY, Oh BC, Stein GS, Ito Y, van Wijnen AJ, Bae SC. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 69: 8111-8119 (2009). *
Chia SY, Chua R, Lo YL, Wong MC, Chan LL, Tan EK. Acute ataxia, Graves' disease, and stiff person syndrome. Mov. Disord. 22: 1969-1971 (2007).
Chianelli M, Parisella MG, Visalli N, Mather SJ, D'Alessandria C, Pozzilli P, Signore A; IMDIAB study group. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab. Res. 24: 115-122 (2008).
Chiang E, Packer CD. Concurrent reactive arthritis, Graves' disease, and warm autoimmune hemolytic anemia: a case report. Cases J. 2: 6988 (2009). *
Chiang JY. Bile acids: regulation of synthesis. J. Lipid Res. 50: 1955-1966 (2009). *
Chiang JY. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 5: 137-147 (2009).
Chiang JY. Nuclear receptor regulation of lipid metabolism: potential therapeutics for dyslipidemia, diabetes, and chronic heart and liver diseases. Curr. Opin. Investig. Drugs 6: 994-1001 (2005).
Chichelnitskiy E, Vegiopoulos A, Diaz MB, Ziegler A, Kleiman A, Rauch A, Tuckermann J, Herzig S. In vivo phosphoenolpyruvate carboxykinase promoter mapping identifies disrupted hormonal synergism as a target of inflammation during sepsis in mice. Hepatology 50: 1963-1971 (2009).
Chikuma S, Abbas AK, Bluestone JA. B7-independent inhibition of T cells by CTLA-4. J. Immunol. 175: 177-181 (2005). *
Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res. 28: 241-253 (2003). *
Chikuma S, Bluestone JA. CTLA-4: acting at the synapse. Mol. Interv. 2: 205-208 (2002). *
Chikuma S, Bluestone JA. Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease. Eur. J. Immunol. 37: 1285-1289 (2007). *
Chilton PM, Rezzoug F, Ratajczak MZ, Fugier-Vivier I, Ratajczak J, Kucia M, Huang Y, Tanner MK, Ildstad ST. Hematopoietic stem cells from NOD mice exhibit autonomous behavior and a competitive advantage in allogeneic recipients. Blood 105: 2189-2197 (2005). *
Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr. Opin. Pharmacol. 5: 177-183 (2005).
Chirino YI, Orozco-Lbarra M, Pedraza-Chaverri J. Role of peroxynitrite anion in different diseases. Rev. Invest. Clin. 58: 350-358 (2006).
Chistiakov D, Zotova E, Savost'anov K, Bursa T, Galeev I, Strokov Ia, Nosikov V. The 262T>C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients. Diabetes Metab. 32: 63-68 (2006).
Chistiakov DA. Interferon induced with helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol. 23: 3-15 (2010).
Chistiakov DA, Chernisheva A, Savost'anov KV, Turakulov RI, Kuraeva TL, Dedov II, Nosikov VV. The TAF5L gene on chromosome 1q42 is associated with type 1 diabetes in Russian affected patients. Autoimmunity 38: 283-293 (2005).
Chistiakov DA, Potapov VA, Khodirev DC, Shamkhalova MS, Shestakova MV, Nosikov VV. Genetic variations in the pancreatic ATP-sensitive potassium channel, beta-cell dysfunction, and susceptibility to type 2 diabetes. Acta Diabetol. 46: 43-49 (2009).
Chistiakov DA, Savost'anov KV, Nosikov VV. CTLA4 gene polymorphisms are associated with, and linked to, insulin-dependent diabetes mellitus in a Russian population. BMC Genet. 2: 6 (2001). *
Chistiakov DA, Savost'anov KV, Shestakova MV, Chugunova LA, Samkhalova MSh, Dedov II, Nosikov VV. Confirmation of a susceptibility locus for diabetic nephropathy on chromosome 3q23-q24 by association study in Russian type 1 diabetic patients. Diabetes Res. Clin. Pract. 66: 79-86 (2004).
Chistiakov DA, Savost'anov KV, Turakulov RI, Titovich EV, Zilberman LI, Kuraeva TL, Dedov II, Nosikov VV. A new type 1 diabetes susceptibility locus containing the catalase gene (chromosome 11p13) in a Russian population. Diabetes Metab. Res. Rev. 20: 219-224 (2004).
Chistiakov DA, Seryogin Y, Savost'anov KV, Zilberman LI, Titovich EV, Kuraeva TL, Dedov II, Nosikov VV. Evidence for a type 1 diabetes susceptibility locus (IDDM10) on chromosome 10p11-q11 in a Russian population. Scand. J. Immunol. 60: 316-323 (2004). *
Chistiakov DA, Seryogin YA, Turakulov RI, Savost'anov KV, Titovich EV, Zilberman LI, Kuraeva TL, Dedov II, Nosikov VV. Evaluation of IDDM8 susceptibility locus in a Russian simplex family data set. J. Autoimmun. 24: 243-250 (2005).
Chistiakov DA, Spitsina EV, Nikitin AG, Strokov IA, Nosikov VV. A splice variant of GNB3 and peripheral polyneuropathy in type 1 diabetes. Dis. Markers. 26: 111-117 (2009).
Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin. Liver Dis. 21: 27-41 (2001).
Chiu MW, Haley JC. Acquired perforating dermatosis associated with primary biliary cirrhosis and Hashimoto thyroiditis. Cutis 79: 451-455 (2007).
Chmaisse HN, Jammal M, Fakhoury H, Fakhoury R. A study on the association between angiotensin-I converting enzyme I/D dimorphism and type-2 diabetes mellitus. Saudi J. Kidney Dis. Transpl. 20: 1038-1046 (2009).
Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439 (2000).
Cho JH. Update on the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 3: 458-463 (2001).
Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr. Top. Med. Chem. 8: 1483-1507 (2008).
Cho SM, Kim J, Ryu HJ, Kim JJ, Kim HH, Park JH, Kim HT, Kim KH, Cho HY, Oh B, Park C, Kimm K, Jo I, Lee JE, Shin HD, Lee JK. Identification of single nucleotide polymorphisms in the tumor necrosis factor (TNF) and TNF receptor superfamily in the Korean population. Hum. Immunol. 65: 710-718 (2004).
Choe SS, Choi AH, Lee JW, Kim KH, Chung JJ, Park J, Lee KM, Park KG, Lee IK, Kim JB. Chronic activation of liver X receptor induces beta-cell apoptosis through hyperactivation of lipogenesis. Diabetes 56: 1534-1543 (2007). *
Choi EK, Kim MH, Kim JC, Han J, Oh SI, Jeong WJ, Jeong JY, Lee SS, Seo DW, Lee SK. The long-term follow-up results after steroid treatment in patients with autoimmune chronic pancreatitis. Korean J. Gastroenterol. 47: 440-448 (2006).
Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 336: 747-753 (2005). *
Choi KM, Kashyap PC, Dutta N, Stoltz GJ, Ordog T, Donohue TS, Bauer AJ, Linden DR, Szurszewski JH, Gibbons SJ, Farrugia G. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology Feb 20 [Epub ahead of print] (2010). *
Choi YS, Hong JM, Lim S, Ko KS, Pak YK. Impaired coactivator activity of the Gly(482) variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem. Biophys. Res. Commun. 344: 708-712 (2006). *
Chong AS, Shen J, Tao J, Yin D, Kuznetsov A, Hara M, Philipson LH. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311: 1774-1775 (2006). *
Choquet H, Cavalcanti-Proenca C, Lecoeur C, Dina C, Cauchi S, Vaxillaire M, Hadjadj S, Horber F, Potoczna N, Charpentier G, Ruiz J, Hercberg S, Maimaitiming S, Roussel R, Boenhnke M, Jackson AU, Patsch W, Krempler F, Voight BF, Altshuler D, Groop L, et al. The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49,279 subjects. Hum. Mol. Genet. 18: 2495-2501 (2009).
Chou FC, Shieh SJ, Sytwu HK. Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur. J. Immunol. 39: 2403-2411 (2009). *
Chou SM, Chong YY, Kinkel R. A proposed pathogenetic process in the formation of Aspergillus mycotic aneurysm in the central nervous system. Ann. Acad. Med. Singapore 22: S518-S525 (1993).
Chou YC, Prakash E, Huang CF, Lien TW, Chen X, Su IJ, Chao YS, Hsieh HP, Hsu JT. Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana. Phytother. Res. 22: 605-613 (2008).
Choudhuri G, Somani SK, Baba CS, Alexander G. Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol. 5: 27 (2005). *
Choudhury RP, Reddy AV, Garg AN. Availability of essential elements in nutrient supplements used as antidiabetic herbal formulations. Biol. Trace Elem. Res. 120: 148-162 (2007).
Choukem SP, Boudou P, Sobngwi E, Villette JM, Ibrahim F, Moulin P, Hadjadj S, Eberle D, Foufelle F, Vexiau P, Gautier JF. The polymorphism Arg585Gln in the gene of the sterol regulatory element binding protein-1 (SREBP-1) is not a determinant of ketosis prone type 2 diabetes (KPD) in Africans. Diabetes Metab. 35: 20-24 (2009).
Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, Giamarellou H. Cholestatic liver injury after glimepiride therapy. J. Hepatol. 42: 944-946 (2005). *
Chowdhury TA, Lasker SS. Subclinical type 1 diabetes. J. R. Soc. Med. 95: 203-204 (2002). *
Chowdhury ZM, McDermott MF, Davey S, Hassan Z, Sinnott PJ, Hemmatpour SK, Sherwin S, Ali L, Aganna E, Allotey RA, North BV, Cassell PG, Azad Khan AK, Hitman GA. Genetic susceptibility to fibrocalculous pancreatic diabetes in Bangladeshi subjects: a family study. Genes Immun. 3: 5-8 (2002). *
Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A, Peng X. Vitamin D target proteins: function and regulation. J. Cell. Biochem. 88: 238-244 (2003). *
Christakos S, Dhawan P, Shen Q, Peng X, Benn B, Zhong Y. New insights into the mechanisms involved in the pleiotropic actions of 1,25dihydroxyvitamin D3. Ann. N. Y. Acad. Sci. 1068: 194-203 (2006). *
Christen U. Chemokines as drug targets in type 1 diabetes. Endocr. Metab. Immune Disord. Drug Targets 7: 7-12 (2007).
Christen U, von Herrath MG. Factors that determine enhancement versus abrogation of autoimmunity by viral infections. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 20 (2004). *
Christen U, Edelmann KH, McGavern DB, Wolfe T, Coon B, Teague MK, Miller SD, Oldstone MB, von Herrath MG. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J. Clin. Invest. 114: 1290-1298 (2004). *
Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J. Autoimmun. Aug 26 [Epub ahead of print] (2009).
Christensen JH, Svensson M, Strandhave C, Madsen T, Schmidt EB. n-3 Fatty acids and cardiac autonomic function in humans. Cell. Mol. Biol. (Noisy-le-grand) 56: 131-139 (2010).
Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother. Res. 23: 1316-1325 (2009).
Christensen T, Moller-Larsen A. Human endogenous retroviruses and disease? Ugeskr. Laeger. 165: 556-561 (2003).
Christiansen FT, Saueracker GC, Leaver AL, Tokunaga K, Cameron PU, Dawkins RL. Characterization of MHC ancestral haplotypes associated with insulin-dependent diabetes mellitus: evidence for involvement of non-HLA genes. J. Immunogenet. 17: 379-386 (1990).
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. J. Clin. Endocrinol. Metab. 94: 3594-3601 (2009).
Christodoulides C, Vidal-Puig A. PPARs and adipocyte function. Mol. Cell. Endocrinol. Sep 19 [Epub ahead of print] (2009).
Christophers E. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 52-55 (2006). *
Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Ann. N. Y. Acad. Sci. 1179: 153-166 (2009). *
Chu X, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, Dean DC, Evers R. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human renal transporters hOAT3, OATP4C1, and MDR1 P-glycoprotein. J. Pharmacol. Exp. Ther. 321: 673-683 (2007). *
Chuah MK. Cutting through the obstacles and resurrecting the promise of gene therapy. IDrugs 8: 818-821 (2005).
Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR. Disseminated cryptococcosis in HIV-uninfected patients. Eur. J. Clin. Microbiol. Infect. Dis. 27: 307-310 (2008). *
Chuang YP, Chu CH, Sytwu HK. Genetic manipulation of islet cells in autoimmune diabetes: from bench to bedside. Front. Biosci. 13: 6155-6169 (2008).
Chui MH, Papanikolaou Y, Fontaine-Bisson B, Turcotte J, Wolever TM, El-Sohemy A, Chiasson JL, Rabasa-Lhoret R, Maheux P, Ryan E, Greenwood CE. The TNF-alpha-238A single-nucleotide polymorphism protects against memory decline in older adults with type 2 diabetes. Behav. Neurosci. 121: 619-624 (2007).
Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity. Autoimmunity 40: 582-590 (2007).
Chung SS, Choi HH, Cho YM, Lee HK, Park KS. Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 348: 253-258 (2006). *
Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells. Mol. Cell. Biol. 29: 20-30 (2009). *
Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 14: 543-553 (2007). *
Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, Maggi A. A novel PPRE-luciferase reporter mouse reveals gender specificity of peroxisome proliferators activated receptor activity in liver. Mol. Endocrinol. 21: 388-400 (2007). *
Ciantar M, Adlam DM. Treatment with infliximab: implications in oral surgery? A case report. Br. J. Oral Maxillofac. Surg. 45: 507-510 (2007).
Cignarella A, Bellosta S, Corsini A, Bolego C. Hypolipidemic therapy for the metabolic syndrome. Pharmacol. Res. 53: 492-500 (2006). *
Cigrovski-Berkovic M, Solter D, Solter M. Why does the patient with Graves' disease remain euthyroid/mildly hyperthyroid following total thyroidectomy - the role of thyrotropin receptor antibodies (TRAb) and vestigial remnants of the thyroglossal tract. Acta Clin. Croat. 47: 171-174 (2008).
Cinek O, Drevinek P, Sumnik Z, Bendlova B, Vavrinec J. Association of insulin gene variants with type 1 diabetes mellitus in Czech population. Cas. Lek. Cesk. 143: 318-322 (2004).
Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, Kulich M, Sumnik Z. No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res. Clin. Pract. 76: 297-303 (2007).
Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. Sep 25 [Epub ahead of print] (2009). *
Ciric B, El-Behi M, Cabrera R, Zhang GX, Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J. Immunol. 182: 5296-5305 (2009).
Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L. The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 55: 1214-1222 (2006). *
Claesson MH, Nicoletti F, Stosic-Grujicic S, Doria A, Zampieri S. Interactions between infections and immune-inflammatory cells in type 1 diabetes mellitus and inflammatory bowel diseases: evidences from animal models. Clin. Exp. Rheumatol. 26: S8-S11 (2008).
Claiborn KC, Stoffers DA. Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. Mt. Sinai J. Med. 75: 362-371 (2008). *
Clapham JC, Arch JR. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes. Metab. 9: 259-275 (2007). *
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98: 960-967 (2003). *
Clarke HJ, Gregoire F, Ma F, Martin R, Zhao S, Lavan BE. Cross-species differential plasma protein binding of MBX-102/JNJ39659100: a novel PPAR-gamma agonist. PPAR Res. 2008: 465715 (2008). *
Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2-4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J. Pediatr. Endocrinol. Metab. 16: 495-508 (2003).
Clee SM, Yandell BS, Schueler KM, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mui ET, Stapleton DS, Gray-Keller MP, Young MB, Stoehr JP, Lan H, Boronenkov I, Raess PW, Flowers MT, Attie AD. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat. Genet. 38: 688-693 (2006). *
Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur. J. Heart Fail. 8: 105-110 (2006).
Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 57: 1405-1413 (2008). *
Clevidence DE, Juckett MB, Lucarelli MJ. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ 108: 462-465 (2009).
Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep. 5: 142-147 (2004). *
Codner E, Deng L, Perez-Bravo F, Roman R, Lanzano P, Cassorla F, Chung WK. Glucokinase mutations in young children with hyperglycemia. Diabetes Metab. Res. Rev. 22: 348-355 (2006).
Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, Meyerovitch J. Psoriasis and diabetes: a population-based cross-sectional study. J. Eur. Acad. Dermatol. Venereol. 22: 585-589 (2008). *
Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, Vardy DA. Psoriasis and the metabolic syndrome. Acta Derm. Venereol. 87: 506-509 (2007).
Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 216: 152-155 (2008).
Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm. Venereol. 90: 23-26 (2010).
Cohen D, Cohen O, Marcadet A, Massart C, Lathrop M, Deschamps I, Hors J, Schuller E, Dausset J. Class II HLA-DC beta-chain DNA restriction fragments differentiate among HLA-DR2 individuals in insulin-dependent diabetes and multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 81: 1774-1778 (1984). *
Cohen IR. Functional immunomics and immune homeostasis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 21 (2004). *
Cohen N, Brautbar C, Font MP, Dausset J, Cohen D. HLA-DR2-associated Dw subtypes correlate with RFLP clusters: most DR2 IDDM patients belong to one of these clusters. Immunogenetics 23: 84-89 (1986).
Cohen ND, Shaw JE. Diabetes: advances in treatment. Intern. Med. J. 37: 383-388 (2007). *
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm. Bowel Dis. 14: 738-743 (2008). *
Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 42: 10-21 (2007). *
Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot. Essent. Fatty Acids 81: 213-221 (2009). *
Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol. Annu. Rev. 12: 269-300 (2006).
Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap S, Folli F, Tripathy D, Mandarino LJ, Cornell JE, Defronzo RA, Jenkinson CP. Effect of acute physiologic hyperinsulinemia on gene expression in human skeletal muscle in vivo. Am. J. Physiol. Endocrinol. Metab. 294: E910-E917 (2008). *
Coletta DK, Schneider J, Hu SL, Dyer TD, Puppala S, Farook VS, Arya R, Lehman DM, Blangero J, Defronzo RA, Duggirala R, Jenkinson CP. Genomewide linkage scan for genes influencing plasma triglyceride levels in the Veterans Administration Genetic Epidemiology Study (VAGES). Diabetes 58: 279-284 (2009). *
Coll T, Palomer X, Blanco-Vaca F, Escola-Gil JC, Sanchez RM, Laguna JC, Vazquez-Carrera M. Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology Dec 18 [Epub ahead of print] (2009). *
Colleoni M, Sacerdote P. Murine models of human neuropathic pain. Biochim. Biophys. Acta Oct 29 [Epub ahead of print] (2009). *
Collet-Gaudillat C, Billon-Bancel A, Beressi JP. Long-term improvement of metabolic control with pioglitazone in a woman with diabetes mellitus related to Dunnigan syndrome: a case report. Diabetes Metab. 35: 151-154 (2009).
Colli ML, Gross JL, Canani LH. Mutation H63D in the HFE gene confers risk for the development of type 2 diabetes mellitus but not for chronic complications. J. Diabetes Complications Jan 22 [Epub ahead of print] (2010).
Collin P, Reunala T, Pukkala E, Laippala P, Keyrilainen O, Pasternack A. Coeliac disease - associated disorders and survival. Gut 35: 1215-1218 (1994). *
Collins JE, Heward JM, Nithiyananthan R, Nejentsev S, Todd JA, Franklyn JA, Gough SC. Lack of association of the vitamin D receptor gene with Graves' disease in UK Caucasians. Clin. Endocrinol. (Oxf.) 60: 618-624 (2004). *
Collins JL. Therapeutic opportunities for liver X receptor modulators. Curr. Opin. Drug Discov. Devel. 7: 692-702 (2004).
Collins S, Reynolds F. How do adults with cystic fibrosis cope following a diagnosis of diabetes? J. Adv. Nurs. 64: 478-487 (2008).
Colome Pavon JA, Arranz Garcia F, Vinuela Alejandre MA, Espinos Perez D. Chronic autoimmune type II hepatitis with various extrahepatic clinical manifestations. An. Med. Interna 10: 390-392 (1993).
Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl. Acad. Sci. U.S.A. 89: 3932-3936 (1992). *
Colucci F, Bergman ML, Penha-Goncalves C, Cilio CM, Holmberg D. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region. Proc. Natl. Acad. Sci. U.S.A. 94: 8670-8674 (1997). *
Colucci F, Cilio CM. Taming killer cells may halt diabetes progression. Nat. Immunol. 11: 111-112 (2010). *
Colwell JA. Does aspirin use reduce cardiovascular risk in diabetes? Nat. Rev. Endocrinol. 5: 188-190 (2009). *
Comabella M, Altet L, Peris F, Villoslada P, Sanchez A, Montalban X. Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Mult. Scler. 10: 618-620 (2004). *
Concannon P, Chen WM, Julier C, Morahan G, Akolkar B, Erlich HA, Hilner JE, Nerup J, Nierras C, Pociot F, Todd JA, Rich SS; and the Type 1 Diabetes Genetics Consortium. Genome-wide scan for linkage to type 1 diabetes in 2,496 multiplex families from the Type 1 Diabetes Genetics Consortium. Diabetes 58: 1018-1022 (2009). *
Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, Pociot F, Todd JA, Rich SS. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1,435 multiplex families. Diabetes 54: 2995-3001 (2005). *
Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N. Engl. J. Med. 360: 1646-1654 (2009). *
Cong GN, Qin MW, You H, Liu W, Xu K. Imaging features of autoimmune pancreatitis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 30: 479-484 (2008).
Conn JJ, Simm PJ, Oats JJ, Nankervis AJ, Jacobs SE, Ellard S, Hattersley AT. Neonatal hyperinsulinaemic hypoglycaemia and monogenic diabetes due to a heterozygous mutation of the HNF4A gene. Aust. N. Z. J. Obstet. Gynaecol. 49: 328-330 (2009).
Connor WE. Importance of n-3 fatty acids in health and disease. Am. J. Clin. Nutr. 71: 171S-175S (2000). *
Connor WE, Connor SL. The importance of fish and docosahexaenoic acid in Alzheimer disease. Am. J. Clin. Nutr. 85: 929-930 (2007). *
Conrad B, Weissmahr RN, Boni J, Arcari R, Schupbach J, Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 90: 303-313 (1997). *
Consoli A, Devangelio E. Thiazolidinediones and inflammation. Lupus 14: 794-797 (2005).
Contreas G, Valletta E, Ulmi D, Cantoni S, Pinelli L. Screening of coeliac disease in north Italian children with type 1 diabetes: limited usefulness of HLA-DQ typing. Acta Paediatr. 93: 628-632 (2004).
Contu D, Morelli L, Santoni F, Foster JW, Francalacci P, Cucca F. Y-chromosome based evidence for pre-neolithic origin of the genetically homogeneous but diverse Sardinian population: inference for association scans. PLoS ONE 3: e1430 (2008). *
Conway BR, Savage DA, Brady HR, Maxwell AP. Association between haptoglobin gene variants and diabetic nephropathy: haptoglobin polymorphism in nephropathy susceptibility. Nephron. Exp. Nephrol. 105: e75-e79 (2007).
Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD002010 (2009).
Cook GP, Savic S, Wittmann M, McDermott MF. The NLRP3 inflammasome, a target for therapy in diverse disease states. Eur. J. Immunol. 40: 631-634 (2010). *
Cooke A. Infection and autoimmunity. Blood Cells Mol. Dis. 42: 105-107 (2009).
Cooke A. Review series on helminths, immune modulation and the hygiene hypothesis: how might infection modulate the onset of type 1 diabetes? Immunology 126: 12-17 (2009). *
Cooke A. Th17 cells in inflammatory conditions. Rev. Diabet. Stud. 3: 72-75 (2006). *
Cooke A, Zaccone P, Raine T, Phillips JM, Dunne DW. Infection and autoimmunity: are we winning the war, only to lose the peace? Trends Parasitol. 20: 316-321 (2004). *
Cooksey RC, Jouihan HA, Ajioka RS, Hazel MW, Jones DL, Kushner JP, McClain DA. Oxidative stress, beta cell apoptosis and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145: 5305-5312 (2004). *
Cooper GS, Miller FW, Pandey JP. The role of genetic factors in autoimmune disease: implications for environmental research. Environ. Health Perspect. 107 Suppl. 5: 693-700 (1999).
Cooper JD, Smyth DJ, Bailey R, Payne F, Downes K, Godfrey LM, Masters J, Zeitels LR, Vella A, Walker NM, Todd JA. The candidate genes TAF5L, TCF7, PDCD1, IL6 and ICAM1 cannot be excluded from having effects in type 1 diabetes. BMC Med. Genet. 8: 71 (2007). *
Cooper JD, Smyth DJ, Smiles AM, Plagnol V, Walker NM, Allen JE, Downes K, Barrett JC, Healy BC, Mychaleckyj JC, Warram JH, Todd JA. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat. Genet. 40: 1399-1401 (2008). *
Cooper JD, Walker NM, Healy BC, Smyth DJ, Downes K, Todd JA. Analysis of 55 autoimmune disease and type II diabetes loci: further confirmation of chromosomes 4q27, 12q13.2 and 12q24.13 as type I diabetes loci, and support for a new locus, 12q13.3-q14.1. Genes Immun. 10: S95-S120 (2009).
Cooper JD, Walker NM, Smyth DJ, Downes K, Healy BC, Todd JA. Follow-up of 1715 SNPs from the Wellcome Trust Case Control Consortium genome-wide association study in type I diabetes families. Genes Immun. 10: S85-S94 (2009).
Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, Rai M, Acquaviva F, Cocozza S, Pandolfo M, Geschwind DH. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia. Hum. Mol. Genet. 18: 2452-2461 (2009). *
Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5' UTR of the gene. Thyroid 16: 625-632 (2006).
Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M. Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 58: 1363-1373 (2009).
Cordovado SK, Hancock LN, Simone AE, Hendrix M, Mueller PW. High-resolution genotyping of HLA-DQA1 in the GoKinD study and identification of novel alleles HLA-DQA1*040102, HLA-DQA1*0402 and HLA-DQA1*0404. Tissue Antigens 65: 448-458 (2005). *
Cordovado SK, Zhao Y, Warram JH, Gong H, Anderson KL, Hendrix MM, Hancock LN, Cleary PA, Mueller PW. Nephropathy in type 1 diabetes is diminished in carriers of HLA-DRB1*04: the genetics of kidneys in diabetes (GoKinD) study. Diabetes 57: 518-522 (2008). *
Corella D, Qi L, Tai ES, Deurenberg-Yap M, Tan CE, Chew SK, Ordovas JM. Perilipin gene variation determines higher susceptibility to insulin resistance in Asian women when consuming a high-saturated fat, low-carbohydrate diet. Diabetes Care 29: 1313-1319 (2006). *
Cornelis F, Faure S, Martinez M, Prud'homme JF, Fritz P, Dib C, Alves H, Barrera P, de Vries N, Balsa A, Pascual-Salcedo D, Maenaut K, Westhovens R, Migliorini P, Tran TH, Delaye A, Prince N, Lefevre C, Thomas G, Poirier M, et al. New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc. Natl. Acad. Sci. U.S.A. 95: 10746-10750 (1998). *
Cornelis MC, Qi L, Kraft P, Hu FB. TCF7L2, dietary carbohydrate, and risk of type 2 diabetes in US women. Am. J. Clin. Nutr. 89: 1256-1262 (2009). *
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O'Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JR. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice. J. Nutr. Biochem. 20: 806-815 (2009). *
Coroi M, Bontas E, Defranceschi M, Bartos D, Dorobantu M. Ocular manifestations of antiphospholipid (Hughes') syndrome - minor features? Oftalmologia 51: 16-22 (2007).
Corpeleijn E, van der Kallen CJ, Kruijshoop M, Magagnin MG, de Bruin TW, Feskens EJ, Saris WH, Blaak EE. Direct association of a promoter polymorphism in the CD36/FAT fatty acid transporter gene with type 2 diabetes mellitus and insulin resistance. Diabet. Med. 23: 907-911 (2006). *
Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 288: 505-511 (2000). *
Corrales PJ, Lopez Garrido MP, Rodriguez SA, Rubio LL, Lopez Jimenez LM, Oliveira CL, Alfaro Martinez JJ, Lozano Garcia JJ, Lopez AH, Castillo RR, Martinez JE, Romero FB. Clinical differences between patients with MODY-3, MODY-2 and type 2 diabetes mellitus with I27L polymorphism in the HNF1alpha gene. Endocrinol. Nutr. 57: 4-8 (2010).
Correa FO, Goncalves D, Figueredo CM, Bastos AS, Gustafsson A, Orrico SR. Effect of periodontal treatment on metabolic control, systemic inflammation and cytokines in patients with type 2 diabetes. J. Clin. Periodontol. Nov 24 [Epub ahead of print] (2009). *
Corte-Real J, Duarte N, Tavares L, Penha-Goncalves C. Autoimmunity triggers in the NOD mouse: a role for natural auto-antibody reactivities in type 1 diabetes. Ann. N. Y. Acad. Sci. 1173: 442-448 (2009). *
Cortez-Pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract. Res. Clin. Gastroenterol. 18: 1089-1104 (2004).
Corton JC, Brown-Borg HM. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity. J. Gerontol. A. Biol. Sci. Med. Sci. 60: 1494-1509 (2005).
Cosar M, Songur A, Sahin O, Uz E, Yilmaz R, Yagmurca M, Ozen OA. The neuroprotective effect of fish n-3 fatty acids in the hippocampus of diabetic rats. Nutr. Neurosci. 11: 161-166 (2008).
Cosentino A, Gambelunghe G, Tortoioli C, Falorni A. CTLA-4 gene polymorphism contributes to the genetic risk for latent autoimmune diabetes in adults. Ann. N. Y. Acad. Sci. 958: 337-340 (2002). *
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166 (2007). *
Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavoie A, Levesque R, Chiasson J, Rabasa-Lhoret R. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab. 31: 221-232 (2005). *
Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Levesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa-Lhoret R. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J. Cyst. Fibros. 6: 376-383 (2007).
Costa V, Casamassimi A, Esposito K, Villani A, Capone M, Iannella R, Schisano B, Ciotola M, Di Palo C, Corrado FC, Santangelo F, Giugliano D, Ciccodicola A. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy. J. Biomed. Biotechnol. 2009: 126917 (2009). *
Costacou T, Ferrell RE, Ellis D, Orchard TJ. Haptoglobin genotype and renal function decline in type 1 diabetes. Diabetes 58: 2904-2909 (2009).
Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 57: 1702-1706 (2008). *
Cotellessa M, Minicucci L, Diana MC, Prigione F, Di Febbraro L, Gagliardini R, Manca A, Battistini F, Taccetti G, Magazzu G, Padoan R, Pizzamiglio G, Raia V, Iapichino L, Cardella F, Grinzich G, Lucidi V, Tuccio G, Bignamini E, Salvatore D, Lorini R. Phenotype/genotype correlation and cystic fibrosis related diabetes mellitus (Italian Multicenter Study). J. Pediatr. Endocrinol. Metab. 13: 1087-1093 (2000).
Coulombe M, Gill RG. The immunobiology of pancreatic islet transplantation. Adv. Exp. Med. Biol. 552: 154-169 (2004).
Couper JJ, Pe�a AS. Folate, homocysteine, and candidate genes for vascular disease in children with type 1 diabetes. Pediatr. Diabetes 9: 345-347 (2008).
Courbebaisse M, Souberbielle JC, Thervet E. Potential nonclassical effects of vitamin D in transplant recipients. Transplantation 89: 131-137 (2010).
Couri CE, Voltarelli JC. Potencial role of stem cell therapy in type 1 diabetes mellitus. Arq. Bras. Endocrinol. Metabol. 52: 407-415 (2008). *
Cousins L, Graham M, Tooze R, Carter C, Miller JR, Powrie FM, Macpherson GG, Butcher GW. Eosinophilic bowel disease controlled by the BB rat-derived lymphopenia/Gimap5 gene. Gastroenterology 131: 1475-1485 (2006). *
Couzin J. Clinical research. Deaths in diabetes trial challenge a long-held theory. Science 319: 884-885 (2008). *
Couzin J. Immunology. Diabetes studies conflict on power of spleen cells. Science 311: 1694 (2006). *
Cox D. Understanding your blood glucose - a new internet-based program. Diabetes Forecast 58: 66 (2005).
Cox NJ, Wapelhorst B, Morrison VA, Johnson L, Pinchuk L, Spielman RS, Todd JA, Concannon P. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am. J. Hum. Genet. 69: 820-830 (2001). *
Cox SL. Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today (Barc.) 42: 139-146 (2006).
Coyle AT, O'keeffe MB, Kinsella BT. 15-Deoxy delta-prostaglandin J suppresses transcription by promoter 3 of the human thromboxane A receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells. FEBS J. 272: 4754-4773 (2005). *
Cozzone D, Debard C, Dif N, Ricard N, Disse E, Vouillarmet J, Rabasa-Lhoret R, Laville M, Pruneau D, Rieusset J, Lefai E, Vidal H. Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49: 990-999 (2006). *
Craig D, Robins G, Howdle PD. Advances in celiac disease. Curr. Opin. Gastroenterol. 23: 142-148 (2007).
Crane IJ, Forrester JV. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. Immunol. 25: 75-102 (2005).
Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 292: E740-E747 (2007). *
Cresci S. Pharmacogenetics of the PPAR genes and cardiovascular disease. Pharmacogenomics 8: 1581-1595 (2007).
Cresti S, Ouaissi M, Sielezneff I, Chaix JB, Pirro N, Berthet B, Consentino B, Sastre B. Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report. World J. Surg. Oncol. 6: 136 (2008). *
Creusot RJ, Fathman CG. Gene therapy for type 1 diabetes: a novel approach for targeted treatment of autoimmunity. J. Clin. Invest. 114: 892-894 (2004). *
Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, Fathman CG. Lymphoid tissue specific homing of bone marrow-derived dendritic cells. Blood 113: 6638-6647 (2009). *
Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG. Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin. Immunol. 127: 176-187 (2008). *
Crimmins NA, Martin LJ. Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes. Rev. 8: 419-423 (2007).
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76: 561-571 (2005). *
Crosas B, Hyndman DJ, Gallego O, Martras S, Pares X, Flynn TG, Farres J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373: 973-979 (2003). *
Crunkhorn S. Metabolic disease: dual benefit of bile acid receptor agonist. Nat. Rev. Drug Discov. 8: 848 (2009).
Cruz AA, Akaishi PM, Vargas MA, de Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases. Ophthal. Plast. Reconstr. Surg. 23: 104-108 (2007).
Cruz JC, Rode EC, Gomez LS, Cabrera JA, Ortega AH, Mato GM, Amador PA, Puig ME, Alonso ED, Diaz-Horta O. Celiac disease associated antibodies in persons with latent autoimmune diabetes of adult and type 2 diabetes. Autoimmunity 40: 103-107 (2007).
Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, Sanchez-Barrera R, Wacher NH, Carvajal-Sandoval G, Kumate J. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. J. Endocrinol. Invest. 31: 694-699 (2008).
Csaszar A, Abel T. Receptor polymorphisms and diseases. Eur. J. Pharmacol. 414: 9-22 (2001). *
Csiszar A, Ungvari ZI. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNFalpha signaling. Am. J. Physiol. Heart Circ. Physiol. 295: H475-H476 (2008). *
Cuadrado A, Aresti S, Cortes MA, Gomez-Ortega JM, Salcines JR. Autoimmune hepatitis and agranulocytosis. Dig. Liver Dis. 41: e14-e16 (2009).
Cubero FJ, Nieto N. Ethanol and arachidonic acid synergize to activate Kupffer cells and modulate the fibrogenic response via tumor necrosis factor alpha, reduced glutathione, and transforming growth factor beta-dependent mechanisms. Hepatology 48: 2027-2039 (2008). *
Cucca F, Congia M, Trowsdale J, Powis SH. Insulin-dependent diabetes mellitus and the major histocompatibility complex peptide transporters TAP1 and TAP2: no association in a population with a high disease incidence. Tissue Antigens 44: 234-240 (1994).
Cucca F, Contu D, Zavattari P, Murru D. Correlation between major histocompatibility complex (MHC)-class II and type 1 diabetes. Minerva Endocrinol. 28: 111-122 (2003).
Cucca F, Dudbridge F, Loddo M, Mulargia AP, Lampis R, Angius E, De Virgiliis S, Koeleman BP, Bain SC, Barnett AH, Gilchrist F, Cordell H, Welsh K, Todd JA. The HLA-DPB1-associated component of the IDDM1 and its relationship to the major loci HLA-DQB1, -DQA1, and -DRB1. Diabetes 50: 1200-1205 (2001). *
Cucca F, Lampis R, Congia M, Angius E, Nutland S, Bain SC, Barnett AH, Todd JA. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum. Mol. Genet. 10: 2025-2037 (2001). *
Cui G, Qin X, Zhang Y, Gong Z, Ge B, Zang YQ. Berberine differentially modulates the activities of Erk, p38 MAPK and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J. Biol. Chem. 284: 28420-28429 (2009). *
Cui G, Zhang Y, Gong Z, Zhang JZ, Zang YQ. Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes. Cell. Res. 19: 574-583 (2009).
Cui H, Tucker-Burden C, Cauffiel SM, Barry AK, Iwakoshi NN, Weber CJ, Safley SA. Long-term metabolic control of autoimmune diabetes in spontaneously diabetic nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. Transplantation 88: 160-169 (2009).
Culverhouse R, Jin W, Jin CH, Hinrichs AL, Suarez BK. Power and false-positive rates for the restricted partition method (RPM) in a large candidate gene data set. BMC Proc. 3 Suppl. 7: S74 (2009). *
Cunninghame Graham DS. Genome-wide association studies in systemic lupus erythematosus: a perspective. Arthritis Res. Ther. 11: 119 (2009). *
Curran DR, McArdle JR, Talwalkar JS. Diabetes mellitus and bone disease in cystic fibrosis. Semin. Respir. Crit. Care Med. 30: 514-530 (2009).
Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin. Liver Dis. 13: 545-563 (2009).
Cussons AJ, Watts GF, Mori TA, Stuckey BG. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovarian syndrome: a randomised controlled trial employing proton magnetic resonance spectroscopy. J. Clin. Endocrinol. Metab. 94: 3842-3848 (2009).
Cvetkovic I, Al-Abed Y, Miljkovic D, Maksimovic-Ivanic D, Roth J, Bacher M, Lan HY, Nicoletti F, Stosic-Grujicic S. Critical role of macrophage migration inhibitory factor (MIF) activity in experimental autoimmune diabetes. Endocrinology 146: 2942-2951 (2005). *
Cvjeticanin T, Miljkovic D, Stojanovic I, Dekanski D, Stosic-Grujicic S. Dried leaf extract of Olea europaea ameliorates islet-directed autoimmunity in mice. Br. J. Nutr. Dec 22 [Epub ahead of print] (2009). *
Cvjeticanin T, Stojanovic I, Timotijevic G, Stosic-Grujicic S, Miljkovic D. T cells cooperate with palmitic acid in induction of beta cell apoptosis. BMC Immunol. 10: 29 (2009). *
Cyganek K, Mirkiewicz-Sieradzka B, Malecki MT, Wolkow P, Skupien J, Bobrek J, Czogala M, Klupa T, Sieradzki J. Clinical risk factors and the role of VDR gene polymorphisms in diabetic retinopathy in Polish type 2 diabetes patients. Acta Diabetol. 43: 114-119 (2006). *
Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *
Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262 (2007).
Czako L, Hegyi P, Rakonczay Z Jr, Wittmann T, Otsuki M. Interactions between the endocrine and exocrine pancreas and their clinical relevance. Pancreatology 9: 351-359 (2009).
Czupryniak L, Mlynarski W, Pawlowski M, Saryusz-Wolska M, Borkowska A, Klich I, Bodalski J, Loba J. Circadian blood pressure variation in normotensive type 2 diabetes patients and angiotensin converting enzyme polymorphism. Diabetes Res. Clin. Pract. 80: 386-391 (2008).
D'Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, Mathis D. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl. Acad. Sci. U.S.A. 105: 19857-19862 (2008). *
d'Annunzio G, Giannattasio A, Poggi E, Castellano E, Calvi A, Pistorio A, Barabino A, Lorini R. beta-Cell autoimmunity in pediatric celiac: the case for routine screening? Diabetes Care 32: 254-256 (2009).
d'Annunzio G, Minuto N, D'Amato E, de Toni T, Lombardo F, Pasquali L, Lorini R. Wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy and deafness): similar phenotypes by different genetic mechanisms. Diabetes Care 31: 1743-1745 (2008). *
D'Arezzo M, Balestra E, Fanciulli E, Freddi P, Sagripanti S, Mazzucchelli R, Montironi R, Cangiotti A, Merlini G, Frasca' GM. Nephrotic proteinuria with type 2 diabetes mellitus and autoimmune thyroiditis. G. Ital. Nefrol. 26: 621-624 (2009).
da Silva Krause M, de Bittencourt PI Jr. Type 1 diabetes: can exercise impair the autoimmune event? The L-arginine/glutamine coupling hypothesis. Cell Biochem. Funct. 26: 406-433 (2008). *
Daberkow U, Dorffel Y, Schmidt H, Scholze J. Multifocal nodular fatty infiltration of the liver associated with porphyria and haemochromatosis. Dtsch. Med. Wochenschr. 129: 617-620 (2004).
Dag A, Firat ET, Arikan S, Kadiroglu AK, Kaplan A. The effect of periodontal therapy on serum TNF-alpha and HbA1c levels in type 2 diabetic patients. Aust. Dent. J. 54: 17-22 (2009).
Dagdelen S, Hascelik G, Bayraktar M. Simultaneous triple organ specific autoantibody profiling in adult patients with type 1 diabetes mellitus and their first-degree relatives. Int. J. Clin. Pract. 63: 449-456 (2009).
Dai J, Su YX, Bartell S, Le NA, Ling WH, Liang YQ, Gao L, Wu HY, Veledar E, Vaccarino V. Beneficial effects of designed dietary fatty acid compositions on lipids in triacylglycerol-rich lipoproteins among Chinese patients with type 2 diabetes mellitus. Metabolism 58: 510-518 (2009). *
Dai YD, Carayanniotis G, Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell. Mol. Immunol. 2: 169-175 (2005). *
Dai YD, Marrero IG, Gros P, Zaghouani H, Wicker LS, Sercarz EE. Slc11a1 enhances the autoimmune diabetogenic T-cell response by altering processing and presentation of pancreatic islet antigens. Diabetes 58: 156-164 (2009). *
Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann. Allergy Asthma Immunol. 90: 23-27 (2003).
Daimon M, Oizumi T, Toriyama S, Karasawa S, Jimbu Y, Wada K, Kameda W, Susa S, Muramatsu M, Kubota I, Kawata S, Kato T. Association of the Ser326Cys polymorphism in the OGG1 gene with type 2 DM. Biochem. Biophys. Res. Commun. 386: 26-29 (2009). *
Daimon M, Sato H, Sasaki S, Toriyama S, Emi M, Muramatsu M, Hunt SC, Hopkins PN, Karasawa S, Wada K, Jimbu Y, Kameda W, Susa S, Oizumi T, Fukao A, Kubota I, Kawata S, Kato T. Salt consumption-dependent association of the GNB3 gene polymorphism with type 2 DM. Biochem. Biophys. Res. Commun. 374: 576-580 (2008). *
Dal Pra C, Chen S, Betterle C, Zanchetta R, McGrath V, Furmaniak J, Rees Smith B. Autoantibodies to human tryptophan hydroxylase and aromatic L-amino acid decarboxylase. Eur. J. Endocrinol. 150: 313-321 (2004). *
Dallaire P, Bellmann K, Laplante M, Gelinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A. Obese mice lacking iNOS are sensitized to the metabolic actions of PPARgamma agonism. Diabetes 57: 1999-2011 (2008). *
Dallos T, Avbelj M, Barak L, Zapletalova J, Pribilincova Z, Krajcirova M, Kostalova L, Battelino T, Kovacs L. CTLA-4 gene polymorphisms predispose to autoimmune endocrinopathies but not to celiac disease. Neuro. Endocrinol. Lett. 29: 334-340 (2008).
Damiani G, Campo I, Zorzetto M, Bozzi V, Disabella E, Caroli A, Ferrarotti I, D'Annunzio G, Pasi A, Martinetti M, Cuccia M. Pro-inflammatory variants of DRB1 and RAGE genes are associated with susceptibility to pediatric type 1 diabetes: a new hypothesis on the adaptive role of autoimmunity. Riv. Biol. 100: 285-304 (2007).
Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 6: e1000058 (2009). *
Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, Pergola PE. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int. 68: 2562-2571 (2005). *
Danescu LG, Levy S, Levy J. Vitamin D and diabetes mellitus. Endocrine 35: 11-17 (2009).
Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit. Rev. Immunol. 25: 103-122 (2005).
Danese S, Rutella S. The Janus face of CD4(+)CD25(+) regulatory T cells in cancer and autoimmunity. Curr. Med. Chem. 14: 649-666 (2007).
Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the Opal study. J. Nutr. Health Aging 13: 198-202 (2009).
Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 206: 1853-1862 (2009). *
Das K, Kar P. Non-alcoholic steatohepatitis. J. Assoc. Physicians India 53: 195-199 (2005).
Das KM. Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294 (2004). *
Das P, Abraham R, David C. HLA transgenic mice as models of human autoimmune diseases. Rev. Immunogenet. 2: 105-114 (2000).
Das S, Bhoi SK, Baliarsinha AK, Baig MA. Autoimmunity, insulin resistance and Beta cell function in subjects with low body weight type 2 diabetes mellitus. Metab. Syndr. Relat. Disord. 5: 136-141 (2007).
Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases. Recent Patents Cardiovasc. Drug Discov. 1: 193-209 (2006).
Das SK, Chu W, Zhang Z, Hasstedt SJ, Elbein SC. Calsquestrin 1 (CASQ1) gene polymorphisms under chromosome 1q21 linkage peak are associated with type 2 diabetes in Northern European Caucasians. Diabetes 53: 3300-3306 (2004). *
Das UN. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 7: 9 (2008). *
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot. Essent. Fatty Acids 72: 343-350 (2005). *
Das UN. Essential fatty acids - a review. Curr. Pharm. Biotechnol. 7: 467-482 (2006).
Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol. J. 1: 420-439 (2006). *
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268 (2007). *
Das UN. Perinatal supplementation of long-chain polyunsaturated fatty acids, immune response and adult diseases. Med. Sci. Monit. 10: HY19-HY25 (2004). *
Das UN, Puskas LG. Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders. Lipids Health Dis. 8: 61 (2009). *
Das UN, Rao AA. Gene expression profile in obesity and type 2 diabetes mellitus. Lipids Health Dis. 6: 35 (2007). *
Dassopoulos T, Nguyen GC, Bitton A, Bromfield GP, Schumm LP, Wu Y, Elkadri A, Regueiro M, Siemanowski B, Torres EA, Gregory FJ, Kane SV, Harrell LE, Franchimont D, Achkar JP, Griffiths A, Brant SR, Rioux JD, Taylor KD, Duerr RH, Silverberg MS, et al. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm. Bowel Dis. 13: 975-983 (2007). *
Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM; NIDDK IBD Genetics Consortium, Burek CL, Brant SR. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am. J. Gastroenterol. Oct 13 [Epub ahead of print] (2009). *
Dasu MR, Devaraj S, Ling Z, Hwang DH, Jialal I. High glucose induces Toll-like receptor expression in human monocytes: mechanism of activation. Diabetes 57: 3090-3098 (2008). *
Dasu MR, Devaraj S, Park S, Jialal I. Increased Toll-like receptor activation and TLR ligands in recently diagnosed type 2 diabetes subjects. Diabetes Care Jan 12 [Epub ahead of print] (2010).
Dasu MR, Park S, Devaraj S, Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 150: 3457-3464 (2009). *
Daum S, Zeitz M. Native sprue. Schweiz. Rundsch. Med. Prax. 95: 1983-1986 (2006).
Davey JC, Nomikos AP, Wungjiranirun M, Sherman JR, Ingram L, Batki C, Lariviere JP, Hamilton JW. Arsenic as an endocrine disruptor: arsenic disrupts retinoic acid receptor-and thyroid hormone receptor-mediated gene regulation and thyroid hormone-mediated amphibian tail metamorphosis. Environ. Health Perspect. 116: 165-172 (2008). *
Davi G, Falco A. Oxidant stress, inflammation and atherogenesis. Lupus 14: 760-764 (2005).
David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB; NASH CRN Research Group. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology 49: 1904-1912 (2009). *
Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin. Drug Saf. 5: 145-156 (2006).
Davidson MH, Yannicelli HD. New concepts in dyslipidemia in the metabolic syndrome and diabetes. Metab. Syndr. Relat. Disord. 4: 299-314 (2006).
Davies E, Tsang CW, Ghazali AR, Harris RM, Waring RH. Effects of culture with TNF-alpha, TGF-beta and insulin on sulphotransferase (SULT 1A1 and 1A3) activity in human colon and neuronal cell lines. Toxicol. In Vitro 18: 749-754 (2004).
Davies H, Brophy S, Fielding A, Bingley P, Chandler M, Hilldrup I, Brooks C, Williams R. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabet. Med. 25: 1354-1357 (2008). *
Davies JM. Molecular mimicry: can epitope mimicry induce autoimmune disease? Immunol. Cell Biol. 75: 113-126 (1997). *
Davila JA. Diabetes and hepatocellular carcinoma: what role does diabetes have in the presence of other known risk factors? Am. J. Gastroenterol. 105: 632-634 (2010). *
Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54: 533-539 (2005). *
Davis PB, di Sant'Agnese PA. Diagnosis and treatment of cystic fibrosis. An update. Chest 85: 802-809 (1984). *
Davison LJ, Weenink SM, Christie MR, Herrtage ME, Catchpole B. Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. Vet. Immunol. Immunopathol. 126: 83-90 (2008).
Davoodi-Semiromi A, McDuffie M, Litherland S, Clare-Salzler M. Truncated pStat5B is associated with the Idd4 locus in NOD mice. Biochem. Biophys. Res. Commun. 356: 655-661 (2007). *
Dawkins RL, Kay PH, Christiansen FT. Immunogenetics of rheumatoid arthritis. Ann. Acad. Med. Singapore 12: 155-163 (1983).
Dawkins RL, Martin E, Saueracker G, Kay PH, Leaver A, Christiansen FT. Supratypes and ancestral haplotypes in IDDM: potential importance of central non-HLA MHC genes. J. Autoimmun. 3 Suppl. 1: 63-68 (1990).
Dayspring T, Pokrywka G. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Curr. Atheroscler. Rep. 8: 356-364 (2006).
de Abreu DA, Eyles D, Feron F. Vitamin D, a neuro-immunomodulator: implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology 34 Suppl. 1: S265-S277 (2009).
de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48 Suppl. 1: S104-S112 (2008). *
De Bellis A, Bizzarro A, Pivonello R, Lombardi G, Bellastella A. Prolactin and autoimmunity. Pituitary 8: 25-30 (2005). *
De Bellis A, Kelestimur F, Sinisi AA, Ruocco G, Tirelli G, Battaglia M, Bellastella G, Conzo G, Tanriverdi F, Unluhizarci K, Bizzarro A, Bellastella A. Anti-hypothalamus and anti-pituitary antibodies may contribute to perpetuate the hypopituitarism in patients with Sheehan's syndrome. Eur. J. Endocrinol. 158: 147-152 (2008). *
De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J. Clin. Endocrinol. Metab. 93: 363-371 (2008). *
De Block CE, De Leeuw IH, Van Gaal LF. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J. Clin. Endocrinol. Metab. 84: 4062-4067 (1999).
De Block CE, Van Campenhout CM, De Leeuw IH, Keenoy BM, Martin M, Van Hoof V, Van Gaal LF. Soluble transferrin receptor level: a new marker of iron deficiency anemia, a common manifestation of gastric autoimmunity in type 1 diabetes. Diabetes Care 23: 1384-1388 (2000).
de Boer RA, Martens FM, Kuipers I, Boomsma F, Visseren FL. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. J. Hum. Hypertens. 24: 74-76 (2010).
de Campo A, Toplak H, Wascher TC, Schallmoser K, Friehs A, Schmidt H, Kostner GM. Evaluation of a newly discovered LDL receptor mutation (exon 10, GAC>AAC, D271N, "FH Graz-1") in familial hypercholesterolemia - a family study. Acta Med. Austriaca 26: 20-25 (1999).
De Carlo E, Tamagno G, Martini C, Maffei P, Rubello D, Luca M, Sicolo N. Autoimmune diabetes mellitus, Hodgkin's disease and Graves' ophthalmopathy in a patient with 8.1 ancestral haplotype. Horm. Metab. Res. 36: 97-100 (2004).
de Carmo Silva R, Kater CE, Dib SA, Laureti S, Forini F, Cosentino A, Falorni A. Autoantibodies against recombinant human steroidogenic enzymes 21-hydroxylase, side-chain cleavage and 17alpha-hydroxylase in Addison's disease and autoimmune polyendocrine syndrome type III. Eur. J. Endocrinol. 142: 187-194 (2000). *
De Carvalho Bittencourt M, Herren S, Graber P, Vilbois F, Pasquali C, Berney C, Plitz T, Nicoletti F, Kosco-Vilbois MH. Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetes. Eur. J. Immunol. 35: 1501-1509 (2005). *
De Cosmo S, Minenna A, Zhang YY, Thompson R, Miscio G, Vedovato M, Rauseo A, Saller A, Mastroianno S, Pellegrini F, Trevisan R, Fioretto P, Doria A, Trischitta V. Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. Am. J. Kidney Dis. 53: 273-280 (2009).
De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P; on behalf of the BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from Benedict. Diabetes 58: 2920-2929 (2009).
De Fabiani E, Mitro N, Godio C, Gilardi F, Caruso D, Crestani M. Bile acid signaling to the nucleus: finding new connections in the transcriptional regulation of metabolic pathways. Biochimie 86: 771-778 (2004).
de Fraia Pinto L, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, de Oliveira Carvalho P, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J Jr, Gambero A. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int. 30: 603-610 (2010). *
De Franco S, Chiocchetti A, Ferretti M, Castelli L, Cadario F, Cerutti F, Rabbone I, Indelicato M, Mazzarino C, Chessa M, Bona G, Dianzani U. Defective function of the Fas apoptotic pathway in type 1 diabetes mellitus correlates with age at onset. Int. J. Immunopathol. Pharmacol. 20: 567-576 (2007).
de Gottardi A, de Saussure P. Celiac disease in disguise. Rev. Med. Suisse. 1: 2008-2011 (2005).
de Graaff LC, Smit JW, Radder JK. Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus. Neth. J. Med. 65: 235-247 (2007). *
De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, Cohen A, Langelier D, Bitton A, Compston A, Hafler DA, Rioux JD. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur. J. Hum. Genet. 14: 317-321 (2006). *
de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis; a cross-sectional study. Ann. Rheum. Dis. 66: 589-598 (2007). *
de Jersey J, Snelgrove SL, Palmer SE, Teteris SA, Mullbacher A, Miller JF, Slattery RM. beta Cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice. Proc. Natl. Acad. Sci. U.S.A. 104: 1295-1300 (2007). *
de Jongh BM, Bruining GJ, Schreuder GM, Schuurman RK, Radder JK, van Loghem E, Meera Khan P, Hauptmann G, van Rood JJ. HLA and GM in insulin-dependent diabetes in the Netherlands: report on a combined multiplex family and population study. Hum. Immunol. 10: 5-21 (1984).
De Juan D, Mart�n-Villa JM, Gomez-Reino JJ, Vicario JL, Corell A, Martinez-Laso J, Benmammar D, Arnaiz-Villena A. Differential contribution of C4 and HLA-DQ genes to systemic lupus erythematosus susceptibility. Hum. Genet. 91: 579-584 (1993).
de Kort S, Hokken-Koelega A. The PPAR-gamma Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age. Eur. J. Endocrinol. 162: 49-52 (2010).
de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J. Alzheimers Dis. 10: 89-109 (2006).
de Ledinghen V, Ratziu V, Causse X, Le Bail B, Capron D, Renou C, Pilette C, Oules V, Gelsi E, Oberti F, Vallet-Pichard A, Le Provost N, Cadranel JF; Association Francaise pour l'Etude du Foie Groupe Epidemiologie et Evaluation. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J. Hepatol. 45: 592-599 (2006). *
de Luis D, Ballesteros M, Cano I, Fernandez M, Izaola O, de la Lama G, Lopez Guzman A, Maldonado A, Martin MA, Munoz C, Ruiz E. Current status of clinical nutrition at the network of public hospitals from Castilla y Leon. Nutr. Hosp. 21: 357-361 (2006).
de Luis DA, Conde R, Aller R, Izaola O, Gonzalez Sagrado M, Perez Castrillon JL, Duenas A, Romero E. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriglyceridemia: an open study. Eur. Rev. Med. Pharmacol. Sci. 13: 51-55 (2009).
de Luis DA, Gonzalez Sagrado M, Aller R, Izaola O, Conde R. Influence of Lys656Asn polymorphism of leptin receptor gene on insulin resistance in patients with diabetes mellitus type 2. Diabetes Res. Clin. Pract. 81: e9-e11 (2008).
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of G308A polymorphism of tumor necrosis factor alpha gene on surgical results of biliopancreatic diversion. Obes. Surg. Jun 20 [Epub ahead of print] (2008). *
de Luis DA, Pacheco D, Aller R, Gonzalez Sagrado M, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T, Perez Castrillon JL. Influence of -55CT polymorphism of UCP3 gene on surgical results of biliopancreatic diversion. Obes. Surg. May 17 [Epub ahead of print] (2008).
de Luis DA, Sagrado MG, Izaola O, Terroba MC, Cuellar L, Conde R, Martin T. Influence of Ala54Thr polymorphism of fatty acid-binding protein-2 on clinical results of biliopancreatic diversion. Nutrition 24: 300-304 (2008). *
de Mestier L, Dahan M, Hammel P, Hillaire S, Felce M, Penfornis A, Levy P, Ruszniewski P. Complete resolution of insulinorequerant diabetes mellitus in a patient with autoimmune pancreatitis following treatment with corticosteroids. Gastroenterol. Clin. Biol. Jan 20 [Epub ahead of print] (2010).
de Rooij SR, Painter RC, Phillips DI, Osmond C, Tanck MW, Defesche JC, Bossuyt PM, Michels RP, Bleker OP, Roseboom TJ. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine. Diabetes Care 29: 1052-1057 (2006). *
De Silva NM, Steele A, Shields B, Knight B, Parnell K, Weedon MN, Hattersley AT, Frayling TM. The transcription factor 7-like 2 (TCF7L2) gene is associated with type 2 diabetes in UK community-based cases, but the risk allele frequency is reduced compared with UK cases selected for genetic studies. Diabet. Med. 24: 1067-1072 (2007). *
de Villiers EM, Kimmel R, Leppik L, Gunst K. Intragenomic rearrangement in TT viruses: a possible role in the pathogenesis of disease. Curr. Top. Microbiol. Immunol. 331: 91-107 (2009).
de Wet H, Rees MG, Shimomura K, Aittoniemi J, Patch AM, Flanagan SE, Ellard S, Hattersley AT, Sansom MS, Ashcroft FM. Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes. Proc. Natl. Acad. Sci. U.S.A. 104: 18988-18992 (2007). *
de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, Rooney CM, Schumacher TN. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J. Immunol. 180: 6365-6373 (2008). *
Deakin S, Guernier S, James RW. Pharmacogenetic interaction between paraoxonase-1 gene promoter polymorphism C-107T and statin. Pharmacogenet. Genomics 17: 451-457 (2007).
Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J. Mol. Med. 79: 30-47 (2001). *
Deckelbaum RJ, Worgall TS, Seo T. n-3 Fatty acids and gene expression. Am. J. Clin. Nutr. 83: 1520S-1525S (2006). *
Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R. D. 7: 99-110 (2006).
Decsi T, Szabo E, Burus I, Marosvolgyi T, Kozari A, Erhardt E, Soltesz G. Low contribution of n-3 polyunsaturated fatty acids to plasma and erythrocyte membrane lipids in diabetic young adults. Prostaglandins Leukot. Essent. Fatty Acids 76: 159-164 (2007). *
Dedoussis GV, Kaliora AC, Panagiotakos DB. Genes, diet and type 2 diabetes mellitus: a review. Rev. Diabet. Stud. 4: 13-24 (2007). *
Dedov II, Khaitov RM, Alekseev LP, Boldyreva MN, Shestakova MV, Trofimov DIu, Kuraeva TL, Peterkova VA. The use of achievements in human molecular immunogenetics in the management of type 1 diabetes mellitus. Vestn. Ross. Akad. Med. Nauk. 10: 45-51 (2008).
Deeb SS, Brunzell JD. The role of the PGC1alpha Gly482Ser polymorphism in weight gain due to intensive diabetes therapy. PPAR Res. 2009: 649286 (2009). *
Deedwania PC, Gupta R. Management issues in the metabolic syndrome. J. Assoc. Physicians India 54: 797-810 (2006).
DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int. J. Clin. Pract. Suppl. 143: 9-21 (2004).
Degli-Esposti MA, Abraham LJ, McCann V, Spies T, Christiansen FT, Dawkins RL. Ancestral haplotypes reveal the role of the central MHC in the immunogenetics of IDDM. Immunogenetics 36: 345-356 (1992).
Dehan C, Tran Van D, Delacour H, Deroudilhe G, Fritsch N, Chiappini J, Dardare E, Gardet V. Diabetic ketoacidosis with a fatal issue: is it a MODY3 (maturity-onset diabetes of the young type 3)? Ann. Biol. Clin. (Paris) 66: 189-193 (2008).
Deitel M. Slow-progression, autoimmune, type 1 diabetes in adults: a cause of failure of resolution of diabetes after bariatric surgery. Surg. Obes. Relat. Dis. 5: 705-706 (2009).
Deitel M. From bariatric to metabolic surgery in non-obese subjects: time for some caution. Arq. Bras. Endocrinol. Metabol. 53: 246-251 (2009). *
Deja G, Myrda A, Jarosz-Chobot P, Siekiera U. The assessment of autoimmunological status and prevalence of different forms of celiac disease among children with type 1 diabetes mellitus and celiac disease. Mediators Inflamm. 2008: 285989 (2008). *
Del Bas JM, Ricketts ML, Vaque M, Sala E, Quesada H, Ardevol A, Salvado MJ, Blay M, Arola L, Moore DD, Pujadas G, Fernandez-Larrea J, Blade C. Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner. Mol. Nutr. Food Res. 53: 805-814 (2009).
Del Poggio P, Mazzoleni M. Screening in liver disease. World J. Gastroenterol. 12: 5272-5280 (2006). *
Del Rio ML, Lucas CL, Buhler L, Rayat G, Rodriguez-Barbosa JI. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation. J. Leukoc. Biol. Dec 14 [Epub ahead of print] (2009). *
Del Rio R, Noubade R, Subramanian M, Saligrama N, Diehl S, Rincon M, Teuscher C. SNPs upstream of the minimal promoter control IL-2 expression and are candidates for the autoimmune disease-susceptibility locus Aod2/Idd3/Eae3. Genes Immun. 9: 115-121 (2008). *
Delarue J, LeFoll C, Corporeau C, Lucas D. n-3 Long chain polyunsaturated fatty acids: a nutritional tool to prevent insulin resistance associated to type 2 diabetes and obesity? Reprod. Nutr. Dev. 44: 289-299 (2004).
Delarue J, Magnan C. Free fatty acids and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 10: 142-148 (2007).
Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80: 16-24 (2002). *
Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation. Ann. N. Y. Acad. Sci. 992: 141-157 (2003). *
Della Manna T. Not every diabetic child has type 1 diabetes mellitus. J. Pediatr. (Rio J.) 83: S178-S183 (2007).
Della Manna T, Setian N, Rodrigues JC. Cystic fibrosis-related diabetes: a frequent co-morbidity. Arq. Bras. Endocrinol. Metabol. 52: 188-197 (2008).
Dellon ES, Shaheen NJ. Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology 129: 1132-1134 (2005). *
Delogu LG, Magrini A, Bergamaschi A, Rosato N, Dawson MI, Bottini N, Bottini M. Conjugation of antisense oligonucleotides to PEGylated carbon nanotubes enables efficient knockdown of PTPN22 in T lymphocytes. Bioconjug. Chem. 20: 427-431 (2009). *
Delorme D, Miller SC. Dietary consumption of Echinacea by mice afflicted with autoimmune (type I) diabetes: effect of consuming the herb on hemopoietic and immune cell dynamics. Autoimmunity 38: 453-461 (2005).
DeLuca HF. Vitamin D and the parenteral nutrition patient. Gastroenterology 137: S79-S91 (2009). *
Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J. 15: 2579-2585 (2001). *
Delvecchio CJ, Capone JP. Protein kinase C alpha modulates liver X receptor alpha transactivation. J. Endocrinol. 197: 121-130 (2008). *
Delvecchio M, Cavallo L. Growth and endocrine function in thalassemia major in childhood and adolescence. J. Endocrinol. Invest. 33: 61-68 (2010).
Delvecchio M, Zecchino C, Faienza MF, Acquafredda A, Barbetti F, Cavallo L. Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet. Diabetes Res. Clin. Pract. 84: 332-334 (2009).
Demenais F, Kanninen T, Lindgren CM, Wiltshire S, Gaget S, Dandrieux C, Almgren P, Sjogren M, Hattersley A, Dina C, Tuomi T, McCarthy MI, Froguel P, Groop LC. A meta-analysis of four European genome screens (GIFT Consortium) shows evidence for a novel region on chromosome 17p11.2-q22 linked to type 2 diabetes. Hum. Mol. Genet. 12: 1865-1873 (2003). *
Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp. Dermatol. 15: 154-160 (2006). *
Demers A, Rodrigue-Way A, Tremblay A. Hexarelin signaling to PPARgamma in metabolic diseases. PPAR Res. 2008: 364784 (2008). *
Demirci H, Yurtcu E, Ergun MA, Yazici AC, Karasu C, Yetkin I. Calpain 10 SNP-44 gene polymorphism affects susceptibility to type 2 diabetes mellitus and diabetic-related conditions. Genet.Test. 12: 305-309 (2008).
Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, Nutland S, Coleman G, Himsworth M, Hardy M, Burren O, Healy B, Walker NM, Koch K, Ouwehand WH, Bradley JR, Wareham NJ, Todd JA, Wicker LS. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat. Genet. 41: 1011-1015 (2009). *
Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 42: 905-914 (2005). *
Deng T, Shan S, Li ZB, Wu ZW, Liao CZ, Ko B, Lu XP, Cheng J, Ning ZQ. A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. Biol. Pharm. Bull. 28: 1192-1196 (2005). *
Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 101: 12634-12639 (2004). *
Denning GM, Stoll LL. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease? Pediatr. Pulmonol. 41: 23-34 (2006).
Dentelli P, Trombetta A, Togliatto G, Zeoli A, Rosso A, Uberti B, Orso F, Taverna D, Pegoraro L, Brizzi MF. Formation of STAT5/PPARgamma transcriptional complex modulates angiogenic cell bioavailability in diabetes. Arterioscler. Thromb. Vasc. Biol. 29: 114-120 (2009).
Deopurkar R, Ghanim H, Friedman J, Abuaysheh S, Sia CL, Mohanty P, Viswanathan P, Chaudhuri A, Dandona P. Differential effects of cream, glucose and orange juice on inflammation, endotoxin and the expression of Toll like receptor-4 and suppressor of cytokine signaling-3. Diabetes Care Jan 12 [Epub ahead of print] (2010).
Depczynski B. Coeliac disease and its relation to glycaemic control in adults with type 1 diabetes mellitus. Diabetes Res. Clin. Pract. 79: e10 (2008).
Derbel S, Doumaguet C, Hubert D, Mosnier-Pudar H, Grabar S, Chelly J, Bienvenu T. Calpain 10 and development of diabetes mellitus in cystic fibrosis. J. Cyst. Fibros. 5: 47-51 (2006).
Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26: 1599-1607 (2004). *
Desai M, Clark A. Autoimmune diabetes in adults: lessons from the UKPDS. Diabet. Med. 25 Suppl. 2: 30-34 (2008).
Desai M, Zeggini E, Horton VA, Owen KR, Hattersley AT, Levy JC, Walker M, Gillespie KM, Bingley PJ, Hitman GA, Holman RR, McCarthy MI, Clark A. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia 50: 68-73 (2007). *
Deschamps I, Hors J, Clerget-Darpoux F, Marcelli-Barge A, Lestradet H, Dausset J. Increased risk of insulin-dependent diabetes for siblings of diabetic children with the DR 3 haplotype of the mother. C. R. Acad. Sci. III. 308: 501-506 (1989).
Deschamps I, Khalil I. The role of the HLA system in the genetics of type I diabetes mellitus. Diabete. Metab. 18: 253-263 (1992).
Deschamps I, Marcelli-Barge A, Lallemand N, Poirier JC, Bochu V, Prevost P, Busson A, Masset M, Lestradet H, Hors J. Study of cis and trans interactions between extended HLA-haplotypes in insulin-dependent diabetes. Tissue Antigens 31: 259-269 (1988).
Deshmukh H, Kim-Howard X, Nath SK. Replication of recently identified associated single-nucleotide polymorphisms from six autoimmune diseases in Genetic Analysis Workshop 16 rheumatoid arthritis data. BMC Proc. 3 Suppl. 7: S31 (2009). *
Deshpande AV, Lahei ER, Shun A, Martin HC, O'loughlin EV. Idiopathic fibrosing pancreatitis in children-a single-center experience. J. Pediatr. Surg. 41: 1987-1991 (2006).
Desmeules P, Cousineau J, Allard P. Biological variation of glycated haemoglobin in a paediatric population and its application to calculation of significant change between results. Ann. Clin. Biochem. Nov 25 [Epub ahead of print] (2009).
Dessein PH, Norton GR, Woodiwiss AJ, Joffe BI, Wolfe F. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J. Rheumatol. 34: 943-951 (2007).
Dessein R, Peyrin-Biroulet L, Chamaillard M. Intestinal microbiota gives a Nod to the hygiene hypothesis in type 1 diabetes. Gastroenterology 137: 381-383 (2009). *
DeStefano F, Mullooly JP, Okoro CA, Chen RT, Marcy SM, Ward JI, Vadheim CM, Black SB, Shinefield HR, Davis RL, Bohlke K; Vaccine Safety Datalink Team. Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus. Pediatrics 108: e112 (2001). *
Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev. Endocrinol. Metab. 5: 19-28 (2010).
Devaraj S, Dasu MR, Rockwood J, Winter W, Griffen SC, Jialal I. Increased TLR2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a pro-inflammatory state. J. Clin. Endocrinol. Metab. 93: 578-583 (2008). *
Devaraj S, Leonard S, Traber MG, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic. Biol. Med. 44: 1203-1208 (2008).
Devendra D, Galloway TS, Horton SJ, Wilkin TJ. Exploring the idiotypes of insulin antibodies as markers for remission in type 1 diabetes. Diabet. Med. 21: 1316-1324 (2004). *
Devendra D, Miao D, Nakayama M, Eisenbarth GS, Liu E. Pancreatic autoimmunity induction with insulin B:9-23 peptide and viral mimics in the NZB mouse. Ann. N. Y. Acad. Sci. 1079: 135-137 (2006). *
Devoss J, Hou Y, Johannes K, Lu W, Liou GI, Rinn J, Chang H, Caspi R, Fong L, Anderson MS. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J. Exp. Med. 203: 2727-2735 (2006). *
Devoss JJ, Anderson MS. Lessons on immune tolerance from the monogenic disease APS1. Curr. Opin. Genet. Dev. 17: 193-200 (2007).
Devoss JJ, Shum AK, Johannes KP, Lu W, Krawisz AK, Wang P, Yang T, Leclair NP, Austin C, Strauss EC, Anderson MS. Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1. J. Immunol. 181: 4072-4079 (2008). *
Dezsofi A, Szebeni B, Hermann CS, Kapitany A, Veres G, Sipka S, Korner A, Madacsy L, Korponay-Szabo I, Rajczy K, Arato A. Frequencies of genetic polymorphisms of TLR4 and CD14 and of HLA-DQ genotypes in children with celiac disease, type 1 diabetes mellitus, or both. J. Pediatr. Gastroenterol. Nutr. 47: 283-287 (2008). *
Dharancy S, Louvet A, Hollebecque A, Desreumaux P, Mathurin P, Dubuquoy L. Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects. Gastroenterol. Clin. Biol. 32: 339-350 (2008).
Dharmaraj P, Smyth RL. Vaccines for preventing influenza in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD001753 (2009).
Dhimolea E. Canakinumab. MAbs. Jan 15 [Epub ahead of print] (2010).
Di Cesare E, Previti M, Lombardo F, Di Benedetto A, Mazzu N, Romano G, De Luca F, Lasco A, Cucinotta D. Serum anti-p53 autoantibodies in patients with type 1 diabetes. Ann. Clin. Lab. Sci. 31: 253-258 (2001).
Di Dio G, Zanetta F, Zanetta S, Petri A, Bellone S, Bona G. Polyuria and polydipsia in a 5 year-old child: diagnostic problems. Minerva Pediatr. 59: 813-816 (2007).
Di Lorenzo TP, Peakman M, Roep BO. Translational mini-meview series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 148: 1-16 (2007). *
Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. N. Engl. J. Med. 356: 1842-1852 (2007). *
Diallo EM, Wilhelm KG Jr, Thompson DL, Koenig RJ. Variable RXR requirements for thyroid hormone responsiveness of endogenous genes. Mol. Cell. Endocrinol. 264: 149-156 (2007).
Diamant AL, Babey SH, Hastert TA, Brown ER. Diabetes: the growing epidemic. Policy Brief UCLA Cent. Health Policy Res. PB2007-9: 1-12 (2007).
D�az Gomez JM. Cardiovascular mortality in kidney transplatation. Nefrologia 28: 27-30 (2008).
Dib SA. Heterogeneity of type 1 diabetes mellitus. Arq. Bras. Endocrinol. Metabol. 52: 205-218 (2008).
Dib SA. Insulin resistance and metabolic syndrome in type 1 diabetes mellitus. Arq. Bras. Endocrinol. Metabol. 50: 250-263 (2006).
Dib SA, Gomes MB. Etiopathogenesis of type 1 diabetes mellitus: prognostic factors for the evolution of residual beta cell function. Diabetol. Metab. Syndr. 1: 25 (2009). *
Diehl AM. Role of the immune system in the pathogenesis of nonalcoholic steatohepatitis. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 78 (2005). *
Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 54: 303-306 (2005). *
Dieterle C. (Auto)immunological aspects of type 1 diabetes mellitus. MMW Fortschr. Med. 148: 36-39 (2006).
Dietert RR, Dewitt J. Developmental immunotoxicity (DIT): the why, when, and how of DIT testing. Methods Mol. Biol. 598: 17-25 (2010). *
Dieude P, Teixeira VH, Pierlot C, Cornelis F, Petit-Teixeira E; ECRAF. Testing for linkage and association with rheumatoid arthritis a PTPN22 promoter polymorphism reported to be associated and linked with type 1 diabetes in the Caucasian population. Ann. Rheum. Dis. 67: 900-901 (2008).
Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary Jul 29 [Epub ahead of print] (2009).
Dilmec F, Uzer E, Akkafa F, Kose E, van Kuilenburg AB. Detection of VDR gene ApaI and TaqI polymorphisms in patients with type 2 diabetes mellitus using PCR-RFLP method in a Turkish population. J. Diabetes Complications Jan 29 [Epub ahead of print] (2009).
Dilorenzo TP, Serreze DV. The good turned ugly: immunopathogenic basis for diabetogenic CD8 T cells in NOD mice. Immunol. Rev. 204: 250-263 (2005). *
Dinarello CA. Interleukin-1 and tumor necrosis factor: effector cytokines in autoimmune diseases. Semin. Immunol. 4: 133-145 (1992).
Dincer A, Onal S, Timur S, Zeytunluoglu A, Duman E, Zihnioglu F. Differentially displayed proteins as a tool for the development of type 2 diabetes. Ann. Clin. Biochem. 46: 306-310 (2009).
Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 361: 1152-1163 (2009). *
Ding H, Cheng H, Fu Z, Yan L, Yang G. Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene. Chin. Med. J. (Engl.) 114: 1263-1266 (2001).
Ding L, Liu G, Guo W, Zhao H, Zong Z. Ghrelin attenuates plasminogen activator inhibitor-1 production induced by tumor necrosis factor-alpha in HepG2 cells via NF-kappaB pathway. Cell Biol. Int. 32: 1310-1317 (2008).
Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56: 1334-1339 (2007). *
Diniz-Santos DR, Brandao F, Adan L, Moreira A, Vicente EJ, Silva LR. Bone mineralization in young patients with type 1 diabetes mellitus and screening-identified evidence of celiac disease. Dig. Dis. Sci. 53: 1240-1245 (2008). *
Dite P, Novotny I, Trna J, Sevcikova A. Autoimmune pancreatitis. Best Pract. Res. Clin. Gastroenterol. 22: 131-143 (2008).
Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J. Clin. Endocrinol. Metab. 88: 2983-2992 (2003). *
Dittmar M, Poppe R, Bischofs C, Fredenhagen G, Kanitz M, Kahaly GJ. Impaired deoxyribonuclease activity in monoglandular and polyglandular autoimmunity. Exp. Clin. Endocrinol. Diabetes 115: 387-391 (2007).
Dizier MH, Deschamps I, Hors J, Blanc M, Rivat-Peran L, Feingold N, Clerget-Darpoux F. Interaction between HLA and Gm for susceptibility to insulin-dependent diabetes. Rev. Epidemiol. Sante Publique 33: 337-340 (1985).
Djilali-Saiah I, Benini V, Schmitz J, Timsit J, Assan R, Boitard C, Bach JF, Caillat-Zucman S. Absence of primary association between DM gene polymorphism and insulin-dependent diabetes mellitus or celiac disease. Hum. Immunol. 49: 22-27 (1996).
Djilali-Saiah I, Bertin E, Larger E, Timsit J, Assan R, Boitard C, Bach JF, Caillat-Zucman S. Major histocompatibility class II genes polymorphism in insulin dependent diabetes mellitus with or without associated thyroid autoimmunity. Hum. Immunol. 59: 176-182 (1998).
Djilali-Saiah I, Larger E, Harfouch-Hammoud E, Timsit J, Clerc J, Bertin E, Assan R, Boitard C, Bach JF, Caillat-Zucman S. No major role for the CTLA-4 gene in the association of autoimmune thyroid disease with IDDM. Diabetes 47: 125-127 (1998).
Djuric Z, Stamenkovic H, Stankovic T, Milicevic R, Brankovic L, Ciric V, Katic V. Celiac disease prevalence in children and adolescents with type 1 diabetes from Serbia. Pediatr Int. Jan 26 [Epub ahead of print] (2010).
Djurica S, Trbojevic B, Milosevic DP, Markovic N. Autoimmune thyroid disease and associated autoimmunity. Srp. Arh. Celok. Lek. 133 Suppl. 1: 16-24 (2005).
Dobretsov M, Romanovsky D, Stimers JR. Early diabetic neuropathy: triggers and mechanisms. World J. Gastroenterol. 13: 175-191 (2007). *
Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Pract. Res. Clin. Gastroenterol. 20: 531-546 (2006).
Dodge R, Loomans C, Sharma A, Bonner-Weir S. Developmental pathways during in vitro progression of human islet neogenesis. Differentiation 77: 135-147 (2009). *
Doffinger R, Helbert MR, Barcenas-Morales G, Yang K, Dupuis S, Ceron-Gutierrez L, Espitia-Pinzon C, Barnes N, Bothamley G, Casanova JL, Longhurst HJ, Kumararatne DS. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin. Infect. Dis. 38: e10-e14 (2004). *
Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006: 59206 (2006). *
Doggrell SA. Bradykinin B2 receptors as a target in diabetic nephropathy. Curr. Opin. Investig. Drugs 7: 251-255 (2006).
Doggrell SA. Muraglitazar: beneficial or detrimental in the treatment of type 2 diabetes? Expert Opin. Pharmacother. 7: 1229-1233 (2006).
Doi Y, Kubo M, Ninomiya T, Yonemoto K, Iwase M, Arima H, Hata J, Tanizaki Y, Iida M, Kiyohara Y. Impact of Kir6.2 E23K polymorphism on the development of type 2 diabetes in a general Japanese population: the Hisayama study. Diabetes 56: 2829-2833 (2007). *
Dolezalova R, Haluzik M, Bosanska L, Lacinova Z, Stulc T, Haluzik M. Effect of PPAR-gama agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus. Physiol. Res. 56: 741-748 (2007). *
Domberg J, Chao L, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum WA, Schloot NC, Schott M. Circulating chemokines in patients with autoimmune thyroid diseases. Horm. Metab. Res. 40: 416-421 (2008).
Dominguez-Garcia A, Quinteiro-Gonzalez S, Pena-Quintana L, Ramos-Macias L, Quintana-Martel M, Saavedra-Santana P. Carbohydrate metabolism changes in cystic fibrosis. J. Pediatr. Endocrinol. Metab. 20: 621-632 (2007).
Dominguez-Gerpe L, Araujo-Vilar D. Prematurely aged children: molecular alterations leading to Hutchinson-Gilford Progeria and Werner syndromes. Curr. Aging Sci. 1: 202-212 (2008).
Donadieu J, Rolon MA, Pion I, Thomas C, Doz F, Barkaoui M, Robert A, Deville A, Mazingue F, David M, Brauner R, Cabrol S, Garel C, Polak M; French LCH Study Group. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J. Clin. Endocrinol. Metab. 89: 604-609 (2004). *
Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, Della Valentina G, Gardenal R, Dal Mas M, Casarin P, Zanette G, Miranda C. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J. Gastroenterol. 15: 2506-2611 (2009). *
Donadon V, Balbi M, Zanette G. Hyperinsulinemia and risk for hepatocellular carcinoma in patients with chronic liver diseases and type 2 diabetes mellitus. Expert Rev. Gastroenterol. Hepatol. 3: 465-467 (2009). *
Donaghue KC, Margan SH, Chan AK, Holloway B, Silink M, Rangel T, Bennetts B. The association of aldose reductase gene (AKR1B1) polymorphisms with diabetic neuropathy in adolescents. Diabet. Med. 22: 1315-1320 (2005). *
Donaldson MS. Nutrition and cancer: a review of the evidence for an anti-cancer diet. Nutr. J. 3: 19 (2004). *
Donaldson PT, Czaja AJ. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin. Liver Dis. 6: 419-437 (2002).
Donath MY, Ehses JA. Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was. Proc. Natl. Acad. Sci. U.S.A. 103: 12217-12218 (2006). *
Dong B, Qatanani M, Moore DD. Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes. Hepatology 50: 622-629 (2009).
Dong B, Saha PK, Huang W, Chen W, Abu-Elheiga LA, Wakil SJ, Stevens RD, Ilkayeva O, Newgard CB, Chan L, Moore DD. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proc. Natl. Acad. Sci. U.S.A. 106: 18831-18836 (2009). *
Dong C, He L, Li J, Ye F, He M, Wang Y. Association of the Pro12Ala and C1431T polymorphism of the PPAR gamma2 gene and their haplotypes with obesity and type 2 diabetes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 447-451 (2008).
Dong GP, Yu ZS, Liang L, Zou CC, Fu JF, Wang CL. IL-18 gene promoter -137C/G and -607C/A polymorphisms in Chinese Han children with type 1 diabetes mellitus. Int. J. Immunogenet. 34: 75-79 (2007). *
Dong JJ, Zhao JJ, Lee KO, Lir MC, Chan SW, Liao L. Distribution of polymorphism in endothelial nitric oxide synthase gene in Singapore Chinese and its association with diabetic nephropathy. Zhonghua Yi Xue Za Zhi 87: 3415-3417 (2007).
Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59: 267-273 (2010).
Donnelly A. Skin signs of systemic disease. Aust. Fam. Physician 28: 1217-1222 (1999).
Donnelly R, Wang B, Qu X. Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments. Br. J. Clin. Pharmacol. 61: 702-705 (2006). *
Donner H, Braun J, Seidl C, Rau H, Finke R, Ventz M, Walfish PG, Usadel KH, Badenhoop K. Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J. Clin. Endocrinol. Metab. 82: 4130-4132 (1997). *
Donner H, Rau H, Walfish PG, Braun J, Siegmund T, Finke R, Herwig J, Usadel KH, Badenhoop K. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 82: 143-146 (1997). *
Donner H, Tonjes RR, Van der Auwera B, Siegmund T, Braun J, Weets I, Herwig J, Kurth R, Usadel KH, Badenhoop K. The presence or absence of a retroviral long terminal repeat influences the genetic risk for type 1 diabetes conferred by human leukocyte antigen DQ haplotypes. Belgian Diabetes Registry. J. Clin. Endocrinol. Metab. 84: 1404-1408 (1999). *
Doo EC, Hoofnagle JH. The hepatitis B research network. Hepatology 49: S196-S197 (2009).
Doolan A, Donaghue K, Fairchild J, Wong M, Williams AJ. Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes. Diabetes Care 28: 806-809 (2005). *
Doran M. Rheumatoid arthritis and diabetes mellitus: evidence for an association? J. Rheumatol. 34: 460-462 (2007).
Doria A, Wojcik J, Xu R, Gervino EV, Hauser TH, Johnstone MT, Nolan D, Hu FB, Warram JH. Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. JAMA 300: 2389-2397 (2008). *
Dorman J, Steenkiste A, O'Leary L, McCarthy B, Lorenzen T, Foley T. Type 1 diabetes in offspring of parents with type 1 diabetes: the tip of an autoimmune iceberg? Pediatr. Diabetes 1: 17-22 (2000).
Dos Santos Jr RR, Sartori A, Deperon Bonato VL, Coelho Castelo AA, Vilella CA, Zollner RL, Lopes Silva C. Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression. Clin. Exp. Immunol. 149: 570-578 (2007). *
Dos Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. The -106CC genotype of the aldose reductase gene is associated with an increased risk of proliferative diabetic retinopathy in Caucasian-Brazilians with type 2 diabetes. Mol. Genet. Metab. 88: 280-284 (2006). *
Dos Santos KG, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. The catalase -262C/T promoter polymorphism and diabetic complications in Caucasians with type 2 diabetes. Dis. Markers 22: 355-359 (2006).
Dotta F, Fondelli C, Falorni A. Can NK cells be a therapeutic target in human type 1 diabetes? Eur. J. Immunol. 38: 2961-2963 (2008). *
Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 50: 886-890 (2001). *
Douroudis K, Laine AP, Heinonen M, Hermann R, Lipponen K, Veijola R, Simell O, Knip M, Uibo R, Ilonen J, Kisand K. Association of CTLA4 but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates. Hum. Immunol. 70: 536-539 (2009).
Douroudis K, Nemvalts V, Rajasalu T, Kisand K, Uibo R. The CD226 gene in susceptibility of type 1 diabetes. Tissue Antigens 74: 417-419 (2009). *
Douroudis K, Prans E, Haller K, Nemvalts V, Rajasalu T, Tillmann V, Kisand K, Uibo R. Protein tyrosine phosphatase non-receptor type 22 gene variants at position 1858 are associated with type 1 and type 2 diabetes in Estonian population. Tissue Antigens 72: 425-430 (2008). *
Douroudis K, Prans E, Kisand K, Nemvalts V, Uibo R. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms are associated with latent autoimmune diabetes in adults. Clin. Chim. Acta 403: 226-228 (2009). *
Douroudis K, Prans E, Uibo R. CTLA-4 promoter polymorphisms are associated with latent autoimmune diabetes in adults. Hum. Immunol. 70: 921-924 (2009).
Dow CT. Paratuberculosis and type I diabetes. Is this the trigger? Med. Hypotheses 67: 782-785 (2006).
Downes M, Liddle C. Look who's talking: nuclear receptors in the liver and gastrointestinal tract. Cell Metab. 7: 195-199 (2008). *
Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J. Hepatol. 52: 252-257 (2010). *
Draghia-Akli R, Khan AS. Muscle and fat mass modulation in different clinical models. Methods Mol. Biol. 423: 449-460 (2008). *
Dragomir E, Manduteanu I, Calin M, Gan AM, Stan D, Koenen RR, Weber C, Simionescu M. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb. Haemost. 100: 1155-1165 (2008).
Dray C, Daviaud D, Guigne C, Valet P, Castan-Laurell I. Caffeine reduces TNFalpha up-regulation in human adipose tissue primary culture. J. Physiol. Biochem. 63: 329-336 (2007).
DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. 355: 1551-1562 (2006). *
Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br. J. Dermatol. 161: 626-629 (2009). *
Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen AD. Psoriasis and dyslipidaemia: a population-based study. Acta Derm. Venereol. 88: 561-565 (2008).
Drel VR, Xu W, Zhang J, Pavlov IA, Shevalye H, Slusher B, Obrosova IG. Poly(adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy. Endocrinology 150: 5273-5283 (2009). *
Dresch C, Edelmann SL, Marconi P, Brocker T. Lentiviral-mediated transcriptional targeting of dendritic cells for induction of T cell tolerance in vivo. J. Immunol. 181: 4495-4506 (2008). *
Drescher KM, Sosnowska D. Being a mouse in a man's world: what TMEV has taught us about human disease. Front. Biosci. 13: 3775-3785 (2008).
Drew BG, Calkin AC. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist. Curr. Opin. Investig. Drugs 8: 324-330 (2007).
Drew PD, Storer PD, Xu J, Chavis JA. Hormone regulation of microglial cell activation: relevance to multiple sclerosis. Brain Res. Brain Res. Rev. 48: 322-327 (2005).
Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation. Int. J. Biochem. Cell Biol. Oct 15 [Epub ahead of print] (2009).
Driscoll KA, Johnson SB, Barker D, Quittner AL, Deeb LC, Geller DE, Gondor M, Silverstein JH. Risk factors associated with depressive symptoms in caregivers of children with type 1 diabetes or cystic fibrosis. J. Pediatr. Psychol. Jan 22 [Epub ahead of print] (2010).
Driver JP, Foreman O, Mathieu C, van Etten E, Serreze DV. Comparative therapeutic effects of orally administered 1,25-dihydroxyvitamin D(3) and 1alpha-hydroxyvitamin D(3) on type-1 diabetes in non-obese diabetic mice fed a normal-calcaemic diet. Clin. Exp. Immunol. 151: 76-85 (2008). *
Driver JP, Scheuplein F, Chen YG, Grier AE, Wilson SB, Serreze DV. iNKT-cell control of type-1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes Nov 10 [Epub ahead of print] (2009).
Drzewoski J, Sliwinska A, Przybylowska K, Sliwinski T, Kasznicki J, Zurawska-Klis M, Kosmalski M, Majsterek I. Gene polymorphisms and antigen levels of matrix metalloproteinase-1 in type 2 diabetes mellitus coexisting with coronary heart disease. Kardiol. Pol. 66: 1042-1048 (2008).
Du T, Zhou ZG, You S, Huang G, Lin J, Yang L, Li X, Zhou WD, Chao C. Modulation of monocyte hyperresponsiveness to TLR ligands by 1,25-dihydroxy-vitamin D3 from LADA and T2DM. Diabetes Res. Clin. Pract. 83: 208-214 (2009).
Du T, Zhou ZG, You S, Lin J, Yang L, Zhou WD, Huang G, Chao C. Regulation by 1,25-dihydroxy-vitamin D3 on altered TLRs expression and response to ligands of monocyte from autoimmune diabetes. Clin. Chim. Acta 402: 133-138 (2009). *
Du W, Sun H, Wang H, Qiang B, Shen Y, Yao Z, Gu J, Xiong M, Huang W, Chen Z, Zuo J, Hua X, Gao W, Sun Q, Fang F. Confirmation of susceptibility gene loci on chromosome 1 in Northern China Han families with type 2 diabetes. Chin. Med. J. (Engl.) 114: 876-878 (2001).
Du W, Wong FS, Li MO, Peng J, Qi H, Flavell RA, Sherwin R, Wen L. TGF-beta signaling is required for the function of insulin-reactive T regulatory cells. J. Clin. Invest. 116: 1360-1370 (2006). *
Du WN, Sun HX, Wang H, Qiang BQ, Yao ZJ, Gu J, Xiong MM, Huang W, Chen Z, Zuo J, Hua XF, Gao W, Sun Q, Fang FD. Fine mapping of susceptibility genes loci within chromosome 1 in Chinese Han families with type 2 diabetes. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24: 234-237 (2002).
Du ZQ, Fan B, Zhao X, Amoako R, Rothschild MF. Association analyses between type 2 diabetes genes and obesity traits in pigs. Obesity (Silver Spring) 17: 323-329 (2009). *
Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hypertens. 18: 128-133 (2009).
Duarte PM, Neto JB, Casati MZ, Sallum EA, Nociti FH Jr. Diabetes modulates gene expression in the gingival tissues of patients with chronic periodontitis. Oral Dis. 13: 594-599 (2007).
Dubaniewicz A, Jamieson SE, Dubaniewicz-Wybieralska M, Fakiola M, Nancy Miller E, Blackwell JM. Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. Eur. J. Hum. Genet. 13: 829-834 (2005). *
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma). Ann. Endocrinol. (Paris) 63: 511-523 (2002).
Dubois PC, van Heel DA. Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease. Clin. Exp. Immunol. 153: 162-173 (2008). *
Dubois SG, Heilbronn LK, Smith SR, Albu JB, Kelley DE, Ravussin E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes. Obesity (Silver Spring) 14: 1543-1552 (2006). *
Dubois-Laforgue D, Timsit J, Djilali-Saiah I, Boitard C, Caillat-Zucman S. Insulin-dependent diabetes mellitus in non-DR3/non-DR4 subjects. Hum. Immunol. 57: 104-109 (1997).
Duchatelet S, Caillat-Zucman S, Dubois-Laforgue D, Blanc H, Timsit J, Julier C. FCRL3 -169CT functional polymorphism in type 1 diabetes and autoimmunity traits. Biomed. Pharmacother. 62: 153-157 (2008).
Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2: 225-231 (2003).
Duclos-Vallee JC, Yilmaz F, Johanet C, Roque-Afonso AM, Gigou M, Trichet C, Feray C, Ballot E, Dussaix E, Castaing D, Bismuth H, Samuel D, Guettier C. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin. Transplant. 19: 591-599 (2005). *
Duda K, Chi YI, Shoelson SE. Structural basis for HNF-4alpha activation by ligand and coactivator binding. J. Biol. Chem. 279: 23311-23316 (2004). *
Duerr RH. Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. Gastroenterology 132: 2045-2049 (2007). *
Dufaitre-Patouraux L, Riveline J, Renard E, Melki V, Belicar-Schaepelynck P, Selam J, Guerci B, Millot L, Brun J, Fermon C, Catargi B, Gin H, Jeandidier N, Lejeune P, Lassmann-Vague V. Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study. Diabetes Metab. 32: 427-432 (2006). *
Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases. Curr. Opin. Allergy Clin. Immunol. 7: 468-474 (2007).
Dufour FD, Baxter AG, Silveira PA. Interactions between B-lymphocytes and type 1 NKT cells in autoimmune diabetes. J. Immunotoxicol. 5: 249-257 (2008).
Dugas V, Beauchamp C, Chabot-Roy G, Hillhouse EE, Lesage S. Implication of the CD47 pathway in autoimmune diabetes. J. Autoimmun. Feb 5 [Epub ahead of print] (2010).
Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 22: 245-260 (1995).
Dultz G, Matheis N, Dittmar M, Bender K, Kahaly GJ. CTLA-4 CT60 polymorphism in thyroid and polyglandular autoimmunity. Horm. Metab. Res. 41: 426-429 (2009).
Dultz G, Matheis N, Dittmar M, Rohrig B, Bender K, Kahaly GJ. The protein tyrosine phosphatase non-receptor type 22 C1858T polymorphism is a joint susceptibility locus for immunthyroiditis and autoimmune diabetes. Thyroid 19: 143-148 (2009).
Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr. Drug Targets Cardiovasc. Haemato. Disord. 5: 377-386 (2005).
Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, Rubbia-Brandt L, Scoazec JY, Hadengue A. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am. J. Gastroenterol. 105: 613-620 (2010). *
Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway. Circulation 115: 909-917 (2007). *
Duncan SA, Navas MA, Dufort D, Rossant J, Stoffel M. Regulation of a transcription factor network required for differentiation and metabolism. Science 281: 692-695 (1998). *
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 9: 463-468 (2003). *
Dunn AC, Walmsley RS, Dedrick RL, Wakefield AJ, Lockwood CM. Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain. J. Infect. 39: 81-87 (1999).
Dunstan JA, Prescott SL. Does fish oil supplementation in pregnancy reduce the risk of allergic disease in infants? Curr. Opin. Allergy Clin. Immunol. 5: 215-221 (2005).
Dupond JL, Essalmi L, Gil H, Meaux-Ruault N, Hafsaoui C. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J. Clin. Neurosci. Jan 11 [Epub ahead of print] (2010).
Dupouy-Camet J. Presidential address of ICT12 Conference: "Trichinella and trichinellosis - a never ending story" Vet. Parasitol. 159: 194-196 (2009).
Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloyn AL, Lindgren CM, Magi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. Jan 17 [Epub ahead of print] (2010). *
Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1alpha,25-dihydroxyvitamin D) is a novel, safe and effective treatment for plaque psoriasis: a pilot study. Br. J. Dermatol. 151: 190-195 (2004).
Duran C, Ediger D, Ersoy C, Coskun NF, Selimoglu H, Ercan I, Kiyici S, Guclu M, Saglam DA, Erturk E, Tuncel E, Imamoglu S. Frequency of atopy and allergic disorders among adults with Type 1 diabetes mellitus in the southern Marmara region of Turkey. J. Endocrinol. Invest. 31: 211-215 (2008).
Duran-Sandoval D, Cariou B, Fruchart JC, Staels B. Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. Biochimie 87: 93-98 (2005).
Duran-Sandoval D, Mautino G, Martin G, Percevault F, Barbier O, Fruchart JC, Kuipers F, Staels B. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53: 890-898 (2004). *
Durand E, Boutin P, Meyre D, Charles MA, Clement K, Dina C, Froguel P. Polymorphisms in the amino acid transporter solute carrier family 6 (neurotransmitter transporter) member 14 gene contribute to polygenic obesity in French Caucasians. Diabetes 53: 2483-2486 (2004). *
Durant S, Coulaud J, Homo-Delarche F. Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. Rev. Diabet. Stud. 4: 185-194 (2007). *
Durieu I. Cystic fibrosis in adulthood. Rev. Med. Interne. 22 Suppl. 3: 367s-373s (2001).
Durieu I, Nove Josserand R. Cystic fibrosis in 2008. Rev. Med. Interne. 29: 901-907 (2008).
Durinovic-Bello I. Autoimmune diabetes: the role of T cells, MHC molecules and autoantigens. Autoimmunity 27: 159-177 (1998).
Durinovic-Bello I, Jelinek E, Schlosser M, Eiermann T, Boehm BO, Karges W, Marchand L, Polychronakos C. Class III alleles at the insulin VNTR polymorphism are associated with regulatory T-cell responses to proinsulin epitopes in HLA-DR4, DQ8 individuals. Diabetes 54: S18-S24 (2005). *
Durinovic-Bello I, Rosinger S, Olson JA, Congia M, Ahmad RC, Rickert M, Hampl J, Kalbacher H, Drijfhout JW, Mellins ED, Al Dahouk S, Kamradt T, Maeurer MJ, Nhan C, Roep BO, Boehm BO, Polychronakos C, Nepom GT, Karges W, McDevitt HO, Sonderstrup G. DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc. Natl. Acad. Sci. U.S.A. 103: 11683-11688 (2006). *
Durinovic-Bello I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT. Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin. Genes Immun. Jan 7 [Epub ahead of print] (2010). *
Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig. Dis. Sci. 52: 2368-2374 (2007). *
Duseja A, Nanda M, Das A, Das R, Bhansali A, Chawla Y. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis. Trop. Gastroenterol. 25: 15-17 (2004).
Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278: 7027-7033 (2003). *
Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 276: 33309-33312 (2001). *
Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. U.S.A. 100: 833-838 (2003). *
Dutra LA, Costa PG, Velasco LF, Amato AA, Barra GB. Allele-specific PCR assay to genotype SNP rs7903146 in TCF7L2 gene for rapid screening of diabetes susceptibility. Arq. Bras. Endocrinol. Metabol. 52: 1362-1366 (2008). *
Dvorak M. Gluten enteropathy - occurrence, diagnosis, therapy. Cas. Lek. Cesk. 144 Suppl. 1: 48-51 (2005).
Dwarakanathan A. Diabetes update. J. Insur. Med. 38: 20-30 (2006).
Dworacka M, Winiarska H, Jagodzinski PP. Impact of the sulfonylurea receptor 1 (SUR1) exon 16-3c/t polymorphism on acute hyperglycaemia in type 2 diabetic patients. Diabetes Res. Clin. Pract. 77: 258-262 (2007).
Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, Risch N, Ebers GC. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum. Mol. Genet. 14: 2019-2026 (2005). *
Dymot JA, McKay GA. Type 1 (distal) renal tubular acidosis in a patient with type 1 diabetes mellitus - not all cases of metabolic acidosis in type 1 diabetes mellitus are due to diabetic ketoacidosis. Diabet. Med. 25: 114-115 (2008). *
Dynyak AK, Dynyak AA, Popova FV. Diabetes mellitus: hypoxia of the islets of Langerhans resulting from the systematic rest prone on the back after a meal? Med. Hypotheses Feb 8 [Epub ahead of print] (2010).
Dzik WH, Cserti-Gazdewich CM, Ssewanyana I, Delelys M, Preffer FI. When monocytes and platelets compete: the effect of platelet count on the flow cytometric measurement of monocyte CD36. Cytometry B. Clin. Cytom. Nov 9 [Epub ahead of print] (2009).
Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, Bluestone JA. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 115: 3-9 (2005). *
Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am. J. Psychiatry 163: 521-528 (2006). *
Eaton WW, Pedersen MG, Atladottir HO, Gregory PE, Rose NR, Mortensen PB. The prevalence of 30 ICD-10 autoimmune diseases in Denmark. Immunol. Res. Jan 12 [Epub ahead of print] (2010). *
Eaves IA, Wicker LS, Ghandour G, Lyons PA, Peterson LB, Todd JA, Glynne RJ. Combining mouse congenic strains and microarray gene expression analyses to study a complex trait: the NOD model of type 1 diabetes. Genome Res. 12: 232-243 (2002). *
Ebbesson SO, Ebbesson LO, Swenson M, Kennish JM, Robbins DC. A successful diabetes prevention study in Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 409-424 (2005).
Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME. Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int. J. Circumpolar Health 64: 396-408 (2005).
Ebmeier KP. Normal cognitive decline or dementia? Practitioner 254: 23-27, 2-3 (2010).
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 365: 1415-1428 (2005). *
Edelman LB, Toia G, Geman D, Zhang W, Price ND. Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases. BMC Genomics 10: 583 (2009). *
Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes. Front. Biosci. 14: 1169-1181 (2009).
Edvardsson U, Alexandersson M, Brockenhuus von Lowenhielm H, Nystrom AC, Ljung B, Nilsson F, Dahllof B. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis 20: 935-942 (1999). *
Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult. Scler. 10: 575-581 (2004). *
Eeckhoute J, Briche I, Kurowska M, Formstecher P, Laine B. Hepatocyte nuclear factor 4 alpha ligand binding and F domains mediate interaction and transcriptional synergy with the pancreatic islet LIM HD transcription factor Isl1. J. Mol. Biol. 364: 567-581 (2006). *
Eerligh P, Koeleman BP, Dudbridge F, Jan Bruining G, Roep BO, Giphart MJ. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun. 5: 36-40 (2004). *
Efanov AM, Sewing S, Bokvist K, Gromada J. Liver X receptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic beta-cells. Diabetes 53 Suppl. 3: S75-S78 (2004). *
Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2: 11-24 (2003).
Efrati O, Harash O, Rivlin J, Bibi H, Meir MZ, Blau H, Mussaffi H, Barak A, Levy I, Vilozni D, Kerem E, Modan-Moses D. Hemoptysis in Israeli CF patients - prevalence, treatment, and clinical characteristics. J. Cyst. Fibros. 7: 301-306 (2008).
Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 68: 1443-1450 (2008). *
Egefjord L, Jensen JL, Bang-Berthelsen CH, Petersen AB, Smidt K, Schmitz O, Karlsen AE, Pociot F, Chimienti F, Rungby J, Magnusson NE. Zinc transporter gene expression is regulated by pro-inflammatory cytokines: a potential role for zinc transporters in beta-cell apoptosis? BMC Endocr. Disord. 9: 7 (2009). *
Egido J, Ortiz A. ACE gene polymorphism and the prognosis and treatment of overt diabetic nephropathy. Nat. Clin. Pract. Nephrol. 4: 472-473 (2008).
Egido J, Ruiz-Ortega M. Anti-inflammatory actions of quinapril. Cardiovasc. Drugs Ther. 21: 211-220 (2007).
Eglen RM, Reisine T. The current status of drug discovery against the human kinome. Assay Drug Dev. Technol. 7: 22-43 (2009).
Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. Pharmacol. Rev. 61: 373-393 (2009). *
Ehrmann J Jr, Vavrusova N, Collan Y, Kolar Z. Peroxisome proliferator-activated receptors (PPARs) in health and disease. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 146: 11-14 (2002). *
Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N, Irminger JC, Kergoat M, Portha B, Homo-Delarche F, Donath MY. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 106: 13998-14003 (2009). *
Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY. Increased number of islet associated macrophages in type 2 diabetes. Diabetes 56: 2356-2370 (2007). *
Eidt-Koch D, Wagner TO, Mittendorf T, Graf von der Schulenburg JM. Outpatient medication costs of patients with cystic fibrosis in Germany. Appl. Health Econ. Health Policy 8: 111-118 (2010).
Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun. 10: 56-67 (2009). *
Eike MC, Humphreys K, Becker T, Olsson M, Lie BA; Diabetes Genetics Consortium. Three microsatellites from the T1DGC MHC data set show highly significant association with type 1 diabetes, independent of the HLA-DRB1, -DQA1 and -DQB1 genes. Diabetes Obes. Metab. 11 Suppl. 1: 17-24 (2009). *
Eike MC, Nordang GB, Karlsen TH, Boberg KM, Vatn MH; IBSEN study group, Dahl-Jorgensen K, Ronningen KS, Joner G, Flato B, Bergquist A, Thorsby E, Forre O, Kvien TK, Undlien DE, Lie BA. The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann. Rheum. Dis. 67: 1287-1291 (2008).
Eike MC, Olsson M, Undlien DE, Dahl-Jorgensen K, Joner G, Ronningen KS, Thorsby E, Lie BA. Genetic variants of the HLA-A, HLA-B and AIF1 loci show independent associations with type 1 diabetes in Norwegian families. Genes Immun. 10: 141-150 (2009). *
Eilat-Adar S, Xu J, Zephier E, O'Leary V, Howard BV, Resnick HE. Adherence to dietary recommendations for saturated fat, fiber, and sodium is low in American Indians and other U.S. adults with diabetes. J. Nutr. 138: 1699-1704 (2008). *
Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, Haraldsson S, Nilsson-Ardnor S, Penha-Goncalves C, Lind L, Holmgren G, Holmberg M, Asplund K, Holmberg D. The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur. J. Hum. Genet. 11: 81-84 (2003). *
Eisenbarth GS. Do NALP5 antibodies correlate with hypoparathyroidism in patients with APS-1? Nat. Clin. Pract. Endocrinol. Metab. 4: 544-545 (2008).
Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N. Engl. J. Med. 350: 2068-2079 (2004). *
Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5: 219-226 (2009). *
Ejrnaes M, Videbaek N, Christen U, Cooke A, Michelsen BK, von Herrath M. Different diabetogenic potential of autoaggressive CD8+ clones associated with IFN-gamma-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics. J. Immunol. 174: 2746-2755 (2005). *
Ejrnaes M, von Herrath MG, Christen U. Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin. Dev. Immunol. 13: 337-347 (2006). *
Ejrnaes M, von Herrath MG, Christen U. Cure of chronic viral infection and virus-induced type 1 diabetes by neutralizing antibodies. Clin. Dev. Immunol. 13: 67-77 (2006). *
Ejskjaer N, Vestergaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L, Kosutic G. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 29: 1179-1187 (2009). *
Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44: 2220-2226 (2001). *
Ek J, Hansen SP, Lajer M, Nicot C, Boesgaard TW, Pruhova S, Johansen A, Albrechtsen A, Yderstraede K, Lauenborg J, Parrizas M, Boj SF, Jorgensen T, Borch-Johnsen K, Damm P, Ferrer J, Lebl J, Pedersen O, Hansen T. A novel -192c/g mutation in the proximal P2 promoter of the hepatocyte nuclear factor-4alpha gene (HNF4A) associates with late-onset diabetes. Diabetes 55: 1869-1873 (2006). *
Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J. Hepatol. 47: 135-141 (2007). *
Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44: 865-873 (2006). *
Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038 (2008). *
El Achhab Y, Meyre D, Bouatia-Naji N, Berraho M, Deweirder M, Vatin V, Delplanque J, Serhier Z, Lyoussi B, Nejjari C, Froguel P, Chikri M. Association of the ENPP1 K121Q polymorphism with type 2 diabetes and obesity in the Moroccan population. Diabetes Metab. 35: 37-42 (2009).
El Hajj G, Yahya AF, Medlej R, Sebaaly G, Souaid M, Halaby G. Autoimmune thyroid disease. Clinical and biological correlations. J. Med. Liban. 57: 218-225 (2009).
El-Hallak M, Binstadt BA, Leichtner AM, Bennett CM, Neufeld EJ, Fuhlbrigge RC, Zurakowski D, Sundel RP. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J. Pediatr. 150: 376-382 (2007). *
El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, Liu JY, Hanson E, Mian S, Fatteh N, Liou GI. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol. Vis. 14: 2190-2203 (2008). *
El-Salhy M. Ghrelin in gastrointestinal diseases and disorders: a possible role in the pathophysiology and clinical implications (review). Int. J. Mol. Med. 24: 727-732 (2009).
El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (5 Suppl. 2): S27-S34 (2004). *
El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, Giordano TP. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 49: 116-123 (2009). *
El-Seraq HB, Johnson ML, Hachem C, Morgan RO. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 136: 1601-1608 (2009). *
El-Sohemy A. Nutrigenetics. Forum Nutr. 60: 25-30 (2007).
El-Zayadi AR. Hepatic steatosis: a benign disease or a silent killer. World J. Gastroenterol. 14: 4120-4126 (2008). *
Elagin RB, Balijepalli S, Diacovo MJ, Baekkeskov S, Jaume JC. Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice. J. Autoimmun. 33: 50-57 (2009).
Elbein SC, Chu WS, Das SK, Yao-Borengasser A, Hasstedt SJ, Wang H, Rasouli N, Kern PA. Transcription factor 7-like 2 polymorphisms and type 2 diabetes, glucose homeostasis traits and gene expression in US participants of European and African descent. Diabetologia 50: 1621-1630 (2007). *
Elbein SC, Das SK, Hallman DM, Hanis CL, Hasstedt SJ. Genome-wide linkage and admixture mapping of type 2 diabetes in African American families from the American Diabetes Association GENNID (Genetics of NIDDM) study Cohort. Diabetes 58: 268-274 (2009). *
Elbelt U, Hahner S, Allolio B. Altered insulin requirement in patients with type 1 diabetes and primary adrenal insufficiency receiving standard glucocorticoid replacement therapy. Eur. J. Endocrinol. 160: 919-924 (2009).
Elder DA, Wooldridge JL, Dolan LM, D'Alessio DA. Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes. J. Pediatr. 151: 653-658 (2007). *
Eldor R, Cohen IR, Raz I. Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitus. Int. Rev. Immunol. 24: 327-339 (2005).
Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results. Diabetes Metab. Res. Rev. 25: 316-320 (2009).
Eldor R, Yeffet A, Baum K, Doviner V, Amar D, Ben-Neriah Y, Christofori G, Peled A, Carel JC, Boitard C, Klein T, Serup P, Eizirik DL, Melloul D. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc. Natl. Acad. Sci. U.S.A. 103: 5072-5077 (2006). *
Elefsiniotis IS, Papatsimpas G, Liatsos GD, Tasidou A, Moulakakis A. Atypical autoimmune polyglandular syndrome type 3 overlapped by chronic HCV infection resulting in carcinogenesis and fatal infection. South. Med. J. 101: 756-758 (2008).
Eleftherohorinou H, Wright V, Hoggart C, Hartikainen AL, Jarvelin MR, Balding D, Coin L, Levin M. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One 4: e8068 (2009). *
Elfaitouri A, Berg AK, Frisk G, Yin H, Tuvemo T, Blomberg J. Recent enterovirus infection in type 1 diabetes: evidence with a novel IgM method. J. Med. Virol. 79: 1861-1867 (2007).
Elfstrom P, Montgomery SM, Kampe O, Ekbom A, Ludvigsson JF. Risk of primary adrenal insufficiency in patients with celiac disease. J. Clin. Endocrinol. Metab. 92: 3595-3598 (2007). *
Elias D, Avron A, Tamir M, Raz I. DiaPep277(R) preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann. N. Y. Acad. Sci. 1079: 340-344 (2006). *
Ellard S, Bellanne-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51: 546-553 (2008). *
Ellard S, Colclough K. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum. Mutat. 27: 854-869 (2006).
Ellard S, Thomas K, Edghill EL, Owens M, Ambye L, Cropper J, Little J, Strachan M, Stride A, Ersoy B, Eiberg H, Pedersen O, Shepherd MH, Hansen T, Harries LW, Hattersley AT. Partial and whole gene deletion mutations of the GCK and HNF1A genes in maturity-onset diabetes of the young. Diabetologia 50: 2313-2317 (2007). *
Eller E, Vardi P, Babu SR, Bugawan TL, Erlich HA, Yu L, Fain PR. Celiac disease and HLA in a Bedouin kindred. Hum. Immunol. 67: 940-950 (2006).
Eller E, Vardi P, McFann KK, Babu SR, Yu L, Bugawan TL, Erlich HA, Eisenbarth GS, Fain PR. Differential effects of DRB1(*)0301 and DQA1(*)0501-DQB1(*)0201 on the activation and progression of islet cell autoimmunity. Genes Immun. 8: 628-633 (2007). *
Ellingsgaard H, Ehses JA, Hammar EB, Van Lommel L, Quintens R, Martens G, Kerr-Conte J, Pattou F, Berney T, Pipeleers D, Halban PA, Schuit FC, Donath MY. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc. Natl. Acad. Sci. U.S.A. 105: 13163-13168 (2008). *
Elliott DE, Summers RW, Weinstock JV. Helminths as governors of immune-mediated inflammation. Int. J. Parasitol. 37: 457-464 (2007). *
Elliott DE, Weinstock JV. Helminthic therapy: using worms to treat immune-mediated disease. Adv. Exp. Med. Biol. 666: 157-166 (2009).
Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 25: 434-440 (2004). *
Elsurer R, Tatar G, Simsek H, Balaban YH, Aydinli M, Sokmensuer C. Celiac disease in the Turkish population. Dig. Dis. Sci. 50: 136-142 (2005). *
Elwing JE, Gao F, Davidson NO, Early DS. Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am. J. Gastroenterol. 101: 1866-1871 (2006). *
Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58: 1302-1311 (2009). *
Emanuelli B, Eberle D, Suzuki R, Kahn CR. Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 105: 3545-3550 (2008). *
Emre Y, Hurtaud C, Karaca M, Nubel T, Zavala F, Ricquier D. Role of uncoupling protein UCP2 in cell-mediated immunity: how macrophage-mediated insulitis is accelerated in a model of autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 104: 19085-19090 (2007). *
Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann. Surg. 248: 84-96 (2008).
Endo T, Takizawa S, Tanaka S, Takahashi M, Fujii H, Kamisawa T, Kobayashi T. Amylase alpha-2A autoantibodies: novel marker of autoimmune pancreatitis and fulminant type 1 diabetes mellitus. Diabetes 58: 732-737 (2009). *
Endreffy E, Laszlo, Szabo A, Roman F, Kurti K, Kalman M, Rasko I. Molecular genetic studies in monogenic and polygenic human diseases. Acta Biol. Hung. 48: 121-128 (1997).
Enee E, Martinuzzi E, Blancou P, Bach JM, Mallone R, van Endert P. Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J. Immunol. 180: 5430-5438 (2008). *
Engkilde K, Menne T, Johansen JD. Inverse relationship between allergic contact dermatitis and type 1 diabetes mellitus: a retrospective clinic-based study. Diabetologia 49: 644-647 (2006). *
Enoki T, Ohnogi H, Nagamine K, Kudo Y, Sugiyama K, Tanabe M, Kobayashi E, Sagawa H, Kato I. Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei. J. Agric. Food Chem. 55: 6013-6017 (2007). *
Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta-cells. Blood 110: 954-961 (2007). *
Epstein DJ. Cis-regulatory mutations in human disease. Brief. Funct. Genomic. Proteomic. 8: 310-316 (2009).
Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic? Bone 43: 3-6 (2008).
Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res. Clin. Pract. 78: 355-359 (2007).
Erichsen MM, Lovas K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocrinol. Metab. 94: 4882-4890 (2009).
Eriksson JG. The role of genes in growth and later health. Nestle Nutr. Workshop Ser. Pediatr. Program 61: 69-77 (2008).
Erikstrup C, Mortensen OH, Nielsen AR, Fischer CP, Plomgaard P, Petersen AM, Krogh-Madsen R, Lindegaard B, Erhardt JG, Ullum H, Benn CS, Pedersen BK. RBP-to-retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes Obes. Metab. 11: 204-212 (2009).
Erkkola M, Kaila M, Nwaru BI, Kronberg-Kippila C, Ahonen S, Nevalainen J, Veijola R, Pekkanen J, Ilonen J, Simell O, Knip M, Virtanen SM. Maternal vitamin D intake during pregnancy is inversely associated with asthma and allergic rhinitis in 5-year-old children. Clin. Exp. Allergy 39: 875-882 (2009). *
Erlich H, Bugawan T, Begovich A, Scharf S. Analysis of HLA class II polymorphism using polymerase chain reaction. Arch. Pathol. Lab. Med. 117: 482-485 (1993).
Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, Mychaleckyj JC, Todd JA, Bonella P, Fear AL, Lavant E, Louey A, Moonsamy P; for the TIDGC. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the Type 1 Diabetes Genetics Consortium Families. Diabetes 57: 1084-1092 (2008). *
Erlich HA. HLA class II sequences and genetic susceptibility to insulin dependent diabetes mellitus. Baillieres Clin. Endocrinol. Metab. 5: 395-411 (1991).
Erlich HA. HLA class II polymorphism and genetic susceptibility to insulin-dependent diabetes mellitus. Curr. Top. Microbiol. Immunol. 164: 41-55 (1990).
Erlich HA, Bugawan TL, Scharf S, Nepom GT, Tait B, Griffith RL. HLA-DQ beta sequence polymorphism and genetic susceptibility to IDDM. Diabetes 39: 96-103 (1990).
Erlich HA, Griffith RL, Bugawan TL, Ziegler R, Alper C, Eisenbarth G. Implication of specific DQB1 alleles in genetic susceptibility and resistance by identification of IDDM siblings with novel HLA-DQB1 allele and unusual DR2 and DR1 haplotypes. Diabetes 40: 478-481 (1991).
Erlich HA, Lohman K, Mack SJ, Valdes AM, Julier C, Mirel D, Noble JA, Morahan GE, Rich SS; for the Type I Diabetes Genetics Consortium. Association analysis of SNPs in the IL4R locus with type I diabetes. Genes Immun. 10: S33-S41 (2009).
Erlich HA, Valdes AM, Julier C, Mirel D, Noble JA. Evidence for association of the TCF7 locus with type I diabetes. Genes Immun. 10: S54-S59 (2009).
Erlich HA, Zeidler A, Chang J, Shaw S, Raffel LJ, Klitz W, Beshkov Y, Costin G, Pressman S, Bugawan T, et al. HLA class II alleles and susceptibility and resistance to insulin dependent diabetes mellitus in Mexican-American families. Nat. Genet. 3: 358-364 (1993). *
Ernestam S, Hafstrom I, Werner S, Carlstrom K, Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. J. Rheumatol. 34: 1451-1458 (2007).
Eroglu Z, Cetinkalp S, Erdogan M, Kosova B, Karadeniz M, Kutukculer A, Gunduz C, Tetik A, Topcuoglu N, Ozgen AG, Tuzun M. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. J. Diabetes Complications 22: 186-190 (2008).
Erskine JM, Lingard C, Sontag M. Update on enteral nutrition support for cystic fibrosis. Nutr. Clin. Pract. 22: 223-232 (2007).
Ertas FS, Hasan T, Ozdol C, Gulec S, Atmaca Y, Tulunay C, Karabulut H, Kocum HT, Dincer I, Kose KS, Erol C. Relationship between angiotensin-converting enzyme gene polymorphism and severity of aortic valve calcification. Mayo Clin. Proc. 82: 944-950 (2007). *
Ertek S, Erdogan G. Postpartum thyroiditis and hypothalamo-hypophysial insufficiency in the same woman with successive pregnancies: a case report. Gynecol. Endocrinol. Aug 22 [Epub ahead of print] (2009).
Ertekin V, Ayse Selimoglu M, Doneray H, Orbak Z, Ozkan B. Prevalence of celiac disease in a sample of Turkish children and adolescents with type 1 diabetes mellitus. J. Clin. Gastroenterol. 40: 655-657 (2006).
Erten G, Gurol AO, Deniz G, Satman I, Yilmaz MT. Organ specific autoantibodies in preclinical and early clinical type 1 diabetes in Turkey. Ups. J. Med. Sci. 112: 231-243 (2007). *
Esensten JH, Lee MR, Glimcher LH, Bluestone JA. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J. Immunol. 183: 75-82 (2009).
Esensten JH, Wofsy D, Bluestone JA. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 560-565 (2009).
Espe K, Galler A, Raila J, Kiess W, Schweigert FJ. High-normal C-reactive protein levels do not affect the vitamin A transport complex in serum of children and adolescents with type 1 diabetes. Pediatr. Res. 62: 741-745 (2007). *
Espinoza-Jimenez A, Rivera-Montoya I, Cardenas-Arreola R, Moran L, Terrazas LI. Taenia crassiceps infection attenuates multiple low-dose streptozotocin-induced diabetes. J. Biomed. Biotechnol. 2010: 850541 (2010). *
Estall JL, Drucker DJ. Glucagon and glucagon-like peptide receptors as drug targets. Curr. Pharm. Des. 12: 1731-1750 (2006).
Esteghamati A, Ashraf H, Nakhjavani M, Najafian B, Hamidi S, Abbasi M. Insulin resistance is an independent correlate of increased urine albumin excretion: a cross-sectional study in Iranian type 2 diabetic patients. Diabet. Med. 26: 177-181 (2009). *
Esteves J, Laranjeira AF, Roggia MF, Dalpizol M, Scocco C, Kramer CK, Azevedo MJ, Canani LH. Diabetic retinopathy risk factors. Arq. Bras. Endocrinol. Metabol. 52: 431-441 (2008).
Estil Les E, Tellez N, Soler J, Montanya E. High sensitivity of beta-cell replication to the inhibitory effects of interleukin-1beta: modulation by adenoviral overexpression of insulin-like growth factor-II in rat islets. J. Endocrinol. 203: 55-63 (2009).
Ettinger RA, Liu AW, Nepom GT, Kwok WW. Beta 57-Asp plays an essential role in the unique SDS stability of HLA-DQA1*0102/DQB1*0602 alpha beta protein dimer, the class II MHC allele associated with protection from insulin-dependent diabetes mellitus. J. Immunol. 165: 3232-3238 (2000). *
Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J. Mol. Med. 79: 198-204 (2001). *
Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta. Curr. Diabetes Rev. 1: 299-307 (2005).
Evans KA, Budzik BW, Ross SA, Wisnoski DD, Jin J, Rivero RA, Vimal M, Szewczyk GR, Jayawickreme C, Moncol DL, Rimele TJ, Armour SL, Weaver SP, Griffin RJ, Tadepalli SM, Jeune MR, Shearer TW, Chen ZB, Chen L, Anderson DL, Becherer JD, et al. Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. J. Med. Chem. 52: 7962-7965 (2009). *
Evans KE, Leeds JS, Sanders DS. Be vigilant for patients with coeliac disease. Practitioner 253: 19-22, 2 (2009).
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat. Med. 10: 355-361 (2004). *
Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG. PPAR-gamma activation restores islet function in diabetic mice through reduction of ER stress and maintenance of euchromatin structure. Mol. Cell. Biol. 29: 2053-2067 (2009). *
Evelson P, Susemihl C, Villarreal I, Llesuy S, Rodriguez R, Peredo H, Lemberg A, Perazzo J, Filinger E. Hepatic morphological changes and oxidative stress in chronic streptozotocin-diabetic rats. Ann. Hepatol. 4: 115-120 (2005). *
Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol. Clin. North Am. 29: 559-578 (2000).
Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; the HALT-C TrialGroup. Weight related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 137: 549-557 (2009). *
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part 3: liver, biliary tract, and pancreas. Gastroenterology 136: 1134-1144 (2009). *
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part 2: lower gastrointestinal diseases. Gastroenterology 136: 741-754 (2009). *
Everhart JE, Ruhl CE. Burden of digestive diseases in the United States. Part 1: overall and upper gastrointestinal diseases. Gastroenterology 136: 376-386 (2009). *
Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegall M. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl. Surg. 5: S48-S57 (1999).
Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY. Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients. Diabetes Metab. 35: 214-219 (2009).
Ezzidi I, Mtiraoui N, Kacem M, Chaieb M, Mahjoub T, Almawi WY. Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy. Diabetes Metab. Res. Rev. 25: 717-724 (2009).
Ezzidi I, Mtiraoui N, Kacem M, Mallat SG, Mohamed MB, Chaieb M, Mahjoub T, Almawi WY. Interleukin-10 -592C/A, -819C/T, and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes patients. Clin. Endocrinol. (Oxf.) 70: 401-407 (2009). *
Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Endothelial nitric oxide synthase Glu298Asp, 4b/a, and T-786C polymorphisms in type 2 diabetic retinopathy. Clin. Endocrinol. (Oxf.) 68: 542-546 (2008). *
Ezzidi I, Mtiraoui N, Mohamed MB, Mahjoub T, Kacem M, Almawi WY. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J. Diabetes Complications 22: 331-338 (2008).
Faesch S, Jennane F, Izembart I, Chatenoud L, Taupin P, Martin D, Polak M, Robert JJ. Thyroiditis and gluten intolerance: extrapancreatic auto-immune diseases associated with type 1 diabetes. Arch. Pediatr. 14: 24-30 (2007).
Faideau B, Larger E, Lepault F, Carel JC, Boitard C. Role of beta-cells in type 1 diabetes pathogenesis. Diabetes 54: S87-S96 (2005). *
Faiyaz-Ul-Haque M, Bin-Abbas B, Al-Abdullatif A, Abdullah Abalkhail H, Toulimat M, Al-Gazlan S, Almutawa A, Al-Sagheir A, Peltekova I, Al-Dayel F, Zaidi S. Novel and recurrent mutations in the AIRE gene of autoimmune polyendocrinopathy syndrome type 1 (APS1) patients. Clin. Genet. 76: 431-440 (2009). *
Fajardy I, Vambergue A, Stuckens C, Weill J, Danze PM, Fontaine P. CTLA-4 49 A/G dimorphism and type 1 diabetes susceptibility: a French case-control study and segregation analysis. Evidence of a maternal effect. Eur. J. Immunogenet. 29: 251-257 (2002).
Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, Markt P, Schuster D, Ellmerer EP, Wolber G, Rollinger JM, Stuppner H, Dirsch VM. Computer-aided discovery, validation and mechanistic characterisation of novel neolignan activators of PPARgamma. Mol. Pharmacol. Jan 11 [Epub ahead of print] (2010). *
Fakler JW, Schmitt-Egenolf M, Vejbaesya S, Boehncke WH, Sterry W, Eiermann TH. Analysis of TAP2 and HLA-DP gene polymorphism in psoriasis. Hum. Immunol. 40: 299-302 (1994).
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin. Liver Dis. 21: 17-26 (2001).
Falcone M, Facciotti F, Ghidoli N, Monti P, Olivieri S, Zaccagnino L, Bonifacio E, Casorati G, Sanvito F, Sarvetnick N. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 172: 5908-5916 (2004). *
Fallahi GH, Ahmadian JH, Rabbani A, Yousefnezhad A, Rezaei N. Screening for celiac disease in diabetic children from Iran. Indian Pediatr. pii: S097475590800435-2 (2009). *
Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, Grohmann U, Becchetti E, Burgevin A, Kratzer R, van Endert P, Boon L, Puccetti P, Calafiore R. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J. Exp. Med. 206: 2511-2526 (2009). *
Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L, Grohmann U. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 183: 6303-6312 (2009).
Falorni A. Immunologic and genetic aspects of latent autoimmune diabetes in the adult. Minerva Endocrinol. 28: 297-312 (2003).
Falorni A, Laureti S, Nikoshkov A, Picchio ML, Hallengren B, Vandewalle CL, Gorus FK, Tortoioli C, Luthman H, Brunetti P, Santeusanio F. 21-Hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. Clin. Exp. Immunol. 107: 341-346 (1997). *
Falorni A, Laureti S, Santeusanio F. Autoantibodies in autoimmune polyendocrine syndrome type II. Endocrinol. Metab. Clin. North Am. 31: 369-389, vii (2002).
Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J. Hepatol. 50: 204-210 (2009). *
Fan Y, Rudert WA, Grupillo M, He J, Sisino G, Trucco M. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J. 28: 2812-2824 (2009). *
Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, Guan Y, Wang X, Staels B, Chien S, Wang N. Suppression of proinflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28: 315-321 (2008).
Fanciulli G, Meloni G, Locatelli M, Bottazzo GF, Delitala G. Diabetes-related autoantibodies in schoolchildren with celiac disease. Ann. Endocrinol. (Paris) 68: 212-213 (2007).
Fang F, Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Mol. Nutr. Food Res. Oct 28 [Epub ahead of print] (2009). *
Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 18: 872-879 (2002). *
Fani F, Kamali-Sarvestani E, Yazdanparast R, Monabati A, Rafiei S. T cell tolerance following bacterial glutamic acid decarboxylase (GAD) feeding in streptozotocin-induced diabetes. Iran. J. Immunol. 3: 169-175 (2006).
Fantuzzi G. Adiponectin and inflammation: consensus and controversy. J. Allergy Clin. Immunol. 121: 326-330 (2008). *
Fareau GG, Maldonado M, Oral E, Balasubramanyam A. Regression of acanthosis nigricans correlates with disappearance of anti-insulin receptor autoantibodies and achievement of euglycemia in type B insulin resistance syndrome. Metabolism 56: 670-675 (2007). *
Faria AM, Weiner HL. Oral tolerance. Immunol. Rev. 206: 232-259 (2005). *
Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 13: 143-157 (2006). *
Farid NR, Thompson C. HLA and autoimmune endocrine disease 1985. Mol. Biol. Med. 3: 85-97 (1986).
Farrell FJ, Keeffe EB. Diabetes and the hepatobiliary system. Clin. Liver Dis. 2: 119-131, vii (1998).
Farrell GC. Drugs and steatohepatitis. Semin. Liver Dis. 22: 185-194 (2002).
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43: S99-S112 (2006). *
Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr. Dir. Autoimmun. 9: 1-17 (2006).
Fasano A. Surprises from celiac disease. Sci. Am. 301: 54-61 (2009).
Fasciano S, Li L. Intervention of Toll-like receptor-mediated human innate immunity and inflammation by synthetic compounds and naturally occurring products. Curr. Med. Chem. 13: 1389-1395 (2006).
Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40: 820-826 (2004). *
Fatehi-Hassanabad Z, Chan CB. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic beta-cell function. Nutr. Metab. (Lond.) 2: 1 (2005). *
Fatimathas L, Moss SE. Annexins as disease modifiers. Histol. Histopathol. 25: 527-532 (2010). *
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (5 Suppl. 2): S35-S50 (2004). *
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040 (1993).
Faustman DL. Immunotherapy on trial for new-onset type 1 diabetes. N. Engl. J. Med. 359: 1956-1958 (2008). *
Faustman DL, Davis M. The primacy of CD8 T lymphocytes in type 1 diabetes and implications for therapies. J. Mol. Med. 87: 1173-1178 (2009). *
Faustman DL, Tran SD, Kodama S, Lodde BM, Szalayova I, Key S, Toth ZE, Mezey E. Comment on papers by Chong et al., Nishio et al., and Suri et al. on diabetes reversal in NOD mice. Science 314: 1243 (2006). *
Fawaz F, Belding RC. Primary sclerosing cholangitis. A case associated with diabetes mellitus. W. V. Med. J. 82: 331-332 (1986).
Fawwaz S, Nikamo P, Torn C, Landin-Olsson M, Lernmark A, Alarcon-Riquelme M, Kockum I; the Diabetes Incidence in Sweden Study Group. No evidence of association of the PDCD1 gene with type 1 diabetes. Diabet. Med. 24: 1473-1477 (2007). *
Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr. Atheroscler. Rep. 6: 148-157 (2004).
Fdez-Morera JL, Rodrigo L, Lopez-Vazquez A, Rodero SR, Martinez-Borra J, Nino P, Gonzalez S, Lopez-Larrea C. MHC class I chain-related gene A transmembrane polymorphism modulates the extension of ulcerative colitis. Hum. Immunol. 64: 816-822 (2003).
Fedetz M, Matesanz F, Caro-Maldonado A, Fernandez O, Tamayo JA, Guerrero M, Delgado C, Lopez-Guerrero JA, Alcina A. OAS1 gene haplotype confers susceptibility to multiple sclerosis. Tissue Antigens 68: 446-449 (2006). *
Fedetz M, Matesanz F, Caro-Maldonado A, Smirnov II, Chvorostinka VN, Moiseenko TA, Alcina A. The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue Antigens 67: 430-433 (2006). *
Fedetz M, Ndagire D, Fernandez O, Leyva L, Guerrero M, Arnal C, Lucas M, Izquierdo G, Delgado C, Alcina A, Matesanz F. Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population. Tissue Antigens 74: 244-247 (2009). *
Fegan PG, Shore AC, Mawson D, Tooke JE, Macleod KM. Microvascular endothelial function in subjects with type 2 diabetes and the effect of lipid-lowering therapy. Diabet. Med. 22: 1670-1676 (2005). *
Feghhi M, Nikzamir A, Esteghamati A, Farahi F, Nakhjavani M, Rashidi A. The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes. Diabetes Res. Clin. Pract. 81: e1-e4 (2008).
Feher J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res. 31: 537-551 (2003).
Feigerlova E, Pruhova S, Dittertova L, Lebl J, Pinterova D, Kolostova K, Cerna M, Pedersen O, Hansen T. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur. J. Pediatr. 165: 446-452 (2006). *
Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr. Opin. Gastroenterol. 20: 560-564 (2004).
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Russo CD. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70: 177-188 (2005). *
Feizy V, Ghobadi A. Atopic dermatitis and systemic autoimmune diseases: a descriptive cross sectional study. Dermatol. Online J. 12: 3 (2006). *
Feld JJ, Liang TJ. Hepatitis C - identifying patients with progressive liver injury. Hepatology 43: S194-S206 (2006). *
Felder TK, Oberkofler H, Weitgasser R, Mackevics V, Krempler F, Paulweber B, Patsch W. The SREBF-1 locus is associated with type 2 diabetes and plasma adiponectin levels in a middle-aged Austrian population. Int. J. Obes. (Lond.) 31: 1099-1103 (2007). *
Felderbauer P, Karakas E, Fendrich V, Bulut K, Werner I, Dekomien G, Klein W, Bartsch D, Schmidt WE. Pancreatitis in primary hyperparathyroidism-related hypercalcaemia is not associated with mutations in the CASR gene. Exp. Clin. Endocrinol. Diabetes 115: 527-529 (2007).
Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr. Top. Med. Chem. 8: 728-749 (2008).
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20-years. Gut 58: 1538-1544 (2009).
Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martinez-Marmol R, Sole L, Ferreres JC, Condom E. Potassium channels: new targets in cancer therapy. Cancer Detect. Prev. 30: 375-385 (2006).
Felipe F, Bonet ML, Ribot J, Palou A. Modulation of resistin expression by retinoic acid and vitamin A status. Diabetes 53: 882-889 (2004). *
Fellous TG, Islam S, Tadrous PJ, Elia G, Kocher HM, Bhattacharya S, Mears L, Turnbull DM, Taylor RW, Greaves LC, Chinnery PF, Taylor G, McDonald SA, Wright NA, Alison MR. Locating the stem cell niche and tracing hepatocyte lineages in human liver. Hepatology 49: 1655-1663 (2009).
Fenalti G, Hampe CS, Arafat Y, Law RH, Banga JP, Mackay IR, Whisstock JC, Buckle AM, Rowley MJ. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 57: 1293-1301 (2008). *
Feng R, Li Y, Zhao D, Wang C, Niu Y, Sun C. Lack of association between TNF 238 G/A polymorphism and type 2 diabetes: a meta-analysis. Acta Diabetol. 46: 339-343 (2009).
Feng RN, Li Y, Sun CH. TNF 308 G/A polymorphism and type 1 diabetes: a meta-analysis. Diabetes Res. Clin. Pract. 85: e4-e7 (2009).
Fennessy M, Metcalfe K, Hitman GA, Niven M, Biro PA, Tuomilehto J, Tuomilehto-Wolf E. A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Childhood Diabetes in Finland (DiMe) Study Group. Diabetologia 37: 937-944 (1994).
Fereday J, Macdougall C, Spizzo M, Darbyshire P, Schiller W. "There's nothing I can't do: I just put my mind to it and I can do it": a qualitative analysis of how children with chronic disease and their parents account for and manage physical activity. BMC Pediatr. 9: 1 (2009). *
Ferguson CA. Disease models of autoimmunity. Trends Immunol. 26: 557-558 (2005). *
Ferguson LR. Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention. OMICS 12: 237-244 (2008).
Ferguson LR, Shelling AN, Lauren D, Heyes JA, McNabb WC; Nutrigenomics New Zealand. Nutrigenomics and gut health. Mutat. Res. 622: 1-6 (2007).
Fernandes AP, Pace AE, Zanetti ML, Foss MC, Donadi EA. Immunogenetic factors associated with type 1 diabetes mellitus. Rev. Lat. Am. Enfermagem. 13: 743-749 (2005).
Fernandes G. Progress in nutritional immunology. Immunol. Res. 40: 244-261 (2008). *
Fernandez A, Maddipati S. A priori inference of cross reactivity for drug-targeted kinases. J. Med. Chem. 49: 3092-3100 (2006). *
Fernandez AZ. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res. 2008: 285842 (2008). *
Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Curr. Opin. Investig. Drugs 5: 936-940 (2004).
Fernandez EB. Monogenic forms of diabetes mellitus. An. R. Acad. Nac. Med. (Madr.) 123: 211-217 (2006).
Fernandez N, Hitman GA, Festenstein H, Garde L, Labeta M, Walker-Smith JA, Sachs JA. Novel HLA class II-associated structural patterns in coeliac disease and type I diabetes. Clin. Exp. Immunol. 72: 362-366 (1988). *
Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26: 1362-1368 (2003). *
Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin. Chem. 51: 1201-1205 (2005). *
Fernandez-Real JM, Moreno JM, Ricart W. Circulating retinol-binding protein-4 concentration might reflect insulin resistance-associated iron overload. Diabetes 57: 1918-1925 (2008). *
Fernandez-Veledo S, Nieto-Vazquez I, Rondinone CM, Lorenzo M. Liver X receptor agonists ameliorate TNFalpha-induced insulin resistance in murine brown adipocytes by downregulating protein tyrosine phosphatase-1B gene expression. Diabetologia 49: 3038-3048 (2006). *
Fernandez-Veledo S, Nieto-Vazquez I, Vila-Bedmar R, Garcia-Guerra L, Alonso-Chamorro M, Lorenzo M. Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach. Arch. Physiol. Biochem. 115: 227-239 (2009).
Fernandez-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M. JNK1/2 activation by TNF-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by LXR agonists. J. Clin. Endocrinol. Metab. 94: 3583-3593 (2009).
Fernandez-Vina M, Ramirez LC, Raskin P, Stastny P. Genes for insulin-dependent diabetes mellitus (IDDM) in the major histocompatibility complex (MHC) of African-Americans. Tissue Antigens 41: 57-64 (1993).
Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 4: e1000024 (2008). *
Ferrara CT, Wang P, Neto EC, Stevens RD, Bain JR, Wenner BR, Ilkayeva OR, Keller MP, Blasiole DA, Kendziorski C, Yandell BS, Newgard CB, Attie AD. Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genet. 4: e1000034 (2008). *
Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl. 1: S43-S50 (2004). *
Ferreira AC, Gomes KB, Sampaio IB, Oliveira VC, Pardini VC, Godard AL. Type 1 diabetes susceptibility determined by HLA alleles and CTLA-4 and insulin genes polymorphisms in Brazilians. Arq. Bras. Endocrinol. Metabol. 53: 368-373 (2009).
Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am. J. Hum. Genet. Dec 30 [Epub ahead of print] (2009). *
Ferrera F, Cava AL, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann. N. Y. Acad. Sci. 1110: 99-111 (2007). *
Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study. Pancreas 38: 631-637 (2009).
Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, McGovern D, Palmieri O, Achkar JP, Xavier RJ, Duerr RH, Daly MJ, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated to ulcerative colitis. Gut 58: 799-804 (2009). *
Festenstein H, Awad J, Hitman GA, Cutbush S, Groves AV, Cassell P, Ollier W, Sachs JA. New HLA DNA polymorphisms associated with autoimmune diseases. Nature 322: 64-67 (1986). *
Feuerer M, Jiang W, Holler PD, Satpathy A, Campbell C, Bogue M, Mathis D, Benoist C. Enhanced thymic selection of FoxP3+ regulatory T cells in the NOD mouse model of autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 104: 18181-18186 (2007). *
Feuerer M, Shen Y, Littman DR, Benoist C, Mathis D. How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 31: 654-664 (2009).
Fex M, Mulder H. Lipases in the pancreatic beta-cell: implications for insulin secretion. Biochem. Soc. Trans. 36: 885-890 (2008). *
Fichna M, Zurawek M, Januszkiewicz-Lewandowska D, Gryczynska M, Fichna P, Sowinski J, Nowak J. Association of the CYP27B1 C(-1260)A polymorphism with autoimmune Addison's disease. Exp. Clin. Endocrinol. Diabetes Dec 8 [Epub ahead of print] (2009).
Fida S, Myers MA, Whittingham S, Rowley MJ, Ozaki S, Mackay IR. Autoantibodies to the transcriptional factor SOX13 in primary biliary cirrhosis compared with other diseases. J. Autoimmun. 19: 251-257 (2002). *
Fidan Yaylali G, Akin F, Turgut S, Kursunluoglu R. IGF-1 gene polymorphism in obese patients with insulin resistance. Mol. Biol. Rep. Aug 13 [Epub ahead of print] (2009). *
Fiedler A, Wichers-Rother M, Hoeft A, Putensen C, von Spiegel T, Schroeder S. Schmidt syndrome presenting as acute liver failure. Exp. Clin. Endocrinol. Diabetes 113: 60-63 (2005).
Field LL, Anderson CE, Neiswanger K, Hodge SE, Spence MA, Rotter JI. Interaction of HLA and immunoglobulin antigens in type 1 (insulin-dependent) diabetes. Diabetologia 27: 504-508 (1984).
Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes 54: 1588-1591 (2005). *
Field LL, Goldstein A, Spence MA, Anderson CE, Rimoin DL. No evidence for linkage between an insulin-dependent diabetes mellitus-susceptibility locus and immunoglobulin loci KM or GM. Genet. Epidemiol. 1: 375-382 (1984).
Field LL, Larsen Z, Pociot F, Nerup J, Tobias R, Bonnevie-Nielsen V. Evidence for a locus (IDDM16) in the immunoglobulin heavy chain region on chromosome 14q32.3 producing susceptibility to type 1 diabetes. Genes Immun. 3: 338-344 (2002). *
Field LL, McArthur RG. The genetics of susceptibility to insulin-dependent diabetes mellitus - possible new markers. Clin. Invest. Med. 10: 437-443 (1987).
Field LL, Tobias R. Unravelling a complex trait: the genetics of insulin-dependent diabetes mellitus. Clin. Invest. Med. 20: 41-49 (1997).
Field LL, Tobias R, Thomson G, Plon S. Susceptibility to insulin-dependent diabetes mellitus maps to a locus (IDDM11) on human chromosome 14q24.3-q31. Genomics 33: 1-8 (1996). *
Field SF, Nejentsev S, Walker NM, Howson JM, Godfrey LM, Jolley JD, Hardy MP, Todd JA. Sequencing-based genotyping and association analysis of the MICA and MICB genes in type 1 diabetes. Diabetes 57: 1753-1756 (2008). *
Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol. 6: 606-614 (2006).
Fievet C, Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease. Curr. Atheroscler. Rep. 11: 281-288 (2009).
Fife BT, Griffin MD, Abbas AK, Locksley RM, Bluestone JA. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J .Clin. Invest. 116: 2252-2261 (2006). *
Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med. 203: 2737-2747 (2006). *
Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 10: 1185-1192 (2009). *
Figueira AC, Neto MD, Bernardes A, Dias SM, Craievich AF, Baxter JD, Webb P, Polikarpov I. Low-resolution structures of thyroid hormone receptor dimers and tetramers in solution. Biochemistry 46: 1273-1283 (2007). *
Filippi C, Bresson D, Herrath M. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int. Rev. Immunol. 24: 341-360 (2005).
Filippi C, von Herrath M. How viral infections affect the autoimmune process leading to type 1 diabetes. Cell. Immunol. 233: 125-132 (2005). *
Filippi CM, Estes EA, Oldham JE, von Herrath MG. Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J. Clin. Invest. 119: 1515-1523 (2009). *
Filippi CM, Juedes AE, Oldham JE, Ling E, Togher L, Peng Y, Flavell RA, von Herrath MG. Transforming growth factor-beta suppresses the activation of CD8+ T cells when naive but promotes their survival and function once antigen-experienced: a two-faced impact on autoimmunity. Diabetes 57: 2684-2692 (2008). *
Filippi CM, von Herrath MG. Islet beta-cell death - fuel to sustain autoimmunity? Immunity 27: 183-185 (2007). *
Filus A, Trzmiel A, Kuliczkowska-Plaksej J, Tworowska U, Jedrzejuk D, Milewicz A, Medras M. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 11: 134-139 (2008).
Fimmers R, Neugebauer M, Dennert J, Wienker T, Baur MP. Association and sibpair analysis for the HLA, Gm, Km, and insulin polymorphisms in multiplex IDDM families. Genet. Epidemiol. 6: 107-112 (1989).
Finck BN. Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle? Expert Rev. Cardiovasc. Ther. 4: 161-171 (2006).
Fine EJ, Lee DE, Hawkins M. Sweet clarity: less invasive measures of hepatic glucose metabolism. Gastroenterology 132: 794-797 (2007). *
Fink E, Oaklander AL. Small-fiber neuropathy: answering the burning questions. Sci. Aging Knowledge Environ. 6: pe7 (2006).
Finsterer J. Systemic and non-systemic vasculitis affecting the peripheral nerves. Acta Neurol. Belg. 109: 100-113 (2009).
Finucane FM, O'Connell J, Kinsley BT. Propylthiouracil induced C-ANCA positive agranulocytosis complicating Graves' thyrotoxicosis in pregnancy. Ir. J. Med. Sci. 177: 69-71 (2008). *
Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J. Immunol. 183: 993-1004 (2009).
Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH. Targeting CD22 reprograms B cells and reverses autoimmune diabetes. Diabetes 57: 3013-3024 (2008). *
Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol. Med. 13: 298-309 (2007). *
Firoz EF, Kamino H, Lehman TJ, Orlow SJ. Morphea, diabetes mellitus type I, and celiac disease: case report and review of the literature. Pediatr. Dermatol. 27: 48-52 (2010).
First MR. Tacrolimus based immunosuppression. J. Nephrol. 17 Suppl. 8: S25-31 (2004).
Fischer B, Elias D, Bretzel RG, Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin. Biol. Ther. Dec 25 [Epub ahead of print] (2009).
Fischer-Rosinsky A, Fisher E, Kovacs P, Bluher M, Mohlig M, Pfeiffer AF, Boeing H, Spranger J. Lack of association between the tagging SNP A+930-->G of SOCS3 and type 2 diabetes mellitus: meta-analysis of four independent study populations. PLoS ONE 3: e3852 (2008). *
Fischler B, Papadogiannakis N, Nemeth A. Aetiological factors in neonatal cholestasis. Acta Paediatr. 90: 88-92 (2001).
Fischman D, Nookala VK. Cystic fibrosis-related diabetes mellitus: etiology, evaluation, and management. Endocr. Pract. 14: 1169-1179 (2008).
Fisher AH, Lomasky SJ, Fisher MJ, Oppenheim YL. Celiac disease and the endocrinologist: a diagnostic opportunity. Endocr. Pract. 14: 381-388 (2008).
Fisher E, Li Y, Burwinkel B, Kuhr V, Hoffmann K, Mohlig M, Spranger J, Pfeiffer A, Boeing H, Schrezenmeir J, Doring F. Preliminary evidence of FABP2 A54T polymorphism associated with reduced risk of type 2 diabetes and obesity in women from a German cohort. Horm. Metab. Res. 38: 341-345 (2006).
Fisman EZ, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv. Cardiol. 45: 44-64 (2008).
Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc. Diabetol. 8: 38 (2009). *
Fisson S, Djelti F, Trenado A, Billiard F, Liblau R, Klatzmann D, Cohen JL, Salomon BL. Therapeutic potential of self-antigen-specific CD4(+)CD25(+) regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol. 36: 817-827 (2006). *
Fitten LJ, Ortiz F, Fairbanks L, Rosenthal M, Cole GN, Nourhashemi F, Sanchez MA. Depression, diabetes and metabolic-nutritional factors in elderly hispanics. J. Nutr. Health Aging 12: 634-640 (2008).
Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin. Proc. 77: 453-468 (2002). *
Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin. Sci. (Lond.) 116: 1-16 (2009). *
Flanders KC. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85: 47-64 (2004). *
Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front. Biosci. 13: 3648-3660 (2008).
Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes. Diabetes 54: 582-586 (2005). *
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 43: 673-680 (2000). *
Flekac M, Skrha J, Hilgertova J, Lacinova Z, Jarolimkova M. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med. Genet. 9: 30 (2008). *
Fleming A. What will it take to get therapies approved for type 1 diabetes? Ann. N. Y. Acad. Sci. 1150: 25-31 (2008). *
Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu. Rev. Physiol. 64: 663-680 (2002). *
Fletcher J, Mijovic C, Odugbesan O, Jenkins D, Bradwell AR, Barnett AH. Trans-racial studies implicate HLA-DQ as a component of genetic susceptibility to type 1 (insulin-dependent) diabetes. Diabetologia 31: 864-870 (1988).
Fletcher MT, Baxter AG. Clinical application of NKT cell biology in type I (autoimmune) diabetes mellitus. Immunol. Cell Biol. 87: 315-323 (2009). *
Flores YN, Yee HF Jr, Leng M, Escarce JJ, Bastani R, Salmeron J, Morales LS. Risk factors for chronic liver disease in blacks, Mexican Americans, and whites in the United States: results from NHANES IV, 1999-2004. Am. J. Gastroenterol. 103: 2231-2238 (2008). *
Flores-Calderon J, Gomez-Diaz RA, Rodriguez-Gomez G, Moran-Villota S. Frequency of increased aminotransferases levels and associated metabolic abnormalities in obese and overweight children of an elementary school in Mexico City. Ann. Hepatol. 4: 279-283 (2005).
Florez JC. Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes? Diabetologia 51: 1100-1110 (2008). *
Florez JC. The new type 2 diabetes gene TCF7L2. Curr. Opin. Clin. Nutr. Metab. Care 10: 391-396 (2007).
Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 355: 241-250 (2006). *
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab. 92: 1502-1509 (2007). *
Florez JC, Saxena R, Winckler W, Burtt NP, Almgren P, Bengtsson Bostrom K, Tuomi T, Gaudet D, Ardlie KG, Daly MJ, Altshuler D, Hirschhorn JN, Groop L. The Kruppel-like factor 11 (KLF11) Q62R polymorphism is not associated with type 2 diabetes in 8,676 people. Diabetes 55: 3620-3624 (2006). *
Florez JC, Sjogren M, Agapakis CM, Burtt NP, Almgren P, Lindblad U, Berglund G, Tuomi T, Gaudet D, Daly MJ, Ardlie KG, Hirschhorn JN, Altshuler D, Groop L. Association testing of common variants in the insulin receptor substrate-1 gene (IRS1) with type 2 diabetes. Diabetologia 50: 1209-1217 (2007). *
Fodor A, Harel C, Fodor L, Armoni M, Salmon P, Trono D, Karnieli E. Adult rat liver cells transdifferentiated with lentiviral IPF1 vectors reverse diabetes in mice: an ex vivo gene therapy approach. Diabetologia 50: 121-130 (2007). *
Fonarow GC. Aggressive treatment of atherosclerosis: the time is now. Cleve. Clin. J. Med. 70: 431-434, 437438, 440 (2003).
Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN. Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol. Neurobiol. Feb 3 [Epub ahead of print] (2010).
Fonseca-Alaniz MH, Takada J, Alonso-Vale MI, Lima FB. Adipose tissue as an endocrine organ: from theory to practice. J. Pediatr. (Rio J.) 83: S192-S203 (2007).
Fontaine-Bisson B, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and plasma high-density lipoprotein-cholesterol concentrations in a population of young adults. J. Nutrigenet. Nutrigenomics 1: 215-223 (2008).
Fontaine-Bisson B, Wolever TM, Chiasson JL, Rabasa-Lhoret R, Maheux P, Josse RG, Leiter LA, Rodger NW, Ryan EA, Connelly PW, Corey PN, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations. Am. J. Clin. Nutr. 86: 768-774 (2007). *
Fontaine-Bisson B, Wolever TM, Connelly PW, Corey PN, El-Sohemy A. NF-kappaB -49Ins/Del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations. Atherosclerosis 204: 465-470 (2009).
Fontana L. The scientific basis of caloric restriction leading to longer life. Curr. Opin. Gastroenterol. 25: 144-150 (2009).
Foo NP, Chen KT, Lin HJ, Guo HR. Characteristics of pyogenic liver abscess patients with and without diabetes mellitus. Am. J. Gastroenterol. Oct 13 [Epub ahead of print] (2009). *
Forbes LV, Brown LJ, Scott RS. HLA-DQ beta typing and non-Asp57 alleles in IDDM and nondiabetic subjects in New Zealand. Diabetes Care 16: 1179-1183 (1993).
Ford McIntyre MS, Young KJ, Gao J, Joe B, Zhang L. Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigen-specific suppression. J. Immunol. 181: 2271-2275 (2008). *
Ford MS, Chen W, Wong S, Li C, Vanama R, Elford AR, Asa SL, Ohashi PS, Zhang L. Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. Eur. J. Immunol. 37: 2234-2241 (2007).
Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G. Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J. Endocrinol. Invest. 31: 146-152 (2008).
Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc. Natl. Acad. Sci. U.S.A. 94: 4312-4317 (1997). *
Forman D, Bulwer BE. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr. Treat. Options Cardiovasc. Med. 8: 47-57 (2006).
Formoso G, De Filippis EA, Michetti N, Di Fulvio P, Pandolfi A, Bucciarelli T, Ciabattoni G, Nicolucci A, Davi G, Consoli A. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab. Res. Rev. 24: 231-237 (2007).
Fornoni A, Lenz O, Striker LJ, Striker GE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes 52: 2594-2602 (2003). *
Forsythe ME, Love DC, Lazarus BD, Kim EJ, Prinz WA, Ashwell G, Krause MW, Hanover JA. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer. Proc. Natl. Acad. Sci. U.S.A. 103: 11952-11957 (2006). *
Foschini MP, Macchia S, Losi L, Dei Tos AP, Pasquinelli G, Di Tommaso L, Del Duca S, Roncaroli F, Dal Monte PR. Identification of mitochondria in liver biopsies. A study by immunohistochemistry, immunogold and Western blot analysis. Virchows. Arch. 433: 267-273 (1998). *
Fosgerau K, Hansen T, Galle P, Albrechtsen A, Rieper C, Pedersen B, Larsen L, Thomsen A, Pedersen O, Hansen M, Steensberg A. Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J. Endocrinol. Dec 16 [Epub ahead of print] (2009). *
Foss NT, Foss-Freitas MC, Ferreira MA, Cardili RN, Barbosa CM, Foss MC. Impaired cytokine production by peripheral blood mononuclear cells in type 1 diabetic patients. Diabetes Metab. 33: 439-443 (2007). *
Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of the glycemic control on intracellular cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes Res. Clin. Pract. 82: 329-334 (2008).
Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. In vitro TNF-alpha and IL-6 production by adherent peripheral blood mononuclear cells obtained from type 1 and type 2 diabetic patients evaluated according to the metabolic control. Ann. N. Y. Acad. Sci. 1079: 177-180 (2006). *
Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; for the DAIS investigators. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes. Pharmacogenetics 14: 823-829 (2004).
Foulis AK. Pancreatic pathology in type 1 diabetes in human. Novartis Found. Symp. 292: 2-13 (2008).
Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG. A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 29: 970-975 (2006). *
Fourlanos S, Varney MD, Tait BD, Morahan G, Honeyman MC, Colman PG, Harrison LC. The rising incidence of type 1 diabetes is accounted for by cases with lower risk HLA genotypes. Diabetes Care 31: 1546-1549 (2008). *
Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D. PPARs and the placenta. Placenta 28: 65-76 (2007).
Fourtner SH, Stanley CA, Kelly A. Protein-sensitive hypoglycemia without leucine sensitivity in hyperinsulinism caused by K(ATP) channel mutations. J. Pediatr. 149: 47-52 (2006). *
Fousteri G, Dave A, Juntti T, von Herrath M. CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J. Autoimmun. 32: 70-77 (2009).
Fousteri G, Hayek A, von Herrath M. Stopping diabetes in its tracks: autologous non-myeloablative stem cell transplantation. Regen. Med. 2: 845-851 (2007).
Fowlkes JL, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK Jr, Thrailkill KM. Runt-related transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are downregulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 149: 1697-1704 (2008). *
Fox JG, Feng Y, Theve EJ, Fry RC, Fiala JL, Doernte AL, Williams M, Raczynski AR, McFaline JL, Essigmann JM, Schauer DB, Tannenbaum SR, Dedon PC, Weinman SA, Lemon SM, Rogers AB. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 59: 88-97 (2010).
Fox RI. Sjogren's syndrome. Curr. Opin. Rheumatol. 7: 409-416 (1995).
Frances CP, Conde MC, Saez ME, Diez SF, Rey CM, Ramirez-Armengol JA, Pascual MH, Gonzalez-Perez A, Torres PP, Real LM, Serrano-Rios M, Lopez JL, Ruiz A, Royo JL. Identification of a protective haplogenotype within CAPN10 gene influencing colorectal cancer susceptibility. J. Gastroenterol. Hepatol. 22: 2298-2302 (2007). *
Franceschi F, Armuzzi A, Cremonini F, Carloni E, Zocco MA, Di Caro S, Padalino C, Genta RM, Pola P, Gasbarrini G, Gasbarrini A. Delta13CO2 excretion and expression of dyspeptic symptoms in patients evaluated for Helicobacter pylori infection by [13C] urea breath test. Dig. Dis. Sci. 47: 804-808 (2002). *
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311 (2003). *
Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3). BMC Med. Genet. 7: 3 (2006). *
Francke S, Manraj M, Lacquemant C, Lecoeur C, Lepretre F, Passa P, Hebe A, Corset L, Yan SL, Lahmidi S, Jankee S, Gunness TK, Ramjuttun US, Balgobin V, Dina C, Froguel P. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum. Mol. Genet. 10: 2751-2765 (2001). *
Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J. Hepatol. Jan 7 [Epub ahead of print] (2010).
Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O'Rahilly S, Barroso I, Wareham NJ. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia 50: 569-573 (2007). *
Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia 50: 2451-2460 (2007). *
Franzese A, Valerio G, Buono P, Spagnuolo MI, Sepe A, Mozzillo E, De Simone I, Raia V. Continuous glucose monitoring system in the screening of early glucose derangements in children and adolescents with cystic fibrosis. J. Pediatr. Endocrinol. Metab. 21: 109-116 (2008).
Franzini L, Ardigo D, Zavaroni I. Dietary antioxidants and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care 11: 471-476 (2008).
Fraser A, Ebrahim S, Davey Smith G, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology 46: 158-165 (2007). *
Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int. 29: 1494-1499 (2009). *
Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat. Rev. Genet. 8: 657-662 (2007). *
Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry JR, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves CJ, Knight B, Patch AM, Ness AR, Ebrahim S, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316: 889-894 (2007). *
Freathy RM, Lonnen KF, Steele AM, Minton JA, Frayling TM, Hattersley AT, Macleod KM. The impact of the angiotensin-converting enzyme insertion/deletion polymorphism on severe hypoglycemia in type 2 diabetes. Rev. Diabet. Stud. 3: 76-81 (2006). *
Freathy RM, Weedon MN, Bennett A, Hypponen E, Relton CL, Knight B, Shields B, Parnell KS, Groves CJ, Ring SM, Pembrey ME, Ben-Shlomo Y, Strachan DP, Power C, Jarvelin MR, McCarthy MI, Davey Smith G, Hattersley AT, Frayling TM. Type 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. Am. J. Hum. Genet. 80: 1150-1161 (2007). *
Fredenrich A, Grimaldi P. PPAR delta: an uncompletely known nuclear receptor. Diabetes Metab. 31: 23-27 (2005). *
Frediani B, Rossini M, Adami S, Bianchi G, Di Munno O, Sinigaglia L, Antonelli M, Minisola G. Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR). Reumatismo 58: 314-318 (2006).
Fredriksson J, Anevski D, Almgren P, Sjogren M, Lyssenko V, Carlson J, Isomaa B, Taskinen MR, Groop L, Orho-Melander M. Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PLoS ONE 2: e285 (2007). *
Freedman BI, Hicks PJ, Sale MM, Pierson ED, Langefeld CD, Rich SS, Xu J, McDonough C, Janssen B, Yard BA, van der Woude FJ, Bowden DW. A leucine repeat in the carnosinase gene CNDP1 is associated with diabetic end-stage renal disease in European Americans. Nephrol. Dial. Transplant. 22: 1131-1135 (2007). *
Freeman HJ. Pancreatic endocrine and exocrine changes in celiac disease. World J. Gastroenterol. 13: 6344-6346 (2007). *
Frelinger JA. Novel epitope begets a novel pathway in type 1 diabetes progression. J. Clin. Invest. 118: 3268-3271 (2008). *
Friday RP, Trucco M, Pietropaolo M. Genetics of type 1 diabetes mellitus. Diabetes Nutr. Metab. 12: 3-26 (1999).
Fridell JA, Vianna R, Kwo PY, Howenstine M, Sannuti A, Molleston JP, Pescovitz MD, Tector AJ. Simultaneous liver and pancreas transplantation in patients with cystic fibrosis. Transplant. Proc. 37: 3567-3569 (2005). *
Fridell JA, Wozniak TC, Powelson JA, Reynolds JM. Simultaneous bilateral lung and pancreas transplantation in recipient with cystic fibrosis. Transplant. Proc. 40: 494-497 (2008). *
Friedman E, Blahut RJ, Bender MD. Hepatic abscesses and fungemia from Torulopsis glabrata. Successful treatment with percutaneous drainage and amphotericin B. J. Clin. Gastroenterol. 9: 711-715 (1987).
Friedrich N, Volzke H, Hampe J, Lerch MM, Jorgensen T. Known risk factors do not explain disparities in gallstone prevalence between Denmark and northeast Germany. Am. J. Gastroenterol. 104: 89-95 (2009). *
Friese MA, Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 66: 132-141 (2009).
Frigoul A, Lefranc MP. MICA: standardized IMGT allele nomenclature, polymorphisms and diseases. Recent Res. Devel. Human Genet. 3: 95-145 (2005). *
Frisk G, Hansson T, Dahlbom I, Tuvemo T. A unifying hypothesis on the development of type 1 diabetes and celiac disease: gluten consumption may be a shared causative factor. Med. Hypotheses 70: 1207-1209 (2008).
Frohlich-Reiterer EE, Hofer S, Kaspers S, Herbst A, Kordonouri O, Schwarz HP, Schober E, Grabert M, Holl RW; on behalf of the DPV-Wiss Study Group. Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus - data from a German/Austrian multicentre survey. Pediatr. Diabetes 9: 546-553 (2008).
Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25: 1776-1785 (2005). *
Frostegard J. SLE, atherosclerosis and cardiovascular disease. J. Intern. Med. 257: 485-495 (2005). *
Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205: 1-8 (2009).
Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis. Pharmacol. Res. 44: 345-352 (2001). *
Frulloni L, Castellani C, Bovo P, Vaona B, Calore B, Liani C, Mastella G, Cavallini G. Natural history of pancreatitis associated with cystic fibrosis gene mutations. Dig. Liver Dis. 35: 179-185 (2003).
Frulloni L, Morana G, Bovo P, Mansueto GC, Vaona B, Di Francesco V, Procacci C, Cavallini G. Salivary gland involvement in patients with chronic pancreatitis. Pancreas 19: 33-38 (1999).
Fry L. Dermatitis herpetiformis. Baillieres Clin. Gastroenterol. 9: 371-393 (1995).
Fu JH, Xie SR, Kong SJ, Wang Y, Wei W, Shan Y, Luo YM. The combination of a high-fat diet and chronic stress aggravates insulin resistance in Wistar male rats. Exp. Clin. Endocrinol. Diabetes 117: 354-360 (2009).
Fu Y, Nathan DM, Li F, Li X, Faustman DL. Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. J. Clin. Invest. 91: 2301-2307 (1993). *
Fuchtenbusch M, Larger E, Thebault K, Boitard C. Transfer of diabetes from prediabetic NOD mice to NOD-SCID/SCID mice: association with pancreatic insulin content. Horm. Metab. Res. 37: 63-67 (2005).
Fuchtenbusch M, Vogel A, Achenbach P, Gummer M, Ziegler AG, Albert E, Standl E, Manns MP. Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Exp. Clin. Endocrinol. Diabetes 111: 288-293 (2003).
Fuchtenbusch M, Ziegler AG, Hummel M. Elimination of dietary gluten and development of type 1 diabetes in high risk subjects. Rev. Diabet. Stud. 1: 39-41 (2004). *
Fueger PT, Schisler JS, Lu D, Babu DA, Mirmira RG, Newgard CB, Hohmeier HE. Trefoil factor 3 stimulates human and rodent pancreatic islet beta-cell replication with retention of function. Mol. Endocrinol. 22: 1251-1259 (2008). *
Fujii H. Nuclear receptor PPARs and magnesium. Clin. Calcium 15: 1814-1826 (2005).
Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J. Pharmacol. Exp. Ther. 318: 863-871 (2006). *
Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 19: 80-94 (2006). *
Fujisawa T, Ikegami H, Noso S, Yamaji K, Nojima K, Babaya N, Itoi-Babaya M, Hiromine Y, Kobayashi M, Makino S, Ogihara T. MHC-linked susceptibility to type 1 diabetes in the NOD mouse: further localization of Idd16 by subcongenic analysis. Ann. N. Y. Acad. Sci. 1079: 118-121 (2006). *
Fukushima T, Dong L, Sakai T, Sawaki T, Miki M, Tanaka M, Masaki Y, Hirose Y, Kuwana M, Umehara H. Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus 17: 210-214 (2008). *
Fuller JM, Bogdani M, Tupling TD, Jensen RA, Pefley R, Manavi S, Cort L, Blankenhorn EP, Mordes JP, Lernmark A, Kwitek AE. Genetic dissection reveals diabetes loci proximal to the Gimap5 lymphopenia gene. Physiol. Genomics 38: 89-97 (2009). *
Fullerton SM, Yu JH, Crouch J, Fryer-Edwards K, Burke W. Population description and its role in the interpretation of genetic association. Hum. Genet. Feb 16 [Epub ahead of print] (2010). *
Funauchi M, Tamaki C, Yamagata T, Nozaki Y, Sugiyama M, Ikoma S, Kinoshita K. A case of autoimmune polyglandular syndrome type III with a slowly progressive form of type-1 diabetes mellitus that manifested in the course of autoimmune diseases. Scand. J. Rheumatol. 35: 81-82 (2006). *
Fung E, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 10: 188-191 (2009). *
Fung MM, Chen Y, Lipkowitz MS, Salem RM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Brophy VH, O'Connor DT; for the AASK Co-Investigators. Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis. Nephrol. Dial. Transplant. 24: 3677-3686 (2009).
Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59: 627-635 (2001). *
Funk M, Endler G, Exner M, Marculescu R, Endler L, Abrahamian H, Mauler H, Grimm A, Raith M, Mannhalter C, Prager R, Irsigler K, Wagner OF. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien. Klin. Wochenschr. 117: 707-710 (2005).
Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447: 959-965 (2007). *
Furukawa N, Miyamura N, Nishida K, Motoshima H, Taketa K, Araki E. Possible relevance of alpha lipoic acid contained in a health supplement in a case of insulin autoimmune syndrome. Diabetes Res. Clin. Pract. 75: 366-367 (2007).
Furuta H, Iwasaki N, Oda N, Hinokio Y, Horikawa Y, Yamagata K, Yano N, Sugahiro J, Ogata M, Ohgawara H, Omori Y, Iwamoto Y, Bell GI. Organization and partial sequence of the hepatocyte nuclear factor-4 alpha/MODY1 gene and identification of a missense mutation, R127W, in a Japanese family with MODY. Diabetes 46: 1652-1657 (1997).
Furuya T, Salstrom JL, McCall-Vining S, Cannon GW, Joe B, Remmers EF, Griffiths MM, Wilder RL. Genetic dissection of a rat model for rheumatoid arthritis: significant gender influences on autosomal modifier loci. Hum. Mol. Genet. 9: 2241-2250 (2000). *
Fux Otta C, Szafryk de Mereshian P, Iraci GS, Ojeda de Pruneda MR. Pregnancies associated with primary adrenal insufficiency. Fertil. Steril. 90: 1199.e17-e20 (2008).
Gaber SA, Mazzola G, Berrino M, Canale L, Cornaglia M, Ghali I, Sergio Curtoni E, Amoroso A. Human leukocyte antigen class II polymorphisms and genetic susceptibility of IDDM in Egyptian children. Diabetes Care 17: 1341-1344 (1994).
Gabory A, Attig L, Junien C. Sexual dimorphism in environmental epigenetic programming. Mol. Cell. Endocrinol. 304: 8-18 (2009).
Gabriely I, Shamoon H. Hypoglycemia in diabetes: common, often unrecognized. Cleve. Clin. J. Med. 71: 335-342 (2004). *
Gach A, Wyka K, Pietrzak I, Wegner O, Malecki MT, Mlynarski W. Neonatal diabetes in a child positive for islet cell antibodies at onset and Kir6.2 activating mutation. Diabetes Res. Clin. Pract. 86: e25-e27 (2009).
Gacka M, Adamiec R. Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications. Postepy. Hig. Med. Dosw. (Online) 58: 483-489 (2004).
Gacka M, Bednarska-Chabowska D, Dobosz T, Szymaniec S, Jakobsche U, Lebioda A, Adamiec R. The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma and immunological processes in patients with type 2 diabetes and insulin resistance. Przegl. Lek. 64: 393-397 (2007).
Gaede PH. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: rationale and effect on late-diabetic complications. Dan. Med. Bull. 53: 258-284 (2006).
Gaens K, van der Kallen C, van Greevenbroek M, Feskens E, Stehouwer C, Schalkwijk C. Receptor for advanced glycation end product polymorphisms and type 2 diabetes: the CODAM study. Ann. N. Y. Acad. Sci. 1126: 162-165 (2008). *
Gagliani N, Ferraro A, Roncarolo MG, Battaglia M. Autoimmune diabetic patients undergoing allogeneic islet transplantation: are we ready for a regulatory T-cell therapy? Immunol. Lett. 127: 1-7 (2009).
Gagne DJ, Papasavas PK, Dovec EA, Urbandt JE, Caushaj PF. Effect of immunosuppression on patients undergoing bariatric surgery. Surg. Obes. Relat. Dis. 5: 339-345 (2009).
Gagnerault MC, Lanvin O, Pasquier V, Garcia C, Damotte D, Lucas B, Lepault F. Autoimmunity during thymectomy-induced lymphopenia: role of thymus ablation and initial effector T cell activation timing in nonobese diabetic mice. J. Immunol. 183: 4913-4920 (2009).
Gahring LC, Rogers SW. Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J. 7: E885-E894 (2006). *
Gaia E, Salacone P, Gallo M, Promis GG, Brusco A, Bancone C, Carlo A. Germline mutations in CFTR and PSTI genes in chronic pancreatitis patients. Dig. Dis. Sci. 47: 2416-2421 (2002). *
Galanakis E, Kofteridis D, Stratigi K, Petraki E, Vazgiourakis V, Fragouli E, Mamoulakis D, Boumpas DT, Goulielmos GN. Intron 4 a/b polymorphism of the endothelial nitric oxide synthase gene is associated with both type 1 and type 2 diabetes in a genetically homogeneous population. Hum. Immunol. 69: 279-283 (2008).
Gale EA. A missing link in the hygiene hypothesis? Diabetologia 45: 588-594 (2002). *
Galera Martinez R, Garc�a Garc�a E, Gamez Gomez MD, Gomez Llorente JL, Garrido Fernandez P, Bonillo Perales A. Final size attained in type 1 diabetes children. An. Pediatr. (Barc.) 70: 235-240 (2009).
Galgani A, Petrone A, Spoletini M, Hodge A, Del Buono ML, Locatelli M, Buzzetti R; Diabfin Study Group. HLA class II typing in newborns reveals a low frequency of the DRB1*04 allele and a high frequency of DRB1*11 allele in three regions of continental Italy. Hum. Immunol. 65: 366-372 (2004).
Galgani JE, Uauy RD, Aguirre CA, Diaz EO. Effect of the dietary fat quality on insulin sensitivity. Br. J. Nutr. 100: 471-479 (2008). *
Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families, and populations. Curr. Gastroenterol. Rep. 6: 44-51 (2004).
Galicka-Latala D, Zwolinska-Wcislo M, Sosin-Rudnicka L, Rozpondek P. The role of celiac disease and type 1 diabetes coexistance. Is celiac disease responsible for diabetic status? Przegl. Lek. 66: 170-175 (2009).
Gallagher MJ, Ding L, Maheshwari A, Macdonald RL. The GABAA receptor alpha1 subunit epilepsy mutation A322D inhibits transmembrane helix formation and causes proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 104: 12999-13004 (2007). *
Gallego O, Ruiz FX, Ardevol A, Dominguez M, Alvarez R, de Lera AR, Rovira C, Farres J, Fita I, Pares X. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. U.S.A. 104: 20764-20769 (2007). *
Gallego PH, Craig ME, Duffin AC, Bennetts B, Jenkins AJ, Hofer S, Lam A, Donaghue KC. Association between p.Leu54Met polymorphism at the paraoxonase-1 gene and plantar fascia thickness in young subjects with type 1 diabetes. Diabetes Care 31: 1585-1589 (2008). *
Gallegos AM, Bevan MJ. Driven to autoimmunity: the nod mouse. Cell 117: 149-151 (2004). *
Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opin. Investig. Drugs 15: 1039-1049 (2006).
Gallo AP, Silva LB, Franco M, Burdmann EA, Bueno V. Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. Int. Immunopharmacol. 6: 1919-1924 (2006).
Gallo AP, Silva LB, Franco M, Burdmann EA, Bueno V. Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. Int. Immunopharmacol. 6: 1723-1728 (2006).
Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and results of videocapillaroscopy in clinical practice. Adv. Med. Sci. 53: 149-157 (2008).
Gambelunghe G, Brozzetti A, Ghaderi M, Candeloro P, Tortoioli C, Falorni A. MICA gene polymorphism in the pathogenesis of type 1 diabetes. Ann. N. Y. Acad. Sci. 1110: 92-98 (2007). *
Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A. Increased risk for endocrine autoimmunity in Italian type 2 diabetic patients with GAD65 autoantibodies. Clin. Endocrinol. (Oxf.) 52: 565-573 (2000). *
Gambelunghe G, Ghaderi M, Cosentino A, Falorni A, Brunetti P, Falorni A, Sanjeevi CB. Association of MHC class I chain-related A (MIC-A) gene polymorphism with type I diabetes. Diabetologia 43: 507-514 (2000). *
Gambelunghe G, Ghaderi M, Tortoioli C, Falorni A, Santeusanio F, Brunetti P, Sanjeevi CB, Falorni A; Umbria Type 1 Diabetes Registry. Two distinct MICA gene markers discriminate major autoimmune diabetes types. J. Clin. Endocrinol. Metab. 86: 3754-3760 (2001). *
Gambelunghe G, Kockum I, Bini V, Giorgi GD, Celi F, Betterle C, Giordano R, Libe R, Falorni A. Retrovirus-like long-terminal repeat DQ-LTR13 and genetic susceptibility to type 1 diabetes and autoimmune Addison's disease. Diabetes 54: 900-905 (2005). *
Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15: 430-435 (2003).
Gammell P, O'Driscoll L, Clynes M. Characterisation of BHK-21 cells engineered to secrete human insulin. Cytotechnology 41: 11-21 (2003). *
Ganesh R Dr, Arvindkumar R, Vasanthi T. Infantile-onset diabetes mellitus: a 1-year follow-up study. Clin. Pediatr. (Phila.) 48: 271-274 (2009).
Gani OA. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiovasc. Diabetol. 7: 6 (2008). *
Gao F, Zhang R, Hu C, Fang QC, Wang CR, Ma XJ, Lu JX, Xu J, Jia WP, Xiang KS. Association of -6735T-->C variant of glucokinase-associated dual-specificity phosphatase 12 gene with type 2 diabetes in Chinese. Zhonghua Yi Xue Za Zhi 88: 2250-2253 (2008).
Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J. Autoimmun. 26: 90-103 (2006).
Gao JX, Xu DL, Shao YH, Lao WY, Lin S, Zhang B. Association of Gly82Ser polymorphism of receptor for advanced glycation end products gene in a type 2 diabetic Chinese population. Nan Fang Yi Ke Da Xue Xue Bao 27: 219-222 (2007).
Gao XL, Yang HX, Zhao Y. Variations of tumor necrosis factor-alpha, leptin and adiponectin in mid-trimester of gestational diabetes mellitus. Chin. Med. J. (Engl.) 121: 701-705 (2008).
Garcia D, Angel B, Carrasco E, Albala C, Santos JL, Perez-Bravo F. VDR polymorphisms influence the immune response in type 1 diabetic children from Santiago, Chile. Diabetes Res. Clin. Pract. 77: 134-140 (2007).
Garcia DD, Oyarzun AA, Angel BB, Carrasco PE, Perez BF. Association of GHRd3 variant of growth hormone receptor gene with autoimmunity in type 1 diabetes. Rev. Med. Chil. 137: 609-616 (2009).
Garcia-Centeno R, Suarez-Llanos JP, Fernandez-Fernandez E, And�a-Melero V, Sanchez P, Jara-Albarran A. Empty sella and primary autoimmune hypothyroidism. Clin. Exp. Med. Oct 1 [Epub ahead of print] (2009). *
Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol. 15: 280-288 (2009). *
Garcia-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes. Current views of an ancient problem. Ann. Hepatol. 8: 13-20 (2009). *
Garcia-Ramirez M, Hernandez C, Villarroel M, Canals F, Alonso MA, Fortuny R, Masmiquel L, Navarro A, Garcia-Arumi J, Simo R. Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia Oct 13 [Epub ahead of print] (2009). *
Gardiner A, Richards KA, Sant AJ, Arneson LS. Conformation of MHC class II I-Ag7 is sensitive to the P9 anchor amino acid in bound peptide. Int. Immunol. 19: 1103-1113 (2007). *
Gardner JM, Anderson MS. The sickness unto Deaf. Nat. Immunol. 10: 934-936 (2009). *
Gardner JM, Devoss JJ, Friedman RS, Wong DJ, Tan YX, Zhou X, Johannes KP, Su MA, Chang HY, Krummel MF, Anderson MS. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 321: 843-847 (2008). *
Gardner JM, Fletcher AL, Anderson MS, Turley SJ. AIRE in the thymus and beyond. Curr. Opin. Immunol. 21: 582-589 (2009).
Garman JH, Mulroney SE, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am. J. Physiol. Renal Physiol. 296: F306-F316 (2009). *
Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E, Defronzo RA. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133: 496-506 (2007). *
Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50: 1087-1093 (2009).
Gastaldelli A, Kozakova M, Hojlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, Balkau B; The RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49: 1537-1544 (2009).
Gatenby PA, Lucas RM, Engelsen O, Ponsonby AL, Clements M. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum. 61: 1417-1424 (2009). *
Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 11: R24 (2009). *
Gatzka M, Walsh CM. Apoptotic signal transduction and T cell tolerance. Autoimmunity 40: 442-452 (2007).
Gaudel C, Schwartz C, Giordano C, Abumrad NA, Grimaldi P. Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 295: E297-E304 (2008). *
Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, Panhuis TM, Mieczkowski P, Secchi A, Bosco D, Berney T, Montanya E, Mohlke KL, Lieb JD, Ferrer J. A map of open chromatin in human pancreatic islets. Nat. Genet. Jan 31 [Epub ahead of print] (2010). *
Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, Luo J, Tong M, Sprau AG, Pugh EW, Doheny KF, Valle TT, Abecasis GR, Tuomilehto J, Bergman RN, Collins FS, Boehnke M, Mohlke KL. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 57: 3136-3144 (2008). *
Gaur LK. Nonhuman primate models for islet transplantation in type 1 diabetes research. ILAR J. 45: 324-333 (2004).
Gautier-Stein A, Zitoun C, Lalli E, Mithieux G, Rajas F. Transcriptional regulation of the glucose-6-phosphatase gene by cAMP/vasoactive intestinal peptide in the intestine. Role of HNF4alpha, CREM, HNF1alpha, and C/EBPalpha. J. Biol. Chem. 281: 31268-31278 (2006). *
Gavanescu I, Benoist C, Mathis D. B cells are required for Aire-deficient mice to develop multi-organ autoinflammation: a therapeutic approach for APECED patients. Proc. Natl. Acad. Sci. U.S.A. 105: 13009-13014 (2008). *
Gavanescu I, Kessler B, Ploegh H, Benoist C, Mathis D. Loss of Aire-dependent thymic expression of a peripheral tissue antigen renders it a target of autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 104: 4583-4587 (2007). *
Gayathri SB, Radha V, Vimaleswaran KS, Mohan V. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41). Metab. Syndr. Relat. Disord. Nov 9 [Epub ahead of print] (2009).
Gaynor JJ, Moon JI, Kato T, Nishida S, Selvaggi G, Levi DM, Island ER, Pyrsopoulos N, Weppler D, Ganz S, Ruiz P, Tzakis AG. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation 84: 155-165 (2007).
Gazit V, Tasher D, Hanukoglu A, Landau Z, Ben-Yehuda Y, Somekh E, Dalal I. Atopy in children and adolescents with insulin-dependent diabetes mellitus. Isr. Med. Assoc. J. 10: 858-861 (2008). *
Ge K, Cho YW, Guo H, Hong TB, Guermah M, Ito M, Yu H, Kalkum M, Roeder RG. Alternative mechanisms by which mediator subunit MED1/TRAP220 regulates peroxisome proliferator-activated receptor gamma-stimulated adipogenesis and target gene expression. Mol. Cell. Biol. 28: 1081-1091 (2008). *
Gebe JA, Falk B, Unrath K, Nepom GT. Autoreactive T cells in a partially humanized murine model of T1D. Ann. N. Y. Acad. Sci. 1103: 69-76 (2007). *
Gebe JA, Unrath KA, Yue BB, Miyake T, Falk BA, Nepom GT. Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. J. Autoimmun. 30: 197-206 (2008).
Gebe JA, Yue BB, Unrath KA, Falk BA, Nepom GT. Restricted autoantigen recognition associated with deletional and adaptive regulatory mechanisms. J. Immunol. 183: 59-65 (2009).
Gellner V, Kurschel S, Scarpatetti M, Mokry M. Lymphocytic hypophysitis in the pediatric population. Childs. Nerv. Syst. 24: 785-792 (2008).
Gelman L, Feige JN, Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes. Biochim. Biophys. Acta 1771: 1094-1107 (2007). *
Geluk A, van Meijgaarden KE, Schloot NC, Drijfhout JW, Ottenhoff TH, Roep BO. HLA-DR binding analysis of peptides from islet antigens in IDDM. Diabetes 47: 1594-1601 (1998). *
Genc S, Genc K, Sercan O, Kizildag S, Gulay Z, Atay T, Dundar B, Sakizli M, Buyukgebiz A. Analysis of cytotoxic T lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism in patients with type 1 diabetes mellitus in a Turkish population. J. Pediatr. Endocrinol. Metab. 17: 731-735 (2004).
Genet C, Strehle A, Schmidt C, Boudjelal G, Lobstein A, Schoonjans K, Souchet M, Auwerx J, Saladin R, Wagner A. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J. Med. Chem. 53: 178-190 (2010). *
Genini D, Carbone GM, Catapano CV. Multiple interactions between peroxisome proliferators-activated receptors and the ubiquitin-proteasome system and implications for cancer pathogenesis. PPAR Res. 2008: 195065 (2008). *
Genini D, Catapano CV. Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system. J. Recept. Signal Transduct. Res. 26: 679-692 (2006).
Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin. Arthritis Rheum. 36: 88-98 (2006). *
Geoffrey R, Jia S, Kwitek AE, Woodliff J, Ghosh S, Lernmark A, Wang X, Hessner MJ. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J. Immunol. 177: 7275-7286 (2006). *
Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R. Dupuytren's disease risk factors. J. Hand Surg. [Br.] 29: 423-426 (2004).
George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 5: 49-59 (2008). *
Georgopoulos A, Bloomfield H, Collins D, Brousseau ME, Ordovas JM, O'Connor JJ, Robins SJ, Schaefer EJ. Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the veterans affairs HDL intervention trial (VA-HIT). Atherosclerosis 194: 169-174 (2007).
Geraldes P, Yamagata M, Rook SL, Sassa Y, Ma RC, Clermont A, Gao B, Aiello LP, Feener EP, King GL. Glypican 4, a membrane binding protein for bactericidal/permeability-increasing protein signaling pathways in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 48: 5750-5755 (2007). *
Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br. J. Dermatol. 159: 1116-1123 (2008). *
Gerhauser C. Cancer chemopreventive potential of apples, apple juice, and apple components. Planta Med. 74: 1608-1624 (2008).
Germolec DR, Frawley RP, Evans E. Markers of inflammation. Methods Mol. Biol. 598: 53-73 (2010). *
Gero L. Treatment of nephrotic syndrome in the adult. Orv. Hetil. 147: 2313-2318 (2006).
Gershon ES, Badner JA. Progress toward discovery of susceptibility genes for bipolar manic-depressive illness and schizophrenia. CNS Spectr. 7: 965-968 (2002).
Gershwin LJ. Veterinary autoimmunity: autoimmune diseases in domestic animals. Ann. N. Y. Acad. Sci. 1109: 109-116 (2007). *
Gersuk VH, Nepom GT. A real-time polymerase chain reaction assay for the rapid identification of the autoimmune disease-associated allele HLA-DQB1*0602. Tissue Antigens 73: 335-340 (2009). *
Gervois P, Fruchart JC, Staels B. Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists. Int. J. Clin. Pract. Suppl. 143: 22-29 (2004).
Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat. Clin. Pract. Endocrinol. Metab. 3: 145-156 (2007). *
Gey T, Bergoin C, Just N, Paupard T, Cazals-Hatem D, Xuan KH, Tavernier JY, Wallaert B. Langerhans cell histiocytosis and sclerosing cholangitis in adults. Rev. Mal. Respir. 21: 997-1000 (2004).
Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell. Mol. Life Sci. 63: 524-539 (2006). *
Ghali P, Lindor KD. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. Semin. Liver Dis. 24: 389-397 (2004).
Ghanaat-Pour H, Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Diabetes Metab. Res. Rev. 25: 163-184 (2009).
Ghandil P, Chelala C, Dubois-Laforgue D, Senee V, Caillat-Zucman S, Kockum I, Luthman H, Nerup J, Pociot F, Timsit J, Julier C. Crohn's disease associated CARD15 (NOD2) variants are not involved in the susceptibility to type 1 diabetes. Mol. Genet. Metab. 86: 379-383 (2005). *
Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez Real JM, Dandona P. Increase in plasma endotoxin concentrations and the expression of Toll like receptors and suppressor of cytokine signaling-3 in mononuclear cells following a high fat high carbohydrate meal: implications for insulin resistance. Diabetes Care 32: 2281-2287 (2009).
Ghanim H, Sia CL, Upadhyay M, Korzeniewski K, Viswanathan P, Abuaysheh S, Mohanty P, Dandona P. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am. J. Clin. Nutr. Mar 3 [Epub ahead of print] (2010). *
Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 49: S174-S184 (2009).
Ghirardello S, Garre ML, Rossi A, Maghnie M. The diagnosis of children with central diabetes insipidus. J. Pediatr. Endocrinol. Metab. 20: 359-375 (2007). *
Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, Glowacki F, Lebranchu Y, Drouet M, Noel C, El Housni H, Cochaux P, Wissing KM, Abramowicz D, Abramowicz M. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J. Am. Soc. Nephrol. 20: 2459-2467 (2009).
Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy 3: 193-198 (2004).
Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clement K, Charles MA, Tauber M, Weill J, Froguel P. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population. BMC Med. Genet. 6: 11 (2005). *
Giacconi R, Bonfigli AR, Testa R, Sirolla C, Cipriano C, Marra M, Muti E, Malavolta M, Costarelli L, Piacenza F, Tesei S, Mocchegiani E. +647 A/C and +1245 MT1A polymorphisms in the susceptibility of diabetes mellitus and cardiovascular complications. Mol. Genet. Metab. 94: 98-104 (2008). *
Giacconi R, Cipriano C, Muti E, Costarelli L, Maurizio C, Saba V, Gasparini N, Malavolta M, Mocchegiani E. Novel -209A/G MT2A polymorphism in old patients with type 2 diabetes and atherosclerosis: relationship with inflammation (IL-6) and zinc. Biogerontology 6: 407-413 (2005). *
Giaginis C, Margeli A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. Expert Opin. Investig. Drugs 16: 1561-1572 (2007).
Giaginis C, Spanopoulou E, Theocharis S. PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. Expert Opin. Ther. Targets 12: 1049-1063 (2008).
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics. Chem. Biol. Drug Des. 72: 257-264 (2008).
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam. Clin. Pharmacol. 21: 231-244 (2007). *
Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, Giamarellou H. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int. J. Antimicrob. Agents 27: 476-481 (2006). *
Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, Kent SC, Hering BJ, West E, Steck A, Bonner-Weir S, Atkinson MA, Coppieters K, von Herrath M, Eisenbarth GS. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia Jan 9 [Epub ahead of print] (2010). *
Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol. Rev. 204: 232-249 (2005). *
Gianazza E, Mainini V, Castoldi G, Chinello C, Zerbini G, Bianchi C, Galbusera C, Stella A, Mauri G, Zoppis I, Magni F, Kienle MG. Different expression of fibrinopeptide A and related fragments in serum of type 1 diabetic patients with nephropathy. J. Proteomics Jul 22 [Epub ahead of print] (2009). *
Giannoukakis N, Phillips B, Trucco M. Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatr. Diabetes 9: 4-13 (2008).
Giannoukakis N, Trucco M. Gene therapy for type 1 diabetes. Am. J. Ther. 12: 512-528 (2005).
Giannoukakis N, Trucco M. Gene therapy for type 1 diabetes: a proposal to move to the next level. Curr. Opin. Mol. Ther. 7: 467-475 (2005).
Giarratana N, Penna G, Adorini L. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol. Biol. 380: 285-312 (2007).
Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J. Immunol. 173: 2280-2287 (2004). *
Giavoli C, Ferrante E, Bergamaschi S, Ronchi CL, Lania AG, Spada A, Beck-Peccoz P. An unusual case of recurrent autoimmune hypophysitis. Exp. Clin. Endocrinol. Diabetes Aug 18 [Epub ahead of print] (2009).
Gibbons LJ, Thomson W, Zeggini E, Worthington J, Barton A, Eyre S, Donn R, Hinks A. The type 1 diabetes susceptibility gene SUMO4 at IDDM5 is not associated with susceptibility to rheumatoid arthritis or juvenile idiopathic arthritis. Rheumatology (Oxford) 44: 1390-1393 (2005). *
Gibbs P, Steel S, McLaughlin S, Jones I, Faragher I, Skinner I, Croxford M, Johns J, Chapman M, Lipton L. Type 2 diabetes mellitus, smoking, and colorectal cancer. Am. J. Gastroenterol. 102: 909-910 (2007). *
Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 71: 1105-1110 (2005). *
Gibson DL, Vallance BA. Intestinal microbiota are transiently altered during Salmonella-induced gastroenteritis. Expert Rev. Gastroenterol. Hepatol. 2: 525-529 (2008).
Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterol. Nurs. 24: 95-97 (2001).
Gigli G, Caielli S, Cutuli D, Falcone M. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation. Immunology 122: 409-417 (2007). *
Gil A, Bengmark S. Advanced glycation and lipoxidation end products - amplifiers of inflammation: the role of food. Nutr. Hosp. 22: 625-640 (2007).
Gilde AJ, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. J. Am. Coll. Cardiol. 48: A24-A32 (2006).
Giles TD, Sander AG. Effects of thiazolidinediones on blood pressure. Curr. Hypertens. Rep. 9: 332-337 (2007).
Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv. Exp. Med. Biol. 606: 423-454 (2008).
Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ 175: 165-170 (2006). *
Gillespie KM, Dix RJ, Williams AJ, Newton R, Robinson ZF, Bingley PJ, Gale EA, Shield JP. Islet autoimmunity in children with Down's syndrome. Diabetes 55: 3185-3188 (2006). *
Gilliam LK, Binder KA, Banga JP, Madec AM, Ortqvist E, Kockum I, Luo D, Hampe CS. Multiplicity of the antibody response to GAD65 in type I diabetes. Clin. Exp. Immunol. 138: 337-341 (2004). *
Gilliam LK, Liese AD, Bloch CA, Davis C, Snively BM, Curb D, Williams DE, Pihoker C; SEARCH for Diabetes in Youth Study Group. Family history of diabetes, autoimmunity, and risk factors for cardiovascular disease among children with diabetes in the SEARCH for Diabetes in Youth Study. Pediatr. Diabetes 8: 354-361 (2007). *
Ginanjar E, Sumariyono , Setiati S, Setiyohadi B. Vitamin D and autoimmune disease. Acta Med. Indones. 39: 133-141 (2007).
Ginsberg A, Stahl Z, Leventhal A. Omega-3 fatty acids: the science and the beliefs. Harefuah. 148: 114-120, 138 (2009).
Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168: 1174-1180 (2008). *
Girona J, Guardiola M, Cabre A, Manzanares JM, Heras M, Ribalta J, Masana L. The apolipoprotein A5 gene -1131T-->C polymorphism affects vitamin E plasma concentrations in type 2 diabetic patients. Clin. Chem. Lab. Med. 46: 453-457 (2008).
Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin. Thromb. Hemost. 35: 313-324 (2009).
Gisondi P, Girolomoni G. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas. Dermosifiliogr. 100: S14-S21 (2009).
Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer - a meta-analysis. J. Steroid Biochem. Mol. Biol. 111: 195-199 (2008).
Giuliani L, Mele R, Di Giovine M, Altieri L, Crino A, Rava L, Fierabracci A. Detection of GAD65 autoreactive T-cells by HLA class I tetramers in type 1 diabetic patients. J. Biomed. Biotechnol. 2009: 576219 (2009). *
Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases. PPAR Res. 2008: 429123 (2008). *
Gladman DD, Ang M, Su L, Tom BD, Schentag CT Phd, Farewell VT. Cardiovascular morbidity in psoriatic arthritis (PsA). Ann. Rheum. Dis. 68: 1131-1135 (2009).
Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, Koletzko S, Folwaczny M, Lohse P, Goke B, Ochsenkuhn T, Muller-Myhsok B, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am. J. Gastroenterol. 104: 1737-1744 (2009). *
Glaser B. Type 2 diabetes: hypoinsulinism, hyperinsulinism, or both? PLoS Med. 4: e148 (2007). *
Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 28: 2170-2175 (2005). *
Glastras SJ, Mohsin F, Donaghue KC. Complications of diabetes mellitus in childhood. Pediatr. Clin. North Am. 52: 1735-1753 (2005).
Glawe JD, Patrick DR, Huang M, Sharp CD, Barlow SC, Kevil CG. Genetic deficiency of Itgb2 or ItgaL prevents autoimmune diabetes through distinctly different mechanisms in NOD/LtJ mice. Diabetes 58: 1292-1301 (2009). *
Gleeson F, Ryan E, Barrett S, Crowe J. Clinical expression of haemochromatosis in Irish C282Y homozygotes identified through family screening. Eur. J. Gastroenterol. Hepatol. 16: 859-863 (2004).
Glenville M. Nutritional supplements in pregnancy: commercial push or evidence based? Curr. Opin. Obstet. Gynecol. 18: 642-647 (2006).
Glew RH, Wold RS, Herbein JH, Wark WA, Martinez MA, Vanderjagt DJ. Low docosahexaenoic acid in the diet and milk of women in New Mexico. J. Am. Diet. Assoc. 108: 1693-1699 (2008). *
Glinka Y, Chang Y, Prud'homme GJ. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand. Mol. Ther. 14: 578-587 (2006).
Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S, Glinsky GV. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 8: 3925-3942 (2009).
Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle 7: 2570-2583 (2008). *
Glisic S, Ehlenbach S, Jailwala P, Waukau J, Jana S, Ghosh S. Inducible regulatory T cells (iTregs) from recent-onset type 1 diabetes subjects show increased in vitro suppression and higher ITCH levels compared with controls. Cell Tissue Res. Feb 9 [Epub ahead of print] (2010). *
Glisic S, Klinker M, Waukau J, Jailwala P, Jana S, Basken J, Wang T, Alemzadeh R, Hagopian W, Ghosh S. Genetic association of HLA DQB1 with CD4+CD25+(high) T-cell apoptosis in type 1 diabetes. Genes Immun. 10: 334-340 (2009).
Gloria-Bottini F, Bottini N, Renzetti G, Bottini E. ACP1 and Th class of immunological disease: evidence of interaction with gender. Int. Arch. Allergy Immunol. 143: 170-176 (2007).
Gloyn AL, Mackay DJ, Weedon MN, McCarthy MI, Walker M, Hitman G, Knight BA, Owen KR, Hattersley AT, Frayling TM. Assessment of the role of common genetic variation in the transient neonatal diabetes mellitus (TNDM) region in type 2 diabetes: a comparative genomic and tagging single nucleotide polymorphism approach. Diabetes 55: 2272-2276 (2006). *
Gluch J, Glaser J. Primary sclerosing cholangitis, ulcerative colitis and type 1 diabetes mellitus. Z. Gastroenterol. 37: 735-738 (1999).
Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52: 725-753 (1996).
Godbout A, Hammana I, Potvin S, Mainville D, Rakel A, Berthiaume Y, Chiasson JL, Coderre L, Rabasa-Lhoret R. No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab. 34: 568-573 (2008).
Godebu E, Summers-Torres D, Lin MM, Baaten BJ, Bradley LM. Polyclonal adaptive regulatory CD4 cells that can reverse type I diabetes become oligoclonal long-term protective memory cells. J. Immunol. 181: 1798-1805 (2008). *
Godkin A, Friede T, Davenport M, Stevanovic S, Willis A, Jewell D, Hill A, Rammensee HG. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int. Immunol. 9: 905-911 (1997). *
Godsland IF, Agbaje OF, Hovorka R. Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. Am. J. Physiol. Endocrinol. Metab. 291: E167-E174 (2006). *
Godsland IF, Johnston DG. Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. Metabolism 57: 1190-1197 (2008). *
Goel A, Chiu H, Felton J, Palmer JP, Brooks-Worrell B. T cell responses to islet antigens improves detection of autoimmune diabetes and identifies patients with more severe beta cell lesion in phenotypic type 2 diabetes. Diabetes 56: 2110-2115 (2007). *
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "curecumin": from kitchen to clinic. Biochem. Pharmacol. 75: 787-809 (2008). *
Goel NK, McBane RD, Kamath PS. Cardiomyopathy associated with celiac disease. Mayo Clin. Proc. 80: 674-676 (2005). *
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN. Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin. Exp. Rheumatol. 21: 333-339 (2003).
Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135: 1935-1944.e1 (2008). *
Goh C, Banerjee K. Prevalence of coeliac disease in children and adolescents with type 1 diabetes mellitus in a clinic based population. Postgrad. Med. J. 83: 132-136 (2007). *
Gohlke H, Ferrari U, Koczwara K, Bonifacio E, Illig T, Ziegler AG. SLC30A8 (ZnT8) polymorphism is associated with young age at type 1 diabetes onset. Rev. Diabet. Stud. 5: 25-27 (2008). *
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. Diab. Vasc. Dis. Res. 4: 204-213 (2007).
Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and type 2 diabetes patients. Mol. Cell. Biochem. 324: 173-181 (2009). *
Goland S, Beilinson N, Kaftouri A, Shimoni S, Caspi A, Malnick SD. Hemochromatosis mutations are not linked to dilated cardiomyopathy in Israeli patients. Eur. J. Heart Fail. 6: 547-550 (2004).
Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Immune-related disease before and after vasectomy: an epidemiological database study. Hum. Reprod. 22: 1273-1278 (2007). *
Goldberg E, Krause I. Infection and type 1 diabetes mellitus - a two edged sword? Autoimmun. Rev. 8: 682-686 (2009).
Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 94: 3171-3182 (2009).
Goldberg RB, Holman R, Drucker DJ. Clinical decisions. Management of type 2 diabetes. N. Engl. J. Med. 358: 293-297 (2008). *
Goldberg RB, Sabharwal AK. Fish oil in the treatment of dyslipidemia. Curr. Opin. Endocrinol. Diabetes Obes. 15: 167-174 (2008).
Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: evidence for common and unique genes. J. Clin. Endocrinol. Metab. 90: 4904-4911 (2005). *
Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J. Clin. Endocrinol. Metab. 92: 124-130 (2007). *
Goldfine ID, Maddux BA, Youngren JF, Reaven G, Accili D, Trischitta V, Vigneri R, Frittitta L. The role of membrane glycoprotein PC-1/ENPP1 in the pathogenesis of insulin resistance and related abnormalities. Endocr. Rev. 29: 62-75 (2008). *
Goldin BR, Gorbach SL. Clinical indications for probiotics: an overview. Clin. Infect. Dis. 46 Suppl. 2: S96-S100 (2008). *
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. Curr. Med. Res. Opin. 22: 2575-2590 (2006).
Goldstein E, Hermann R, Renfors TJ, Nanto-Salonen KM, Korhonen T, Karkkainen M, Veijola RK, Knip M, Simell TT, Simell OG. From genetic risk awareness to overt type 1 diabetes: parental stress in a placebo-controlled prevention trial. Diabetes Care 32: 2181-2183 (2009).
Golembesky AK, Gammon MD, North KE, Bensen JT, Schroeder JC, Teitelbaum SL, Neugut AI, Santella RM. Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study. Carcinogenesis 29: 1944-1949 (2008). *
Golson ML, Loomes KM, Oakey R, Kaestner KH. Ductal malformation and pancreatitis in mice caused by conditional Jag1 deletion. Gastroenterology 136: 1761-1771.e1 (2009). *
Golusinski W, Kordylewska M, Krzysztof M, Wasko R, Sowinski J. Endoscopic decompresion of orbital cavity in the course of the Graves' ophthalmopathy. Otolaryngol. Pol. 62: 587-592 (2008).
Gombos Z, Hermann R, Kiviniemi M, Nejentsev S, Reimand K, Fadeyev V, Peterson P, Uibo R, Ilonen J. Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations. Eur. J. Endocrinol. 157: 757-761 (2007). *
Gomes Mde B. Glitazones and the metabolic syndrome: mechanism of action, pathophysiology and therapeutic indications. Arq. Bras. Endocrinol. Metabol. 50: 271-280 (2006).
Gomez LM, Anaya JM, Gonzalez CI, Pineda-Tamayo R, Otero W, Arango A, Martin J. PTPN22 C1858T polymorphism in Colombian patients with autoimmune diseases. Genes Immun. 6: 628-631 (2005). *
Gong X, Xie Z, Zuo H. In vivo insulin deficiency as a potential etiology for demyelinating disease. Med. Hypotheses 71: 399-403 (2008).
Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L, Zang YQ. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150: 104-113 (2009). *
Gong Z, Jin Y, Zhang Y. Oral administration of a cholera toxin B subunit-insulin fusion protein produced in silkworm protects against autoimmune diabetes. J. Biotechnol. 119: 93-105 (2005). *
Gong Z, Jin Y, Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in silkworm. Vaccine 25: 1444-1451 (2007). *
Gong Z, Long X, Pan L, Le Y, Liu Q, Wang S, Guo J, Xiao B, Zhou M, Mei D. Cloning, expression, purification and characterization of the cholera toxin B subunit and triple glutamic acid decarboxylase epitopes fusion protein in E. coli. Protein Expr. Purif. 66: 191-197 (2009). *
Gong ZH, Jin HQ, Jin YF, Zhang YZ. Expression of cholera toxin B subunit and assembly as functional oligomers in silkworm. J. Biochem. Mol. Biol. 38: 717-724 (2005). *
Gony J, Vexiau P, Lhomme C, Marcelli A, Poirier JC, Bochu V, Cathelineau G, Assan R, Deschamps I, Hors J. MHC classes I, II, III antigens study in 70 insulin-dependent diabetics with associated auto-immune diseases. Tissue Antigens 31: 229-234 (1988).
Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. (Lond.) 5: 17 (2008). *
Gonzalez R, Tirado A, Rojas LA, Ossandon FJ, Alvo M, Wolff C, Seelenfreund D, Durruty P, Lobos S. Analysis of the intronic single nucleotide polymorphism rs#466452 of the nephrin gene in patients with diabetic nephropathy. Biol. Res. 42: 189-198 (2009). *
Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 24: 83-86 (2006).
Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11: 8-15 (2005). *
Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 13: 1113-1139 (2007).
Gonzalez-Sanchez JL, Zabena C, Martinez-Larrad MT, Martinez-Calatrava MJ, Perez-Barba M, Serrano-Rios M. Association of ENPP1 (PC-1) K121Q polymorphism with obesity-related parameters in subjects with metabolic syndrome. Clin. Endocrinol. (Oxf.) 68: 724-729 (2008). *
Good DA, Busfield F, Fletcher BH, Duffy DL, Kesting JB, Andersen J, Shaw JT. Linkage of Paget disease of bone to a novel region on human chromosome 18q23. Am. J. Hum. Genet. 70: 517-525 (2002). *
Good RA. Progress toward production of immunologic tolerance with no or minimal toxic immunosuppression for prevention of immunodeficiency and autoimmune diseases. World J. Surg. 24: 797-810 (2000). *
Gopal KV, Rama Rao GR, Kumar YH, Appa Rao MV, Vasudev P; Srikant. Vitiligo: a part of a systemic autoimmune process. Indian J. Dermatol. Venereol. Leprol. 73: 162-165 (2007). *
Gopal L, Forbes J, Uzel G, Holland SM, Heller T. Gastrointestinal fistulae in chronic granulomatous disease. Am. J. Gastroenterol. 104: 2112-2113 (2009). *
Gopinath B, Wang JJ, Flood VM, Burlutsky G, Wong TY, Mitchell P. The associations between blood levels of homocysteine, folate, vitamin B(12), and retinal vascular caliber. Am. J. Ophthalmol. 148: 902-909 (2009). *
Gordeladze AS, Smirnov OA, Radchenko VG, Saburova GS. Clinico-morphologic characteristics of primary hemochromatosis. Arkh. Patol. 57: 44-48 (1995).
Gordin D, Forsblom C, Ronnback M, Parkkonen M, Waden J, Hietala K, Groop PH. Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann. Med. 40: 627-633 (2008).
Goreti Catorze M, Pereira F, Fonseca F, Morbey A, Assis Pacheco F. Pyoderma gangrenosum associated with sclerosing cholangitis, type 1 diabetes mellitus and ulcerative colitis. J. Eur. Acad. Dermatol. Venereol. 15: 257-259 (2001).
Gorodezky C, Alaez C, Murguia A, Rodriguez A, Balladares S, Vazquez M, Flores H, Robles C. HLA and autoimmune diseases: type 1 diabetes (T1D) as an example. Autoimmun. Rev. 5: 187-194 (2006).
Gorodezky C, Olivo A, Alaez C, Vazquez MN, de la Rosa G, Debaz H, Robles C, Altamirano N, Layrisse Z, Balducci PL, Dominguez E, Herrera F, Montagnani S, Esparza B, Balbas O, Gunczler P, Lanes R, Amaro R, Zaro R, Fuenmayor V, Montoya F, Bedoya CI, et al. High- and low-risk molecular sequences in autoimmune diseases. An analysis of type I diabetes in Latin America. Gac. Med. Mex. 133 Suppl. 1: 125-132 (1997).
Goswami R, Gupta N, Ray D, Rani R, Tomar N, Sarin R, Vupputuri MR. Polymorphisms at +49A/G and CT60 sites in the 3' UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism. Int. J. Immunogenet. 32: 393-400 (2005). *
Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N, Ray D, Kanwar R, Agarwal R. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. Br. J. Nutr. 102: 382-386 (2009). *
Goswami R, Mishra SK, Kochupillai N. Prevalence and potential significance of vitamin D deficiency in Asian Indians. Indian J. Med. Res. 127: 229-238 (2008). *
Goto A, Takahashi Y, Kishimoto M, Nakajima Y, Nakanishi K, Kajio H, Noda M. A case of fulminant type 1 diabetes associated with significant elevation of mumps titers. Endocr. J. 55: 561-564 (2008). *
Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H, Schatz DA, Moran AM, Lachin JM, Skyler JS; for the Type 1 Diabetes TrialNet MMF/DZB Study Group. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care Jan 12 [Epub ahead of print] (2010).
Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am. J. Epidemiol. Feb 23 [Epub ahead of print] (2010).
Goudy KS, Tisch R. Immunotherapy for the prevention and treatment of type 1 diabetes. Int. Rev. Immunol. 24: 307-326 (2005).
Goudy KS, Wang B, Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes in nonobese diabetic mice. Clin. Immunol. 129: 49-57 (2008).
Gounarides JS, Korach-Andre M, Killary K, Argentieri G, Turner O, Laurent D. Effect of dexamethasone on glucose tolerance and fat metabolism in a diet-induced obesity mouse model. Endocrinology 149: 758-766 (2008). *
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183: 336-341 (2005).
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. Association of the promoter polymorphism -232C/G of the phosphoenolpyruvate carboxykinase gene (PCK1) with type 2 diabetes mellitus. Diabet. Med. 23: 419-425 (2006). *
Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, Berthold HK, Krone W. The Pro387Leu variant of protein tyrosine phosphatase-1B is not associated with diabetes mellitus type 2 in a German population. J. Intern. Med. 257: 272-280 (2005). *
Gouni-Berthold I, Krone W. Favorable effects of decreasing lipids in patients with diabetes mellitus. Dtsch. Med. Wochenschr. 131 Suppl. 8: S252-S254 (2006).
Grabacka M, Reiss K. Anticancer properties of PPARalpha - effects on cellular metabolism and inflammation. PPAR Res. 2008: 930705 (2008). *
Graca L, Silva-Santos B, Coutinho A. The blind-spot of regulatory T cells. Eur. J. Immunol. 36: 802-805 (2006). *
Gragnoli C, Cronsell J. Meta-analysis of the IPF1 D76N polymorphism in a worldwide type 2 diabetes population. Minerva Med. 98: 163-166 (2007).
Gragnoli C, Lindner T, Cockburn BN, Kaisaki PJ, Gragnoli F, Marozzi G, Bell GI. Maturity-onset diabetes of the young due to a mutation in the hepatocyte nuclear factor-4 alpha binding site in the promoter of the hepatocyte nuclear factor-1 alpha gene. Diabetes 46: 1648-1651 (1997).
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590 (2004). *
Graham KL, Sanders N, Tan Y, Allison J, Kay TW, Coulson BS. Rotavirus infection accelerates type 1 diabetes in mice with established insulitis. J. Virol. 82: 6139-6149 (2008). *
Graham S, Courtois P, Malaisse WJ, Rozing J, Scott FW, Mowat AM. Enteropathy precedes type 1 diabetes in the BB rat. Gut 53: 1437-1444 (2004). *
Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354: 2552-2563 (2006). *
Grainge MJ, West J, Solaymani-Dodaran M, Aithal GP, Card TR. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br. J. Cancer 100: 178-180 (2009). *
Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 23: 397-418 (2009).
Grant SF, Baldassano RN, Hakonarson H. Classification of genetic profiles of Crohn's disease: a focus on the ATG16L1 gene. Expert Rev. Mol. Diagn. 8: 199-207 (2008).
Grant SF, Hakonarson H. Microarray technology and applications in the arena of genome-wide association. Clin. Chem. 54: 1116-1124 (2008). *
Grant SF, Hakonarson H. Genome-wide association studies in type 1 diabetes. Curr. Diab. Rep. 9: 157-163 (2009).
Grant SF, Hakonarson H. Recent development in pharmacogenomics: from candidate genes to genome-wide association studies. Expert Rev. Mol. Diagn. 7: 371-393 (2007).
Grant SF, Hakonarson H, Schwartz S. Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults? Endocr. Rev. Dec 14 [Epub ahead of print] (2009).
Grant WB. Does vitamin D reduce the risk of dementia? J. Alzheimers Dis. 17: 151-159 (2009).
Grant WB. Epidemiology of disease risks in relation to vitamin D insufficiency. Prog. Biophys. Mol. Biol. 92: 65-79 (2006). *
Grant WB. Hypothesis: ultraviolet-B irradiance and vitamin D reduce the risk of viral infections and thus their sequelae, including autoimmune diseases and some cancers. Photochem. Photobiol. 84: 356-365 (2008).
Grant WB, Cross HS, Garland CF, Gorham ED, Moan J, Peterlik M, Porojnicu AC, Reichrath J, Zittermann A. Estimated benefit of increased vitamin D status in reducing the economic burden of disease in Western Europe. Prog. Biophys. Mol. Biol. 99: 104-113 (2009). *
Grant WB, Garland CF. The health benefits of vitamin D greatly outweigh the health risks. Bioessays 30: 506-507 (2008). *
Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern. Med. Rev. 10: 94-111 (2005). *
Grant WB, Strange RC, Garland CF. Sunshine is good medicine. The health benefits of ultraviolet-B induced vitamin D production. J. Cosmet. Dermatol. 2: 86-98 (2003).
Grarup N, Andersen MK, Andreasen CH, Albrechtsen A, Borch-Johnsen K, Jorgensen T, Auwerx J, Schmitz O, Hansen T, Pedersen O. Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7,342 Danish whites. J. Clin. Endocrinol. Metab. 92: 363-366 (2007). *
Grarup N, Urhammer SA, Ek J, Albrechtsen A, Glumer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. Diabetologia 49: 2097-2104 (2006). *
Grassetto G, Rubello D. Thyroid disorders and diabetes mellitus. Minerva Med. 99: 263-267 (2008).
Graves DT, Kayal RA. Diabetic complications and dysregulated innate immunity. Front. Biosci. 13: 1227-1239 (2008).
Gravholt CH. Clinical practice in Turner syndrome. Nat. Clin. Pract. Endocrinol. Metab. 1: 41-52 (2005). *
Gray DH, Gavanescu I, Benoist C, Mathis D. Danger-free autoimmune disease in Aire-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 104: 18193-18198 (2007). *
Green CB, Takahashi JS, Bass J. The meter of metabolism. Cell 134: 728-742 (2008). *
Green CD, Jump DB, Olson LK. Elevated insulin secretion from liver X receptor-activated pancreatic beta-cells involves increased de novo lipid synthesis and triacylglyceride turnover. Endocrinology 150: 2637-2645 (2009). *
Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 100: 10878-10883 (2003). *
Greenberg L. Case management implications of celiac disease. Prof. Case Manag. 13: 211-217 (2008).
Greene CN, Keong LM, Cordovado SK, Mueller PW. Sequence variants in the PLEKHH2 region are associated with diabetic nephropathy in the GoKinD study population. Hum. Genet. 124: 255-262 (2008). *
Greenfield JR, Tuthill A, Soos MA, Semple RK, Halsall DJ, Chaudhry A, O'Rahilly S. Severe insulin resistance due to anti-insulin antibodies: response to plasma exchange and immunosuppressive therapy. Diabet. Med. 26: 79-82 (2009). *
Greenhalf W, Malats N, Nilsson M, Bartsch D, Neoptolemos J. International registries of families at high risk of pancreatic cancer. Pancreatology 8: 558-565 (2008).
Gregersen PK. Closing the gap between genotype and phenotype. Nat. Genet. 41: 958-959 (2009). *
Gregersen PK. Gaining insight into PTPN22 and autoimmunity. Nat. Genet. 37: 1300-1302 (2005). *
Gregg RK, Bell JJ, Lee HH, Jain R, Schoenleber SJ, Divekar R, Zaghouani H. IL-10 diminishes CTLA-4 expression on islet-resident T cells and sustains their activation rather than tolerance. J. Immunol. 174: 662-670 (2005). *
Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, Lenhard J, Rentzeperis D, Clemens LE, Mu Y, Lavan BE. MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-gamma ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects. Mol. Endocrinol. 23: 975-988 (2009). *
Gregori S, Battaglia M, Roncarolo MG. Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. Novartis Found. Symp. 292: 174-183 (2008).
Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, Prentki M, Wahli W. Pancreatic islet adaptation to fasting is dependent on PPARalpha transcriptional up-regulation of fatty acid oxidation. Endocrinology 146: 375-382 (2005). *
Grennan DM, Sanders PA, Thomson W, Dyer PA. Rheumatoid arthritis: inheritance and association with other autoimmune diseases. Dis. Markers 4: 157-162 (1986).
Greve B, Reddy J, Waldner HP, Sobel RA, Kuchroo VK. Dissimilar background genes control susceptibility to autoimmune disease in the context of different MHC haplotypes: NOD.H-2(s) congenic mice are relatively resistant to both experimental autoimmune encephalomyelitis and type I diabetes. Eur. J. Immunol. 34: 1828-1838 (2004). *
Greve B, Simonenko R, Illes Z, Peterfalvi A, Hamdi N, Mycko MP, Selmaj KW, Rozsa C, Rajczy K, Bauer P, Berger K, Weissert R. Multiple sclerosis and the CTLA4 autoimmunity polymorphism CT60: no association in patients from Germany, Hungary and Poland. Mult. Scler. 14: 153-158 (2008). *
Greve B, Vijayakrishnan L, Kubal A, Sobel RA, Peterson LB, Wicker LS, Kuchroo VK. The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J. Immunol. 173: 157-163 (2004). *
Grey A. Thiazolidinedione-induced skeletal fragility - mechanisms and implications. Diabetes Obes. Metab. 11: 275-284 (2009). *
Griesel BA, Weems J, Russell RA, Abel ED, Humphries K, Olson AL. Acute inhibition of fatty acid import inhibits GLUT4 transcription in adipose tissue, but not skeletal or cardiac muscle tissue, partly through LXR signaling. Diabetes Jan 26 [Epub ahead of print] (2010).
Griffiths MM, Remmers EF. Genetic analysis of collagen-induced arthritis in rats: a polygenic model for rheumatoid arthritis predicts a common framework of cross-species inflammatory/autoimmune disease loci. Immunol. Rev. 184: 172-183 (2001). *
Grigorian A, Lee SU, Tian W, Chen IJ, Gao G, Mendelsohn R, Dennis JW, Demetriou M. Control of T cell mediated autoimmunity by metabolite flux to N-glycan biosynthesis. J. Biol. Chem. 282: 20027-20035 (2007). *
Grimwood J, Gordon LA, Olsen A, Terry A, Schmutz J, Lamerdin J, Hellsten U et al. The DNA sequence and biology of human chromosome 19. Nature 428: 529-535 (2004). *
Griseri T, Beaudoin L, Novak J, Mars LT, Lepault F, Liblau R, Lehuen A. Invariant NKT cells exacerbate type 1 diabetes induced by CD8 T cells. J. Immunol. 175: 2091-2101 (2005). *
Grocock CJ, Rebours V, Delhaye M, Andren-Sandberg A, Weiss FU, Mountford R, Harcus M, Niemczyck E, Vitone L, Dodd S, Joergensen MT, Ammann RW, Schaffalitzky de Muckadell O, Butler JV, Burgess P, Kerr B, Charnley R, Sutton R, Raraty M, Deviere J, et al. The variable phenotype of the p.A16V mutation of cationic trypsinogen (PRSS1) in pancreatitis families. Gut Dec 1 [Epub ahead of print] (2009).
Grodzinsky E, Falth-Magnusson K, Hogberg L, Jansson G, Laurin P, Stenhammar L. IgA endomysium antibodies - an early predictor for celiac disease in children without villous atrophy. Acta Paediatr. 97: 972-976 (2008).
Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).
Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug Discov. 3: 950-964 (2004). *
Gronski MA. Novel insights in the regulation of the immune system: a report on the FASEB Summer Research Conference on Autoimmunity (June 14-19, 2003, Saxton's River, Vermont, USA). Rev. Diabet. Stud. 1: 47-50 (2004). *
Groop L. Open chromatin and diabetes risk. Nat. Genet. 42: 190-192 (2010). *
Groop L, Lyssenko V. Genes and type 2 diabetes mellitus. Curr. Diab. Rep. 8: 192-197 (2008).
Grosjean F. PPAR agonists: elixir of eternal youth for the kidney? G. Ital. Nefrol. 27: 4 (2010).
Grosjean OV. The resistible growth of health care costs. Acta Chir. Belg. 108: 4-14 (2008).
Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21: 687-710 (2007).
Grosu M, Stavaru C, Gutu D, Radu DL. Pancreatic beta cell allotransplant in double transgenic mouse model of type 1 diabetes mellitus. Roum. Arch. Microbiol. Immunol. 66: 57-61 (2007).
Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, Hitman GA, Walker M, Wiltshire S, Hattersley AT, McCarthy MI. Association analysis of 6,736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 55: 2640-2644 (2006). *
Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW. Type 2 deiodinase expression is induced by PPAR-gamma agonists in skeletal myocytes. Endocrinology 150: 1976-1983 (2009). *
Grumbach IM, Chen W, Mertens SA, Harrison DG. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J. Mol. Cell. Cardiol. 39: 595-603 (2005). *
Grun F, Blumberg B. Perturbed nuclear receptor signaling by environmental obesogens as emerging factors in the obesity crisis. Rev. Endocr. Metab. Disord. 8: 161-171 (2007). *
Grundmann RT, Hermanek P, Merkel S, Germer CT, Grundmann RT, Hauss J, Henne-Bruns D, Herfarth K, Hermanek P, Hopt UT, Junginger T, Klar E, Klempnauer J, Knapp WH, Kraus M, Lang H, Link KH, Lohe F, Merkel S, Oldhafer KJ, Raab HR, Rau HG, et al. Diagnosis and treatment of colorectal liver metastases - workflow. Zentralbl. Chir. 133: 267-284 (2008).
Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program; National Heart, Lung, and Blood Institute. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24: e149-e161 (2004). *
Grungreiff K, Reinhold D. Liver cirrhosis and "liver" diabetes mellitus are linked by zinc deficiency. Med. Hypotheses 64: 316-317 (2005).
Gu CC, Hunt SC, Kardia S, Turner ST, Chakravarti A, Schork N, Olshen R, Curb D, Jaquish C, Boerwinkle E, Rao DC. An investigation of genome-wide associations of hypertension with microsatellite markers in the family blood pressure program (FBPP). Hum. Genet. 121: 577-590 (2007). *
Gu EL, Yao GB. The clinical characteristics of primary biliary cirrhosis in China: a systimatic review. Zhonghua Gan Zang Bing Za Zhi 17: 861-866 (2009).
Gu HF, Alvarsson A, Efendic S, Brismar K. SOX2 has gender-specific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. Gend. Med. 6: 555-564 (2009).
Gu HF, Efendic S, Brismar K. Lack of an association between GHR exon 3 polymorphism and diabetic nephropathy in the Genetics of Kidneys in Diabetes (GoKinD) population. Diabetologia 51: 2333-2334 (2008). *
Gu W, Lu J, Yang G, Dou J, Mu Y, Meng J, Pan C. Plasma homocysteine thiolactone associated with risk of macrovasculopathy in Chinese patients with type 2 diabetes mellitus. Adv. Ther. 25: 914-924 (2008).
Gu Y, Luo T, Yang J, Zhang D, Dai M, Jian W, Zheng S, Zhou W, Zhou W, Wu Y, Liu Y, Liu Y, Li J, Xie X, Li G, Luo M. The -822G/A polymorphism in the promoter region of the MAP4K5 gene is associated with reduced risk of type 2 diabetes in Chinese Hans from Shanghai. J. Hum. Genet. 51: 605-610 (2006). *
Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, Yamashita M, Suda T. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 15: 20-25 (2008). *
Guan R, Mariuzza RA. Peptidoglycan recognition proteins of the innate immune system. Trends Microbiol. 15: 127-134 (2007). *
Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J. Am. Soc. Nephrol. 15: 2801-2815 (2004). *
Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes. Drug News Perspect. 15: 147-154 (2002).
Guandalini S. The influence of gluten: weaning recommendations for healthy children and children at risk for celiac disease. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 139-155 (2007).
Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, Majluf-Cruz A, Tene-Perez CE, Goldschmidt L, Hart J, Perego C, Comuzzie AG, Tejero ME, Finzi G, Placidi C, La Rosa S, Capella C, Halff G, Gastaldelli A, Defronzo RA, Folli F. Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. Proc. Natl. Acad. Sci. U.S.A. 106: 13992-13997 (2009). *
Guarneri F, Benvenga S. Environmental factors and genetic background that interact to cause autoimmune thyroid disease. Curr. Opin. Endocrinol. Diabetes Obes. 14: 398-409 (2007).
Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernandez-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 55: 216-224 (2006). *
Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T, Gudbjartsson D, Agnarsson BA, Baker A, Sigurdsson A, Benediktsdottir KR, Jakobsdottir M, Blondal T, Stacey SN, Helgason A, Gunnarsdottir S, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet. 39: 977-983 (2007). *
Guenther L, Gulliver W. Psoriasis comorbidities. J. Cutan. Med. Surg. 13 Suppl. 2: S77-S87 (2009).
Guerau-de-Arellano M, Mathis D, Benoist C. Transcriptional impact of Aire varies with cell type. Proc. Natl. Acad. Sci. U.S.A. 105: 14011-14016 (2008). *
Guerin V, Leniaud L, Pedron B, Guilmin-Crepon S, Tubiana-Rufi N, Sterkers G. HLA-associated genetic resistance and susceptibility to type I diabetes in French North Africans and French natives. Tissue Antigens 70: 214-218 (2007). *
Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50: 2809-2814 (2001). *
Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clement K, Magre J, Gorden P. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin. Endocrinol. (Oxf.) 68: 547-554 (2008). *
Guibal F, Baran R, Duhard E, Feuilhade de Chauvin M. Epidemiology and management of onychomycosis in private dermatological practice in France. Ann. Dermatol. Venereol. 135: 561-566 (2008).
Guillen MD, Goicoechea E. Toxic oxygenated alpha,beta-unsaturated aldehydes and their study in foods: a review. Crit. Rev. Food Sci. Nutr. 48: 119-136 (2008).
Guimaraes RL, Segat L, Rocha CR, Brandao LA, Zanin V, Araujo J, Naslavsky MS, de Lima Filho JL, Crovella S. Functional polymorphisms of DEFB1 gene in type 1 diabetes Brazilian children. Autoimmunity 42: 406-413 (2009).
Guimond M, Veenstra RG, Grindler DJ, Zhang H, Cui Y, Murphy RD, Kim SY, Na R, Hennighausen L, Kurtulus S, Erman B, Matzinger P, Merchant MS, Mackall CL. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat. Immunol. 10: 149-157 (2009). *
Guja C, Guja L, Nutland S, Rance H, Sebastien M, Todd JA, Ionescu-Tirgoviste C. Type 1 diabetes genetic susceptibility encoded by HLA DQB1 genes in Romania. J. Cell. Mol. Med. 8: 249-256 (2004). *
Guja C, Guja L, Nutland S, Rance H, Todd JA, Ionescu-Tirgoviste C. Strong association of insulin gene INS-VNTR polymorphisms with type 1 diabetes in the Romanian population. Rom. J. Intern. Med. 42: 313-323 (2004).
Guja C, Marshall S, Welsh K, Merriman M, Smith A, Todd JA, Ionescu-Tirgoviste C. The study of CTLA-4 and vitamin D receptor polymorphisms in the Romanian type 1 diabetes population. J. Cell. Mol. Med. 6: 75-81 (2002). *
Guler ML, Ligons DL, Wang Y, Bianco M, Broman KW, Rose NR. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J. Immunol. 174: 2167-2173 (2005). *
Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin. Immunol. 125: 16-25 (2007). *
Gullstrand C, Wahlberg J, Ilonen J, Vaarala O, Ludvigsson J. Progression to type 1 diabetes and autoantibody positivity in relation to HLA-risk genotypes in children participating in the ABIS study. Pediatr. Diabetes 9: 182-190 (2008).
Gundling F, Schumm-Draeger PM, Schepp W. Hepatogenous diabetes - diagnostics and treatment. Z. Gastroenterol. 47: 436-445 (2009).
Gundling F, Seidl H, Loffler N, Strassen I, Schepp W. Metabolic disturbances in liver cirrhosis (part 2), hepatogenous diabetes. Dtsch. Med. Wochenschr. 135: 22-24 (2010).
Gunes Y, Tuncer M, Calka O, Guntekin U, Akdeniz N, Simsek H, Ozdemir IY. Increased frequency of pulmonary hypertension in psoriasis patients. Arch. Dermatol. Res. 300: 435-440 (2008). *
Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 14: 144-150 (2009). *
Gunthorpe MJ, Szallasi A. Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr. Pharm. Des. 14: 32-41 (2008).
Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 10: 349-360 (2006).
Guo LH, Achenbach P. Tracing the pathogenesis of type 1 diabetes: a report on the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD). Rev. Diabet. Stud. 5: 171-174 (2008). *
Guo SW, Magnuson VL, Schiller JJ, Wang X, Wu Y, Ghosh S. Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: a HuGE review of genetic association studies. Am. J. Epidemiol. 164: 711-724 (2006). *
Gupta D, Hess B. Granuloma annulare. ScientificWorldJournal 10: 384-386 (2010).
Gupta D, Jetton TL, Mortensen RM, Zhong Duan S, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse PDX-1 promoter. J. Biol. Chem. 283: 32462-32470 (2008). *
Gupta M, Graham J, McNeeny B, Zarghami M, Landin-Olsson M, Hagopian WA, Palmer J, Lernmark A, Sanjeevi CB. MHC class I chain-related gene-A is associated with IA2 and IAA but not GAD in Swedish type 1 diabetes mellitus. Ann. N. Y. Acad. Sci. 1079: 229-239 (2006). *
Gupta M, Ludvigsson J, Sanjeevi CB. Frequency of MICA in all babies in Southeast Sweden (ABIS) positive for high-risk HLA-DQ associated with type 1 diabetes. Ann. N. Y. Acad. Sci. 1037: 138-144 (2004). *
Gupta M, Nikitina-Zake L, Zarghami M, Landin-Olsson M, Kockum I, Lernmark A, Sanjeevi CB. Association between the transmembrane region polymorphism of MHC class I chain related gene-A and type 1 diabetes mellitus in Sweden. Hum. Immunol. 64: 553-561 (2003).
Gupta N, Khera S, Vempati RP, Sharma R, Bijlani RL. Effect of yoga based lifestyle intervention on state and trait anxiety. Indian J. Physiol. Pharmacol. 50: 41-47 (2006).
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J. Gastroenterol. Hepatol. 19: 854-858 (2004). *
Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, Achdout H, Ghadially H, Dor Y, Nir T, Doviner V, Hershkovitz O, Mendelson M, Naparstek Y, Mandelboim O. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat. Immunol. Dec 20 [Epub ahead of print] (2009). *
Guran T, Bircan R, Turan S, Bereket A. Alopecia: association with resistance to thyroid hormones. J. Pediatr. Endocrinol. Metab. 22: 1075-1081 (2009).
Gurgel MH, Montenegro Junior RM, Magalhaes RA, Lima GE, Montenegro RM, Magalhaes PK, Maciel LM. E449X mutation in the thyroid hormone receptor beta associated with autoimmune thyroid disease and severe neuropsychomotor involvement. Arq. Bras. Endocrinol. Metabol. 52: 1205-1210 (2008). *
Gurgul-Convey E, Lenzen S. Protection against cytokine toxicity through ER and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells. J. Biol. Chem. Feb 16 [Epub ahead of print] (2010). *
Guri AJ, Hontecillas R, Bassaganya-Riera J. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome. J. Nutrigenet. Nutrigenomics 1: 126-135 (2008).
Gurnell M. 'Striking the right balance' in targeting PPARgamma in the metabolic syndrome: novel insights from human genetic studies. PPAR Res. 2007: 83593 (2007). *
Gurr W, Shaw M, Li Y, Sherwin R. RegII is a beta-cell protein and autoantigen in diabetes of NOD mice. Diabetes 56: 34-40 (2007). *
Gurrola-Diaz CM, Sanchez-Enriquez S, Oregon-Romero E, Garcia-Lopez PM, Garzon de la Mora P, Bastidas-Ramirez BE, Gonzalez-Hita M, Munoz-Valle JF. Establishment of a cut-point value of serum TNF-alpha levels in the metabolic syndrome. J. Clin. Lab. Anal. 23: 51-56 (2009). *
Gursoy S, Guven K, Arikan T, Yurci A, Torun E, Baskol M, Ozbakir O, Yucesoy M. Clostridium difficile infection frequency in patients with nosocomial infections or using antibiotics. Hepatogastroenterology 54: 1720-1724 (2007).
Guruvayoorappan C, Sudha G. Phytopharmacological evaluation of Byesukar for hypoglycaemic activity and its effect on lipid profile and hepatic enzymes of glucose metabolism in diabetic rats. Ann. Hepatol. 7: 358-363 (2008).
Gustafson B, Hammarstedt A, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27: 2276-2283 (2007).
Gustavsson C, Agardh E, Bengtsson B, Agardh CD. TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J. Diabetes Complications 22: 309-316 (2008).
Gutenberg A, Bell JJ, Lupi I, Tzou SC, Landek-Salgado MA, Kimura H, Su J, Karaviti LP, Salvatori R, Caturegli P. Pituitary and systemic autoimmunity in a case of intrasellar germinoma. Pituitary May 26 [Epub ahead of print] (2009).
Gutenberg A, Hans V, Puchner MJ, Kreutzer J, Bruck W, Caturegli P, Buchfelder M. Primary hypophysitis: clinical-pathological correlations. Eur. J. Endocrinol. 155: 101-107 (2006). *
Gutierrez-Roelens I, Lauwerys BR. Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies. Curr. Mol. Med. 8: 551-861 (2008).
Guvenc S, Kaymakoglu S, Gurel N, Karsidag K, Demir K, Dincer D, Kekik C, Salman S, Yilmaz T, Besisik F, Cakaloglu Y. The prevalence of manifest and latent celiac disease in type 1 diabetes mellitus. Turk. J. Gastroenterol. 13: 103-107 (2002). *
Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 58: 591-610 (2007). *
Gylvin T, Bergholdt R, Nerup J, Pociot F. Characterization of a nuclear-factor-kappa B (NFkappaB) genetic marker in type 1 diabetes (T1DM) families. Genes Immun. 3: 430-432 (2002). *
Gysemans C, Callewaert H, Moore F, Nelson-Holte M, Overbergh L, Eizirik DL, Mathieu C. Interferon regulatory factor-1 is a key transcription factor in murine beta cells under immune attack. Diabetologia Sep 8 [Epub ahead of print] (2009). *
Gysemans C, van Etten E, Overbergh L, Giulietti A, Eelen G, Waer M, Verstuyf A, Bouillon R, Mathieu C. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 57: 269-275 (2008). *
Gysemans CA, Cardozo AK, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in NOD mice. Endocrinology 146: 1956-1964 (2005). *
Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am. J. Gastroenterol. 104: 1445-1451 (2009).
Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 50: 727-734 (2009).
Haag M, Malipa AC, van Papendorp DH, Stivaktas PI, Alummoottil S, Koorts AM. Short-term fatty acid effects on adipocyte glucose uptake: mechanistic insights. Prostaglandins Leukot. Essent. Fatty Acids 80: 247-253 (2009). *
Haaland WC, Scaduto DI, Maldonado MR, Mansouri DL, Nalini R, Iyer D, Patel S, Guthikonda A, Hampe CS, Balasubramanyam A, Metzker ML. A-beta-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. Diabetes Care 32: 873-877 (2009).
Haase C, Markholst H. CD40 is required for development of islet inflammation in the RIP-CD154 transgenic mouse model of type 1 diabetes. Ann. N. Y. Acad. Sci. 1107: 373-379 (2007). *
Haberbosch W. Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective? Herz. 32: 51-57 (2007).
Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am. J. Gastroenterol. 104: 1241-1248 (2009). *
Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs 66: 1949-1969 (2006).
Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid. Based Complement. Alternat. Med. Nov 1 [Epub ahead of print] (2009).
Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, Travert F, Khalil CA, Miot A, Alhenc-Gelas F, Lievre M, Marre M; on behalf of the DIABHYCAR, DIAB2NEPHROGENE & SURDIAGENE study groups. Prognostic value of the insertion/deletion polymorphism of angiotensin I converting enzyme gene in type 2 diabetic subjects: results from the DIABHYCAR, DIAB2NEPHROGENE & SURDIAGENE studies. Diabetes Care 31: 1847-1852 (2008). *
Hadjiliadis D. Special considerations for patients with cystic fibrosis undergoing lung transplantation. Chest 131: 1224-1231 (2007). *
Hadjiyanni I, Li KK, Drucker DJ. Glucagon like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the non obese diabetic mouse. Endocrinology 150: 592-599 (2009). *
Haesebaert J, Bourdy S, Perceval M, Chabloz C, Nove-Josserand R, Reix P, Llerena C, Wion N, Touzet S. Screening and management of glucose metabolism disorders in cystic fibrosis patients. Practices survey in 4 French reference centers. Arch. Pediatr. 16: 1435-1442 (2009).
Hafler DA, Kent SC, Chen Y, Bregoli L, Clemmings SM, Hering B, Kenyon NS, Ricordi C. Immunology: insulin auto-antigenicity in type 1 diabetes (Reply). Nature 438: E5-E6 (2005). *
Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, Stevens HE, Walker NM, Healy B, Howson JM, Maisuria M, Duley S, Coleman G, Gough SC; The International Multiple Sclerosis Genetics Consortium (IMSGC), Worthington J, Kuchroo VK, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun. 10: 5-10 (2009). *
Hagege AA. Management of the patient with chronic coronary artery disease. Rev. Prat. 58: 1541-1548 (2008).
Hagforsen E. The cutaneous non-neuronal cholinergic system and smoking related dermatoses: studies of the psoriasis variant palmoplantar pustulosis. Life Sci. 80: 2227-2234 (2007). *
Hagglof B, Holmgren G, Holmlund G, Lindblom B, Olaisen B, Teisberg P. Studies of HLA, factor B (Bf), complement C2 and C4 haplotypes in type 1 diabetic and control families from northern Sweden. Hum. Hered. 36: 201-212 (1986).
Hagopian WA, Lernmark A, Rewers MJ, Simell OG, She JX, Ziegler AG, Krischer JP, Akolkar B. TEDDY-The Environmental Determinants of Diabetes in the Young: an observational clinical trial. Ann. N. Y. Acad. Sci. 1079: 320-326 (2006). *
Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H. No association between rheumatoid arthritis and insulin dependent diabetes mellitus: an epidemiologic and immunogenetic study. J. Rheumatol. 19: 856-858 (1992).
Hakonarson H, Grant SF. Genome-wide association studies in type 1 diabetes, inflammatory bowel disease and other immune-mediated disorders. Semin. Immunol. 21: 355-362 (2009). *
Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N, De Prost Y, Fischer A, Goulet O, Bodemer C. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br. J. Dermatol. 160: 645-651 (2009). *
Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr. Top. Med. Chem. 9: 309-319 (2009).
Halim MA, Al-Otaibi T, Elsisi A, El-Sayed A, Nair P, Said T, Balaha MA, Nampoory M. De novo post renal transplantation inflammatory bowel disease. Saudi J. Kidney Dis. Transpl. 19: 624-626 (2008). *
Halim MA, Said T, Nair P, Schmidt I, Hassan A, Johny KV, Al-Muzairai I, Samhan M, Nampoory MR, Al-Mousawi M. De novo Crohn's disease in a renal transplant recipient. Transplant. Proc. 39: 1278-1279 (2007). *
Hall JM, McDonnell DP. The molecular mechanisms underlying the pro-inflammatory actions of thiazolidinediones (TZDs) in human macrophages. Mol. Endocrinol. 21: 1756-1768 (2007). *
Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR. An autoimmune diabetes locus (Idd21) on mouse chromosome 18. Mamm. Genome 14: 335-339 (2003). *
Hall RJ, Merriman ME, Green RA, Markham VH, Smyth DJ, Heward JM, Jennings CE, Braithwaite AW, Cundy T, Darlow BA, Gow PJ, Harrison AA, Highton J, Hunt PJ, Manning P, Pokorny V, Scott RS, Taylor BJ, Willis JA, Yeoman S, McLean L, Gough SC, Pearce SH, et al. The deleted in colorectal carcinoma (DCC) gene 201 R-->G polymorphism: no evidence for genetic association with autoimmune disease. Eur. J. Hum. Genet. 11: 840-844 (2003). *
Hall TR, Bogdani M, Leboeuf RC, Kirk EA, Maziarz M, Banga JP, Oak S, Pennington CA, Hampe CS. Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology 123: 547-554 (2008). *
Hallenbeck PL, Marks MS, Lippoldt RE, Ozato K, Nikodem VM. Heterodimerization of thyroid hormone (TH) receptor with H-2RIIBP (RXR beta) enhances DNA binding and TH-dependent transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 89: 5572-5576 (1992). *
Haller K, Kisand K, Nemvalts V, Laine AP, Ilonen J, Uibo R. Type 1 diabetes is insulin -2221 MspI and CTLA-4 +49 A/G polymorphism dependent. Eur. J. Clin. Invest. 34: 543-548 (2004).
Haller K, Kisand K, Pisarev H, Salur L, Laisk T, Nemvalts V, Uibo R. Insulin gene VNTR, CTLA-4 +49A/G and HLA-DQB1 alleles distinguish latent autoimmune diabetes in adults from type 1 diabetes and from type 2 diabetes group. Tissue Antigens 69: 121-127 (2007). *
Haller MJ, Atkinson MA, Schatz DA. The road not taken: a path to curing type 1 diabetes? Eur. J. Immunol. 39: 2054-2058 (2009). *
Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going? Curr. Opin. Endocrinol. Diabetes Obes. 14: 283-287 (2007).
Haller MJ, Schatz DA, Schwartz ID, Keymeulen B, Pipeleers D, Chatenoud L. CD3-antibody therapy in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 353: 2086-2087 (2005). *
Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp. Hematol. 36: 710-715 (2008).
Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS, Shuster JJ, Atkinson MA, Schatz DA. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 32: 2041-2046 (2009).
Hallows KR, Mount PF, Pastor-Soler NM, Power DA. Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am. J. Physiol. Renal Physiol. Feb 24 [Epub ahead of print] (2010). *
Halmos T, Suba I. Type 2 diabetes and metabolic syndrome as conditions leading to malignant tumors. Orv. Hetil. 149: 2403-2411 (2008).
Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J. AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J. Clin. Endocrinol. Metab. 87: 2568-2574 (2002). *
Halperin F, Ingelfinger JR, McMahon GT. Clinical decisions. Management of type 2 diabetes - polling results. N. Engl. J. Med. 358: e8 (2008). *
Haluzik M, Anderlova K, Dolelalova R, Adamikova A, Haluzikova D, Housova J, Svacina S, Haluzik M. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. Physiol. Res. 58: 93-99 (2009). *
Ham J, Rees DA. The adenosine A2b receptor: its role in inflammation. Endocr. Metab. Immune Disord. Drug Targets 8: 244-254 (2008).
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 56: 1345-1349 (2007). *
Hamada Y. Diabetes and bone health. The relationship between insulin resistance and bone metabolism. Clin. Calcium 19: 1269-1274 (2009).
Hamaguchi K, Kimura A, Seki N, Higuchi T, Yasunaga S, Takahashi M, Sasazuki T, Kusuda Y, Okeda T, Itoh K, Sakata T. Analysis of tumor necrosis factor-alpha promoter polymorphism in type 1 diabetes: HLA-B and -DRB1 alleles are primarily associated with the disease in Japanese. Tissue Antigens 55: 10-16 (2000). *
Hamamy H, Al-Hait S, Alwan A, Ajlouni K. Jordan: communities and community genetics. Community Genet. 10: 52-60 (2007).
Hameed S, Morton JR, Jaffe A, Field PI, Belessis Y, Yoong T, Katz T, Verge CF. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care Nov 12 [Epub ahead of print] (2009).
Hamilton FA. Health care in minority patients with IBD. Am. J. Gastroenterol. 102: 1350-1351 (2007). *
Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC, Owen MJ, Powell JF, Lovestone S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144: 508-16 (2007).
Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 4: 89-102 (2007). *
Hamilton-Shield JP. Overview of neonatal diabetes. Endocr. Dev. 12: 12-23 (2007).
Hamilton-Williams EE, Martinez X, Clark J, Howlett S, Hunter KM, Rainbow DB, Wen L, Shlomchik MJ, Katz JD, Beilhack GF, Wicker LS, Sherman LA. Expression of diabetes-associated genes by dendritic cells and CD4 T cells drives the loss of tolerance in nonobese diabetic mice. J. Immunol. 183: 1533-1541 (2009).
Hamlat N, Forcheron F, Neggazi S, Del Carmine P, Feugier P, Bricca G, Aouichat-Bouguerra S, Beylot M. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance. Cardiovasc. Diabetol. 8: 64 (2009). *
Hammana I, Coderre L, Potvin S, Costa M, Berthiaume Y, Lavoie A, Chiasson JL, Levy E, Rabasa-Lhoret R. Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. J. Cyst. Fibros. 8: 128-134 (2009).
Hammana I, Malet A, Costa M, Brochiero E, Berthiaume Y, Potvin S, Chiasson JL, Coderre L, Rabasa-Lhoret R. Normal adiponectin levels despite abnormal glucose tolerance (or diabetes) and inflammation in adult patients with cystic fibrosis. Diabetes Metab. 33: 213-219 (2007). *
Hammana I, Potvin S, Tardif A, Berthiaume Y, Coderre L, Rabasa-Lhoret R. Validation of insulin secretion indices in cystic fibrosis patients. J. Cyst. Fibros. 8: 378-381 (2009).
Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance. Prostaglandins Leukot. Essent. Fatty Acids 73: 65-75 (2005). *
Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, Liu ET. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS ONE 4: e4907 (2009). *
Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and aAnkylosing spondylitis. J. Rheumatol. 33: 2167-2172 (2006).
Han CY, Kargi AY, Omer M, Chan CK, Wabitsch M, O'Brien KD, Wight TN, Chait A. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 59: 386-396 (2010).
Han G, Wang R, Chen G, Wang J, Xu R, Feng J, Yu M, Wu X, Qian J, Shen B, Li Y. Gene delivery GAD(500) autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol. Lett. 115: 110-116 (2008).
Han G, Wang R, Chen G, Wang J, Xu R, Wang L, Feng J, Li X, Guo R, Fu L, Shen B, Li Y. Interleukin-17-producing gammadelta(+) T cells protect NOD mice from type 1 diabetes through a mechanism involving transforming growth factor-beta. Immunology 129: 197-206 (2010). *
Han HS, Jun HS, Utsugi T, Yoon JW. Molecular role of TGF-beta, secreted from a new type of CD4+ suppressor T cell, NY4.2, in the prevention of autoimmune IDDM in NOD mice. J. Autoimmun. 10: 299-307 (1997).
Han J, Luo T, Gu Y, Li G, Jia W, Luo M. Cathepsin K regulates adipocyte differentiation: possible involvement of type I collagen degradation. Endocr. J. 56: 55-63 (2009). *
Han J, Zhong J, Wei W, Wang Y, Huang Y, Yang P, Purohit S, Dong Z, Wang MH, She JX, Gong F, Stern DM, Wang CY. Extracellular high-mobility group box 1 acts as an innate immune-mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes 57: 2118-2127 (2008). *
Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 57: 737-745 (2008). *
Han SH, Quon MJ, Koh KK. Beneficial vascular and mtabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 46: 1086-1092 (2005).
Han XY, Ji LN. Contribution of MODY2 gene to the pathogenesis of Chinese early onset familial type 2 diabetes. Beijing Da Xue Xue Bao 37: 591-594 (2005).
Hanafusa T, Imagawa A. Insulitis in human type 1 diabetes. Ann. N. Y. Acad. Sci. 1150: 297-299 (2008). *
Hanasono GK, Witschi H, Plaa GL. Potentiation of the hepatotoxic responses to chemicals in alloxan-diabetic rats. Proc. Soc. Exp. Biol. Med. 149: 903-907 (1975).
Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr. Rev. 27: 728-735 (2006). *
Hanefeld M, Marx N, Pfutzner A, Baurecht W, Lubben G, Karagiannis E, Stier U, Forst T. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J. Am. Coll. Cardiol. 49: 290-297 (2007).
Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ. Increased alkaline phosphatase isoforms in autoimmune diseases. Clin. Chem. 43: 1357-1364 (1997). *
Hanninen A, Harrison LC. Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans? Rev. Diabet. Stud. 1: 113-121 (2004). *
Hansen D, Brock-Jacobsen B, Lund E, Bjorn C, Hansen LP, Nielsen C, Fenger C, Lillevang ST, Husby S. Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-detected celiac disease: a population-based screening study with 2 years' follow-up. Diabetes Care 29: 2452-2456 (2006). *
Hansen D, Brock-Jacobsen B, Lund E, Bjorn C, Hansen LP, Nielsen C, Fenger C, Lillevang ST, Husby S. Prevalence of coeliac disease (CD) in children with type 1 diabetes (T1D). Ugeskr. Laeger. 169: 2029-2032 (2007).
Hansen L, Ekstrom CT, Palacios RT, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for PPARgamma/alpha agonist induced edema in type 2 diabetic patients. J. Clin. Endocrinol. Metab. 91: 3446-3450 (2006). *
Hansen SK, Rose CS, Glumer C, Drivsholm T, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T. Variation near the hepatocyte nuclear factor (HNF)-4alpha gene associates with type 2 diabetes in the Danish population. Diabetologia 48: 452-458 (2005). *
Hansen TK. Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm. Metab. Res. 37 Suppl. 1: 95-98 (2005).
Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, Schalkwijk CG, Parving HH, Flyvbjerg A. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53: 1570-1576 (2004). *
Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 88: 4857-4861 (2003). *
Hanson RL, Knowler WC. Design and analysis of genetic association studies to finely map a locus identified by linkage analysis: assessment of the extent to which an association can account for the linkage. Ann. Hum. Genet. 72: 126-139 (2008). *
Hao J, Shen W, Yu G, Jia H, Li X, Feng Z, Wang Y, Weber P, Wertz K, Sharman E, Liu J. Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes. J. Nutr. Biochem. Jul 1 [Epub ahead of print] (2009). *
Hao L, Noguchi S, Kamada Y, Sasaki A, Matsuda M, Shimizu K, Hiramatsu Y, Nakatsuka M. Adverse effects of advanced glycation end products on embryonal development. Acta Med. Okayama 62: 93-99 (2008).
Haque S, Bruce IN. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2: 423-430 (2005).
Hara K, Horikoshi M, Kitazato H, Ito C, Noda M, Ohashi J, Froguel P, Tokunaga K, Tobe K, Nagai R, Kadowaki T. Hepatocyte nuclear factor-4alpha P2 promoter haplotypes are associated with type 2 diabetes in the Japanese population. Diabetes 55: 1260-1264 (2006). *
Hara M, Shen J, Pugh W, Polonsky KS, Le Beau MM, Bell GI. Sustained expression of hepatocyte nuclear factor-6 leads to loss of pancreatic beta-cells by apoptosis. Exp. Clin. Endocrinol. Diabetes 115: 654-661 (2007).
Haram K, Gjelland K. Foetal growth restriction. Tidsskr. Nor. Laegeforen. 127: 2665-2669 (2007).
Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 26: 613-620 (2006). *
Harashima SI, Harashima C, Nishimura T, Hu Y, Notkins AL. Overexpression of the autoantigen IA-2 puts beta cells into a pre-apoptotic state: autoantigen-induced, but non-autoimmune-mediated, tissue destruction. Clin. Exp. Immunol. 150: 49-60 (2007). *
Hardin DS. A review of the management of two common clinical problems found in patients with cystic fibrosis: cystic fibrosis-related diabetes and poor growth. Horm. Res. 68 Suppl. 5: S113-S116 (2007).
Hardin DS, Ahn C, Rice J, Rice M, Rosenblatt R. Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes. J. Investig. Med. 56: 567-573 (2008).
Hardin DS, Rice J, Rice M, Rosenblatt R. Use of the insulin pump in treat cystic fibrosis related diabetes. J. Cyst. Fibros. 8: 174-178 (2009).
Harding A. Fine-tuning our defenses. The Scientist May, 2007 (http://www.the-scientist.com/2007/05/01/s56/1/) (2007).
Harding AH, Loos RJ, Luan J, O'Rahilly S, Wareham NJ, Barroso I. Polymorphisms in the gene encoding sterol regulatory element-binding factor-1c are associated with type 2 diabetes. Diabetologia 49: 2642-2648 (2006). *
Hardisty JF, Elwell MR, Ernst H, Greaves P, Kolenda-Roberts H, Malarkey DE, Mann PC, Tellier PA. Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists. Toxicol. Pathol. 35: 928-941 (2007). *
Hardt PD, Killinger A, Nalop J, Schnell-Kretschmer H, Zekorn T, Klor HU. Chronic pancreatitis and diabetes mellitus. A retrospective analysis of 156 ERCP investigations in patients with insulin-dependent and non-insulin-dependent diabetes mellitus. Pancreatology 2: 30-33 (2002).
Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality? Ann. N. Y. Acad. Sci. 1069: 322-345 (2006). *
Harfouch-Hammoud E, Walk T, Otto H, Jung G, Bach JF, van Endert PM, Caillat-Zucman S. Identification of peptides from autoantigens GAD65 and IA-2 that bind to HLA class II molecules predisposing to or protecting from type 1 diabetes. Diabetes 48: 1937-1947 (1999). *
Hari Kumar KV, Pushkaraj SG, Krishnaleela BL, Modi KD. Peripartum cardiomyopathy in type II autoimmune polyendocrine syndrome. Int. J. Cardiol. Mar 19 [Epub ahead of print] (2009).
Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035 (2008). *
Hariri S, Yoon PW, Qureshi N, Valdez R, Scheuner MT, Khoury MJ. Family history of type 2 diabetes: a population-based screening tool for prevention? Genet. Med. 8: 102-108 (2006).
Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin. Immunopathol. 28: 119-130 (2006). *
Harnett MM, Melendez AJ, Harnett W. The therapeutic potential of the filarial nematode-derived immunodulator, ES-62 in inflammatory disease. Clin. Exp. Immunol. Dec 1 [Epub ahead of print] (2009). *
Harnett W, Harnett MM. Filarial nematode secreted product es-62 is an anti-inflammatory agent: therapeutic potential of small molecule derivatives and ES-62 peptide mimetics. Clin. Exp. Pharmacol. Physiol. 33: 511-518 (2006).
Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, Njolstad PR, Ellard S, Hattersley AT. The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development. Diabetes 57: 1745-1752 (2008). *
Harrington WW, S Britt C, G Wilson J, O Milliken N, G Binz J, C Lobe D, R Oliver W, C Lewis M, M Ignar D. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res. 2007: 97125 (2007). *
Harris M, Smith B, Veale A. Printed patient education interventions to facilitate shared management of chronic disease: a literature review. Intern. Med. J. 35: 711-716 (2005). *
Harris MF, McGown IN, Cowley DM. Paediatric diabetes - which children can gain insulin independence? Med. J. Aust. 187: 478 (2007). *
Harris PE, Ferrara C, Barba P, Polito T, Freeby M, Maffei A. VMAT2 gene expression and function as it applies to imaging beta-cell mass. J. Mol. Med. 86: 5-16 (2008). *
Harris WS. Fish oil supplementation: evidence for health benefits. Cleve. Clin. J. Med. 71: 208-210, 212, 215-218 (2004). *
Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids. Am. J. Clin. Nutr. 86: 1621-1625 (2007). *
Harris WS, Reid KJ, Sands SA, Spertus JA. Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am. J. Cardiol. 99: 154-158 (2007). *
Harrison LC. The prospect of vaccination to prevent type 1 diabetes. Hum. Vaccin. 1: 143-150 (2005).
Harrison LC. Vaccination against self to prevent autoimmune disease: the type 1 diabetes model. Immunol. Cell Biol. 86: 139-145 (2008). *
Harrison LC, Honeyman MC, Morahan G, Wentworth JM, Elkassaby S, Colman PG, Fourlanos S. Type 1 diabetes: lessons for other autoimmune diseases? J. Autoimmun. 31: 306-310 (2008).
Harrison SA. Non-alcoholic steatohepatitis. Preface. Clin. Liver Dis. 13: xiii-xiv (2009). *
Harrison SA, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin. Liver Dis. 8: 861-879, ix (2004).
Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57: 1441-1447 (2008).
Hart CM. The role of PPARgamma in pulmonary vascular disease. J. Investig. Med. 56: 518-521 (2008).
Hart CM, Roman J, Reddy R, Sime PJ. PPARgamma: a novel molecular target in lung disease. J. Investig. Med. 56: 515-517 (2008).
Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res. 4: 84-88 (2007).
Hartoft-Nielsen ML, Rasmussen AK, Bock T, Feldt-Rasmussen U, Kaas A, Buschard K. Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats. Autoimmunity 42: 131-138 (2009).
Hartweg J, Farmer AJ, Holman RR, Neil A. Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes. Curr. Opin. Lipidol. 20: 30-38 (2009).
Hartweg J, Farmer AJ, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia 50: 250-258 (2007). *
Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HA. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 50: 1593-1602 (2007). *
Hartweg J, Perera R, Montori V, Dinneen S, Neil H, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 1: CD003205 (2008). *
Harvald B. Genetic epidemiology of Greenland. Clin. Genet. 36: 364-367 (1989).
Hasani Ranjbar S, Amiri P, Zineh I, Langaee TY, Namakchian M, Heshmet R, Sajadi M, Mirzaee M, Rezazadeh E, Balaei P, Tavakkoly Bazzaz J, Gonzalez-Gay MA, Larijani B, Amoli MM. CXCL5 gene polymorphism association with diabetes mellitus. Mol. Diagn. Ther. 12: 391-394 (2008).
Haseeb A, Iliyas M, Chakrabarti S, Farooqui AA, Naik SR, Ghosh S, Suragani M, Ehtesham NZ. Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population. J. Biosci. 34: 405-414 (2009). *
Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20: 995-1001 (2008).
Hashimoto K, Inoue T, Higashi T, Takei SI, Awata T, Katayama S, Takagi R, Okada H, Matsushita S. Dopamine D1-like receptor antagonist, SCH23390, exhibits a preventive effect on diabetes mellitus that occurs naturally in NOD mice. Biochem. Biophys. Res. Commun. 383: 460-463 (2009). *
Hashimoto K, Maruyama H, Nishiyama M, Asaba K, Ikeda Y, Takao T, Iwasaki Y, Kumon Y, Suehiro T, Tanimoto N, Mizobuchi M, Nakamura T. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population. Horm. Res. 64: 253-260 (2005).
Hashimura Y, Nozu K, Kanegane H, Miyawaki T, Hayakawa A, Yoshikawa N, Nakanishi K, Takemoto M, Iijima K, Matsuo M. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr. Nephrol. 24: 1181-1186 (2009).
Haskins K. Pathogenic T-cell clones in autoimmune diabetes: more lessons from the NOD mouse. Adv. Immunol. 87: 123-162 (2005).
Hasnain BI, Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve. Clin. J. Med. 71: 327-334 (2004). *
Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 49: 1563-1570 (2009).
Hassan Z, Mohan V, Ali L, Allotey R, Barakat K, Faruque MO, Deepa R, McDermott MF, Jackson AE, Cassell P, Curtis D, Gelding SV, Vijayaravaghan S, Gyr N, Whitcomb DC, Khan AK, Hitman GA. SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Indian subcontinent. Am. J. Hum. Genet. 71: 964-968 (2002). *
Hassanali Z, Ametaj B, Field CJ, Proctor SD, Vine DF. Dietary supplementation of n-3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR:LA-cp rat. Diabetes Obes. Metab. Nov 16 [Epub ahead of print] (2009).
Hasselmann DO, Bens G, Tilgen W, Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J. Dtsch. Dermatol. Ges. 5: 560-564 (2007).
Hassler S, Peltonen L, Sandler S, Winqvist O. Aire deficiency causes increased susceptibility to streptozotocin-induced murine type 1 diabetes. Scand. J. Immunol. 67: 569-580 (2008). *
Hasstedt SJ, Chu WS, Das SK, Wang H, Elbein SC. Type 2 diabetes susceptibility genes on chromosome 1q21-24. Ann. Hum. Genet. 72: 163-169 (2008). *
Hassumi MY, Silva-Filho VJ, Campos-Junior JC, Vieira SM, Cunha FQ, Alves PM, Alves JB, Kawai T, Goncalves RB, Napimoga MH. PPAR-gamma agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int. Immunopharmacol. 9: 1150-1158 (2009).
Hathout EH, Beeson WL, Ischander M, Rao R, Mace JW. Air pollution and type 1 diabetes in children. Pediatr. Diabetes 7: 81-87 (2006). *
Hattori H, Sato H, Ito D, Tanahashi N, Murata M, Saito I, Watanabe K, Suzuki N. A561C polymorphism of E-selectin is associated with ischemic cerebrovascular disease in the Japanese population without diabetes mellitus and hypercholesterolemia. Brain Res. 1108: 221-223 (2006).
Hauache OM, Reis AF, Oliveira CS, Vieira JG, Sjoroos M, Ilonen J. Estimation of diabetes risk in Brazilian population by typing for polymorphisms in HLA-DR-DQ, INS and CTLA-4 genes. Dis. Markers 21: 139-145 (2005).
Hauben E, Roncarolo MG, Nevo U, Schwartz M. Beneficial autoimmunity in type 1 diabetes mellitus. Trends Immunol. 26: 248-253 (2005). *
Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148: 5478-5486 (2007). *
Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, Rey G, McClain KL, Janka-Schaub G, Egeler RM. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr. Blood Cancer 42: 438-444 (2004). *
Havas M. Electromagnetic hypersensitivity: biological effects of dirty electricity with emphasis on diabetes and multiple sclerosis. Electromagn. Biol. Med. 25: 259-268 (2006).
Havermans T, Colpaert K, Vanharen L, Dupont LJ. Health related quality of life in cystic fibrosis: to work or not to work? J. Cyst. Fibros. 8: 218-223 (2009).
Haversen L, Danielsson KN, Fogelstrand L, Wiklund O. Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages. Atherosclerosis 202: 382-393 (2009).
Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, Hunter S, Buzzetti R, De Leiva A, Pozzilli P, Leslie RD; on behalf of the Action LADA Group. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 32: 160-164 (2009).
Hawiger D, Tran E, Du W, Booth CJ, Wen L, Dong C, Flavell RA. ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice. J. Immunol. 180: 3140-3147 (2008). *
Hawkins BR, Lam KS, Ma JT, Low LC, Cheung PT, Serjeantson SW, Yeung RT. Strong association of HLA-DR3/DRw9 heterozygosity with early-onset insulin-dependent diabetes mellitus in Chinese. Diabetes 36: 1297-1300 (1987).
Hayakawa T, Takamura T, Abe T, Kaneko S. Association of the C825T polymorphism of the G-protein beta3 subunit gene with hypertension, obesity, hyperlipidemia, insulin resistance, diabetes, diabetic complications, and diabetic therapies among Japanese. Metabolism 56: 44-48 (2007). *
Hayashi M, Kataoka Y, Tachikawa K, Koguchi H, Tanaka H. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Diabetes Res. Clin. Pract. 86: e19-e21 (2009).
Hayashi T, Faustman DL. Role of defective apoptosis in type 1 diabetes and other autoimmune diseases. Recent Prog. Horm. Res. 58: 131-153 (2003).
Hayashi T, Iwamoto Y, Kaku K, Hirose H, Maeda S. Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia 50: 980-984 (2007). *
Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49: 277-300 (2003).
Haystead TA. The purinome, a complex mix of drug and toxicity targets. Curr. Top. Med. Chem. 6: 1117-1127 (2006).
Hazra A, Fuchs CS, Chan AT, Giovannucci EL, Hunter DJ. Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. Cancer Causes Control 19: 975-980 (2008). *
He C, Hamon S, Li D, Barral-Rodriguez S, Ott J; Diabetes Genetics Consortium. MHC fine mapping of human type 1 diabetes using the T1DGC data. Diabetes Obes. Metab. 11 Suppl. 1: 53-59 (2009). *
He CQ, Ding NZ, Fan W. YY1 repressing peroxisome proliferator-activated receptor delta promoter. Mol. Cell. Biochem. 308: 247-252 (2008). *
He J, Haskins K. Pathogenicity of T helper 2 T-cell clones from T-cell receptor transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha. Immunology 123: 108-117 (2008). *
He W. PPARgamma2 polymorphism and human health. PPAR Res. 2009: 849538 (2009). *
He YY, Zhang R, Shao XY, Hu C, Wang CR, Lu JX, Bao YQ, Jia WP, Xiang KS. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol. Sin. 29: 983-989 (2008).
Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern. Med. Rev. 11: 294-299 (2006). *
Heaney AP. PPAR-gamma in Cushing's disease. Pituitary 7: 265-269 (2004).
Heaney RP. Vitamin D in health and disease. Clin. J. Am. Soc. Nephrol. 3: 1535-1541 (2008). *
Heap GA, van Heel DA. The genetics of chronic inflammatory diseases. Hum. Mol. Genet. 18: R101-R106 (2009).
Heath RB, Karpe F, Milne RW, Burdge GC, Wootton S, Frayn KN. Dietary fatty acids make a rapid and substantial contribution to VLDL-triacylglycerol in the fed state. Am. J. Physiol. Endocrinol. Metab. 292: E732-E739 (2007). *
Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127 (5 Suppl. 2): S294-S302 (2004). *
Heazell AE, Sinha A, Bhatti NR. A case of gestational diabetes arising following treatment with glucocorticosteroids for pemphigoid gestationis. J. Matern. Fetal Neonatal Med. 18: 353-355 (2005).
Heding PE, Karlsen AE, Veijola R, Nerup J, Pociot F. No evidence of a functionally significant polymorphism of the BCL2 gene in Danish, Finnish and Basque type 1 diabetes families. Genes Immun. 2: 398-400 (2001). *
Hedman M, Faresjo M, Axelsson S, Ludvigsson J, Casas R. Impaired CD4 and CD8 T cell phenotype and reduced chemokine secretion in recent-onset type 1 diabetic children. Clin. Exp. Immunol. 153: 360-368 (2008). *
Hedman M, Ludvigsson J, Faresjo MK. Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J. Interferon Cytokine Res. 26: 207-213 (2006).
Hee Kim Y, Jae Han H. High glucose-induced prostaglandin E2 and peroxisome proliferator-activated receptor delta promotes mouse embryonic stem cells proliferation. Stem Cells 26: 745-755 (2008). *
Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, Demaine AG. NFkappaB polymorphisms and susceptibility to type 1 diabetes. Genes Immun. 2: 304-308 (2001). *
Hegde KR, Varma SD. Electron impact mass spectroscopic studies on mouse retinal fatty acids. Effect of diabetes. Ophthalmic Res. 42: 9-14 (2009).
Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R663-R669 (2005). *
Heijmans BT, Westendorp RG, Droog S, Kluft C, Knook DL, Slagboom PE. Association of the tumour necrosis factor alpha -308G/A polymorphism with the risk of diabetes in an elderly population-based cohort. Genes Immun. 3: 225-228 (2002). *
Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 14: 1225-1230 (2008).
Hein GJ, Bernasconi AM, Montanaro MA, Pellon-Maison M, Finarelli G, Chicco A, Lombardo YB, Brenner RR. Nuclear receptors and hepatic lipidogenic enzymes response to a dyslipidemic sucrose rich diet and its revertion by fish oil n-3 polyunsaturated fatty acids. Am. J. Physiol. Endocrinol. Metab. Dec 1 [Epub ahead of print] (2009). *
Heinaniemi M, Uski JO, Degenhardt T, Carlberg C. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol. 8: R147 (2007). *
Heitmeier MR, Kelly CB, Ensor NJ, Gibson KA, Mullis KG, Corbett JA, Maziasz TJ. Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets. J. Biol. Chem. 279: 53145-53151 (2004). *
Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, Jaaskelainen JE, Kyo Y, Lenk GM, Sakalihasan N, Kostulas K, Gottsater A, Flex A, Stefansson H, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40: 217-224 (2008). *
Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J. 274: 6094-6105 (2007). *
Hellemans KH, Hannaert JC, Denys B, Steffensen KR, Raemdonck C, Martens GA, Van Veldhoven PP, Gustafsson JA, Pipeleers D. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase. PLoS One 4: e7266 (2009). *
Heller T, Saito S, Auerbach J, Williams T, Moreen TR, Jazwinski A, Cruz B, Jeurkar N, Sapp R, Luo G, Liang TJ. An in vitro model of hepatitis C virion production. Proc. Natl. Acad. Sci. U.S.A. 102: 2579-2583 (2005). *
Hellquist A, Zucchelli M, Kivinen K, Saarialho-Kere U, Koskenmies S, Widen E, Julkunen H, Wong A, Karjalainen-Lindsberg ML, Skoog T, Vendelin J, Cunninghame-Graham DS, Vyse TJ, Kere J, Lindgren CM. The human GIMAP5 gene has a common polyadenylation polymorphism increasing risk to systemic lupus erythematosus (SLE). J. Med. Genet. 44: 314-321 (2007). *
Helms S. Celiac disease and gluten-associated diseases. Altern. Med. Rev. 10: 172-192 (2005). *
Hemminki K, Li X, Sundquist J, Sundquist K. Familial association between type 1 diabetes and other autoimmune and related diseases. Diabetologia 52: 1820-1828 (2009). *
Hemminki K, Li X, Sundquist J, Sundquist K. The epidemiology of Graves' disease: evidence of a genetic and an environmental contribution. J. Autoimmun. Dec 26 [Epub ahead of print] (2009).
Hempel P, Karczewski P, Kohnert KD, Raabe J, Lemke B, Kunze R, Bimmler M. Sera from patients with type 2 diabetes contain agonistic autoantibodies against g protein-coupled receptors. Scand. J. Immunol. 70: 159-160 (2009). *
Hendig D, Schulz V, Eichgrun J, Szliska C, Gotting C, Kleesiek K. New ABCC6 gene mutations in German pseudoxanthoma elasticum patients. J. Mol. Med. 83: 140-147 (2005). *
Heng TS, Painter MW; Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9: 1091-1094 (2008). *
Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA Jr, Noble SA, Oliver W Jr, et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41: 5020-5036 (1998). *
Henkel J, Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Puschel GP. Aggravation by prostaglandin E(2) of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 50: 781-790 (2009).
Hennig BJ, Fry AE, Hirai K, Tahara H, Tamori A, Moller M, Hopkin J, Hill AV, Bodmer W, Beverley P, Tchilian E. PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging. Tissue Antigens 71: 458-463 (2008). *
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 374: 126-135 (2009). *
Hensrud DD. Diet and obesity. Curr. Opin. Gastroenterol. 20: 119-124 (2004).
Henzen C. Secondary forms of diabetes mellitus. Praxis (Bern 1994) 98: 1135-1140 (2009).
Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, Colditz G, Hinney A, Hebebrand J, Koberwitz K, Zhu X, Cooper R, Ardlie K, Lyon H, Hirschhorn JN, Laird NM, Lenburg ME, Lange C, Christman MF. A common genetic variant is associated with adult and childhood obesity. Science 312: 279-283 (2006). *
Herbon N, Werner M, Braig C, Gohlke H, Dutsch G, Illig T, Altmuller J, Hampe J, Lantermann A, Schreiber S, Bonifacio E, Ziegler A, Schwab S, Wildenauer D, van den Boom D, Braun A, Knapp M, Reitmeir P, Wjst M. High-resolution SNP scan of chromosome 6p21 in pooled samples from patients with complex diseases. Genomics 81: 510-518 (2003). *
Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsumoto I, Ihm SH, Zhang HJ, Parkey J, Hunter DW, Sutherland DE. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293: 830-835 (2005). *
Hering BJ, Wijkstrom M, Graham ML, Hardstedt M, Aasheim TC, Jie T, Ansite JD, Nakano M, Cheng J, Li W, Moran K, Christians U, Finnegan C, Mills CD, Sutherland DE, Bansal-Pakala P, Murtaugh MP, Kirchhof N, Schuurman HJ. Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med. 12: 301-303 (2006). *
Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O, Akin F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol. 28: 515-519 (2009).
Hermann C, Krikovszky D, Fust G, Kovacs M, Korner A, Szabo A, Vannay A, Madacsy L. Association between interleukin-6 polymorphism and age-at-onset of type 1 diabetes. Epistatic influences of the tumor necrosis factor-alpha and interleukin-1beta polymorphisms. Eur. Cytokine Netw. 16: 277-281 (2005).
Hermann C, Krikovszky D, Vasarhelyi B, Dezsofi A, Madacsy L. Polymorphisms of the TNF-alpha gene and risk of celiac disease in T1DM children. Pediatr. Diabetes 8: 138-141 (2007). *
Hermann R, Bartsocas CS, Soltesz G, Vazeou A, Paschou P, Bozas E, Malamitsi-Puchner A, Simell O, Knip M, Ilonen J. Genetic screening for individuals at high risk for type 1 diabetes in the general population using HLA class II alleles as disease markers. A comparison between three European populations with variable rates of disease incidence. Diabetes Metab. Res. Rev. 20: 322-329 (2004). *
Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O, Knip M, Ilonen J. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49: 1198-1208 (2006). *
Hermann R, Soltesz G. Predictive genetic screening for type-1 diabetes in the Hungarian population. Orv. Hetil. 145: 337-342 (2004).
Hermann R, Turpeinen H, Laine AP, Veijola R, Knip M, Simell O, Sipil� I, Akerblom HK, Ilonen J. HLA DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens 62: 162-169 (2003). *
Hernandez-Hernandez BA. Differences in the electrophysiological patterns in the distinct variations of the presentation of chronic inflammatory demyelinating polyneuropathy. Rev. Neurol. 46: 589-592 (2008).
Hernandez-Pedro N, Ordonez G, Ortiz-Plata A, Palencia-Hernandez G, Garc�a-Ulloa AC, Flores-Estrada D, Sotelo J, Arrieta O. All-trans retinoic acid induces nerve regeneration and increases serum and nerve contents of neural growth factor in experimental diabetic neuropathy. Transl. Res. 152: 31-37 (2008). *
Hernell O, West C. Do we need personalized recommendations for infants at risk of developing disease? Nestle Nutr. Workshop Ser. Pediatr. Program 62: 239-252 (2008).
Herr M, Dudbridge F, Zavattari P, Cucca F, Guja C, March R, Campbell RD, Barnett AH, Bain SC, Todd JA, Koeleman BP. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum. Mol. Genet. 9: 1291-1301 (2000). *
Herraiz I, Arbues J, Camano I, Gomez-Montes E, Graneras A, Galindo A. Application of a first-trimester prediction model for pre-eclampsia based on uterine arteries and maternal history in high-risk pregnancies. Prenat. Diagn. 29: 1123-1129 (2009).
Herraiz I, Lopez-Jimenez EA, Garc�a-Burguillo A, Nieto O, Villar OP, Escribano D, Galindo A. Role of uterine artery Doppler in interpreting low PAPP-A values in first-trimester screening for Down syndrome in pregnancies at high risk of impaired placentation. Ultrasound Obstet. Gynecol. 33: 518-523 (2009).
Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud DJ, Muller M, Stellaard F, Groen AK, Kuipers F. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptoralpha-controlled metabolic pathways in mice. Hepatology 51: 806-816 (2010). *
Herrera JL, Fernandez-Montesinos R, Gonzalez-Rey E, Delgado M, Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann. N. Y. Acad. Sci. 1070: 337-341 (2006). *
Herrero L, Shapiro H, Nayer A, Lee J, Shoelson SE. Inflammation and adipose tissue macrophages in lipodystrophic mice. Proc. Natl. Acad. Sci. U.S.A. Dec 14 [Epub ahead of print] (2009). *
Herrmann J, Rubin D, Hasler R, Helwig U, Pfeuffer M, Auinger A, Laue C, Winkler P, Bell D, Schreiber S, Schrezenmeir J. Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARgamma2 P12A polymorphism. Lipids Health Dis. 8: 35 (2009). *
Herrmann W, Schorr H, Obeid R, Makowski J, Fowler B, Kuhlmann MK. Disturbed homocysteine and methionine cycle intermediates S-adenosylhomocysteine and S-adenosylmethionine are related to degree of renal insufficiency in type 2 diabetes. Clin. Chem. 51: 891-897 (2005). *
Hertel JK, Johansson S, Raeder H, Midthjell K, Lyssenko V, Groop L, Molven A, Njolstad PR. Genetic analysis of recently identified type 2 diabetes loci in 1,638 unselected patients with type 2 diabetes and 1,858 control participants from a Norwegian population-based cohort (the HUNT study). Diabetologia 51: 971-977 (2008). *
Hertz R, Ben-Haim N, Petrescu AD, Kalderon B, Berman I, Eldad N, Schroeder F, Bar-Tana J. Rescue of MODY-1 by agonist ligands of hepatocyte nuclear factor-4alpha. J. Biol. Chem. 278: 22578-22585 (2003). *
Herzer M, Umfress K, Aljadeff G, Ghai K, Zakowski SG. Interactions with parents and friends among chronically ill children: examining social networks. J. Dev. Behav. Pediatr. 30: 499-508 (2009).
Hewagama A, Richardson B. The genetics and epigenetics of autoimmune diseases. J. Autoimmun. 33: 3-11 (2009).
Heward J, Gordon C, Allahabadia A, Barnett AH, Franklyn JA, Gough SC. The A-G polymorphism in exon 1 of the CTLA-4 gene is not associated with systemic lupus erythematosus. Ann. Rheum. Dis. 58: 193-195 (1999). *
Heward J, Gough SC. Genetic susceptibility to the development of autoimmune disease. Clin. Sci. (Lond.) 93: 479-491 (1997).
Heward JM, Allahabadia A, Carr-Smith J, Daykin J, Cockram CS, Gordon C, Barnett AH, Franklyn JA, Gough SC. No evidence for allelic association of a human CTLA-4 promoter polymorphism with autoimmune thyroid disease in either population-based case-control or family-based studies. Clin. Endocrinol. (Oxf.) 49: 331-334 (1998). *
Heward JM, Mijovic CH, Kelly MA, Morrison E, Barnett AH. HLA-DQ and DRB1 polymorphism and susceptibility to type 1 diabetes in Jamaica. Eur. J. Immunogenet. 29: 47-52 (2002). *
Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J, Michalek J. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 260: 70-74 (2010). *
Higa R, Gonzalez E, Pustovrh MC, White V, Capobianco E, Martinez N, Jawerbaum A. PPARdelta and its activator PGI2 are reduced in diabetic embryopathy: involvement of PPARdelta activation in lipid metabolic and signalling pathways in rat embryo early organogenesis. Mol. Hum. Reprod. 13: 103-110 (2007). *
Higashide T, Kawamura T, Nagata M, Kotani R, Kimura K, Hirose M, Inada H, Niihira S, Yamano T. T cell epitope mapping study with insulin overlapping peptides using ELISPOT assay in Japanese children and adolescents with type 1 diabetes. Pediatr. Res. 59: 445-450 (2006). *
Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am. J. Clin. Nutr. 91: 267S-272S (2010). *
Hildebrand MS, Sorensen JL, Jensen M, Kimberling WJ, Smith RJ. Autoimmune disease in a DFNA6/14/38 family carrying a novel missense mutation in WFS1. Am. J. Med. Genet. A. 146A: 2258-2265 (2008).
Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg EJ, Horvath K, Murray JA, Pivor M, Seidman EG. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 40: 1-19 (2005). *
Hill JA, Benoist C, Mathis D. T(reg) cells: guardians for life. Nat. Immunol. 8: 124-125 (2007). *
Hill JA, Feuerer M, Tash K, Haxhinasto S, Perez J, Melamed R, Mathis D, Benoist C. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27: 786-800 (2007). *
Hill JA, Hall JA, Sun CM, Cai Q, Ghyselinck N, Chambon P, Belkaid Y, Mathis D, Benoist C. Retinoic acid enhances Foxp3 induction indirectly by relieving inhibition from CD4(+)CD44(hi) cells. Immunity 29: 758-770 (2008). *
Hill NJ, Hultcrantz M, Sarvetnick N, Flodstrom-Tullberg M. The target tissue in autoimmunity - an influential niche. Eur. J. Immunol. 37: 589-597 (2007). *
Hill NJ, King C, Flodstrom-Tullberg M. Recent acquisitions on the genetic basis of autoimmune disease. Front. Biosci. 13: 4838-4851 (2008).
Hill PG, McMillan SA. Anti-tissue transglutaminase antibodies and their role in the investigation of coeliac disease. Ann. Clin. Biochem. 43: 105-117 (2006).
Hillebrands JL, van der Werf N, Klatter FA, Bruggeman CA, Rozing J. Role of peritoneal macrophages in cytomegalovirus-induced acceleration of autoimmune diabetes in BB-rats. Clin. Dev. Immunol. 10: 133-139 (2003).
Hillebrands JL, Whalen B, Visser JT, Koning J, Bishop KD, Leif J, Rozing J, Mordes JP, Greiner DL, Rossini AA. A regulatory CD4+ T cell subset in the BB rat model of autoimmune diabetes expresses neither CD25 nor Foxp3. J. Immunol. 177: 7820-7832 (2006). *
Hillman M, Torn C, Landin-Olsson M; DISS study group. The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset. Clin. Exp. Immunol. 157: 255-260 (2009). *
Hills CE, Willars GB, Brunskill NJ. Proinsulin C-peptide antagonizes the profibrotic effects of TGF-beta1 via up-regulation of retinoic acid and HGF-related signaling pathways. Mol. Endocrinol. Mar 2 [Epub ahead of print] (2010).
Hilpert KF, West SG, Kris-Etherton PM, Hecker KD, Simpson NM, Alaupovic P. Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes. Am. J. Clin. Nutr. 85: 369-376 (2007). *
Hiltunen M, Lonnrot M, Hyoty H. Immunisation and type 1 diabetes mellitus: is there a link? Drug Saf. 20: 207-212 (1999).
Hinke SA. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Curr. Opin. Mol. Ther. 10: 516-525 (2008).
Hinkmann C, Knerr I, Hahn EG, Lohmann T, Seifarth CC. Reduced frequency of peripheral plasmacytoid dendritic cells in type 1 diabetes. Horm. Metab. Res. 40: 767-771 (2008).
Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE, Donn R, Thomson W, Silman A, Worthington J. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 52: 1694-1699 (2005). *
Hinks A, Barton A, John S, Shephard N, Worthington J. Fine mapping of genes within the IDDM8 region in rheumatoid arthritis (RA). Arthritis Res. Ther. 8: R145 (2006). *
Hinks A, Ke X, Barton A, Eyre S, Bowes J, Worthington J, Thompson SD, Langefeld CD, Glass DN, Thomson W; UK Rheumatoid Arthritis Genetics Consortium. Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis. Arthritis Rheum. 60: 251-257 (2009). *
Hinokio Y, Horikawa Y, Furuta H, Cox NJ, Iwasaki N, Honda M, Ogata M, Iwamoto Y, Bell GI. Beta-cell transcription factors and diabetes: no evidence for diabetes-associated mutations in the hepatocyte nuclear factor-3beta gene (HNF3B) in Japanese patients with maturity-onset diabetes of the young. Diabetes 49: 302-305 (2000). *
Hintermann E, Christen U. Viral infection - a cure for type 1 diabetes? Curr. Med. Chem. 14: 2048-2052 (2007).
Hintzpeter B, Mensink GB, Thierfelder W, Muller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur. J. Clin. Nutr. 62: 1079-1089 (2008). *
Hirabara SM, Curi R, Maechler P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J. Cell Physiol. 222: 187-194 (2010).
Hirai H, Miura J, Hu Y, Larsson H, Larsson K, Lernmark A, Ivarsson SA, Wu T, Kingman A, Tzioufas AG, Notkins AL. Selective screening of secretory vesicle-associated proteins for autoantigens in type 1 diabetes: VAMP2 and NPY are new minor autoantigens. Clin. Immunol. 127: 366-374 (2008). *
Hiraki S, Ormond KE, Kim K, Ross LF. Attitudes of genetic counselors towards expanding newborn screening and offering predictive genetic testing to children. Am. J. Med. Genet. A. 140: 2312-2319 (2006).
Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 42: 1429-1437 (2003). *
Hiromine Y, Fujisawa T, Noso S, Babaya N, Kawabata Y, Ikegami H. Congenic mapping of the MHC-linked susceptibility to type 1 diabetes in the NOD mouse: at least two genes contribute to the Idd16 effect. Ann. N. Y. Acad. Sci. 1150: 90-92 (2008). *
Hiromine Y, Ikegami H, Fujisawa T, Kawabata Y, Noso S, Yamaji K, Asano K, Ogihara T. Molecular scanning of the gene for programmed cell death-1 (PDCD-1) as a candidate for type 1 diabetes susceptibility. Ann. N. Y. Acad. Sci. 1079: 285-288 (2006). *
Hiromine Y, Ikegami H, Fujisawa T, Nojima K, Kawabata Y, Noso S, Asano K, Fukai A, Ogihara T. Trinucleotide repeats of programmed cell death-1 gene are associated with susceptibility to type 1 diabetes mellitus. Metabolism 56: 905-909 (2007). *
Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J. Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels of tumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res. Clin. Pract. 82: 58-65 (2008).
Hirota Y, Kasuga M. Search for type 2 diabetes susceptibility genes. Tanpakushitsu Kakusan Koso 50: S2084-S2089 (2005).
Hitman GA, Niven MJ, Festenstein H, Cassell PG, Awad J, Walker-Smith J, Leonard JN, Fry L, Ciclitira P, Kumar P, et al. HLA class II alpha chain gene polymorphisms in patients with insulin-dependent diabetes mellitus, dermatitis herpetiformis, and celiac disease. J. Clin. Invest. 79: 609-615 (1987). *
Hiukka A, Leinonen E, Jauhiainen M, Sundvall J, Ehnholm C, Keech AC, Taskinen MR. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 50: 2067-2075 (2007). *
Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, O'Donnell CJ, Cupples LA, Meigs JB. Common variants in the adiponectin gene (ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes 57: 3353-3359 (2008). *
Hivert MF, Sullivan LM, Fox CS, Nathan DM, D'Agostino RB Sr, Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J. Clin. Endocrinol. Metab. 93: 3165-3172 (2008). *
Ho CH, Kuo BI, Kong CW, Chau WK, Hsu HC, Gau JP, Yu YB. Influence of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, B vitamins and other factors on plasma homocysteine and risk of thromboembolic disease in Chinese. J. Chin. Med. Assoc. 68: 560-565 (2005).
Ho HH, Yu KH, Chen JY, Lin JL, Wu YJ, Luo SF, Liou LB. Coexisting ankylosing spondylitis and gouty arthritis. Clin. Rheumatol. 26: 1655-1661 (2007). *
Hochberg I, Roguin A, Nikolsky E, Chanderashekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 161: 441-446 (2002).
Hodgkinson AD, Page T, Millward BA, Demaine AG. A novel polymorphism in the 5' flanking region of the glucose transporter (GLUT1) gene is strongly associated with diabetic nephropathy in patients with type 1 diabetes mellitus. J. Diabetes Complications 19: 65-69 (2005).
Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the Toll-like 4 receptor pathway: implications for diabetic atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28: 2275-2281 (2008).
Hodis HN, Mack WJ, Dustin L, Mahrer PR, Azen SP, Detrano R, Selhub J, Alaupovic P, Liu CR, Liu CH, Hwang J, Wilcox AG, Selzer RH; for the BVAIT Research Group. High-dose B vitamin supplementation and progression of subclinical atherosclerosis. A randomized controlled trial. Stroke 40: 730-736 (2009).
Hoe E, McKay FC, Schibeci SD, Gandhi K, Heard RN, Stewart GJ, Booth DR. Functionally significant differences in expression of disease-associated IL-7 receptor alpha haplotypes in CD4 T cells and dendritic cells. J. Immunol. Jan 22 [Epub ahead of print] (2010).
Hoeks J, Hesselink MK, Russell AP, Mensink M, Saris WH, Mensink RP, Schrauwen P. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids. Diabetologia 49: 2419-2426 (2006). *
Hofer J, Hofer S, Zlamy M, Jeller V, Koppelstaetter C, Brandstatter A, Kern H, Kohle J, Zimmerhackl LB, Prelog M. Elevated proportions of recent thymic emigrants in children and adolescents with type 1 diabetes. Rejuvenation Res. 12: 311-320 (2009).
Hofer SE, Bennetts B, Chan AK, Holloway B, Karschimkus C, Jenkins AJ, Silink M, Donaghue KC. Association between PON 1 polymorphisms, PON activity and diabetes complications. J. Diabetes Complications 20: 322-328 (2006).
Hoffenberg EJ, Bao F, Eisenbarth GS, Uhlhorn C, Haas JE, Sokol RJ, Rewers M. Transglutaminase antibodies in children with a genetic risk for celiac disease. J. Pediatr. 137: 356-360 (2000). *
Hoffmann K, Mattheisen M, Dahm S, Nurnberg P, Roe C, Johnson J, Cox NJ, Wichmann HE, Wienker TF, Schulze J, Schwarz PE, Lindner TH. A German genome-wide linkage scan for type 2 diabetes supports the existence of a metabolic syndrome locus on chromosome 1p36.13 and a type 2 diabetes locus on chromosome 16p12.2. Diabetologia 50: 1418-1422 (2007). *
Holdsworth-Carson S, Lim R, Mitton A, Whitehead C, Rice G, Permezel M, Lappas M. Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia. Placenta Dec 30 [Epub ahead of print] (2009).
Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol. Aspects Med. 29: 361-368 (2008).
Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv. Exp. Med. Biol. 624: 1-15 (2008). *
Holick MF. Deficiency of sunlight and vitamin D. BMJ 336: 1318-1319 (2008).
Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann. Epidemiol. 19: 73-78 (2009).
Holick MF. Vitamin D and sunlight: strategies for cancer prevention and other health benefits. Clin. J. Am. Soc. Nephrol. 3: 1548-1554 (2008).
Holick MF. Diabetes and the vitamin D connection. Curr. Diab. Rep. 8: 393-398 (2008).
Holick MF. Vitamin D deficiency. N. Engl. J. Med. 357: 266-281 (2007). *
Holick MF. Vitamin D: a D-lightful health perspective. Nutr. Rev. 66: S182-S194 (2008). *
Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res. 164: 3-28 (2003).
Holick MF. Vitamin D: a millenium perspective. J. Cell Biochem. 88: 296-307 (2003). *
Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South. Med. J. 98: 1024-1027 (2005).
Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J. Clin. Invest. 115: 32-34 (2005). *
Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80: 1678S-1688S (2004). *
Holick MF. The vitamin D epidemic and its health consequences. J. Nutr. 135: 2739S-2748S (2005). *
Holick MF. Vitamin D for health and in chronic kidney disease. Semin. Dial. 18: 266-275 (2005).
Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 81: 353-373 (2006). *
Holick MF, Chen TC, Lu Z, Sauter E. Vitamin D and skin physiology: a D-lightful story. J. Bone Miner. Res. 22 Suppl. 2: V28-V33 (2007). *
Hollis BW. Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr. Opin. Endocrinol. Diabetes Obes. 15: 489-494 (2008).
Holloway GP, Gurd BJ, Snook LA, Lally J, Bonen A. Compensatory increases in nuclear PGC1alpha protein are primarily associated with subsarcolemmal mitochondrial adaptations in ZDF rats. Diabetes Jan 26 [Epub ahead of print] (2010).
Holm P, Rydlander B, Luthman H, Kockum I; European Consortium for IDDM Genome Studies. Interaction and association analysis of a type 1 diabetes susceptibility locus on chromosome 5q11-q13 and the 7q32 chromosomal region in Scandinavian families. Diabetes 53: 1584-1591 (2004). *
Holm TL, Lundsgaard D, Markholst H. Characteristics of rat CD4CD25 T cells and their ability to prevent not only diabetes but also insulitis in an adoptive transfer model in BB rats. Scand. J. Immunol. 64: 17-29 (2006). *
Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; on behalf of the AFORRD study group. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52: 50-59 (2009). *
Holmberg H, Vaarala O, Sadauskaite-Kuehne V, Ilonen J, Padaiga Z, Ludvigsson J. Higher prevalence of autoantibodies to insulin and GAD(65) in Swedish compared to Lithuanian children with type 1 diabetes. Diabetes Res. Clin. Pract. 72: 308-314 (2006).
Holmes A, Mesa J, Neill B, Chung J, Carey A, Steinberg G, Kemp B, Southgate R, Lancaster G, Bruce C, Watt M, Febbraio M. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J. Endocrinol. 198: 367-374 (2008). *
Holmkvist J, Almgren P, Lyssenko V, Lindgren CM, Eriksson KF, Isomaa B, Tuomi T, Nilsson P, Groop L. Common variants in MODY genes and future risk of type 2 diabetes. Diabetes 57: 1738-1744 (2008). *
Holmkvist J, Almgren P, Parikh H, Zucchelli M, Kere J, Groop L, Lindgren CM. Haplotype construction of the FRDA gene and evaluation of its role in type II diabetes. Eur. J. Hum. Genet. 13: 849-855 (2005). *
Holmkvist J, Cervin C, Lyssenko V, Winckler W, Anevski D, Cilio C, Almgren P, Berglund G, Nilsson P, Tuomi T, Lindgren CM, Altshuler D, Groop L. Common variants in HNF-1 alpha and risk of type 2 diabetes. Diabetologia 49: 2882-2891 (2006). *
Holmlund JT. Applying antisense technology: Affinitak(TM) and other antisense oligonucleotides in clinical development. Ann. N. Y. Acad. Sci. 1002: 244-251 (2003). *
Holness MJ, Caton PW, Sugden MC. Acute and long-term nutrient-led modifications of gene expression: potential role of SIRT1 as a central co-ordinator of short and longer-term programming of tissue function. Nutrition Jan 22 [Epub ahead of print] (2010). *
Holness MJ, Greenwood GK, Smith ND, Sugden MC. Peroxisome proliferator-activated receptor-alpha and glucocorticoids interactively regulate insulin secretion during pregnancy. Diabetes 55: 3501-3508 (2006). *
Holopainen P, Arvas M, Sistonen P, Mustalahti K, Collin P, Maki M, Partanen J. CD28/CTLA4 gene region on chromosome 2q33 confers genetic susceptibility to celiac disease. A linkage and family-based association study. Tissue Antigens 53: 470-475 (1999). *
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease. Verh. K. Acad. Geneeskd. Belg. 70: 193-219 (2008).
Holzapfel C, Klopp N, Grallert H, Huth C, Gieger C, Meisinger C, Strassburger K, Giani G, Wichmann HE, Laumen H, Hauner H, Herder C, Rathmann W, Illig T. Genetic variants in the leukemia-associated Rho guanine nucleotide exchange factor (ARHGEF12) gene are not associated with T2DM and related parameters in Caucasians (KORA study). Eur. J. Endocrinol. 157: R1-R5 (2007). *
Homann D, Dummer W, Wolfe T, Rodrigo E, Theofilopoulos AN, Oldstone MB, von Herrath MG. Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity. J. Virol. 80: 270-280 (2006). *
Homann D, Eisenbarth GS. An immunologic homunculus for type 1 diabetes. J. Clin. Invest. 116: 1212-1215 (2006). *
Hombach AA, Kofler D, Rappl G, Abken H. Redirecting human CD4(+)CD25(+) regulatory T cells from the peripheral blood with pre-defined target specificity. Gene Ther. 16: 1088-1096 (2009).
Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 7: 1333-1339 (1987).
Homo-Delarche F. Neuroendocrine immuno-ontogeny of the pathogenesis of autoimmune disease in the nonobese diabetic (NOD) mouse. ILAR J. 45: 237-258 (2004). *
Homo-Delarche F, Calderari S, Irminger JC, Gangnerau MN, Coulaud J, Rickenbach K, Dolz M, Halban P, Portha B, Serradas P. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 55: 1625-1633 (2006). *
Hondares E, Mora O, Yubero P, de la Concepcion MR, Iglesias R, Giralt M, Villarroya F. Thiazolidinediones and rexinoids induce PGC-1alpha gene transcription. An auto-regulatory loop controls PGC-1alpha expression in adipocytes via PPARgamma co-activation. Endocrinology 147: 2829-2838 (2006). *
Honeyman MC, Harrison LC. Congenital rubella, diabetes and HLA. Diabetologia 52: 371-372 (2009). *
Honeyman MC, Harrison LC, Drummond B, Colman PG, Tait BD. Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol. Med. 1: 576-582 (1995). *
Hong EG, Ko HJ, Cho YR, Kim HJ, Ma Z, Yu TY, Friedline RH, Kurt-Jones E, Finberg R, Fischer MA, Granger EL, Norbury CC, Hauschka SD, Philbrick WM, Lee CG, Elias JA, Kim JK. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 58: 2525-2535 (2009).
Hong KW, Jin HS, Lim JE, Ryu HJ, Go MJ, Lee JY, Woo JT, Park HK, Oh B. RAPGEF1 gene variants associated with type 2 diabetes in the Korean population. Diabetes Res. Clin. Pract. 84: 117-122 (2009).
Hong MG, Pawitan Y, Magnusson PK, Prince JA. Strategies and issues in the detection of pathway enrichment in genome-wide association studies. Hum. Genet. 126: 289-301 (2009). *
Honiden S, Gong MN. Diabetes, insulin, and development of acute lung injury. Crit. Care Med. 37: 2455-2464 (2009).
Honka MJ, Vanttinen M, Iozzo P, Virtanen KA, Lautamaki R, Hallsten K, Borra RJ, Takala T, Viljanen AP, Kemppainen J, Pihlajamaki J, Knuuti J, Nuutila P, Laakso M. The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus. Metabolism 58: 541-546 (2009).
Honkanen-Scott M, Johnson J, Hering B, Bansal-Pakala P. Blockade of OX40 signals enhance survival of xenoislet grafts in spontaneously diabetic NOD mice. Transplant. Proc. 40: 483-485 (2008). *
Honscheid A, Rink L, Haase H. T-lymphocytes: a target for stimulatory and inhibitory effects of zinc ions. Endocr. Metab. Immune Disord. Drug Targets 9: 132-134 (2009).
Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clin. Nutr. 27: 764-772 (2008).
Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J. Am. Coll. Nutr. 28: 184-195 (2009). *
Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, Fong CH, Tam S, Chan L, Lam KS. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler. Thromb. Vasc. Biol. 27: 2777-2782 (2007).
Hoofnagle JH. Reactivation of hepatitis B. Hepatology 49: S156-S165 (2009).
Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 40: 773 (2004). *
Hoofnagle JH. Hepatobiliary pathophysiology study section. Hepatology 39:1476-1476 (2004). *
Hoofnagle JH. The national commission on digestive diseases. Hepatology 44: 6 (2006). *
Hoover ML, Marta RT. Molecular modelling of HLA-DQ suggests a mechanism of resistance in type 1 diabetes. Scand. J. Immunol. 45: 193-202 (1997).
Hoppenbrouwers IA, Cortes LM, Aulchenko YS, Sintnicolaas K, Njajou O, Snijders PJ, Oostra BA, van Duijn CM, Hintzen RQ. Familial clustering of multiple sclerosis in a Dutch genetic isolate. Mult. Scler. 13: 17-24 (2007). *
Hoppin AG. Obesity and the liver: developmental perspectives. Semin. Liver Dis. 24: 381-387 (2004).
Horie H, Okada M, Kojima M, Nagai H. Favorable effects of preoperative enteral immunonutrition on a surgical site infection in patients with colorectal cancer without malnutrition. Surg. Today 36: 1063-1068 (2006). *
Horikoshi M, Hara K, Ohashi J, Miyake K, Tokunaga K, Ito C, Kasuga M, Nagai R, Kadowaki T. A polymorphism in the AMPKalpha2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes 55: 919-923 (2006). *
Horiuchi A, Kaneko T, Yamamura N, Nagata A, Nakamura T, Akamatsu T, Mukawa K, Kawa S, Kiyosawa K. Autoimmune chronic pancreatitis simulating pancreatic lymphoma. Am. J. Gastroenterol. 91: 2607-2609 (1996).
Horn GT, Bugawan TL, Long CM, Erlich HA. Allelic sequence variation of the HLA-DQ loci: relationship to serology and to insulin-dependent diabetes susceptibility. Proc. Natl. Acad. Sci. U.S.A. 85: 6012-6016 (1988). *
Horn GT, Bugawan TL, Long CM, Manos MM, Erlich HA. Sequence analysis of HLA class II genes from insulin-dependent diabetic individuals. Hum. Immunol. 21: 249-263 (1988).
Hornum L, Lundsgaard D, Markholst H. PolyI:C induction of diabetes is controlled by Iddm4 in rats with a full regulatory T cell pool. Ann. N. Y. Acad. Sci. 1110: 65-72 (2007). *
Hornum L, Markholst H. New autoimmune genes and the pathogenesis of type 1 diabetes. Curr. Diab. Rep. 4: 135-142 (2004).
Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 40: 211-225 (1999). *
Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278: 36652-36660 (2003). *
Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, Lush MJ, Povey S, Talbot CC, Wright MW, Wain HM, Trowsdale J, Ziegler A, Beck S. Gene map of the extended human MHC. Nat. Rev. Genet. 5: 889-899 (2004). *
Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, Manley S, Holman R, Turner R. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42: 608-616 (1999). *
Horvath G, David K. Iron storage disease. Orv. Hetil. 145: 1979-1984 (2004).
Horwitz MS, Efrat S, Christen U, von Herrath MG, Oldstone MB. Adenovirus E3 MHC inhibitory genes but not TNF/Fas apoptotic inhibitory genes expressed in beta cells prevent autoimmune diabetes. Proc. Natl. Acad. Sci. U.S.A. 106: 19450-19454 (2009). *
Hoshino A, Fujii H. Nuclear translocation of 2-amino-3-ketobutyrate coenzyme A ligase by cold and osmotic stress. Cell Stress Chaperones 12: 186-191 (2007). *
Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue H, Ogawa W, Tobimatsu K, Takazawa K, Sakai M, Matsuki Y, Hiramatsu R, Yasuda T, Lazar MA, Yamanashi Y, Kasuga M. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat. Med. 14: 188-193 (2008). *
Hosszufalusi N, Karcagi V, Horvath R, Palik E, Varkonyi J, Rajczy K, Prohaszka Z, Szentirmai C, Karadi I, Romics L, Panczel P. A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C-peptide secretion, HLA-DR and -DQ status and autoantibody pattern. Diabetes Metab. Res. Rev. 25: 127-135 (2009). *
Hostetler HA, Syler LR, Hall LN, Zhu G, Schroeder F, Kier AB. A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions. J. Biomol. Screen 13: 855-861 (2008).
Hou C, Wang JP, Yang L, Li X, Huang G, Zhou WD, Lin J, Zhou ZG. Immunological characteristics and islet function in first-degree relatives of latent autoimmune diabetes in adults. Zhonghua Yi Xue Za Zhi 89: 1820-1824 (2009).
Hou G, Abrams GD, Dick R, Brewer GJ. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl. Res. 152: 239-244 (2008). *
Hou L, Xu J, Gao YT, Rashid A, Zheng SL, Sakoda LC, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Meyers DA, Fraumeni JF Jr, Hsing AW. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: a population-based study in Shanghai, China. Int. J. Cancer 118: 2847-2853 (2006). *
Hou R, Ohtsuji M, Ohtsuji N, Zhang L, Adachi T, Hirose S, Tsubata T. Centromeric interval of chromosome 4 derived from C57BL/6 mice accelerates type 1 diabetes in NOD.CD72(b) congenic mice. Biochem. Biophys. Res. Commun. 380: 193-197 (2009). *
Houlston RS, Tomlinson IP, Ford D, Seal S, Marossy AM, Ferguson A, Holmes GK, Hosie KB, Howdle PD, Jewell DP, Godkin A, Kerr GD, Kumar P, Logan RF, Love AH, Johnston S, Marsh MN, Mitton S, O'Donoghue D, Roberts A, Walker-Smith JA, Stratton MF. Linkage analysis of candidate regions for coeliac disease genes. Hum. Mol. Genet. 6: 1335-1339 (1997). *
Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest. Anim. Endocrinol. 22: 1-23 (2002). *
Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25: 1419-1425 (2006). *
Hovhannisyan Z, Weiss A, Martin A, Wiesner M, Tollefsen S, Yoshida K, Ciszewski C, Curran SA, Murray JA, David CS, Sollid LM, Koning F, Teyton L, Jabri B. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 456: 534-538 (2008). *
Hovind P, Lamberts S, Hop W, Deinum J, Tarnow L, Parving HH, Janssen JA. An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. Eur. J. Endocrinol. 156: 83-90 (2007). *
Hovnik T, Dolzan V, Natasa Ursic B, Trebusak Podkrajsek K, Battelino T. Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes. Diabetes Care 32: 2258-2262 (2009).
Howard BV, Comuzzie A, Devereux RB, Ebbesson SO, Fabsitz RR, Howard WJ, Laston S, Maccluer JW, Silverman A, Umans JG, Wang H, Weissman NJ, Wenger CR. Cardiovascular disease prevalence and its relation to risk factors in Alaska Eskimos. Nutr. Metab. Cardiovasc. Dis. Oct 1 [Epub ahead of print] (2009).
Howard DD, White CQ, Harden TR, Ellis CN. Incidence of surgical site infections postcolorectal resections without preoperative mechanical or antibiotic bowel preparation. Am. Surg. 75: 659-663 (2009).
Howes LG. The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. Diabetes Obes. Metab. 8: 8-14 (2006).
Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy. Clin. Endocrinol. (Oxf.) Dec 18 [Epub ahead of print] (2009). *
Howson JM, Dunger DB, Nutland S, Stevens H, Wicker LS, Todd JA. A type 1 diabetes subgroup with a female bias is characterised by failure in tolerance to thyroid peroxidase at an early age and a strong association with the cytotoxic T-lymphocyte-associated antigen-4 gene. Diabetologia 50: 741-746 (2007). *
Howson JM, Walker NM, Clayton D, Todd JA; Diabetes Genetics Consortium. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes. Metab. 11 Suppl. 1: 31-45 (2009). *
Howson JM, Walker NM, Smyth DJ, Todd JA. Analysis of 19 genes for association with type I diabetes in the Type I Diabetes Genetics Consortium families. Genes Immun. 10: S74-S84 (2009).
Hruby E, Sassi L, Gorbe E, Hupuczi P, Papp Z. The maternal and fetal outcome of 122 triplet pregnancies. Orv. Hetil. 148: 2315-2328 (2007).
Hsieh CH, Liang KH, Hung YJ, Huang LC, Pei D, Liao YT, Kuo SW, Bey MS, Chen JL, Chen EY. Analysis of epistasis for diabetic nephropathy among type 2 diabetic patients. Hum. Mol. Genet. 15: 2701-2708 (2006). *
Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism Dec 30 [Epub ahead of print] (2009). *
Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, Childs RW, Rodgers GP, Powell JD, Tisdale JF. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N. Engl. J. Med. 361: 2309-2317 (2009). *
Hsing LC, Kirk EA, McMillen TS, Hsiao SH, Caldwell M, Houston B, Rudensky AY, Leboeuf RC. Roles for cathepsins S, L, and B in insulitis and diabetes in the NOD mouse. J. Autoimmun. Aug 5 [Epub ahead of print] (2009).
Hsu TC. Feasibility of colectomy with mini-incision. Am. J. Surg. 190: 48-50 (2005). *
Hsueh WC, Silver KD, Pollin TI, Bell CJ, O'Connell JR, Mitchell BD, Shuldiner AR. A genome-wide linkage scan of insulin level derived traits: the Amish family diabetes study. Diabetes 56: 2643-2648 (2007). *
Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, Bell CJ, Sakul H, Wagner MJ, Burns DK, Shuldiner AR. Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24. Diabetes 52: 550-557 (2003). *
Hsun-Wei Huang T, Peng G, Qian Li G, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol. Appl. Pharmacol. 210: 225-235 (2006). *
Hu C, Deng S, Wong FS, Wen L. Anti-CD20 treatment prolongs syngeneic islet graft survival and delays the onset of recurrent autoimmune diabetes. Ann. N. Y. Acad. Sci. 1150: 217-219 (2008). *
Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet. Med. 23: 1307-1312 (2006). *
Hu CM, Lin HH, Chiang MT, Chang PF, Chau LY. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 56: 1240-1247 (2007). *
Hu CY, Allen M, Chuang LM, Lin BJ, Gyllensten U. Association of insulin-dependent diabetes mellitus in Taiwan with HLA class II DQB1 and DRB1 alleles. Hum. Immunol. 38: 105-114 (1993).
Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117: 3857-3867 (2007). *
Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Jousilahti P. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 48: 129-136 (2008). *
Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, Leng Y. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol. Sin. 27: 1346-1352 (2006).
Huang CC, Lu YF, Wen SN, Hsieh WC, Lin YC, Liu MR, Chiang E, Chang CN, Lin RH. A novel apoptosis-inducing anti-PSGL-1 antibody for T cell-mediated diseases. Eur. J. Immunol. 35: 2239-2249 (2005). *
Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc. Natl. Acad. Sci. U.S.A. Feb 22 [Epub ahead of print] (2010). *
Huang H, Kearney JF, Grusby MJ, Benoist C, Mathis D. Induction of tolerance in arthritogenic B cells with receptors of differing affinity for self-antigen. Proc. Natl. Acad. Sci. U.S.A. 103: 3734-3739 (2006). *
Huang HS, Peng JT, She JY, Zhang LP, Chao CC, Liu KH, She JX. HLA-encoded susceptibility to insulin-dependent diabetes mellitus is determined by DR and DQ genes as well as their linkage disequilibria in a Chinese population. Hum. Immunol. 44: 210-219 (1995).
Huang J, Karakucuk V, Levitsky LL, Rhoads DB. Expression of HNF4alpha variants in pancreatic islets and Ins-1 beta cells. Diabetes Metab. Res. Rev. 24: 533-543 (2008).
Huang J, Levitsky LL, Rhoads DB. Novel P2 promoter-derived HNF4alpha isoforms with different N-terminus generated by alternate exon insertion. Exp. Cell Res. 315: 1200-1211 (2009).
Huang JF, Dai CY, Yu ML, Shin SJ, Hsieh MY, Huang CF, Lee LP, Lin KD, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL. Serum retinol-binding protein 4 is inversely correlated with disease severity of chronic hepatitis C. J. Hepatol. 50: 471-478 (2009).
Huang Q, Wang TH, Lu WS, Mu PW, Yang YF, Liang WW, Li CX, Lin GP. Estrogen receptor alpha gene polymorphism associated with type 2 diabetes mellitus and the serum lipid concentration in Chinese women in Guangzhou. Chin. Med. J. (Engl.) 119: 1794-1801 (2006). *
Huang T, Wahlqvist ML, Xu T, Xu A, Zhang A, Li D. Increased plasma n-3 polyunsaturated fatty acid is associated with improved insulin sensitivity in type 2 diabetes in China. Mol. Nutr. Food Res. Dec 8 [Epub ahead of print] (2009). *
Huang TH, Kota BP, Razmovski V, Roufogalis BD. Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin. Pharmacol. Toxicol. 96: 3-14 (2005). *
Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol. Res. 60: 195-206 (2009). *
Huang W, Connor E, Rosa TD, Muir A, Schatz D, Silverstein J, Crockett S, She JX, Maclaren NK. Although DR3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplotype is implicated only in beta-cell autoimmunity. J. Clin. Endocrinol. Metab. 81: 2559-2563 (1996). *
Huang W, Wang P, Liu Z, Zhang L. Identifying disease associations via genome-wide association studies. BMC Bioinformatics 10 Suppl. 1: S68 (2009). *
Huang X, Moore DJ, Ketchum RJ, Nunemaker CS, Kovatchev B, McCall AL, Brayman KL. Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation. Endocr. Rev. 29: 603-630 (2008). *
Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y. Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. Endocr. Rev. 29: 697-725 (2008). *
Hucl T, Kylanpaa-Back ML, Witt H, Kunzli B, Lempinen M, Schneider A, Kemppainen E, Lohr M, Friess H, Ockenga J, Rosendahl J, Schulz HU, Gress T, Singer MV, Pfutzer RH. HFE genotypes in patients with chronic pancreatitis and pancreatic adenocarcinoma. Genet. Med. 9: 479-483 (2007).
Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch. Dermatol. 143: 1559-1565 (2007). *
Huffmyer JL, Littlewood KE, Nemergut EC. Perioperative management of the adult with cystic fibrosis. Anesth. Analg. 109: 1949-1961 (2009).
Hug BA, Ahmed N, Robbins JA, Lazar MA. A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene. J. Biol. Chem. 279: 825-830 (2004). *
Hughes P, Bouillet P, Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr. Dir. Autoimmun. 9: 74-94 (2006).
Huisman AM, de Valk HW, Prins HJ, Bijlsma JW, Jacobs JW. Arthritis as a consequence of diabetes mellitus or haemochromatosis. Ned. Tijdschr. Geneeskd. 149: 196-200 (2005).
Hull JH, Garrod R, Ho TB, Knight RK, Cockcroft JR, Shale DJ, Bolton CE. Increased augmentation index in patients with cystic fibrosis. Eur. Respir. J. 34: 1322-1328 (2009).
Hull K, Horenstein R, Naglieri R, Munir K, Ghany M, Celi FS. Two cases of thyroid storm-associated cholestatic jaundice. Endocr. Pract. 13: 476-480 (2007).
Hultcrantz M, Huhn MH, Wolf M, Olsson A, Jacobson S, Williams BR, Korsgren O, Flodstrom-Tullberg M. Interferons induce an antiviral state in human pancreatic islet cells. Virology 367: 92-101 (2007).
Humar A, Crotteau S, Gruessner A, Kandaswamy R, Gruessner R, Payne W, Lake J. Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes. Clin. Transplant. 21: 526-531 (2007). *
Humbert P, Dupond JL. Multiple autoimmune syndromes. Ann. Med. Interne. (Paris) 139: 159-168 (1988).
Hummel M, Bonifacio E, Naserke HE, Ziegler AG. Elimination of dietary gluten does not reduce titers of type 1 diabetes-associated autoantibodies in high-risk subjects. Diabetes Care 25: 1111-1116 (2002). *
Hummel M, Durinovic-Bello I, Ziegler AG. Relation between cellular and humoral immunity to islet cell antigens in type 1 diabetes. J. Autoimmun. 9: 427-430 (1996).
Hummel S, Hummel M, Banholzer J, Hanak D, Mollenhauer U, Bonifacio E, Ziegler AG. Development of autoimmunity to transglutaminase C in children of patients with type 1 diabetes: relationship to islet autoantibodies and infant feeding. Diabetologia 50: 390-394 (2007). *
Hunger-Battefeld W, Fath K, Mandecka A, Kiehntopf M, Kloos C, Muller UA, Wolf G. Prevalence of polyglandular autoimmune syndrome in patients with diabetes mellitus type 1. Med. Klin. (Munich) 104: 183-191 (2009).
Hunt KA, McGovern DP, Kumar PJ, Ghosh S, Travis SP, Walters JR, Jewell DP, Playford RJ, van Heel DA. A common CTLA4 haplotype associated with coeliac disease. Eur. J. Hum. Genet. 13: 440-444 (2005). *
Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, Gwilliam R, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJ, et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 40: 395-402 (2008). *
Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N. Engl. J. Med. 357: 436-439 (2007). *
Hunter K, Rainbow D, Plagnol V, Todd JA, Peterson LB, Wicker LS. Interactions between Idd5.1/Ctla4 and other type 1 diabetes genes. J. Immunol. 179: 8341-8349 (2007). *
Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, Loong CC, Chiang JH, Chiou YY, Lee SD. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int. 30: 198-207 (2010). *
Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int. 24: 210-215 (2004). *
Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, Chang FY, Lee SD. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am. J. Gastroenterol. 99: 1479-1487 (2004). *
Huotari A, Herzig KH. Vitamin D and living in northern latitudes - an endemic risk area for vitamin D deficiency. Int. J. Circumpolar Health 67: 164-178 (2008).
Husain Z, Kelly MA, Eisenbarth GS, Pugliese A, Awdeh ZL, Larsen CE, Alper CA. The MHC type 1 diabetes susceptibility gene is centromeric to HLA-DQB1. J. Autoimmun. 30: 266-272 (2008).
Hussain K, Padidela R, Kapoor RR, James C, Banerjee K, Harper J, Wilson LC, Hennekam RC. Diabetes mellitus, exocrine pancreatic deficiency, hypertrichosis, hyperpigmentation, and chronic inflammation: confirmation of a syndrome. Pediatr. Diabetes 10: 193-197 (2009).
Hussain N, Quezado M, Huizing M, Geho D, White JG, Gahl W, Mannon P. Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype. Clin. Gastroenterol. Hepatol. 4: 73-80 (2006). *
Hussain S. Role of surfactant protein A in the innate host defense and autoimmunity. Autoimmunity 37: 125-130 (2004).
Hussain S, Delovitch TL. Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J. Immunol. 179: 7225-7232 (2007). *
Hussain S, Delovitch TL. Dysregulated b7-1 and b7-2 expression on nonobese diabetic mouse B cells is associated with increased T cell costimulation and the development of insulitis. J. Immunol. 174: 680-687 (2005). *
Hutchings HA, Upton P, Cheung WY, Maddocks A, Eiser C, Williams J, Russell I, Jackson S, Jenney M. Adaptation of the Manchester-Minneapolis Quality of Life instrument for use in the UK population. Arch. Dis. Child. 92: 855-860 (2007). *
Hutchings HA, Upton P, Cheung WY, Maddocks A, Eiser C, Williams JG, Russell IT, Jackson S, Jenney ME. Development of a parent version of the Manchester-Minneapolis quality of life survey for use by parents and carers of UK children: MMQL-UK (PF). Health Qual. Life Outcomes 6: 19 (2008). *
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention. MedGenMed. 7: 18 (2005). *
Huth C, Illig T, Herder C, Gieger C, Grallert H, Vollmert C, Rathmann W, Hamid YH, Pedersen O, Hansen T, Thorand B, Meisinger C, Doring A, Klopp N, Gohlke H, Lieb W, Hengstenberg C, Lyssenko V, Groop L, Ireland H, Stephens JW, et al. Joint analysis of individual participants' data from 17 studies on the association of the IL6 variant -174G >C with circulating glucose levels, interleukin-6 levels, and body mass index. Ann. Med. 41: 128-138 (2009).
Hutton MJ, Westwell-Roper C, Soukhatcheva G, Plesner A, Dutz JP, Verchere CB. Islet allograft rejection is independent of Toll-like receptor signaling in mice. Transplantation 88: 1075-1080 (2009).
Huurman VA, Unger WW, Koeleman BP, Oaks MK, Chandraker AK, Terpstra OT, Roep BO. Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y. Clin. Exp. Immunol. 150: 487-493 (2007). *
Huurman VA, Velthuis JH, Hilbrands R, Tree TI, Gillard P, van der Meer-Prins PM, Duinkerken G, Pinkse GG, Keymeulen B, Roelen DL, Claas FH, Pipeleers DG, Roep BO. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am. J. Transplant. 9: 382-388 (2009).
Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N. Engl. J. Med. 350: 1398-1404 (2004). *
Hwang B, Jeoung NH, Harris RA. Pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) deficiency attenuates the long-term negative effects of a high-saturated fat diet. Biochem. J. 423: 243-252 (2009). *
Hwang JS, Shin CH, Yang SW, Jung SY, Huh N. Genetic and clinical characteristics of Korean maturity-onset diabetes of the young (MODY) patients. Diabetes Res. Clin. Pract. 74: 75-81 (2006).
Hwang JT, Lee MS, Kim HJ, Sung MJ, Kim HY, Kim MS, Kwon DY. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother. Res. 23: 262-266 (2009).
Hwang JY, Park JE, Choi YJ, Huh KB, Kim WY. SNP276G>T polymorphism in the adiponectin gene is associated with metabolic syndrome in patients with type II diabetes mellitus in Korea. Eur. J. Clin. Nutr. Aug 19 [Epub ahead of print] (2009). *
Hwang MT, Goldfarb DS. Uric acid stones following hepatic transplantation. Urol. Res. 32: 423-426 (2004).
Hwang WS, Roh SI, Lee BC, Kang SK, Kwon DK, Kim S, Kim SJ, Park SW, Kwon HS, Lee CK, Lee JB, Kim JM, Ahn C, Paek SH, Chang SS, Koo JJ, Yoon HS, Hwang JH, Hwang YY, Park YS, Oh SK, Kim HS, Park JH, Moon SY, Schatten G. Patient-specific embryonic stem cells derived from human SCNT blastocysts. Obstet. Gynecol. Surv. 60: 587-589 (2005).
Hyer RN, Julier C, Buckley JD, Trucco M, Rotter J, Spielman R, Barnett A, Bain S, Boitard C, Deschamps I, et al. High-resolution linkage mapping for susceptibility genes in human polygenic disease: insulin-dependent diabetes mellitus and chromosome 11q. Am. J. Hum. Genet. 48: 243-257 (1991). *
Hyman SJ, Shreffler WG, Rapaport R. Type 1 diabetes, autoimmune thyroid disease, and chronic urticaria. Pediatr. Diabetes 9: 508-511 (2008).
Hyun E, Ramachandran R, Cenac N, Houle S, Rousset P, Saxena A, Liblau RS, Hollenberg MD, Vergnolle N. Insulin modulates protease-activated receptor 2 signaling: implications for the innate immune response. J. Immunol. Jan 29 [Epub ahead of print] (2010).
Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am. J. Nephrol. 27: 554-564 (2007). *
Iciek R, Wender-Ozegowska E, Seremak-Mrozikiewicz A, Drews K, Brazert J, Pietryga M. Leptin gene, leptin gene receptor polymorphisms and body weight in pregnant women with type 1 diabetes mellitus. Ginekol. Pol. 79: 592-601 (2008).
Iciek R, Wender-Ozegowska E, Seremak-Mrozikiewicz A, Drews K, Sodowski K, Pietryga M, Brazert J. Leptin gene, leptin gene polymorphisms and body weight in pregnant women with diabetes mellitus type I. J. Physiol. Pharmacol. 59 Suppl. 4: 19-31 (2008). *
Ide A, Babu SR, Robles DT, Wang T, Erlich HA, Bugawan TL, Rewers M, Fain PR, Eisenbarth GS. "Extended" A1, B8, DR3 haplotype shows remarkable linkage disequilibrium but is similar to nonextended haplotypes in terms of diabetes risk. Diabetes 54: 1879-1883 (2005). *
Ide A, Babu SR, Robles DT, Wang T, Erlich HA, Bugawan TL, Rewers M, Fain PR, Eisenbarth GS. Homozygosity for premature stop codon of the MHC class I chain-related gene A (MIC-A) is associated with early activation of islet autoimmunity of DR3/4-DQ2/8 high risk DAISY relatives. J. Clin. Immunol. 25: 303-308 (2005). *
Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Ishii R, Takahashi R, Kuwahara H, Fujita N, Kita A, Imaizumi M, Oshima K, Usa T, Uotani S, Ejima E, Yamasaki H, Ashizawa K, Yamaguchi Y, Eguchi K. Association of interleukin-18 gene promoter polymorphisms in type 1 diabetes and autoimmune thyroid disease. Ann. N. Y. Acad. Sci. 1005: 436-439 (2003). *
Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Ishii R, Takahashi R, Kuwahara H, Fujita N, Kita A, Imaizumi M, Oshima K, Usa T, Uotani S, Ejima E, Yamasaki H, Ashizawa K, Yamaguchi Y, Eguchi K. Interleukin-10 gene promoter region polymorphisms in patients with type 1 diabetes and autoimmune thyroid disease. Ann. N. Y. Acad. Sci. 1005: 344-347 (2003). *
Ide A, Kawasaki E, Abiru N, Sun F, Kobayashi M, Fukushima T, Takahashi R, Kuwahara H, Kita A, Oshima K, Uotani S, Yamasaki H, Yamaguchi Y, Eguchi K. Association between IL-18 gene promoter polymorphisms and CTLA-4 gene 49A/G polymorphism in Japanese patients with type 1 diabetes. J. Autoimmun. 22: 73-78 (2004).
Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol. 154: 613-621 (2006). *
Ihara K, Ahmed S, Nakao F, Kinukawa N, Kuromaru R, Matsuura N, Iwata I, Nagafuchi S, Kohno H, Miyako K, Hara T. Association studies of CTLA-4, CD28, and ICOS gene polymorphisms with type 1 diabetes in the Japanese population. Immunogenetics 53: 447-454 (2001).
Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen. Physiol. Biophys. 26: 159-167 (2007).
Ikeda F, Doi Y, Yonemoto K, Ninomiya T, Kubo M, Shikata K, Hata J, Tanizaki Y, Matsumoto T, Iida M, Kiyohara Y. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 136: 1234-1241 (2009). *
Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Path. Int. 56: 40-45 (2006). *
Ikegami H, Awata T, Kawasaki E, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Amemiya S, Kawabata Y, Kurihara S, Tanaka S, Kanazawa Y, Mochizuki M, Ogihara T. The association of CTLA4 polymorphism with type 1 diabetes is concentrated in patients complicated with autoimmune thyroid disease: a multi-center collaborative study in Japan. J. Clin. Endocrinol. Metab. 91: 1087-1092 (2006). *
Ikegami H, Fujisawa T, Kawabata Y, Noso S, Ogihara T. Genetics of type 1 diabetes: similarities and differences between Asian and Caucasian populations. Ann. N. Y. Acad. Sci. 1079: 51-59 (2006). *
Ikegami H, Fujisawa T, Makino S, Ogihara T. Genetic dissection of type 1 diabetes susceptibility gene, Idd3, by ancestral haplotype congenic mapping. Ann. N. Y. Acad. Sci. 958: 325-328 (2002). *
Ikegami H, Kawabata Y, Noso S, Fujisawa T, Ogihara T. Genetics of type 1 diabetes in Asian and Caucasian populations. Diabetes Res. Clin. Pract. 77 Suppl. 1: S116-S121 (2007).
Ikegami H, Noso S, Babaya N, Hiromine Y, Kawabata Y. Genetic basis of type 1 diabetes: similarities and differences between East and West. Rev. Diabet. Stud. 5: 64-72 (2008). *
Ikegami H, Ono M, Fujisawa T, Hiromine Y, Kawabata Y, Yamato E. Molecular scanning of the gene for thioredoxin, an antioxidative and antiapoptotic protein, and genetic susceptibility to type 1 diabetes. Ann. N. Y. Acad. Sci. 1150: 103-105 (2008). *
Ikegami H, Tahara Y, Cha T, Yamato E, Ogihara T, Noma Y, Shima K. Aspartic acid at position 57 of the HLA-DQ beta chain is not protective against insulin-dependent diabetes mellitus in Japanese people. J. Autoimmun. 3: 167-174 (1990).
Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today (Barc.) 38: 103-111 (2002).
Ikehara S. Bone marrow transplantation for autoimmune diseases. Acta Haematol. 99: 116-132 (1998).
Ikemoto T, Noguchi H, Shimoda M, Naziruddin B, Jackson A, Tamura Y, Fujita Y, Onaca N, Levy MF, Matsumoto S. Islet cell transplantation for the treatment of type 1 diabetes in the USA. J. Hepatobiliary Pancreat. Surg. 16: 118-123 (2009). *
Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, Kasis I, Axelrod E, Zolotarov L, Klein A, El Haj M, Gandhi R, Baecher-Allan C, Wu H, Murugaiyan G, Kivisakk P, Farez MF, Quintana FJ, Khoury SJ, Weiner HL. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent Immunologic effect in T cells and dendritic cells. J. Clin. Immunol. Sep 16 [Epub ahead of print] (2009). *
Iles RA. Nuclear magnetic resonance spectroscopy and genetic disorders. Curr. Med. Chem. 15: 15-36 (2008).
Ilhan N, Kahraman N, Seckin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell. Biochem. Funct. 25: 527-532 (2007). *
Iliaki E, Poulaki V, Mitsiades N, Mitsiades CS, Miller JW, Gragoudas ES. Role of alpha4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 50: 4898-4904 (2009). *
Illig T, Bongardt F, Schopfer A, Holle R, Muller S, Rathmann W, Koenig W, Meisinger C, Wichmann HE, Kolb H; KORA Study Group. The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 52: 2861-2864 (2003). *
Ilonen J, Kocova M, Lipponen K, Sukarova-Angelovska E, Jovanovska A, Knip M. HLA-DR-DQ haplotypes and type 1 diabetes in Macedonia. Hum. Immunol. 70: 461-463 (2009).
Im SS, Kim JW, Kim TH, Song XL, Kim SY, Kim HI, Ahn YH. Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter. Exp. Mol. Med. 37: 101-110 (2005). *
Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Res. Clin. Pract. 82: 233-237 (2008).
Imai J, Katagiri H, Yamada T, Ishigaki Y, Suzuki T, Kudo H, Uno K, Hasegawa Y, Gao J, Kaneko K, Ishihara H, Niijima A, Nakazato M, Asano T, Minokoshi Y, Oka Y. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science 322: 1250-1254 (2008). *
Imai T. Functional genetic dissection of nuclear receptor signalling in obesity, diabetes and liver regeneration using spatiotemporally controlled somatic mutagenesis in the mouse. Keio. J. Med. 52: 198-203 (2003). *
Inada Y, Ikeda K, Tojo K, Sakamoto M, Takada Y, Tajima N. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation. Peptides 30: 365-372 (2009). *
Inerot A, Enerback C, Enlund F, Martinsson T, Samuelsson L, Wahlstrom J, Swanbeck G. Collecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders. BMC Dermatol. 5: 10 (2005). *
Ingegnosi C, Caruso-Nicoletti M, D'Amato E, d'Annunzio G, Lorini R. Hyperglycemia in celiac disease: not always pretype 1 diabetes? Pediatr. Diabetes 9: 335-337 (2008).
Ingelfinger JR. Aliskiren and dual therapy in type 2 diabetes mellitus. N. Engl. J. Med. 358: 2503-2505 (2008). *
Ingerski LM, Modi AC, Hood KK, Pai AL, Zeller M, Piazza-Waggoner C, Driscoll KA, Rothenberg ME, Franciosi J, Hommel KA. Health-related quality of life across pediatric chronic conditions. J. Pediatr. Jan 29 [Epub ahead of print] (2010).
Ings S. Diet therapy - a forgotten art? Paediatr. Nurs. 12: 14-17 (2000).
Innocenti F, Hepp J, Humeres R, Sanhueza E, Zapata R, Rios H, Suarez L, Sandoval R, Rius M, Zamboni M. Rapid steroid taper and neoral monotherapy in liver transplantation in Chile: a step in the right direction? Transplant Proc. 36: 1675-1676 (2004). *
Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, Hashimoto N, Kido Y, Mori T, Sakaue H, Teshigawara K, Jin S, Iguchi H, Hiramatsu R, LeRoith D, Takeda K, Akira S, Kasuga M. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat. Med. 10: 168-174 (2004). *
Inoue I. Lipid metabolism and magnesium. Clin. Calcium 15: 1827-1838 (2005).
Inoue K, Matsumoto M, Miyoshi Y, Kobayashi Y. Elevated liver enzymes in women with a family history of diabetes. Diabetes Res. Clin. Pract. 79: e4-e7 (2008).
Inoue Y, Kaifu T, Sugahara-Tobinai A, Nakamura A, Miyazaki J, Takai T. Activating Fcgamma receptors participate in the development of autoimmune diabetes in NOD mice. J. Immunol. 179: 764-774 (2007). *
International Multiple Sclerosis Genetics Consortium (IMSGC). The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun. 10: 11-14 (2009). *
Inuo M, Ihara K, Matsuo T, Kohno H, Hara T. Association study between B- and T-lymphocyte attenuator gene and type 1 diabetes mellitus or systemic lupus erythematosus in the Japanese population. Int. J. Immunogenet. 36: 65-68 (2009). *
Invernizzi P, Gershwin ME. The genetic basis of primary biliary cirrhosis: premises, not promises. Gastroenterology 135: 1044-1047 (2008). *
Ioachimescu AG, Bauer TW, Licata A. Active Crohn disease and hypercalcemia treated with infliximab: case report and literature review. Endocr. Pract. 14: 87-92 (2008).
Ioannou GN. Cholelithiasis, cholecystectomy, and liver disease. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *
Ioannou GN, Morrow OB, Connole ML, Lee SP. Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the United States population. Hepatology 50: 175-184 (2009).
Ionescu-T�rgoviste C. For a new paradigm of diabetes. Rom. J. Intern. Med. 45: 3-15 (2007).
Ionescu-Tirgoviste C, Guja C, Herr M, Cucca E, Welsh K, Bunce M, Marshall S, Todd JA. Low frequency of HLA DRB1*03 - DQB1*02 and DQB1*0302 haplotypes in Romania is consistent with the country's low incidence of type I diabetes. Diabetologia 44 Suppl. 3: B60-B66 (2001).
Iordanidou M, Tavridou A, Petridis I, Arvanitidis KI, Christakidis D, Vargemezis V, Manolopoulos VG. The serotonin transporter promoter polymorphism (5-HTTLPR) is associated with type 2 diabetes. Clin. Chim. Acta Nov 2 [Epub ahead of print] (2009). *
Iordanidou M, Tavridou A, Vasiliadis MV, Arvanitidis KI, Petridis J, Christakidis D, Vargemezis V, Bougioukas G, Manolopoulos VG. The -759C/T polymorphism of the 5-HT2C receptor is associated with type 2 diabetes in male and female Caucasians. Pharmacogenet. Genomics 18: 153-159 (2008).
Irace C, Cortese C, Fiaschi E, Scavelli F, Liberatoscioli L, Federici G, Gnasso A. The influence of PON1 192 polymorphism on endothelial function in diabetic subjects with or without hypertension. Hypertens. Res. 31: 507-513 (2008).
Irace C, Cortese C, Migale M, Liberatoscioli L, Mannucci L, Federici G, Gnasso A. Stromelysin gene promoter polymorphism and common carotid geometry in diabetic subjects. Int. Angiol. 27: 413-418 (2008).
Irie J, Ridgway WM. A modular theory of autoimmunity. Keio. J. Med. 54: 121-126 (2005). *
Irie J, Wu Y, Kachapati K, Mittler RS, Ridgway WM. Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes 56:186-196 (2007). *
Irie J, Wu Y, Sass DA, Ridgway WM. Genetic control of anti-Sm autoantibody production in NOD congenic mice narrowed to the Idd9.3 region. Immunogenetics 58: 9-14 (2006). *
Irshad M, Chaudhuri PS. Oxidant-antioxidant system: role and significance in human body. Indian J. Exp. Biol. 40: 1233-1239 (2002).
Irving-Rodgers HF, Ziolkowski AF, Parish CR, Sado Y, Ninomiya Y, Simeonovic CJ, Rodgers RJ. Molecular composition of the peri-islet basement membrane in NOD mice: a barrier against destructive insulitis. Diabetologia 51: 1680-1688 (2008). *
Irwin MR, Carrillo C, Olmstead R. Sleep loss activates cellular markers of inflammation: sex differences. Brain Behav. Immun. 24: 54-57 (2010).
Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch. Intern. Med. 166: 1756-1762 (2006). *
Isaacs JD. T cell immunomodulation - the Holy Grail of therapeutic tolerance. Curr. Opin. Pharmacol. 7: 418-425 (2007).
Isermann B, Bierhaus A, Humpert PM, Rudofsky G, Chavakis T, Ritzel R, Wendt T, Morcos M, Kasperk C, Hamann A, Nawroth PP. AGE-RAGE: a hypothesis or a mechanism? Herz. 29: 504-509 (2004).
Isharwal S, Arya S, Misra A, Wasir JS, Pandey RM, Rastogi K, Vikram NK, Luthra K, Sharma R. Dietary nutrients and insulin resistance in urban Asian Indian adolescents and young adults. Ann. Nutr. Metab. 52: 145-151 (2008).
Isharwal S, Misra A, Wasir JS, Nigam P. Diet and insulin resistance: a review and Asian Indian perspective. Indian J. Med. Res. 129: 485-499 (2009).
Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *
Ishida H, Kuruta Y, Gotoh O, Yamashita C, Yoshida Y, Noshiro M. Structure, evolution, and liver-specific expression of sterol 12alpha-hydroxylase P450 (CYP8B). J. Biochem. 126: 19-25 (1999).
Ishida Y, Ohara T, Okuno Y, Ito T, Hirota Y, Furukawa K, Sakaguchi K, Ogawa W, Kasuga M. Alpha-lipoic acid and insulin autoimmune syndrome. Diabetes Care 30: 2240-2241 (2007). *
Ishii M, Hasegawa G, Fukui M, Obayashi H, Ohta M, Ogata M, Yoshioka K, Kitagawa Y, Nakano K, Yoshikawa T, Nakamura N. Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/ml) of antibodies to glutamic acid decarboxylase. Immunol. Lett. 99: 180-185 (2005).
Ishizuka T, Ogawa S, Mori T, Nako K, Nakamichi T, Oka Y, Ito S. Characteristics of the antibodies of two patients who developed daytime hyperglycemia and morning hypoglycemia because of insulin antibodies. Diabetes Res. Clin. Pract. 84: e21-e23 (2009).
Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 103: 1-9 (2004).
Israni N, Goswami R, Kumar A, Rani R. Interaction of vitamin D receptor with HLA DRB1*0301 in type 1 diabetes patients from North India. PLoS One 4: e8023 (2009). *
Istfan NW, Person KS, Holick MF, Chen TC. 1alpha,25-Dihydroxyvitamin D and fish oil synergistically inhibit G(1)/S-phase transition in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 103: 726-730 (2007).
Ito M, Suzuki J, Sasaki M, Watanabe K, Tsujioka S, Takahashi Y, Gomori A, Hirose H, Ishihara A, Iwaasa H, Kanatani A. Development of nonalcoholic steatohepatitis model through combination of high-fat diet and tetracycline with morbid obesity in mice. Hepatol. Res. 34: 92-98 (2006).
Ito T, Shimada K, Gang M, Uchikoshi F, Tori M, Komoda H, Fumimoto Y, Ohmori K, Kawamoto K, Tanemura M, Nozawa M. Pancreas transplantation using type I and type II spontaneously diabetic rats - our experimental experience. Microsurgery 27: 305-311 (2007).
Itoh H. PPARs and hypertension Nippon Rinsho 63: 631-642 (2005).
Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig. Dis. Sci. 48: 2182-2186 (2003). *
Ittah M, Gottenberg JE, Proust A, Hachulla E, Puechal X, Loiseau P, Mariette X, Miceli-Richard C. No evidence for association between 1858 C/T single-nucleotide polymorphism of PTPN22 gene and primary Sjogren's syndrome. Genes Immun. 6: 457-458 (2005). *
Ivakine EA, Fox CJ, Paterson AD, Mortin-Toth SM, Canty A, Walton DS, Aleksa K, Ito S, Danska JS. Sex-specific effect of insulin-dependent diabetes 4 on regulation of diabetes pathogenesis in the nonobese diabetic mouse. J. Immunol. 174: 7129-7140 (2005). *
Ivarsson SA, Eriksson S, Kockum I, Lernmark A, Lindgren S, Nilsson KO, Sundkvist G, Wassmuth R. HLA-DR3, DQ2 homozygosity in two patients with insulin-dependent diabetes mellitus superimposed with ulcerative colitis and primary sclerosing cholangitis. J. Intern. Med. 233: 281-286 (1993).
Iwanaga Y, Matsumoto S, Okitsu T, Noguchi H, Nagata H, Yonekawa Y, Yamada Y, Fukuda K, Tsukiyama K, Tanaka K. Living donor islet transplantation, the alternative approach to overcome the obstacles limiting transplant. Ann. N. Y. Acad. Sci. 1079: 335-339 (2006). *
Iwanczak F, Smigiel R, Stawarski A, Pawlowicz J, Stembalska A, Mowszet K, Sasiadek M. Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis. Pol. Merkur. Lekarski. 18: 205-209 (2005).
Iwasaki N, Cox NJ, Wang YQ, Schwarz PE, Bell GI, Honda M, Imura M, Ogata M, Saito M, Kamatani N, Iwamoto Y. Mapping genes influencing type 2 diabetes risk and BMI in Japanese subjects. Diabetes 52: 209-213 (2003). *
Iwase K, Shimada A, Kawai T, Okubo Y, Kanazawa Y, Irie J, Oikawa Y, Hirose H, Maruyama T, Itoh H. FOXP3/Scurfin gene polymorphism is associated with adult onset type 1 diabetes in Japanese, especially in women and slowly progressive-type patients. Autoimmunity 42: 159-167 (2009).
Izar MC, Helfenstein T, Ihara SS, Relvas WG, Santos AO, Fischer SC, Pinto LE, Lopes IE, Pomaro DR, Fonseca MI, Bodanese LC, Moriguchi EH, Saraiva JF, Introcaso L, Souza AD, Scartezini M, Torres KP, Zagury L, Jardim PC, Costa EA, Tacito LH, Forti A, et al. Association of lipoprotein lipase D9N polymorphism with myocardial infarction in type 2 diabetes: the genetics, outcomes, and lipids in type 2 diabetes (GOLD) study. Atherosclerosis 204: 165-170 (2009).
Izumi Y, Tominaga M, Iwanaga N, Huang M, Tanaka F, Aratake K, Arima K, Tamai M, Kamachi M, Nakamura H, Ida H, Origuchi T, Kawakami A, Eguchi K. Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis. Mod. Rheumatol. 16: 20-23 (2006). *
Jaakkola U, Koulu M, Karvonen MK, Seppala H, Pesonen U, Vahlberg T, Kallio J. Impact of the Leu7Pro polymorphism of preproNPY on diurnal NPY and hormone secretion in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 115: 281-286 (2007).
Jaakkola U, Pesonen U, Vainio-Jylha E, Koulu M, Pollonen M, Kallio J. The Leu7Pro polymorphism of neuropeptide Y is associated with younger age of onset of type 2 diabetes mellitus and increased risk for nephropathy in subjects with diabetic retinopathy. Exp. Clin. Endocrinol. Diabetes 114: 147-152 (2006).
Jackson DG, Capra JD. TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility. Proc. Natl. Acad. Sci. U.S.A. 90: 11079-11083 (1993). *
Jacob T, Hingorani A, Ascher E. Evidence for telomerase activation in VSMCs exposed to hyperglycemic and hyperhomocysteinemic conditions. Angiology 60: 562-568 (2009).
Jacobsen PK. Preventing end stage renal disease in diabetic patients - genetic aspect (part I). J. Renin Angiotensin Aldosterone Syst. 6: 1-14 (2005).
Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84: 223-243 (1997).
Jacobson EM, Concepcion E, Oashi T, Tomer Y. A Graves' disease associated Kozak sequence SNP enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 146: 2684-2691 (2005). *
Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG. Medicinal chemistry of the A(3) adenosine receptor: agonists, antagonists, and receptor engineering. Handb. Exp. Pharmacol. 193: 123-159 (2009).
Jacobson P, Rankinen T, Tremblay A, Perusse L, Chagnon YC, Bouchard C. Resting metabolic rate and respiratory quotient: results from a genome-wide scan in the Quebec Family Study. Am. J. Clin. Nutr. 84: 1527-1533 (2006). *
Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin. Ther. 29: 763-777 (2007).
Jacobsson G, Dashti S, Wahlberg T, Andersson R. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand. J. Infect. Dis. 39: 6-13 (2007). *
Jadaho SB, Yang RZ, Lin Q, Hu H, Anania FA, Shuldiner AR, Gong DW. Murine alanine aminotransferase: cDNA cloning, functional expression, and differential gene regulation in mouse fatty liver. Hepatology 39: 1297-1302 (2004). *
Jaeckel E, Mpofu N, Saal N, Manns MP. Role of regulatory T cells for the treatment of type 1 diabetes mellitus. Horm. Metab. Res. 40: 126-136 (2008).
Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 54: 306-310 (2005). *
Jafar-Mohammadi B, McCarthy MI. Genetics of type 2 diabetes mellitus and obesity - a review. Ann. Med. 40: 2-10 (2008).
Jaffe JR, Nag SS, Landsman PB, Alexander CM. Reassessment of cardiovascular risk in diabetes. Curr. Opin. Lipidol. 17: 644-652 (2006).
Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A, Rubin D, McDonnell ME, Van Dyke TE, Ganley-Leal LM, Nikolajczyk BS. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J. Immunol. 183: 7461-7470 (2009).
Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J. Clin. Immunol. 27: 19-35 (2007). *
Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum. 52: 4039-4043 (2005). *
Jahromi MM, Eisenbarth GS. Genetic determinants of type 1 diabetes across populations. Ann. N. Y. Acad. Sci. 1079: 289-299 (2006). *
Jahromi MM, Eisenbarth GS. Cellular and molecular pathogenesis of type 1A diabetes. Cell. Mol. Life Sci. 64: 865-872 (2007). *
Jahromi MM, Millward BA, Demaine AG. Significant correlation between association of polymorphism in codon 10 of the transforming growth factor-beta1 T (29) C with type 1 diabetes and patients with nephropathy disorder. J. Interferon Cytokine Res. Dec 29 [Epub ahead of print] (2009).
Jaidane H, Sane F, Gharbi J, Aouni M, Romond MB, Hober D. Coxsackievirus B4 and type 1 diabetes pathogenesis: contribution of animal models. Diabetes Metab. Res. Rev. 25: 591-603 (2009).
Jailwala P, Waukau J, Glisic S, Jana S, Ehlenbach S, Hessner M, Alemzadeh R, Matsuyama S, Laud P, Wang X, Ghosh S. Apoptosis of CD4+ CD25(high) T cells in type 1 diabetes may be partially mediated by IL-2 deprivation. PLoS One 4: e6527 (2009). *
Jain R, Tartar DM, Gregg RK, Divekar RD, Bell JJ, Lee HH, Yu P, Ellis JS, Hoeman CM, Franklin CL, Zaghouani H. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 205: 207-218 (2008). *
Jain SK, Rains J, Croad J, Larson B, Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid. Redox Signal. 11: 241-249 (2009).
Jain SK, Velusamy T, Croad JL, Rains JL, Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, oxidative stress and inhibits NFkB activation in the livers of Zucker diabetic rats. Free Radic. Biol. Med. 46: 1633-1638 (2009).
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins? Ann. Med. 38: 2-10 (2006).
Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet. 5: e1000337 (2009). *
Jalel A, Hamdaoui MH. Study of total antioxidant status and glutathione peroxidase activity in Tunisian vitiligo patients. Indian J. Dermatol. 54: 13-16 (2009). *
James EA, Kwok WW. CD8(+) suppressor-mediated regulation of human CD4(+) T cell responses to glutamic acid decarboxylase 65. Eur. J. Immunol. 37: 78-86 (2007). *
James I, McKinnon E, Gaudieri S, Morahan G; Diabetes Genetics Consortium. Missingness in the T1DGC MHC fine-mapping SNP data: association with HLA genotype and potential influence on genetic association studies. Diabetes Obes. Metab. 11 Suppl. 1: 101-107 (2009). *
James SP. 19. Immunologic, gastroenterologic, and hepatobiliary disorders. J. Allergy Clin. Immunol. 111: S645-S658 (2003). *
Jamroz-Wisniewska A, Wojcicka G, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy. Hig. Med. Dosw. (Online) 61: 760-785 (2007). *
Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis 163: 183-192 (2002).
Jana S, Jailwala P, Haribhai D, Waukau J, Glisic S, Grossman W, Mishra M, Wen R, Wang D, Williams CB, Ghosh S. The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. Eur. J. Immunol. 39: 2571-2583 (2009). *
Jandeleit-Dahm KA, Calkin A, Tikellis C, Thomas M. Direct antiatherosclerotic effects of PPAR agonists. Curr. Opin. Lipidol. 20: 24-29 (2009).
Jang JY, Kim KM, Kim GH, Yu E, Lee JJ, Park YS, Yoo HW. Clinical characteristics and VPS33B mutations in patients with ARC syndrome. J. Pediatr. Gastroenterol. Nutr. 48: 348-354 (2009).
Jansen PL. Nonalcoholic steatohepatitis. Neth. J. Med. 62: 217-224 (2004). *
Jansen PL. Nonalcoholic steatohepatitis: diagnosis, pathogenesis, treatment and prognosis. Ned. Tijdschr. Geneeskd. 149: 289-294 (2005).
Jansen PL. Non-alcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 16: 1079-1085 (2004).
Jarad NA, Giles K. Risk factors for increased need for intravenous antibiotics for pulmonary exacerbations in adult patients with cystic fibrosis. Chron. Respir. Dis. 5: 29-33 (2008).
Jarchum I, Dilorenzo TP. Ins2 deficiency augments spontaneous HLA-A*0201-restricted T cell responses to insulin. J. Immunol. 184: 658-665 (2010).
Jarchum I, Nichol L, Trucco M, Santamaria P, Dilorenzo TP. Identification of novel IGRP epitopes targeted in type 1 diabetes patients. Clin. Immunol. 127: 359-365 (2008). *
Jarrar MH, Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J. Cell. Mol. Med. 11: 71-87 (2007). *
Jarvinen TM, Harjutsalo V, Kinnunen L, Miettinen ME, Tuomilehto-Wolf E, Tuomilehto J. A population-specific diabetogenic haplotype HLA-A2,Cw1,B56,DR4,DQ8 is associated with high birthweight in Finnish diabetic families. Genes Immun. 9: 207-213 (2008). *
Jaspan JB, Luo H, Ahmed B, Tenenbaum S, Voss T, Sander DM, Bollinger K, Baquet T, Garry RF. Evidence for a retroviral trigger in Graves' disease. Autoimmunity 20: 135-142 (1995).
Jatla M, Bokhari A, Bierly P, Russo P, Verma R. Anthropometric, serologic, and laboratory correlation with villous blunting in pediatric celiac disease: diabetics are different. J. Clin. Gastroenterol. 43: 622-626 (2009).
Jatwa R, Parmar HS, Panda S, Kar A. Amelioration of corticosteroid-induced type 2 diabetes mellitus by rosiglitazone is possibly mediated through stimulation of thyroid function and inhibition of tissue lipid peroxidation in mice. Basic Clin. Pharmacol. Toxicol. 101: 177-180 (2007).
Javor ED, Ghany MG, Cochran EK, Oral EA, Depaoli AM, Premkumar A, Kleiner DE, Gorden P. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41: 753-760 (2005). *
Jay CL, Butt Z, Ladner DP, Skaro AI, Abecassis MM. A review of quality of life instruments used in liver transplantation. J. Hepatol. 51: 949-959 (2009). *
Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr. Diabetes Rev. 3: 33-39 (2007).
Jayaraman S, Patel T, Patel V, Ajani S, Garza R, Jayaraman A, Kwon S, Singh R, Rondelli D, Prabhakar BS, Holterman M. Transfusion of nonobese diabetic mice with allogeneic newborn blood ameliorates autoimmune diabetes and modifies the expression of selected immune response genes. J. Immunol. Feb 17 [Epub ahead of print] (2010).
Jaziri R, Lobbens S, Aubert R, Pean F, Lahmidi S, Vaxillaire M, Porchay I, Bellili N, Tichet J, Balkau B, Froguel P, Marre M, Fumeron F. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the data from an epidemiological study � Diabetes 55: 1157-1162 (2006). *
Jean G, Lafage-Proust MH, Massy ZA, Drueke TB. Guidelines for vitamin D prescription in dialysis patients. Nephrol. Ther. 5: 520-532 (2009).
Jeffcoat R. Obesity - a perspective based on the biochemical interrelationship of lipids and carbohydrates. Med. Hypotheses 68: 1159-1171 (2007).
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27: 2422-2428 (2004). *
Jenkins DJ, Hu FB, Tapsell LC, Josse AR, Kendall CW. Possible benefit of nuts in type 2 diabetes. J. Nutr. 138: 1752S-1756S (2008). *
Jenkins DJ, Kendall CW. Resistant starches. Curr. Opin. Gastroenterol. 16: 178-183 (2000).
Jennings CE, Owen CJ, Wilson V, Pearce SH. No association of the codon 55 methionine to valine polymorphism in the SUMO4 gene with Graves' disease. Clin. Endocrinol. (Oxf.) 62: 362-365 (2005). *
Jensen K, Gluud C. The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey). Hepatology 20: 1061-1077 (1994).
Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J. Natl. Cancer Inst. 99: 895-897 (2007). *
Jessen N, Buhl ES, Schmitz O, Lund S. Impaired insulin action despite upregulation of proximal insulin signaling: novel insights into skeletal muscle insulin resistance in liver cirrhosis. J. Hepatol. 45: 797-804 (2006). *
Jew S, AbuMweis SS, Jones PJ. Evolution of the human diet: linking our ancestral diet to modern functional foods as a means of chronic disease prevention. J. Med. Food 12: 925-934 (2009).
Jeyakumar M, Webb P, Baxter JD, Scanlan TS, Katzenellenbogen JA. Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor. Biochemistry 47: 7465-7476 (2008). *
Ji C, Kaplowitz N. Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J. Gastroenterol. 10: 1699-1708 (2004). *
Ji C, Shinohara M, Kuhlenkamp J, Chan C, Kaplowitz N. Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology 46: 1586-1596 (2007). *
Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, Qin LX, Yang W, Wang HJ, Tang ZY, Croce CM, Wang XW. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480 (2009). *
Ji L, Malecki M, Warram JH, Yang Y, Rich SS, Krolewski AS. New susceptibility locus for NIDDM is localized to human chromosome 20q. Diabetes 46: 876-881 (1997).
Ji SL, Huang QY. PPARgamma variants and complex diseases. Yi Chuan 28: 993-1002 (2006).
Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z, Mattis TA. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians. Arch. Med. Res. 40: 411-415 (2009).
Jia HT, Zhang SH, Ji LN, Han XY. Molecular scanning of MODY1 gene mutations in pedigrees of early onset type 2 diabetes in Beijing. Nan Fang Yi Ke Da Xue Xue Bao 26: 1301-1303 (2006).
Jia Y, Guo GL, Surapureddi S, Sarkar J, Qi C, Guo D, Xia J, Kashireddi P, Yu S, Cho YW, Rao MS, Kemper B, Ge K, Gonzalez FJ, Reddy JK. Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicity. Proc. Natl. Acad. Sci. U.S.A. 102: 12531-12536 (2005). *
Jiang F, Yoshida T, Nakaki F, Terawaki S, Chikuma S, Kato Y, Okazaki IM, Honjo T, Okazaki T. Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1-/- mice. Int. Immunol. 21: 499-509 (2009).
Jiang GX, Cui YF, Zhong XY, Tai S, Liu W, Wang ZD, Shi YG. Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes. Arch. Med. Res. 40: 424-426 (2009).
Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 56: 2485-2493 (2007). *
Jiang W, Anderson MS, Bronson R, Mathis D, Benoist C. Modifier loci condition autoimmunity provoked by Aire deficiency. J. Exp. Med. 202: 805-815 (2005). *
Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, Chuang LM. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in type 2 diabetic subjects. Diabet. Med. 22: 1690-1695 (2005).
Jimenez Caballero PE. Stiff person syndrome: presentation of a case with repetitive complex discharges in electromiograms. Neurologist 15: 227-229 (2009).
Jin C, Zang C, Wei G, Cui K, Peng W, Zhao K, Felsenfeld G. H3.3/H2A.Z double variant-containing nucleosomes mark 'nucleosome-free regions' of active promoters and other regulatory regions. Nat. Genet. 41: 941-945 (2009). *
Jin L, Zhu A, Wang Y, Chen Q, Xiong Q, Li J, Sun Y, Li T, Cao R, Wu J, Liu J. A Th1-recognized peptide P277, when tandemly repeated, enhances a Th2 immune response toward effective vaccines against autoimmune diabetes in nonobese diabetic mice. J. Immunol. 180: 58-63 (2008). *
Jin P, Xiang B, Lin J, Huang G, Zhou WD, Zheng C, Chao C, Zhou ZG. Association of CTLA-4 + 49A/G and CT60 gene polymorphism with type 1 diabetes and thyroid autoimmunity. Zhonghua Yi Xue Za Zhi 89: 1246-1249 (2009).
Jin Y, Chen X, Podolsky R, Hopkins D, Makala LH, Muir A, She JX. APC dysfunction is correlated with defective suppression of T cell proliferation in human type 1 diabetes. Clin. Immunol. 130: 272-279 (2009). *
Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA. NALP1 in vitiligo-associated multiple autoimmune disease. N. Engl. J. Med. 356: 1216-1225 (2007). *
Johannesen J. Aspects of the molecular and functional genetics in T1DM - a study of selected candidate genes. Dan. Med. Bull. 53: 122-171 (2006).
Johannesen J, Pociot F, Kristiansen OP, Karlsen AE, Nerup J; DIEGG and DSGD Danish IDDM Epidemiology and Genetics Group, Danish Study Group of Diabetis in Childhood. No evidence for linkage in the promoter region of the inducible nitric oxide synthase gene (NOS2) in a Danish type 1 diabetes population. Genes Immun. 1: 362-366 (2000). *
Johannesson M, Hultqvist M, Holmdahl R. Genetics of autoimmune diseases: a multistep process. Curr. Top. Microbiol. Immunol. 305: 259-276 (2006).
Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O; The Danish Society of Childhood Diabetes. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes? Diabetes Obes. Metab. 8: 75-82 (2006).
Johansen BH, Jensen T, Thorpe CJ, Vartdal F, Thorsby E, Sollid LM. Both alpha and beta chain polymorphisms determine the specificity of the disease-associated HLA-DQ2 molecules, with beta chain residues being most influential. Immunogenetics 45: 142-150 (1996).
Johansson A, Hermansson G, Ludvigsson J; ABIS Study Group. Tobacco exposure and diabetes-related autoantibodies in children: results from the ABIS study. Ann. N. Y. Acad. Sci. 1150: 197-199 (2008). *
Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res. Ther. 8: R19-R25 (2005). *
Johansson S, Lie BA, Cambon-Thomsen A, Pociot F, Nerup J, Kockum I, Thorsby E, Undlien DE. No evidence of type 1 diabetes susceptibility genes in the region centromeric of the HLA complex. Hum. Immunol. 64: 951-959 (2003).
Johansson S, Lie BA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, Thorsby E, Undlien DE. HLA associations in type 1 diabetes: DPB1 alleles may act as markers of other HLA-complex susceptibility genes. Tissue Antigens 61: 344-351 (2003). *
Johansson S, Lie BA, Todd JA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, Akselsen HE, Thorsby E, Undlien DE. Evidence of at least two type 1 diabetes susceptibility genes in the HLA complex distinct from HLA-DQB1, -DQA1 and -DRB1. Genes Immun. 4: 46-53 (2003). *
Johansson S, Raeder H, Eide SA, Midthjell K, Hveem K, Sovik O, Molven A, Njolstad PR. Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate that variants in the hepatocyte nuclear factor 4 alpha (HNF4A) P2 region are associated with type 2 diabetes in Scandinavians. Diabetes 56: 3112-3117 (2007). *
Johnnidis JB, Venanzi ES, Taxman DJ, Ting JP, Benoist CO, Mathis DJ. Chromosomal clustering of genes controlled by the aire transcription factor. Proc. Natl. Acad. Sci. U.S.A. 102: 7233-7238 (2005). *
Johnsen AK, Plenge RM, Butty V, Campbell C, Dieguez-Gonzalez R, Gomez-Reino JJ, Shadick N, Weinblatt M, Gonzalez A, Gregersen PK, Benoist C, Mathis D. A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum. 58: 1947-1957 (2008). *
Johnsen-Soriano S, Garcia-Pous M, Arnal E, Sancho-Tello M, Garcia-Delpech S, Miranda M, Bosch-Morell F, Diaz-Llopis M, Navea A, Romero FJ. Early lipoic acid intake protects retina of diabetic mice. Free Radic. Res. 42: 613-617 (2008).
Johnson JD, Bernal-Mizrachi E, Alejandro EU, Han Z, Kalynyak TB, Li H, Beith JL, Gross J, Warnock GL, Townsend RR, Permutt MA, Polonsky KS. Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proc. Natl. Acad. Sci. U.S.A. 103: 19575-19580 (2006). *
Johnson JS, Nobmann ED, Asay E, Lanier AP. Dietary intake of Alaska Native people in two regions and implications for health: the Alaska Native Dietary and Subsistence Food Assessment Project. Int. J. Circumpolar Health 68: 109-122 (2009).
Johnson MB, Enns CA. Regulation of transferrin receptor 2 by transferrin: diferric transferrin regulates transferrin receptor 2 protein stability. Blood 104: 4287-4293 (2004). *
Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 99: 1044-1059 (2006). *
Johnson W, Harris SE, Starr JM, Whalley LJ, Deary IJ. PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes. Neurosci. Lett. 434: 50-55 (2008).
Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPAR-gamma activity after administration of poloxamer 407 to mice. Can. J. Physiol. Pharmacol. 86: 643-649 (2008).
Jolly M. How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J. Rheumatol. 32: 1706-1708 (2005).
Jones DB, Coulson AF, Duff GW. Sequence homologies between hsp60 and autoantigens. Immunol. Today 14: 115-118 (1993).
Jones DE. Experimental models for primary biliary cirrhosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 41-42 (2004). *
Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat. Rev. Immunol. 6: 271-282 (2006). *
Jones GT, van Rij AM, Cole J, Williams MJ, Bateman EH, Marcovina SM, Deng M, McCormick SP. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin. Chem. 53: 679-685 (2007). *
Jones HN, Jansson T, Powell T. IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2. Am. J. Physiol. Cell Physiol. 297: C1228-C1235 (2009). *
Jones PM, Courtney MJ, Burns CJ, Persaud SJ. Cell-based treatments for diabetes. Drug Discov. Today 13: 888-893 (2008).
Jongjaroenprasert W, Chanprasertyothin S, Kongsuksai A, Bunnag P, Puavilai G, Ongphiphadhanakul B. Association of genetic variations near P2 promoter of the hepatocyte nuclear factor-4alpha gene and insulin secretion index in Thais. Acta Diabetol. 44: 227-232 (2007).
Jonson CO, Hedman M, Karlsson Faresjo M, Casas R, Ilonen J, Ludvigsson J, Vaarala O; for the ABIS Study Group. The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children. Clin. Exp. Immunol. 145: 48-55 (2006). *
Jonson CO, Lernmark A, Ludvigsson J, Rutledge EA, Hinkkanen A, Faresjo M. The importance of CTLA-4 polymorphism and human leukocyte antigen genotype for the induction of diabetes-associated cytokine response in healthy school children. Pediatr. Diabetes 8: 185-192 (2007). *
Jordan MA, Fletcher JM, Pellicci D, Baxter AG. Slamf1, the NKT cell control gene nkt1. J. Immunol. 178: 1618-1627 (2007). *
Jores RD, Frau F, Cucca F, Clemente MG, Orru S, Rais M, De Virgiliis S, Congia M. HLA-DQB1*0201 homozygosis predisposes to severe intestinal damage in celiac disease. Scand. J. Gastroenterol. 42: 48-53 (2007). *
Jorge A, Findor J, Esley C, Bruch E. Primary sclerosing cholangitis. Z. Gastroenterol. 26: 322-330 (1988).
Jorgensen KT, Rostgaard K, Bache I, Biggar RJ, Nielsen NM, Tommerup N, Frisch M. Autoimmune diseases in women with Turner's Syndrome. Arthritis Rheum. 62: 658-666 (2010). *
Jorgensen ME, Bjerregaard P, Kjaergaard JJ, Borch-Johnsen K. High prevalence of markers of coronary heart disease among Greenland Inuit. Atherosclerosis 196: 772-778 (2008).
Jorgensen SP, Bartels LE, Agnholt J, Glerup H, Nielsen SL, Hvas CL, Dahlerup JF. Vitamin D insufficiency - possible influence on the development of autoimmune diseases. Ugeskr. Laeger. 169: 3655-3660 (2007).
Jorgenson E, Witte JS. Genome-wide association studies of cancer. Future Oncol. 3: 419-427 (2007).
Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH. The PPARgamma2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Mol. Genet. Metab. 94: 347-351 (2008). *
Joseph B, Kapoor S, Schilsky ML, Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology 49: 1616-1624 (2009).
Joseph B, Kumaran V, Berishvili E, Bhargava KK, Palestro CJ, Gupta S. Monocrotaline promotes transplanted cell engraftment and advances liver repopulation in rats via liver conditioning. Hepatology 44: 1411-1420 (2006). *
Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, Poulaki V, Semkova I, Kociok N. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol. Vis. 15: 1418-1428 (2009). *
Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P. Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists. J. Soc. Biol. 202: 289-312 (2008).
Ju LY, Sun YP, Semana G, Gu XF, Krishnamoorty R, Fauchet R, Charron D. Aspartic acid at position 57 of the HLA-DQ beta chain in insulin-dependent diabetes mellitus: an association with one DRw9-DQw9 subtype in the Chinese population. Tissue Antigens 37: 218-223 (1991).
Judkowski V, Rodriguez E, Pinilla C, Masteller E, Bluestone JA, Sarvetnick N, Wilson DB. Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes. Clin. Immunol. 113: 29-37 (2004). *
Judkowski VA, Allicotti GM, Sarvetnick N, Pinilla C. Peptides from common viral and bacterial pathogens can efficiently activate diabetogenic T-cells. Diabetes 53: 2301-2309 (2004). *
Juedes AE, Von Herrath MG. Regulatory T-cells in type 1 diabetes. Diabetes Metab. Res. Rev. 20: 446-451 (2004).
Julier C, Akolkar B, Concannon P, Morahan G, Nierras C, Pugliese A; the Type I Diabetes Genetics Consortium. The Type I Diabetes Genetics Consortium 'Rapid Response' family-based candidate gene study: strategy, genes selection, and main outcome. Genes Immun. 10: S121-S127 (2009).
Julier C, Hyer RN, Davies J, Merlin F, Soularue P, Briant L, Cathelineau G, Deschamps I, Rotter JI, Froguel P, et al. Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. Nature 354: 155-159 (1991). *
Jump DB. Fatty acid regulation of gene transcription. Crit. Rev. Clin. Lab. Sci. 41: 41-78 (2004).
Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem. Phys. Lipids 153: 3-13 (2008). *
Jun HS. Regeneration of pancreatic beta cells. Front. Biosci. 13: 6170-6182 (2008).
Jun HS, Yoon JW. Approaches for the cure of type 1 diabetes by cellular and gene therapy. Curr. Gene Ther. 5: 249-262 (2005).
Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19: 8-31 (2003). *
Jung MH, Yu J, Shin CH, Suh BK, Yang SW, Lee BC. Association of cytotoxic T lymphocyte antigen-4 gene polymorphisms and HLA class II alleles with the development of type 1 diabetes in Korean children and adolescents. J. Korean Med. Sci. 24: 1004-1009 (2009).
Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, Kim SM, Lee SY, Ahn SM, Kim YK, Kim HJ, Kim DJ, Lee KW. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J. Nutr. Biochem. 19: 371-375 (2008). *
Jung TW, Lee MW, Lee YJ, Kim SM, Lee KT, Whang WK, Cheon HJ, Jeong YT, Chung KW, Cho JM, Kim DH, Jung TW. Regulation of adiponectin receptor 2 expression via PPAR-alpha in NIT-1 cells. Endocr. J. 56: 377-382 (2009). *
Kaaja R. Predictors and risk factors of pre-eclampsia. Minerva Ginecol. 60: 421-429 (2008).
Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 294: 2751-2757 (2005). *
Kabagambe EK, Glasser SP, Ordovas JM, Warodomwichit D, Tsai MY, Hopkins PN, Borecki IB, Wojczynski MK, Arnett DK. TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate. Diabetol. Metab. Syndr. 1: 16 (2009).
Kabelitz D, Geissler EK, Soria B, Schroeder IS, Fandrich F, Chatenoud L. Toward cell-based therapy of type I diabetes. Trends Immunol. 29: 68-74 (2008). *
Kabir M, Skurnik G, Naour N, Pechtner V, Meugnier E, Rome S, Quignard-Boulange A, Vidal H, Slama G, Clement K, Guerre-Millo M, Rizkalla SW. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am. J. Clin. Nutr. 86: 1670-1679 (2007). *
Kacerovsky-Bielesz G, Chmelik M, Ling C, Pokan R, Szendroedi J, Farukuoye M, Kacerovsky M, Schmid AI, Gruber S, Wolzt M, Moser E, Pacini G, Smekal G, Groop L, Roden M. Short-term exercise training does not stimulate skeletal muscle ATP synthesis in relatives of humans with type 2 diabetes. Diabetes 58: 1333-1341 (2009). *
Kadarmideen HN, von Rohr P, Janss LL. From genetical genomics to systems genetics: potential applications in quantitative genomics and animal breeding. Mamm. Genome 17: 548-564 (2006). *
Kaddai V, Jager J, Gonzalez T, Najem-Lendom R, Bonnafous S, Tran A, Le Marchand-Brustel Y, Gual P, Tanti JF, Cormont M. Involvement of TNF-alpha in abnormal adipocyte and muscle sortilin expression in obese mice and humans. Diabetologia 52: 932-940 (2009). *
Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, Alevizos M. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur. J. Cardiovasc. Prev. Rehabil. 14: 837-843 (2007).
Kadowaki T. Recent advances in PPARs research - basic and clinical aspects. Nippon Rinsho 63: 539-548 (2005).
Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp. Biol. Med. (Maywood) 228: 1111-1117 (2003). *
Kagami-Takasugi M, Katsumata N, Tanaka T, Tajima T, Fujieda K. Molecular genetic analysis of MODY candidate genes in Japanese patients with non-obese juvenile onset diabetes mellitus. J. Pediatr. Endocrinol. Metab. 19: 143-148 (2006).
Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves' orbitopathy. Clin. Endocrinol. (Oxf.) 63: 395-402 (2005). *
Kahles H, Kordonouri O, Ramos Lopez E, Walter M, Rosinger S, Boehm BO, Badenhoop K, Seidl C, Ziegler A; Diabetes Genetics Consortium. Mating in parents of type 1 diabetes families as a function of the HLA DR-DQ haplotype. Diabetes Obes. Metab. 11 Suppl. 1: 84-87 (2009). *
Kahles H, Morahan G, Todd JA, Badenhoop K. Association analyses of the vitamin D receptor gene in 1654 families with type I diabetes. Genes Immun. 10: S60-S63 (2009).
Kahles H, Ramos-Lopez E, Lange B, Zwermann O, Reincke M, Badenhoop K. Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population. Eur. J. Endocrinol. 153: 895-899 (2005). *
Kaidashev IP, Rasin AM, Shlykova OA, Gorbas' IM, Smirnova IP, Petrushov AV, Rasin MS. Frequency of the Pro 12Ala gene polymorphism PPARgamma2 in Ukrainian population and its possible role in metabolic syndrome development. Tsitol. Genet. 41: 43-47 (2007).
Kaimal R, Song X, Yan B, King R, Deng R. Differential modulation of farnesoid X receptor signaling pathway by thiazolidinediones. J. Pharmacol. Exp. Ther. 330: 125-134 (2009). *
Kaiser J. Genetics. Mysterious, widespread obesity gene found through diabetes study. Science 316: 185 (2007). *
Kaistha A, Castells S. Celiac disease in African American children with type 1 diabetes mellitus in inner city Brooklyn. Pediatr. Endocrinol. Rev. 5 Suppl. 4: 994-998 (2008).
Kakiuchi-Kiyota S, Vetro JA, Suzuki S, Varney ML, Han HY, Nascimento M, Pennington KL, Arnold LL, Singh RK, Cohen SM. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse. Toxicol. Appl. Pharmacol. 237: 83-90 (2009). *
Kakleas K, Paschali E, Kefalas N, Fotinou A, Kanariou M, Karayianni C, Karavanaki K. Factors for thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Ups. J. Med. Sci. 114: 214-220 (2009).
Kakourou T, Psychou F, Voutetakis A, Xaidara A, Stefanaki K, Dacou-Voutetakis C. Low serum insulin values in children with multiple lesions of granuloma annulare: a prospective study. J. Eur. Acad. Dermatol. Venereol. 19: 30-34 (2005).
Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidinediones beyond glycaemic control. Curr. Pharm. Des. 15: 529-536 (2009).
Kalliokoski T, Nuutila P, Virtanen KA, Iozzo P, Bucci M, Svedstrom E, Roivainen A, Nagren K, Viljanen T, Minn H, Knuuti J, Ronnemaa T, Simell O. Pancreatic glucose uptake in vivo in men with newly diagnosed type 1 diabetes. J. Clin. Endocrinol. Metab. 93: 1909-1914 (2008). *
Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J. Gastroenterol. 43: 811-822 (2008). *
Kamanaka M, Rainbow D, Schuster-Gossler K, Eynon EE, Chervonsky AV, Wicker LS, Flavell RA. Amino acid polymorphisms altering the glycosylation of IL-2 do not protect from type 1 diabetes in the NOD mouse. Proc. Natl. Acad. Sci. U.S.A. 106: 11236-11240 (2009). *
Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report. Ryumachi 43: 667-671 (2003).
Kamen DL, Cooper GS, Bouali H, Shaftman SR, Hollis BW, Gilkeson GS. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun. Rev. 5: 114-117 (2006).
Kameyama N, Arisawa S, Ueyama J, Kagota S, Shinozuka K, Hattori A, Tatsumi Y, Hayashi H, Takagi K, Wakusawa S. Increase in P-glycoprotein accompanied by activation of protein kinase Calpha and NF-kappaB p65 in the livers of rats with streptozotocin-induced diabetes. Biochim. Biophys. Acta 1782: 355-360 (2008). *
Kaminitz A, Mizrahi K, Yaniv I, Farkas DL, Stein J, Askenasy N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J. Autoimmun. 33: 83-91 (2009).
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Extrapancreatic lesions in autoimmune pancreatitis. J. Clin. Gastroenterol. 39: 904-907 (2005).
Kamisawa T, Imai M, Egawa N, Tsuruta K, Okamoto A. Serum IgG4 levels and extrapancreatic lesions in autoimmune pancreatitis. Eur. J. Gastroenterol. Hepatol. 20: 1167-1170 (2008).
Kamisawa T, Okamoto A, Wakabayashi T, Watanabe H, Sawabu N. Appropriate steroid therapy for autoimmune pancreatitis based on long-term outcome. Scand. J. Gastroenterol. 43: 609-613 (2008). *
Kamisawa T, Okazaki K, Kawa S, Shimosegawa T, Tanaka M; Working members of Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J. Gastroenterol. Mar 9 [Epub ahead of print] (2010).
Kamisawa T, Satake K. Therapeutic strategy for autoimmune pancreatitis. Adv. Med. Sci. 53: 145-148 (2008).
Kamisawa T, Satake K. Clinical management of autoimmune pancreatitis. Adv. Med. Sci. 52: 61-65 (2007). *
Kamisawa T, Yoshiike M, Egawa N, Nakajima H, Tsuruta K, Okamoto A. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 5: 234-240 (2005).
Kamphuis MH, Geerlings MI, Tijhuis MA, Kalmijn S, Grobbee DE, Kromhout D. Depression and cardiovascular mortality: a role for n-3 fatty acids? Am. J. Clin. Nutr. 84: 1513-1517 (2006). *
Kanazawa A, Tsukada S, Sekine A, Tsunoda T, Takahashi A, Kashiwagi A, Tanaka Y, Babazono T, Matsuda M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakamura Y, Maeda S. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am. J. Hum. Genet. 75: 832-843 (2004). *
Kanazawa Y, Motohashi Y, Yamada S, Oikawa Y, Shigihara T, Okubo Y, Maruyama T, Shimada A. Frequency of CTLA-4 gene CT60 polymorphism may not be affected by vitamin D receptor gene Bsm I polymorphism or HLA DR9 in autoimmune-related type 1 diabetes in the Japanese. Ann. N. Y. Acad. Sci. 1079: 251-256 (2006). *
Kanazawa Y, Shimada A, Oikawa Y, Okubo Y, Tada A, Imai T, Miyazaki J, Itoh H. Induction of anti-whole GAD65 reactivity in vivo results in disease suppression in type 1 diabetes. J. Autoimmun. 32: 104-109 (2009).
Kanczkowski W, Ziegler CG, Zacharowski K, Bornstein SR. Toll-like receptors in endocrine disease and diabetes. Neuroimmunomodulation 15: 54-60 (2008).
Kane MA, Folias AE, Napoli JL. HPLC/UV quantitation of retinal, retinol, and retinyl esters in serum and tissues. Anal. Biochem. 378: 71-79 (2008). *
Kane MA, Folias AE, Wang C, Napoli JL. Quantitative profiling of endogenous retinoic acid in vivo and in vitro by tandem mass spectrometry. Anal. Chem. 80: 1702-1708 (2008). *
Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 273: 4416-4424 (2006). *
Kaneto H, Matsuoka TA, Katakami N, Kawamori D, Miyatsuka T, Yoshiuchi K, Yasuda T, Sakamoto K, Yamasaki Y, Matsuhisa M. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr. Mol. Med. 7: 674-686 (2007).
Kang BY, Kim TS. Targeting cytokines of the interleukin-12 family in autoimmunity. Curr. Med. Chem. 13: 1149-1156 (2006).
Kang ES, Cha BS, Kim HJ, Kim HJ, Kim SH, Hur KY, Lee HJ, Shim WS, Ahn CW, Lee HC. The 11482G>A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. Diabetes Care 29: 1320-1324 (2006). *
Kang ES, Kim HJ, Nam M, Nam CM, Ahn CW, Cha BS, Lee HC. A novel 111/121 diplotype in the Calpain-10 gene is associated with type 2 diabetes. J. Hum. Genet. 51: 629-633 (2006). *
Kang ES, Nam M, Kim HJ, Kim HJ, Myoung SM, Rhee Y, Ahn CW, Cha BS, Lee HC. Haplotype combination of Calpain-10 gene polymorphism is associated with metabolic syndrome in type 2 diabetes. Diabetes Res. Clin. Pract. 73: 268-275 (2006).
Kang EW, Nam JY, Yoo TH, Shin SK, Kang SW, Han DS, Han SH. Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am. J. Nephrol. 28: 908-913 (2008).
Kang JH, Tsuyoshi G, Han IS, Kawada T, Kim YM, Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity (Silver Spring) Oct 1 [Epub ahead of print] (2009). *
Kang K, Hatano B, Lee CH. PPARdelta agonists and metabolic diseases. Curr. Atheroscler. Rep. 9: 72-77 (2007).
Kang MS, Hirai S, Goto T, Kuroyanagi K, Lee JY, Uemura T, Ezaki Y, Takahashi N, Kawada T. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation. Biochem. Biophys. Res. Commun. 369: 333-338 (2008). *
Kang Y, Xu L, Wang B, Chen A, Zheng G. Cutting edge: immunosuppressant as adjuvant for tolerogenic immunization. J. Immunol. 180: 5172-5176 (2008). *
Kanga U, Vaidyanathan B, Jaini R, Menon PS, Mehra NK. HLA haplotypes associated with type 1 diabetes mellitus in North Indian children. Hum. Immunol. 65: 47-53 (2004).
Kania G, Blyszczuk P, Valaperti A, Dieterle T, Leimenstoll B, Dirnhofer S, Zulewski H, Eriksson U. Prominin-1+/CD133+ bone marrow-derived heart-resident cells suppress experimental autoimmune myocarditis. Cardiovasc. Res. 80: 236-245 (2008).
Kankova K, Vasku A, Hajek D, Zahejsky J, Vasku V. Association of G82S polymorphism in the RAGE gene with skin complications in type 2 diabetes. Diabetes Care 22: 1745 (1999).
Kantarci A, Van Dyke TE. Resolution of inflammation in periodontitis. J. Periodontol. 76: 2168-2174 (2005). *
Kantarova D, Buc M. Genetic susceptibility to type 1 diabetes mellitus in humans. Physiol. Res. 56: 255-266 (2007). *
Kantartzis K, Peter A, Machicao F, Machann J, Wagner S, Konigsrainer I, Konigsrainer A, Schick F, Fritsche A, Haring HU, Stefan N. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58: 2616-2623 (2009).
Kao KT, Pedraza BA, McClune AC, Rios DA, Mao YQ, Zuch RH, Kanter MH, Wirio S, Conteas CN. Microscopic colitis: a large retrospective analysis from a health maintenance organization experience. World J. Gastroenterol. 15: 3122-3127 (2009). *
Kao YH, Hsieh HP, Chitlimalla SK, Pan WY, Kuo CC, Tsai YC, Lin WH, Chuang SE, Chang JY. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. Anticancer Drugs 19: 151-158 (2008).
Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front. Biosci. 13: 1813-1826 (2008).
Kaplan MJ. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc. Health Risk Manag. 4: 1229-1235 (2008).
Kapoor R, Huang YS. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr. Pharm. Biotechnol. 7: 531-534 (2006).
Kapoor RR, Locke J, Colclough K, Wales J, Conn JJ, Hattersley AT, Ellard S, Hussain K. Persistent hyperinsulinemic hypoglycemia and maturity-onset diabetes of the young due to heterozygous HNF4A mutations. Diabetes 57: 1659-1663 (2008). *
Kapoor S. Diabetes mellitus in patients with autoimmune pancreatitis: an often overlooked complication. Gastrointest. Endosc. 68: 405 (2008).
Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F, Donmez H. Empty sella may be the final outcome in lymphocytic hypophysitis. Endocr. Res. 34: 10-17 (2009).
Karagiannides I, Pothoulakis C. Substance P, obesity, and gut inflammation. Curr. Opin. Endocrinol. Diabetes Obes. 16: 47-52 (2009).
Karavanaki K, Kakleas K, Paschali E, Kefalas N, Konstantopoulos I, Petrou V, Kanariou M, Karayianni C. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm. Res. 71: 201-206 (2009).
Karavanaki K, Tsoka E, Liacopoulou M, Karayianni C, Petrou V, Pippidou E, Brisimitzi M, Mavrikiou M, Kakleas K, Dacou-Voutetakis C. Psychological stress as a factor potentially contributing to the pathogenesis of type 1 diabetes mellitus. J. Endocrinol. Invest. 31: 406-415 (2008).
Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835 (2006). *
Kariz S, Milutinovic A, Bregar D, Terzic I, Terzic R, Lovrecic L, Herova M, Hruskovicova H, Peterlin B, Petrovic D, Zorc-Pleskovic R. The interleukin-1 receptor antagonist gene and the inhibitor of kappa B-like protein gene polymorphisms are not associated with myocardial infarction in Slovene population with type 2 diabetes. Coll. Antropol. 31: 503-507 (2007).
Karlson CW, Rapoff MA. Attrition in randomized controlled trials for pediatric chronic conditions. J. Pediatr. Psychol. 34: 782-793 (2009).
Karlsson E, Shaat N, Groop L. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)? Diabet. Med. 25: 788-791 (2008). *
Karlsson Faresjo MG, Ernerudh J, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand. J. Immunol. 59: 517-526 (2004). *
Karlsson HK, Ahlsen M, Zierath JR, Wallberg-Henriksson H, Koistinen HA. Insulin signaling and glucose transport in skeletal muscle from first-degree relatives of type 2 diabetic patients. Diabetes 55: 1283-1288 (2006). *
Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH, Kim SK. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318: 806-809 (2007). *
Kartal Durmazlar SP, Akgul A, Eskioglu F. Hyperhomocysteinemia in patients with stasis dermatitis and ulcer: a novel finding with important therapeutic implications. J. Dermatolog. Treat. Jan 1 [Epub ahead of print] (2009).
Karumuthil-Melethil S, Perez N, Li R, Vasu C. Induction of innate immune response through TLR2 and dectin 1 prevents type 1 diabetes. J. Immunol. 181: 8323-8334 (2008). *
Karunarathne W, Ku CJ, Spence DM. The dual nature of extracellular ATP as a concentration-dependent platelet P2X1 agonist and antagonist. Integr. Biol. (Camb.) 1: 655-663 (2009).
Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci. 108: 40-48 (2008). *
Kashef S, Ghaedian MM, Rajaee A, Ghaderi A. Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol. Int. 27: 235-241 (2007). *
Kasliwal R, Wilton LV, Shakir SA. Monitoring the safety of pioglitazone: results of a prescription-event monitoring study of 12,772 patients in England. Drug Saf. 31: 839-850 (2008).
Kasperlik-Zaluska AA, Czarnocka B, Czech W, Walecki J, Makowska AM, Brzezinski J, Aniszewski J. Secondary adrenal insufficiency associated with autoimmune disorders: a report of twenty-five cases. Clin. Endocrinol. (Oxf.) 49: 779-783 (1998). *
Kaspers S, Kordonouri O, Schober E, Grabert M, Hauffa BP, Holl RW; German Working Group for Pediatric Diabetology. Anthropometry, metabolic control, and thyroid autoimmunity in type 1 diabetes with celiac disease: a multicenter survey. J. Pediatr. 145: 790-795 (2004). *
Kass NE, Medley AM, Natowicz MR, Hull SC, Faden RR, Plantinga L, Gostin LO. Access to health insurance: experiences and attitudes of those with genetic versus non-genetic medical conditions. Am. J. Med. Genet. A. 143: 707-717 (2007).
Kassab A, Ajmi T, Issaoui M, Chaeib L, Miled A, Hammami M. Homocysteine enhances LDL fatty acid peroxidation, promoting microalbuminuria in type 2 diabetes. Ann. Clin. Biochem. 45: 476-480 (2008).
Kastelan S, Zjacic-Rotkvic V, Kastelan Z. Could diabetic retinopathy be an autoimmune disease? Med. Hypotheses 68: 1016-1018 (2007).
Kasznicki J, Blasiak J, Majsterek I, Przybylowska K, Drzewoski J. The Trp64Arg beta3-adrenergic receptor amino-acid variant is not associated with overweight and type 2 diabetes mellitus in Polish population. Exp. Clin. Endocrinol. Diabetes 113: 593-597 (2005).
Kasznicki J, Krupa R, Blasiak J, Drzewoski J. Association between polymorphisms of the DNA repair genes XRCC1 and hOGG1 and type 2 diabetes mellitus in the Polish population. Pol. Arch. Med. Wewn. 119: 122-128 (2009).
Katahira M, Ishiguro T, Segawa S, Kuzuya-Nagao K, Hara I, Nishisaki T. Reevaluation of human leukocyte antigen DR-DQ haplotype and genotype in type 1 diabetes in the Japanese population. Horm. Res. 69: 284-289 (2008).
Katahira M, Maeda H, Tosaki T, Segawa S. The human leukocyte antigen class II gene has different contributions to autoimmune type 1 diabetes with or without autoimmune thyroid disease in the Japanese population. Diabetes Res. Clin. Pract. 85: 293-297 (2009).
Katakami N, Sakamoto K, Kaneto H, Matsuhisa M, Shimizu I, Ishibashi F, Osonoi T, Kashiwagi A, Kawamori R, Hori M, Yamasaki Y. Association between the connexin37 polymorphism and peripheral arterial disease in subjects with type 2 diabetes. Diabetes Care 32: e53-e54 (2009).
Katakami N, Takahara M, Kaneto H, Shimizu I, Ohno K, Ishibashi F, Osonoi T, Kashiwagi A, Kawamori R, Shimomura I, Matsuhisa M, Yamasaki Y. Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes. Diabetes Care 33: 390-395 (2010).
Katarina K, Daniela P, Peter N, Marianna R, Pavlina C, Stepanka P, Jan L, Ludmila T, Michal A, Marie C. HLA, NFKB1 and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients. Exp. Clin. Endocrinol. Diabetes 115: 124-129 (2007).
Kato S, Itoh K, Ochiai M, Iwai A, Park Y, Hata S, Takeuchi K, Ito M, Imaki J, Miura S, Yakabi K, Kobayashi M. Increased pentosidine, an advanced glycation end-product, in urine and tissue reflects disease activity in inflammatory bowel diseases. J. Gastroenterol. Hepatol. 23 Suppl. 2: S140-S145 (2008). *
Katoh M, Katoh M. Human FOX gene family (review). Int. J. Oncol. 25: 1495-1500 (2004).
Katon W, Lin EH, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen. Hosp. Psychiatry 29: 147-155 (2007).
Katona-Durekovic A. The role of virus infections in the pathogenesis of type 1 diabetes - a case report. Med. Pregl. 60: 397-400 (2007).
Katsara M, Tselios T, Deraos S, Deraos G, Matsoukas MT, Lazoura E, Matsoukas J, Apostolopoulos V. Round and round we go: cyclic peptides in disease. Curr. Med. Chem. 13: 2221-2232 (2006).
Katulanda P, Shine B, Katulanda GW, Silva A, Asfir EL, Sheriff R, Somasundaram N, Long AE, Bingley PJ, McCarthy MI, Clark A, Matthews DR. Diabetes mellitus among young adults in Sri Lanka-role of GAD antibodies in classification and treatment: the Sri Lanka Young Diabetes study. Diabetologia 51: 1368-1374 (2008). *
Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun. Rev. 6: 257-259 (2007).
Kaufman KM, Kelly JA, Herring BJ, Adler AJ, Glenn SB, Namjou B, Frank SG, Dawson SL, Bruner GR, James JA, Harley JB. Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. Arthritis Rheum. 54: 2533-2540 (2006). *
Kaur I, Hussain A, Hussain N, Das T, Pathangay A, Mathai A, Hussain A, Nutheti R, Nirmalan PK, Chakrabarti S. Analysis of CFH, TLR4, and APOE polymorphism in India suggests the Tyr402His variant of CFH to be a global marker for age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 47: 3729-3735 (2006). *
Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Long-chain omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. Am. J. Clin. Nutr. 90: 613-620 (2009). *
Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, Ghaderi A, Gough SC, Hiromatsu Y, Ploski R, Wang PW, Ban Y, Bednarczuk T, Chistiakova EI, Chojm M, Heward JM, Hiratani H, Juo SH, Karabon L, Katayama S, Kurihara S, Liu RT, Miyake I, et al. Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. J. Clin. Endocrinol. Metab. 92: 3162-3170 (2007). *
Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE review and meta-analysis. Am. J. Epidemiol. 162: 3-16 (2005). *
Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H; on behalf of the Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia Oct 8 [Epub ahead of print] (2009). *
Kawabata Y, Ikegami H, Fujisawa T, Noso S, Asano K, Hiromine Y, Ogihara T. A second component of HLA-linked susceptibility to type 1 diabetes maps to class I region. Ann. N. Y. Acad. Sci. 1079: 278-284 (2006). *
Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Hotta M, Ueda H, Shintani M, Nojima K, Ono M, Nishino M, Taniguchi H, Noso S, Yamada K, Babaya N, Ogihara T. Age-related association of MHC class I chain-related gene A (MICA) with type 1 (insulin-dependent) diabetes mellitus. Hum. Immunol. 61: 624-629 (2000).
Kawada T. Lipid metabolism related nuclear receptor - the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR). Nippon Rinsho 56: 1722-1728 (1998).
Kawaguchi T, Taniguchi E, Morita Y, Shirachi M, Tateishi I, Nagata E, Sata M. Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int. Dec 22 [Epub ahead of print] (2009). *
Kawahito Y, Cannon GW, Gulko PS, Remmers EF, Longman RE, Reese VR, Wang J, Griffiths MM, Wilder RL. Localization of quantitative trait loci regulating adjuvant-induced arthritis in rats: evidence for genetic factors common to multiple autoimmune diseases. J. Immunol. 161: 4411-4419 (1998). *
Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Uga M, Kurihara S, Kawabata Y, Tanaka S, Kanazawa Y, Lee I, Eguchi K. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. Am. J. Med. Genet. A. 140: 586-593 (2006).
Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, Nakanishi K, Shimada A, Uga M, Kurihara S, Kawabata Y, Tanaka S, Kanazawa Y, Lee I, Eguchi K; Japanese Study Group on Type 1 Diabetes Genetics. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. American Journal of Medical Genetics 140A:586-593 (2006). Am. J. Med. Genet. A. 143A: 1812-1813 (2007).
Kawasaki E, Eguchi K. Genetics of fulminant type 1 diabetes. Ann. N. Y. Acad. Sci. 1079: 24-30 (2006). *
Kawasaki E, Ide A, Abiru N, Kobayashi M, Fukushima T, Kuwahara H, Kita A, Uotani S, Yamasaki H, Eguchi K. Stromal cell-derived factor-1 chemokine gene variant in patients with type 1 diabetes and autoimmune thyroid disease. Ann. N. Y. Acad. Sci. 1037: 79-83 (2004). *
Kawasaki E, Imagawa A, Makino H, Uga M, Abiru N, Hanafusa T, Uchigata Y, Eguchi K. Differences in the contribution of CTLA4 gene to susceptibility to fulminant and type 1A diabetes in Japanese patients. Diabetes Care 31: 1608-1610 (2008). *
Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 49: 828-836 (2006). *
Kawasaki E, Nakamura K, Kuriya G, Satoh T, Kuwahara H, Kobayashi M, Abiru N, Yamasaki H, Eguchi K. Autoantibodies to insulin, insulinoma-associated antigen-2, and zinc transporter 8 improve the prediction of early insulin requirement in adult-onset autoimmune diabetes. J. Clin. Endocrinol. Metab. Jan 8 [Epub ahead of print] (2010). *
Kawasaki E, Uga M, Nakamura K, Kuriya G, Satoh T, Fujishima K, Ozaki M, Abiru N, Yamasaki H, Wenzlau JM, Davidson HW, Hutton JC, Eguchi K. Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes. Diabetologia 51: 2299-2302 (2008). *
Kawashima H, Ihara T, Ioi H, Oana S, Sato S, Kato N, Takami T, Kashiwagi Y, Takekuma K, Hoshika A, Mori T. Enterovirus-related type 1 diabetes mellitus and antibodies to glutamic acid decarboxylase in Japan. J. Infect. 49: 147-151 (2004).
Kay M, Wyllie R, Michener W, Caulfield M, Steffen R. Associated ulcerative colitis, sclerosing cholangitis, and insulin-dependent diabetes mellitus. Cleve. Clin. J. Med. 60: 473-478 (1993).
Kay TW, Dudek NL, Graham K, Estella E, Angstetra E, McKenzie MD, Allison J, Thomas HE. Cytotoxic T cell mechanisms of beta cell destruction in non-obese diabetic mice. Novartis Found. Symp. 292: 68-78 (2008).
Kaya S, Demirci M, Sesli Cetin E, Cicioglu Aridogan B, Sahin M, Tas T, Korkmaz M. Investigation of the presence of autoantibodies in patients with toxocariasis. Mikrobiyol. Bul. 43: 661-666 (2009).
Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br. J. Dermatol. 159: 895-902 (2008). *
Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res. Clin. Pract. 59: 181-189 (2003).
KeBler MS, Murgatroyd C, Bunck M, Czibere L, Frank E, Jacob W, Horvath C, Muigg P, Holsboer F, Singewald N, Spengler D, Landgraf R. Diabetes insipidus and, partially, low anxiety-related behaviour are linked to a SNP-associated vasopressin deficit in LAB mice. Eur. J. Neurosci. 26: 2857-2864 (2007).
Keckler SJ, St Peter SD, Spilde TL, Tsao K, Ostlie DJ, Holcomb GW 3rd, Snyder CL. Current significance of meconium plug syndrome. J. Pediatr. Surg. 43: 896-898 (2008).
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovasc. Diabetol. 4: 13 (2005). *
Keech AC, The Field Study Investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study ISRCTN64783481. Cardiovasc. Diabetol. 3: 9 (2004). *
Keim V, Witt H, Bauer N, Bodeker H, Rosendahl J, Teich N, Mossner J. The course of genetically determined chronic pancreatitis. JOP 4: 146-154 (2003). *
Kelemen K, Gottlieb PA, Putnam AL, Davidson HW, Wegmann DR, Hutton JC. HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes. J. Immunol. 172: 3955-3962 (2004). *
Keller U. From obesity to diabetes. Int. J. Vitam. Nutr. Res. 76: 172-177 (2006).
Kelly FJ. Use of antioxidants in the prevention and treatment of disease. J. Int. Fed. Clin. Chem. 10: 21-23 (1998).
Kelly KJ, Wu P, Patterson CE, Temm CJ, Dominguez JH. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. Am. J. Physiol. Renal Physiol. 294: F1136-F1145 (2008). *
Kelsen J, Hvas CL, Agnholt J, Dahlerup JF. Regulatory T cells and their importance to human illnesses. Ugeskr. Laeger. 168: 32-37 (2006).
Kemp EH, Gavalas NG, Krohn KJ, Brown EM, Watson PF, Weetman AP. Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 94: 4749-4756 (2009). *
Kempa H, Sadlak-Nowicka J, Kedzia A, Staron P. Candida infections of the oral mucosa - not only a dental problem. Przegl. Lek. 63: 257-260 (2006).
Kempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C, Martin S, Algenstaedt P. Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm. Metab. Res. 39: 596-600 (2007).
Kempna P, Hofer G, Mullis PE, Fluck CE. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol. Pharmacol. 71: 787-798 (2007). *
Kendall CW, Emam A, Augustin LS, Jenkins DJ. Resistant starches and health. J. AOAC Int. 87: 769-774 (2004).
Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, Defronzo RA. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin � Diabetes Care 29: 1016-1023 (2006). *
Kendall PL, Moore DJ, Hulbert C, Hoek KL, Khan WN, Thomas JW. Reduced diabetes in BTK-deficient nonobese diabetic mice and restoration of diabetes with provision of an anti-insulin IgH chain transgene. J. Immunol. 183: 6403-6412 (2009).
Kennedy A, Van Zant RS. Diverse applications of negative pressure wound therapy: a multiple case report. Physiother. Theory Pract. 22: 83-90 (2006).
Kennedy AM, Inada M, Krane SM, Christie PT, Harding B, Lopez-Otin C, Sanchez LM, Pannett AA, Dearlove A, Hartley C, Byrne MH, Reed AA, Nesbit MA, Whyte MP, Thakker RV. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMDMO). J. Clin. Invest. 115: 2832-2842 (2005). *
Kennedy LJ, Barnes A, Short A, Brown JJ, Seddon J, Fleeman L, Brkljacic M, Happ GM, Catchpole B, Ollier WE. Canine DLA diversity: 3. Disease studies. Tissue Antigens 69 Suppl. 1: S292-S296 (2007).
Kennedy LJ, Davison LJ, Barnes A, Short AD, Fretwell N, Jones CA, Lee AC, Ollier WE, Catchpole B. Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus. Tissue Antigens 68: 467-476 (2006). *
Kennon B, Connell JM. ACE gene polymorphism and diabetic complications: is there a connection? BioDrugs 14: 73-81 (2000).
Kenny AP, Crimmins NA, Mackay DJ, Hopkin RJ, Bove KE, Leonis MA. Concurrent course of transient neonatal diabetes with cholestasis and paucity of interlobular bile ducts: a case report. Pediatr. Dev. Pathol. 12: 417-420 (2009).
Kent JW Jr. Analysis of multiple phenotypes. Genet. Epidemiol. 33 Suppl. 1: S33-S39 (2009).
Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C, Hering BJ, Hafler DA. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435: 224-228 (2005). *
Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, Mourich DV. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3 T cells in pancreatic lymph nodes. Immunotherapy 1: 539-547 (2009).
Kersten S. Peroxisome proliferator activated receptors and obesity. Eur. J. Pharmacol. 440: 223-234 (2002). *
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 405: 421-424 (2000). *
Ketikoglou I, Moulakakis A. Autoimmune pancreatitis. Dig. Liver Dis. 37: 211-215 (2005).
Khadra A, Santamaria P, Edelstein-Keshet L. The role of low avidity T cells in the protection against type 1 diabetes: a modeling investigation. J. Theor. Biol. 256: 126-141 (2009). *
Khalangot M, Kravchenko V, Tronko M, Gur'ianov V. Correlation between the prevalence of type 1 diabetes with the daily insulin dose and the autoimmune process against glutamic acid decarboxylase in adults. Eur. J. Intern. Med. 20: 611-615 (2009).
Khalil I, d'Auriol L, Gobet M, Morin L, Lepage V, Deschamps I, Park MS, Degos L, Galibert F, Hors J. A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J. Clin. Invest. 85: 1315-1319 (1990). *
Khalil I, Deschamps I, Lepage V, Morin L, Galibert F, Degos L, Hors J. HLA DQ alpha/beta molecule associated with the susceptibility to insulin-dependent diabetes mellitus. A model for HLA/autoimmune disease association. Nouv. Rev. Fr. Hematol. 32: 445-447 (1990).
Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl. 10: 349-355 (2004). *
Khalkhali-Ellis Z, Moore TL, Hendrix MJ. Could hormones make a difference in the treatment of juvenile rheumatoid arthritis? BioDrugs 13: 77-86 (2000).
Khammar A, Stremler N, Dubus JC, Gross G, Sarles J, Reynaud R. Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis. Arch. Pediatr. 16: 1540-1546 (2009).
Khan MW, Sherwani S, Khan WA, Ali R. Characterization of hydroxyl radical modified GAD65: a potential autoantigen in type 1 diabetes. Autoimmunity 42: 150-158 (2009).
Khansari N, Shakiba Y, Mahmoudi M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 3: 73-80 (2009).
Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM, Eizirik DL, Cnop M. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 49: 2350-2358 (2006). *
Khazaee MH, Tavakol Afshari J, Khazaee B, Daneshvar R, Akbarzadeh J, Khazaee L, Ganjali R, Raygan F. HLA-DQB1 subtypes predict diabetic retinopathy in patients with type I diabetes mellitus. Eur. J. Ophthalmol. 19: 638-645 (2009).
Khazai NB, Judd S, Jeng L, Wolfenden L, Stecenko A, Ziegler TR, Tangpricha V. Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol and UV light. J. Clin. Endocrinol. Metab. 94: 2037-2043 (2009). *
Khemiri M, Ben Rhouma A, Bouzid S, Messaoud T, Guesmi M, Hamzaoui M, Fattoum S, Khaldi F, Barsaoui S. Clinical characteristics and outcome of cystic fibrosis: report of 16 cases. Tunis. Med. 86: 567-572 (2008).
Khil LY, Jun HS, Kwon H, Yoo JK, Kim S, Notkins AL, Yoon JW. Human chorionic gonadotropin is an immune modulator and can prevent autoimmune diabetes in NOD mice. Diabetologia 50: 2147-2155 (2007). *
Khoo CP, Valorani MG, Brittan M, Alison MR, Warnes G, Johansson U, Hawa M, Pozzilli P. Characterization of endothelial progenitor cells in the NOD mouse as a source for cell therapies. Diabetes Metab. Res. Rev. 25: 89-93 (2009). *
Kieback E, Charo J, Sommermeyer D, Blankenstein T, Uckert W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. U.S.A. 105: 623-628 (2008). *
Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation. J. Physiol. Pharmacol. 56: 149-162 (2005). *
Kiechle FL, Holland-Staley CA. Genomics, transcriptomics, proteomics, and numbers. Arch. Pathol. Lab. Med. 127: 1089-1097 (2003). *
Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Saemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes Jan 27 [Epub ahead of print] (2010).
Kikuoka N, Sugihara S, Yanagawa T, Ikezaki A, Kim HS, Matsuoka H, Kobayashi Y, Wataki K, Konda S, Sato H, Miyamoto S, Sasaki N, Sakamaki T, Niimi H, Murata M. Cytotoxic T lymphocyte antigen 4 gene polymorphism confers susceptibility to type 1 diabetes in Japanese children: analysis of association with HLA genotypes and autoantibodies. Clin. Endocrinol. (Oxf.) 55: 597-603 (2001). *
Kilpealinen TO, Lakka TA, Laaksonen DE, Lindstorm J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M, Laakso M. SNPs in PPARg associate with type 2 diabetes and interact with physical activity. Med. Sci. Sports Exerc. 40: 25-33 (2008).
Kilpelainen T, Lakka T, Laaksonen D, Mager U, Salopuro T, Kubaszek A, Todorova B, Laukkanen O, Lindstrom J, Eriksson J, Hamalainen H, Aunola S, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Laakso M, Uusitupa M. Interaction of single nucleotide polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of the metabolic syndrome. Metabolism 57: 428-436 (2008). *
Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, Kintscher U, Bohm M. The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes Obes. Metab. 11: 1060-1067 (2009).
Kim CH, Park JH, Park TS, Baek HS. Autoimmune hypoglycemia in a type 2 diabetic patient with anti-insulin and insulin receptor antibodies. Diabetes Care 27: 288-289 (2004). *
Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, Song EK, Han MK, Park JW, Ryu DG, Park BH. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NFkappaB pathway. Int. J. Biochem. Cell Biol. 39: 1260-1275 (2007). *
Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol. Lett. 120: 1-5 (2008).
Kim EY, Shin CH, Yang SW. Polymorphisms of HLA class II predispose children and adolescents with type 1 diabetes mellitus to autoimmune thyroid disease. Autoimmunity 36: 177-181 (2003).
Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ. Res. 100: 1589-1596 (2007). *
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52: 1770-1778 (2003). *
Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, Pajvani UB, Scherer PE, Leroith D. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47: 2215-2225 (2004). *
Kim HJ, Jung CG, Jensen MA, Dukala D, Soliven B. Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy. J. Immunol. 181: 8753-8760 (2008). *
Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. Metabolism 56: 676-685 (2007). *
Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas Feb 22 [Epub ahead of print] (2010).
Kim HM, Kang JS, Kim JY, Park SK, Kim HS, Lee YJ, Yun J, Hong JT, Kim Y, Han SB. Evaluation of antidiabetic activity of polysaccharide isolated from Phellinus linteus in non-obese diabetic mouse. Int. Immunopharmacol. Oct 4 [Epub ahead of print] (2009).
Kim HM, Kang JS, Park SK, Lee K, Kim JY, Kim YJ, Hong JT, Kim Y, Han SB. Antidiabetic activity of angelan isolated from Angelica gigas Nakai. Arch. Pharm. Res. 31: 1489-1496 (2008).
Kim HR, Lee MK, Park AJ. The -308 and -238 polymorphisms of the TNF-alpha promoter gene in type 2 diabetes mellitus. Korean J. Lab. Med. 26: 58-63 (2006).
Kim HS, Han MS, Chung KW, Kim S, Kim E, Kim MJ, Jang E, Lee HA, Youn J, Akira S, Lee MS. Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27: 321-333 (2007). *
Kim HS, Lee MS. Diabetes. Curr. Mol. Med. 9: 30-44 (2009).
Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53: 2748-2756 (2004). *
Kim JH, Shin HD, Park BL, Moon MK, Cho YM, Hwang YH, Oh KW, Kim SY, Lee HK, Ahn C, Park KS. SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy. Diabetes 55: 843-848 (2006). *
Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM. FoxO1 haploinsufficiency protects against high fat diet-induced insulin resistance with enhanced PPARgamma activation in adipose tissue. Diabetes 58: 1275-1282 (2009). *
Kim JK. Fat uses a Toll-road to connect inflammation and diabetes. Cell. Metab. 4: 417-419 (2006). *
Kim JW, You YH, Ham DS, Cho JH, Ko SH, Song KH, Son HY, Suh-Kim H, Lee IK, Yoon KH. Suppression of PGC-1alpha (PPAR-gamma-coactivator-1alpha) normalizes the glucolipotoxicity induced decreased BETA2 gene transcription and improved glucose tolerance in diabetic rats. Endocrinology 150: 4074-4083 (2009). *
Kim KA, Lee MS. Recent progress in research on beta-cell apoptosis by cytokines. Front. Biosci. 14: 657-664 (2009).
Kim KP, Kim MH, Lee YJ, Song MH, Park do H, Lee SS, Seo DW, Lee SK, Min YI, Song DE, Yu ES. Clinical characteristics of 17 cases of autoimmune chronic pancreatitis. Korean J. Gastroenterol. 43: 112-119 (2004).
Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes. Mol. Pharmacol. 71: 1554-1562 (2007). *
Kim MS, Polychronakos C. Immunogenetics of type 1 diabetes. Horm. Res. 64: 180-188 (2005).
Kim S, Millet I, Kim HS, Kim JY, Han MS, Lee MK, Kim KW, Sherwin RS, Karin M, Lee MS. NF-kappaB prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad. Sci. U.S.A. 104: 1913-1918 (2007). *
Kim SU, Choi GH, Han WK, Kim BK, Park JY, Kim DY, Choi JS, Yang SC, Choi EH, Ahn SH, Han KH, Chon CY. What are 'true normal' liver stiffness values using FibroScan?: a prospective study in healthy living liver and kidney donors in South Korea. Liver Int. 30: 268-274 (2010). *
Kim SY, Jo DS, Hwang PH, Park JH, Park SK, Yi HK, Lee DY. Preproghrelin Leu72Met polymorphism is not associated with type 2 diabetes mellitus. Metabolism 55: 366-370 (2006). *
Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann. N. Y. Acad. Sci. 1043: 553-561 (2005). *
Kim Y. Electronic house calls: high-tech medicine at your doorstep. Conf. Proc. IEEE Eng. Med. Biol. Soc. 7: 5216 (2004).
Kim YS, Hwang YJ, Kim SY, Yang SM, Lee KY, Park IB. Rarity of TLR4 Asp299Gly and Thr399Ile polymorphisms in the Korean population. Yonsei. Med. J. 49: 58-62 (2008). *
Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L, Sharma K, Adler SG, Natarajan R. Novel interactions between TGF-beta1 actions and the 12/15-lipoxygenase pathway in mesangial cells. J. Am. Soc. Nephrol. 16: 352-362 (2005). *
Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, Fraeman K, Bala M. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 217: 27-37 (2008). *
Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: is the hypothesis validated by geophysical data? J. Photochem. Photobiol. B. 86: 234-239 (2007).
Kimmel AR. An orphan nuclear receptor finds a home. Mol. Cell. 37: 155-157 (2010). *
Kimura A, Rieger MA, Simone JM, Chen W, Wickre MC, Zhu BM, Hoppe PS, O'Shea JJ, Schroeder T, Hennighausen L. The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis. Blood 114: 4721-4728 (2009). *
Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20: 379-386 (2005). *
King AL, Moodie SJ, Fraser JS, Curtis D, Reid E, Dearlove AM, Ciclitira PJ. Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur. J. Immunogenet. 30: 427-432 (2003). *
King GL. The role of inflammatory cytokines in diabetes and its complications. J. Periodontol. 79: S1527-S1534 (2008).
King M, Pearson T, Rossini AA, Shultz LD, Greiner DL. Humanized mice for the study of type 1 diabetes and beta cell function. Ann. N. Y. Acad. Sci. 1150: 46-53 (2008). *
Kingsmore SF, Lindquist IE, Mudge J, Gessler DD, Beavis WD. Genome-wide association studies: progress and potential for drug discovery and development. Nat. Rev. Drug Discov. 7: 221-230 (2008). *
Kingston J, Bowen D, Sweeney M, Lawless S, Jackson H, Worwood M. Heteroduplex analysis for the three common HFE variants: methodology, reliablity and analysis of over 5000 requests for testing. J. Clin. Pathol. 60: 1244-1248 (2007).
Kinik ST, Ozcay F, Varan B. Type I diabetes mellitus, Hashimoto's thyroiditis and celiac disease in an adolescent with Down syndrome. Pediatr. Int. 48: 433-435 (2006). *
Kinkel MD, Prince VE. On the diabetic menu: zebrafish as a model for pancreas development and function. Bioessays 31: 139-152 (2009). *
Kinnaird KE, Sauerwein TJ. 1,5-Anhydroglucitol assay does not correlate with oral glucose tolerance test in cystic fibrosis patients. Endocr. Pract. Oct 15 [Epub ahead of print] (2009).
Kinoshita J, Hata S, Yamazaki H, Tajima N. Slowly progressive insulin-dependent diabetes mellitus associated with pernicious anemia. Intern. Med. 49: 155-159 (2010). *
Kinoshita Y, Kizaki Z, Ishihara Y, Nakajima H, Adachi S, Kosaka K, Kinugasa A, Sugimoto T. The relationship in Japanese infants between a genetic polymorphism in the promoter region of the insulin-like growth factor I gene and the plasma level. Neonatology 92: 116-119 (2007).
Kinross JM, von Roon AC, Holmes E, Darzi A, Nicholson JK. The human gut microbiome: implications for future health care. Curr. Gastroenterol. Rep. 10: 396-403 (2008).
Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6: 12 (2007). *
Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur. J. Pharmacol. 401: 259-270 (2000). *
Kirk JK, Namak S. Diabetes: rethinking risk and the Dx that fits. J. Fam. Pract. 58: 248-256 (2009).
Kirkpatrick RB, Kraft BG. Effect of streptozotocin-induced diabetes on bile acid sulfation in male rat liver. Am. J. Physiol. 247: G226-G230 (1984). *
Kis J, Engelmann P, Farkas K, Richman G, Eck S, Lolley J, Jalahej H, Borowiec M, Kent SC, Treszl A, Orban T. Reduced CD4+ subset and Th1 bias of the human iNKT cells in type 1 diabetes mellitus. J. Leukoc. Biol. 81: 654-662 (2007). *
Kishi A, Kawabata Y, Ugi S, Iwai T, Tanaka Y, Yoshizaki T, Uzu T, Nishio Y, Ikegami H, Kashiwagi A, Maegawa H. The onset of diabetes in three out of four sisters: a Japanese family with type 1 diabetes. A case report. Endocr. J. 56: 767-772 (2009). *
Kishi M, Yasuda H, Abe Y, Sasaki H, Shimizu M, Arai T, Okumachi Y, Moriyama H, Hara K, Yokono K, Nagata M. Regulatory CD8(+) T cells induced by exposure to all-trans retinoic acid and TGF-beta suppress autoimmune diabetes. Biochem. Biophys. Res. Commun. Mar 2 [Epub ahead of print] (2010). *
Kissler S, Anderton SM, Wraith DC. Antigen-presenting cell activation: a link between infection and autoimmunity? J. Autoimmun. 16: 303-308 (2001).
Kissler S, Stern P, Takahashi K, Hunter K, Peterson LB, Wicker LS. In vivo RNA interference demonstrates a role for Nramp1 in modifying susceptibility to type 1 diabetes. Nat. Genet. 38: 479-483 (2006). *
Kissler S, Van Parijs L. Exploring the genetic basis of disease using RNA interference. Expert Rev. Mol. Diagn. 4: 645-651 (2004).
Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am. J. Gastroenterol. 97: 1849-1851 (2002). *
Kitamura T, Ido Kitamura Y. Role of FoxO proteins in pancreatic beta cells. Endocr. J. 54: 507-515 (2007). *
Kitanaka S, Sato U, Igarashi T. Regulation of human insulin, IGF-I, and multidrug resistance protein 2 promoter activity by hepatocyte nuclear factor (HNF)-1beta and HNF-1alpha and the abnormality of HNF-1beta mutants. J. Endocrinol. 192: 141-147 (2007). *
Kitz Kramer D, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem. 282: 19313-19320 (2007). *
Kivling A, Nilsson L, Falth-Magnusson K, Sollvander S, Johanson C, Faresjo M. Diverse Foxp3 expression in children with type 1 diabetes and celiac disease. Ann. N. Y. Acad. Sci. 1150: 273-277 (2008). *
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003). *
Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 127 (5 Suppl. 2): S17-S26 (2004). *
Kizilisik AT, Grewal HP, Shokouh-Amiri MH, Vera SR, Hathaway DK, Gaber AO. Impact of long-term immunosuppressive therapy on psychosocial and physical well being in liver transplant recipients. Prog. Transplant. 13: 278-283 (2003).
Kjellev S, Haase C, Lundsgaard D, Urso B, Tornehave D, Markholst H. Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur. J. Immunol. 37: 1397-1406 (2007). *
Klapper M, Bohme M, Nitz I, Doring F. The human intestinal fatty acid binding protein (hFABP2) gene is regulated by HNF-4alpha. Biochem. Biophys. Res. Commun. 356: 147-152 (2007). *
Kleeff J, Welsch T, Esposito I, Lohr M, Singer R, Buchler MW, Friess H. Autoimmune pancreatitis - a surgical disease? Chirurg. 77: 154-165 (2006).
Kleemann R, Bucala R. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm. 2010: 610479 (2010). *
Klein D, Timoneri F, Ichii H, Ricordi C, Pastori RL. CD40 activation in human pancreatic islets and ductal cells. Diabetologia 51: 1853-1861 (2008). *
Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, Black S, Galindo C, Schmidt J, Baxter R. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 28: 1062-1068 (2010). *
Klemetti P, Savilahti E, Ilonen J, Akerblom HK, Vaarala O. T-cell reactivity to wheat gluten in patients with insulin-dependent diabetes mellitus. Scand. J. Immunol. 47: 48-53 (1998). *
Klemola P, Kaijalainen S, Ylipaasto P, Roivainen M. Diabetogenic effects of the most prevalent enteroviruses in Finnish sewage. Ann. N. Y. Acad. Sci. 1150: 210-212 (2008). *
Klett EL, Lu K, Kosters A, Vink E, Lee MH, Altenburg M, Shefer S, Batta AK, Yu H, Chen J, Klein R, Looije N, Oude Elferink RP, Groen AK, Maeda N, Salen G, Patel SB. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med. 2: 5 (2004). *
Klett EL, Patel SB. Biomedicine. Will the real cholesterol transporter please stand up. Science 303: 1149-1150 (2004). *
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 56: 239-263 (2001). *
Klinker MW, Schiller JJ, Magnuson VL, Wang T, Basken J, Veth K, Pearce KI, Kinnunen L, Harjutsalo V, Wang X, Tuomilehto J, Sarti C, Ghosh S. Single-nucleotide polymorphisms in the IL2RA gene are associated with age at diagnosis in late-onset Finnish type 1 diabetes subjects. Immunogenetics Dec 23 [Epub ahead of print] (2009). *
Klitz W, Bugawan TL, Panelo A, Solfelix CM, Buzzetti R, Pozzilli P, Steiner L, Alejandrino M, Erlich HA. Association of CTLA-4 variation with type I diabetes in Filipinos. Immunogenetics 54: 310-313 (2002). *
Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR agonist treatment in melanoma cells: functional importance of S100A2. PPAR Res. 2010: 729876 (2010). *
Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, Muller-Wieland D. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants. Exp. Clin. Endocrinol. Diabetes 116: 481-486 (2008).
Kniepeiss D, Iberer F, Schaffellner S, Jakoby E, Duller D, Tscheliessnigg Kh. Dyslipidemia during sirolimus therapy in patients after liver transplantation. Clin. Transplant. 18: 642-646 (2004). *
Knight JC. Regulatory polymorphisms underlying complex disease traits. J. Mol. Med. 83: 97-109 (2005). *
Knip M. Disease-associated autoimmunity and prevention of insulin-dependent diabetes mellitus. Ann. Med. 29: 447-451 (1997).
Knip M, Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun. Rev. 7: 550-557 (2008).
Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 96: 987-993 (1995). *
Knouff C, Auwerx J. PPARgamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr. Rev. 25: 899-918 (2004). *
Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728 (2005). *
Ko GT, Szeto CC, Yeung VT, Chow CC, Chan H, Cockram CS. Autoimmune polyglandular syndrome and primary biliary cirrhosis. Br. J. Clin. Pract. 50: 344-346 (1996).
Koarada S, Wu Y, Fertig N, Sass DA, Nalesnik M, Todd JA, Lyons PA, Fenyk-Melody J, Rainbow DB, Wicker LS, Peterson LB, Ridgway WM. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J. Immunol. 173: 2315-2323 (2004). *
Kobashi G, Ohta K, Washio M, Okamoto K, Sasaki S, Yokoyama T, Miyake Y, Sakamoto N, Hata A, Tamashiro H, Inaba Y, Tanaka H, et al. FokI variant of vitamin D receptor gene and factors related to atherosclerosis associated with ossification of the posterior longitudinal ligament of the spine: a multi-hospital case-control study. Spine 33: E553-E558 (2008).
Kobayashi M, Jasinski J, Liu E, Li M, Miao D, Zhang L, Yu L, Nakayama M, Eisenbarth GS. Conserved T cell receptor alpha-chain induces insulin autoantibodies. Proc. Natl. Acad. Sci. U.S.A. 105: 10090-10094 (2008). *
Kobayashi N. Bioartificial pancreas for the treatment of diabetes. Cell Transplant. 17: 11-17 (2008).
Kobayashi N, Kiptoo P, Kobayashi H, Ridwan R, Brocke S, Siahaan TJ. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin. Immunol. 129: 69-79 (2008). *
Kobayashi T, Tanaka S, Harii N, Aida K, Shimura H, Ohmori M, Kanesige M, Shimada A, Maruyama T. Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults. Ann. N. Y. Acad. Sci. 1079: 60-66 (2006). *
Kobayashi T, Tanaka S, Shimada A, Maruyama T. High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes: response to Buzzetti et al. Diabetes Care 30: e126 (2007). *
Kocaman O, Aygun C, Gurbuz Y, Cefle A, Konduk T, Senturk O, Celebi A, Hulagu S. Burst of autoimmunity with the emergence of primary Sjogren syndrome, cholestatic autoimmune hepatitis and latent autoimmune diabetes of adults (LADA). South. Med. J. 99: 1014-1015 (2006).
Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S; Investigators of the ERCF. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr. Pulmonol. 31: 1-12 (2001). *
Kockum I, Sanjeevi CB, Eastman S, Landin-Olsson M, Dahlquist G, Lernmark A. Complex interaction between HLA DR and DQ in conferring risk for childhood type 1 diabetes. Eur. J. Immunogenet. 26: 361-372 (1999). *
Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell. Mol. Life Sci. 62: 1850-1862 (2005). *
Koeck T, Willard B, Crabb JW, Kinter M, Stuehr DJ, Aulak KS. Glucose-mediated tyrosine nitration in adipocytes: targets and consequences. Free Radic. Biol. Med. 46: 884-892 (2009).
Koehn J, Fountoulakis M, Krapfenbauer K. Multiple drug resistance associated with function of ABC-transporters in diabetes mellitus: molecular mechanism and clinical relevance. Infect. Disord. Drug Targets 8: 109-118 (2008).
Koeleman BP, Herr MH, Zavattari P, Dudbridge F, March R, Campbell D, Barnett AH, Bain SC, Mulargia AP, Loddo M, Amos W, Cucca F, Todd JA. Conditional ETDT analysis of the human leukocyte antigen region in type 1 diabetes. Ann. Hum. Genet. 64: 215-221 (2000).
Koeleman BP, Lie BA, Undlien DE, Dudbridge F, Thorsby E, de Vries RR, Cucca F, Roep BO, Giphart MJ, Todd JA. Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun. 5: 381-388 (2004). *
Koenig RJ. Detection of the PAX8-PPARgamma fusion protein in thyroid tumors. Clin. Chem. Jan 14 [Epub ahead of print] (2010). *
Kofteridis D, Krasoudaki E, Kavousanaki M, Zervou MI, Panierakis C, Boumpas DT, Goulielmos GN. STAT4 is not associated with type 2 diabetes in the genetically homogeneous population of Crete. Genet. Test. Mol. Biomarkers 13: 281-284 (2009).
Kogawa K, Kudoh J, Nagafuchi S, Ohga S, Katsuta H, Ishibashi H, Harada M, Hara T, Shimizu N. Distinct clinical phenotype and immunoreactivity in Japanese siblings with autoimmune polyglandular syndrome type 1 (APS-1) associated with compound heterozygous novel AIRE gene mutations. Clin. Immunol. 103: 277-283 (2002).
Koh AS, Kuo AJ, Park SY, Cheung P, Abramson J, Bua D, Carney D, Shoelson SE, Gozani O, Kingston RE, Benoist C, Mathis D. Aire employs a histone-binding module to mediate immunological tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc. Natl. Acad. Sci. U.S.A. 105: 15878-15883 (2008). *
Koh C, Kleiner DE, Heller T. Don't forget to polarize your lenses! Talc in the liver. Gastroenterology 137: e3-e4 (2009).
Koh C, Liang TJ. Settling the "score" with liver cancer. J. Hepatol. 50: 7-9 (2009). *
Koh SJ, Jang Y, Hyun YJ, Park JY, Song YD, Shin KK, Chae JS, Kim BK, Ordovas JM, Lee JH. The interleukin-6 -572C-->G promoter polymorphism is associated with type 2 diabetes risk in Koreans. Clin. Endocrinol. (Oxf.) 70: 238-244 (2009). *
Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor. Drug Metab. Dispos. 35: 1495-1501 (2007). *
Kohler S, Wass JA. Hypoparathyroidism and coeliac disease: a potentially dangerous combination. J. R. Soc. Med. 102: 311-314 (2009).
Kohlstedt K, Gershome C, Trouvain C, Hofmann WK, Fichtlscherer S, Fleming I. Angiotensin converting enzyme (ACE) inhibitors modulate CRBP1 and adiponectin expression in adipocytes via the ACE-dependent signaling cascade. Mol. Pharmacol. 75: 685-692 (2009). *
Kohn LD, Napolitano G, Singer DS, Molteni M, Scorza R, Shimojo N, Kohno Y, Mozes E, Nakazato M, Ulianich L, Chung HK, Matoba H, Saunier B, Suzuki K, Schuppert F, Saji M. Graves' disease: a host defense mechanism gone awry. Int. Rev. Immunol. 19: 633-664 (2000).
Kohonen-Corish MR, Serjeantson SW, Lee HK, Zimmet P. Insulin-dependent diabetes mellitus: HLA-DR and -DQ genotyping in three ethnic groups. Dis. Markers 5: 153-164 (1987).
Kohsaka S, Volcik KA, Folsom AR, Wu KK, Ballantyne CM, Willerson JT, Boerwinkle E. Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis 196: 926-930 (2008).
Koike K. Hepatitis C as a metabolic disease: implication for the pathogenesis of NASH. Hepatol. Res. 33: 145-150 (2005).
Kojima K, Yamamuro W, Mori T, Hata S, Machida Y, Higa M. A case of gas-forming pyogenic liver abscess. Nippon Shokakibyo Gakkai Zasshi 104: 1063-1068 (2007).
Koletzko B, Larque E, Demmelmair H. Placental transfer of long-chain polyunsaturated fatty acids (LC-PUFA). J. Perinat. Med. 35 Suppl. 1: S5-S11 (2007).
Kolla VK, Madhavi G, Pulla Reddy B, Srikanth Babu BM, Yashovanthi J, Valluri VL, Ramesh J, Akka J. Association of tumor necrosis factor alpha, interferon gamma and interleukin 10 gene polymorphisms with peripheral neuropathy in South Indian patients with type 2 diabetes. Cytokine 47: 173-177 (2009).
Komada H, Yamamoto M, Okubo S, Nagai K, Iida K, Nakamura T, Hirota Y, Sakaguchi K, Kasuga M, Takahashi Y. A case of hypothalamic panhypopituitarism with empty sella syndrome: case report and review of the literature. Endocr. J. 56: 585-589 (2009). *
Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, Nishiyama S, Matsuda I. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum. Genet. 103: 435-440 (1998). *
Komatsu A, Node K. Effects of PPARgamma agonist on dyslipidemia and atherosclerosis. Nippon Rinsho 68: 294-298 (2010).
Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, Yamashita T, Ohta T, Shimizu K, Nakamoto Y, Honda M, Takamura T, Kaneko S. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am. J. Gastroenterol. 102: 1939-1946 (2007). *
Komura T, Sakai Y, Honda M, Takamura T, Matsushima K, Kaneko S. CD14+ monocytes are vulnerable and functionally impaired under ER stress in patients with type 2 diabetes. Diabetes Dec 3 [Epub ahead of print] (2009).
Kondo S, Akashi T, Katsuta H, Iwakiri R, Anzai K, Nagafuchi S, Niho Y, Harada M. B cells as key contributors in determining the level of immune responses - B-cell-targeted therapy in patients with autoimmune diseases. Fukuoka Igaku Zasshi 96: 86-92 (2005).
Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S, Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML, Gylfason A, Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson B, Benediktsdottir KR, et al. Parental origin of sequence variants associated with complex diseases. Nature 462: 868-874 (2009). *
Kong MF, Lawden M, Howlett T. The Addison's disease dilemma - autoimmune or ALD? Lancet 371: 1970 (2008). *
Konno S, Ichijo T, Murata M, Toda T, Nakazora H, Nomoto N, Sugimoto H, Nemoto H, Kurihara T, Wakata N, Fujioka T. Autoimmune polyglandular syndrome type 2 with myasthenia gravis crisis. Neurologist 15: 361-363 (2009).
Kono S, Suzuki H, Takahashi K, Takahashi Y, Shirakawa K, Murakawa Y, Yamaguchi S, Miyajima H. Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia. Gastroenterology 131: 240-245 (2006). *
Koo SH, Montminy M. Fatty acids and insulin resistance: a perfect storm. Mol. Cell 21: 449-450 (2006). *
Koop I, Ilchmann R, Izzi L, Adragna A, Koop H, Barthelmes H. Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis. Am. J. Gastroenterol. 95: 2009-2014 (2000). *
Kopecky J, Rossmeisl M, Flachs P, Kuda O, Brauner P, Jilkova Z, Stankova B, Tvrzicka E, Bryhn M. n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc. Nutr. Soc. 68: 361-369 (2009). *
Kopp A, Gross P, Falk W, Bala M, Weigert J, Buechler C, Neumeier M, Scholmerich J, Schaffler A. Fatty acids as metabolic mediators in innate immunity. Eur. J. Clin. Invest. 39: 924-933 (2009).
Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E. Nuclear receptor-coregulator profiling identifies TRIP3 as a novel PPARgamma cofactor. Mol. Cell. Proteomics 8: 2212-2226 (2009). *
Korach-Andre M, Parini P, Larsson L, Arner A, Steffensen KR, Gustafsson JA. Separate and overlapping metabolic functions of LXRalpha and LXRbeta in C57Bl/6 female mice. Am. J. Physiol. Endocrinol. Metab. Aug 18 [Epub ahead of print] (2009). *
Kordonouri O, Danne T. Diabetes-associated autoimmune disease in children and juveniles: how important is early recognition? Dtsch. Med. Wochenschr. 129: 1145-1148 (2004).
Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch. Dis. Child. 90: 411-414 (2005). *
Kordonouri O, von Schutz W, Meyer N, Aschemeier B, Kracht T, Danne T. Type 1 diabetes in children and adolescents - new strategies in management and treatment. Med. Monatsschr. Pharm. 31: 200-206 (2008).
Korner A, Kiess W, Stumvoll M, Kovacs P. Polygenic contribution to obesity: genome-wide strategies reveal new targets. Front. Horm. Res. 36: 12-36 (2008).
Korner A, Toth-Heyn P, Dezsofi A, Veres G, Madacsy L, Arato A. Occurence of thyroid autoimmunity in children with type 1 diabetes mellitus. Orv. Hetil. 149: 401-406 (2008).
Korniszewski L, Kurzyna M, Stolarski B, Torbicki A, Smerdel A, Ploski R. Fatal primary pulmonary hypertension in a 30-yr-old female with APECED syndrome. Eur. Respir. J. 22: 709-711 (2003). *
Kortylewski MT, Barthel A. STAT-3 and the liver: a new STATion on our way to understand diabetes? Hepatology 40: 1008-1010 (2004). *
Koskinen L, Romanos J, Kaukinen K, Mustalahti K, Korponay-Szabo I, Barisani D, Bardella MT, Ziberna F, Vatta S, Szeles G, Pocsai Z, Karell K, Haimila K, Ad�ny R, Not T, Ventura A, M�ki M, Partanen J, Wijmenga C, Saavalainen P. Cost-effective HLA typing with tagging SNPs predicts celiac disease risk haplotypes in the Finnish, Hungarian, and Italian populations. Immunogenetics 61: 247-256 (2009). *
Kosmopoulou A, Vlassi M, Stavrakoudis A, Sakarellos C, Sakarellos-Daitsiotis M. T-cell epitopes of the La/SSB autoantigen: prediction based on the homology modeling of HLA-DQ2/DQ7 with the insulin-B peptide/HLA-DQ8 complex. J. Comput. Chem. 27: 1033-1044 (2006). *
Kosoy R, Concannon P. Functional variants in SUMO4, TAB2, and NFkappaB and the risk of type 1 diabetes. Genes Immun. 6: 231-235 (2005). *
Kosoy R, Yokoi N, Seino S, Concannon P. Polymorphic variation in the CBLB gene in human type 1 diabetes. Genes Immun. 5: 232-235 (2004). *
Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am. J. Cardiovasc. Drugs 10: 11-28 (2010).
Koster B, Fenger M, Poulsen P, Vaag A, Bentzen J. Novel polymorphisms in the GCKR gene and their influence on glucose and insulin levels in a Danish twin population. Diabet. Med. 22: 1677-1682 (2005). *
Koster JC, Cadario F, Peruzzi C, Colombo C, Nichols CG, Barbetti F. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J. Clin. Endocrinol. Metab. 93: 1054-1061 (2008). *
Koster JC, Permutt MA, Nichols CG. Diabetes and insulin secretion: the ATP-sensitive K+ channel (KATP) connection. Diabetes 54: 3065-3072 (2005). *
Kosters A, Frijters RJ, Kunne C, Vink E, Schneiders MS, Schaap FG, Nibbering CP, Patel SB, Groen AK. Diosgenin-induced biliary cholesterol secretion in mice requires Abcg8. Hepatology 41: 141-150 (2005). *
Kostinov MP, Skochilova TV, Vorob'eva VA, Tarasova AA, Korovkina TI, Lukachev IV, Iushkova IIu, Vaneeva NP. Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type I diabetes mellitus. Zh. Mikrobiol. Epidemiol. Immunobiol. 2: 53-57 (2009).
Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE. FASEB J. Feb 2 [Epub ahead of print] (2010). *
Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol. Res. 51: 85-94 (2005). *
Kotani K, Fujiwara S, Tsuzaki K, Sano Y, Matsuoka Y, Hamada T, Sakane N. An association between angiotensin II type 2 receptor gene A/C3123 polymorphism and glycemic control marker in a general Japanese population. Mol. Biol. Rep. 36: 917-920 (2009). *
Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, Lundbom N, Rissanen A, Ridderstrale M, Groop L, Orho-Melander M, Yki-Jarvinen H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137: 865-872 (2009). *
Kotronen A, Seppala-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, Yki-Jarvinen H. Liver fat and lipid oxidation in humans. Liver Int. 29: 1439-1446 (2009). *
Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen K, Westerbacka J, Talmud P, Humphries S, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehrenborg E, Fisher R. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 160: 593-602 (2009).
Kotze LM, Nisihara RM, Utiyama SR, Custodio Piovezan GC, Kotze LR. Thyroid disorders in Brazilian patients with celiac disease. J. Clin. Gastroenterol. 40: 33-36 (2006).
Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis. Arthritis Res. Ther. 10: R6 (2008). *
Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation 32: 169-175 (2009). *
Koukourakis MI, Maltezos E. Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. Anticancer Drugs 17: 133-138 (2006).
Koul PB, Sussmane JB. Metabolic hyperglycemic emergencies with acute pancreatitis in a child with known insulin-dependent diabetes mellitus. Eur. J. Emerg. Med. 12: 309-311 (2005).
Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, Shi H, Bonner-Weir S, Putheti P, Degauque N, Libermann TA, Auchincloss H Jr, Flier JS, Strom TB. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U.S.A. 105: 16242-16247 (2008). *
Kouyama K, Miyake K, Zenibayashi M, Hirota Y, Teranishi T, Tamori Y, Kanda H, Sakaguchi K, Ohara T, Kasuga M. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J. Med. Sci. 53: E345-E354 (2008).
Kovacs T. Therapy of Alzheimer disease. Neuropsychopharmacol. Hung. 11: 27-33 (2009).
Koyama C, Wakusawa S, Hayashi H, Suzuki R, Yano M, Yoshioka K, Kozuru M, Takayamam Y, Okada T, Mabuchi H. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica 90: 302-307 (2005). *
Kozieradzka A, Kaminski K, Pepinski W, Janica J, Korecki J, Szepietowska B, Musial WJ. The association between type 2 diabetes mellitus and A1/A2 polymorphism of glycoprotein IIIa gene. Acta Diabetol. 44: 30-33 (2007). *
Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, Fischer CP, Lindegaard B, Petersen AM, Taudorf S, Secher NH, Pilegaard H, Bruunsgaard H, Pedersen BK. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50: 431-438 (2007). *
Krach K, Badenhoop K, Tonjes RR. The IDDM-associated solitary retroviral promoters DQ-LTR3 and DQ-LTR13 have a distinct impact on the expression of selected DQB1 genes in different cell lines in vitro. Immunogenetics 55: 521-529 (2003). *
Kraemer A, Lewin M, Balladur P, Mourra N, Tiret E, Paye F. Autoimmune pancreatitis mimicking an intra-ductal papillary mucinous neoplasm of the pancreas: an original case. Gastroenterol. Clin. Biol. 32: 635-639 (2008).
Krag MB, Rasmussen LM, Hansen TK, Frystyk J, Flyvbjerg A, Moller N, Jorgensen JO. Peroxisome proliferator-activated receptor gamma agonism reduces the insulin-stimulated increase in circulating interleukin-6 in growth hormone (GH) replaced GH-deficient adults. Clin. Endocrinol. (Oxf.) 71: 363-368 (2009). *
Kraichely RE, Farrugia G, Pittock SJ, Castell DO, Lennon VA. Neural autoantibody profile of primary achalasia. Dig. Dis. Sci. 55: 307-311 (2010). *
Krajewska M, Weyde W, Klinger M. The significance of regulatory CD4+CD25+ T cells in the pathogenesis and treatment of kidney disease. Postepy. Hig. Med. Dosw. (Online) 61: 178-184 (2007).
Kralovicova J, Gaunt TR, Rodriguez S, Wood PJ, Day IN, Vorechovsky I. Variants in the human insulin gene that affect pre-mRNA splicing: is -23HphI a functional single nucleotide polymorphism at IDDM2? Diabetes 55: 260-264 (2006). *
Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J. Periodontol. 78: 1083-1093 (2007).
Kramer M, Schulte BM, Toonen LW, de Bruijni MA, Galama JM, Adema GJ, van Kuppeveld FJ. Echovirus infection causes rapid loss-of-function and cell death in human dendritic cells. Cell. Microbiol. 9: 1507-1518 (2007). *
Krassas GE, Tziomalos K, Pontikides N, Lewy H, Laron Z. Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population. Eur. J. Endocrinol. 156: 631-636 (2007). *
Kratzner R, Frohlich F, Lepler K, Schroder M, Roher K, Dickel C, Tzvetkov MV, Quentin T, Oetjen E, Knepel W. A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription. Mol. Pharmacol. 73: 509-517 (2008). *
Kraus TA, Mayer L. Oral tolerance and inflammatory bowel disease. Curr. Opin. Gastroenterol. 21: 692-696 (2005).
Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, Abad V, Arango A, Garc�a J, Shoenfeld Y. Anti-infectious antibodies and autoimmune-associated autoantibodies in patients with type I diabetes mellitus and their close family members. Ann. N. Y. Acad. Sci. 1173: 633-639 (2009). *
Krayenbuehl PA, Wiesli P, Schmid M, Schmid C, Ehses JA, Hersberger M, Vetter W, Schulthess G. TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Exp. Clin. Endocrinol. Diabetes 115: 322-326 (2007).
Kremke B, Bergwitz C, Ahrens W, Schutt S, Schumacher M, Wagner V, Holterhus PM, Juppner H, Hiort O. Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp. Clin. Endocrinol. Diabetes 117: 49-56 (2009).
Krentz AJ, Friedmann PS. Type 2 diabetes, psoriasis and thiazolidinediones. Int. J. Clin. Pract. 60: 362-363 (2006).
Kriegel MA, Li MO, Sanjabi S, Wan YY, Flavell RA. Transforming growth factor-beta: recent advances on its role in immune tolerance. Curr. Rheumatol. Rep. 8: 138-144 (2006).
Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, Colman PG, Harrison LC, Lew AM, Thomas HE, Kay TW. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J. Clin. Invest. 116: 3258-3265 (2006). *
Kristiansen OP, Karlsen AE, Larsen ZM, Johannesen J, Pociot F, Mandrup-Poulsen T; Danish IDDM Epidemiology and Genetics Group and Danish Study Group of IDDM in Childhood. Identification of a type 1 diabetes-associated CD4 promoter haplotype with high constitutive activity. Scand. J. Immunol. 59: 582-591 (2004). *
Kristiansen OP, Larsen ZM, Pociot F. CTLA-4 in autoimmune diseases - a general susceptibility gene to autoimmunity? Genes Immun. 1: 170-184 (2000). *
Kristiansen OP, Nolsoe RL, Holst H, Reker S, Larsen ZM, Johannesen J, Nerup J, Pociot F, Mandrup-Poulsen T; Danish Study Group of IDDM in Childhood. The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics 52: 107-111 (2000). *
Krohn N, Kapoor S, Enami Y, Follenzi A, Bandi S, Joseph B, Gupta S. Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells. Gastroenterology 136: 1806-1817 (2009).
Krokowski M, Bodalski J, Bratek A, Boitard C, Caillat-Zucman S. HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish population. Hum. Immunol. 59: 451-455 (1998).
Krupanidhi S, Sedimbi SK, Vaishnav G, Madhukar SS, Sanjeevi CB. Diabetes - role of epigenetics, genetics, and physiological factors. Zhong Nan Da Xue Xue Bao Yi Xue Ban 34: 837-845 (2009).
Krysiak R, Okopien B, Boldys A. Autoimmune polyglandular syndromes. Przegl. Lek. 65: 393-400 (2008).
Ksiazek P, Buraczynska K, Buraczynska M. Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press. Res. 29: 338-343 (2006).
Kubicky RA, Faerber EN, de Chadarevian JP, Wu S, Rezvani I, De Luca F. An adolescent with a mediastinal mass, diagnosed with Graves disease and thymic hyperplasia. Pediatrics Jan 25 [Epub ahead of print] (2010). *
Kubodera N. D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol. Mini Rev. Med. Chem. 9: 1416-1422 (2009).
Kubota K, Iida H, Fujisawa T, Yoneda M, Inamori M, Abe Y, Kirikoshi H, Saito S, Ohshiro H, Kakuta Y, Nakajima A. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest. Endosc. 66: 1142-1151 (2007).
Kubota K, Wada T, Kato S, Mozaki Y, Yoneda M, Fujita K, Takahashi H, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Saito S, Inayama Y, Nakajima A. Highly active state of autoimmune pancreatitis with Mikulicz disease. Pancreas 39: e6-e10 (2010).
Kubryn I, Mlynarski W, Trippenbach-Dulska H, Szalecki M, Lisowicz L, Surdej B, Pilecki O, Heinrich A, Wyka K, Perenc M, Bodalski J. Alleles of HLA-DQB1 and familial aggregation of type 1 diabetes. Med. Wieku. Rozwoj. 7: 157-164 (2003).
Kudo T, Horikawa K, Shibata S. Circadian rhythms in the CNS and peripheral clock disorders: the circadian clock and hyperlipidemia. J. Pharmacol. Sci. 103: 139-143 (2007). *
Kudo T, Shimada T, Toda T, Igeta S, Suzuki W, Ikarashi N, Ochiai W, Ito K, Aburada M, Sugiyama K. Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica Sep 23 [Epub ahead of print] (2009).
Kudo T, Shimada T, Toda T, Igeta S, Suzuki W, Ikarashi N, Ochiai W, Ito K, Aburada M, Sugiyama K. Altered expression of CYP in TSOD mice: a model of type 2 diabetes and obesity. Xenobiotica 39: 889-902 (2009).
Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol. Biochem. Behav. 92: 251-259 (2009).
Kuhad A, Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFkB signaling pathway. Life Sci. 84: 296-301 (2009). *
Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur. J. Pharmacol. 576: 34-42 (2007).
Kuhn A, Beissert S, Krammer PH. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch. Dermatol. Res. 301: 71-81 (2009). *
Kuhn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res. 45: 334-356 (2006). *
Kukreja A, Maclaren NK. Current cases in which epitope mimicry is considered as a component cause of autoimmune disease: immune-mediated (type 1) diabetes. Cell. Mol. Life Sci. 57: 534-541 (2000). *
Kulah E, Dursun A, Acikgoz S, Can M, Kargi S, Ilikhan S, Bozdogan S. The relationship of target organ damage and 24-hour ambulatory blood pressure monitoring with vitamin D receptor gene Fok-I polymorphism in essential hypertension. Kidney Blood Press. Res. 29: 344-350 (2006).
Kulkarni RN, Kahn CR. Molecular biology. HNFs - linking the liver and pancreatic islets in diabetes. Science 303: 1311-1312 (2004). *
Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol. Res. 38: 745-761 (2008). *
Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J. Mol. Med. 82: 434-448 (2004). *
Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin. Proc. 75: 733-739 (2000). *
Kumar N, Kaur G, Tandon N, Mehra NK. Allotyping human complement factor B in Asian Indian type 1 diabetic patients. Tissue Antigens 72: 517-524 (2008). *
Kumar PG, Laloraya M, She JX. Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol. Metab. Clin. North Am. 31: 321-338, vi (2002).
Kumar PG, Laloraya M, Wang CY, Ruan QG, Davoodi-Semiromi A, Kao KJ, She JX. The autoimmune regulator (AIRE) is a DNA-binding protein. J. Biol. Chem. 276: 41357-41364 (2001). *
Kumar R, Goswami R, Agarwal S, Israni N, Singh SK, Rani R. Association and interaction of the TNF-alpha gene with other pro- and anti-inflammatory cytokine genes and HLA genes in patients with type 1 diabetes from North India. Tissue Antigens 69: 557-567 (2007). *
Kumaran V, Joseph B, Benten D, Gupta S. Integrin and extracellular matrix interactions regulate engraftment of transplanted hepatocytes in the rat liver. Gastroenterology 129: 1643-1653 (2005). *
Kumari R, Willing LB, Patel SD, Krady JK, Zavadoski WJ, Gibbs EM, Vannucci SJ, Simpson IA. The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J. Cereb. Blood Flow Metab. Oct 28 [Epub ahead of print] (2009).
Kunika K, Tanahashi T, Kudo E, Mizusawa N, Ichiishi E, Nakamura N, Yoshikawa T, Yamaoka T, Yasumo H, Tsugawa K, Moritani M, Inoue H, Itakura M. Effect of +36T > C in intron 1 on the glutamine: fructose-6-phosphate amidotransferase 1 gene and its contribution to type 2 diabetes in different populations. J. Hum. Genet. 51: 1100-1109 (2006). *
Kunz M, Ibrahim SM. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009: 979258 (2009). *
Kupfer TM, Crawford ML, Pham K, Gill RG. MHC-mismatched islet allografts are vulnerable to autoimmune recognition in vivo. J. Immunol. 175: 2309-2316 (2005). *
Kurien BT, Hensley K, Bachmann M, Scofield RH. Oxidatively modified autoantigens in autoimmune diseases. Free Radic. Biol. Med. 41: 549-356 (2006).
Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun. Rev. 7: 567-573 (2008).
Kurohara M, Yasuda H, Moriyama H, Nakayama M, Sakata M, Yamada K, Kotani R, Hara K, Yokono K, Nagata M. Low-dose warfarin functions as an immunomodulator to prevent cyclophosphamide-induced NOD diabetes. Kobe J. Med. Sci. 54: E1-E13 (2008).
Kurreeman FS, Alizadeh BZ, Goulielmos GN, Rueda B, Houwing-Duistermaat J, Sanchez E, Bevova M, Radstake TR, Vonk MC, Galanakis E, Ortego N, Verduyn W, Zervou MI, Roep BO, Dema B, Espino L, Urcelay E, Boumpas DT, van den Berg LH, Wijmenga C, et al. The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Ann. Rheum. Dis. May 10 [Epub ahead of print] (2009).
Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens. Res. 32: 826-834 (2009).
Kurylowicz A, Nauman J. The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta Biochim. Pol. 55: 629-647 (2008).
Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. Exp. Clin. Endocrinol. Diabetes 114: 329-335 (2006).
Kurzawski M, Dziewanowski K, Kedzierska K, Gornik W, Banas A, Drozdzik M. Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J. Sep 15 [Epub ahead of print] (2009).
Kusaka I, Nagasaka S, Fujibayashi K, Hayashi H, Kawakami A, Nakamura T, Rokkaku K, Saito T, Higashiyama M, Honda K, Ishikawa S, Saito T. Immunologically-related or incidental coexistence of diabetes mellitus and Graves' disease; discrimination by anti-GAD antibody measurement. Endocr. J. 46: 747-754 (1999).
Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, Kumar S, McTernan PG. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J. Clin. Endocrinol. Metab. 92: 270-276 (2007). *
Kusminski CM, Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status. Clin. Pharmacol. Ther. 86: 592-595 (2009). *
Kuwahara M, Marumo F. Diseases caused by disorders of membrane transport: an overview. Nippon Rinsho 54: 581-585 (1996).
Kuzuya M, Ando F, Iguchi A, Shimokata H. Glutathione peroxidase 1 Pro198Leu variant contributes to the metabolic syndrome in men in a large Japanese cohort. Am. J. Clin. Nutr. 87: 1939-1944 (2008). *
Kwok WW, Lotshaw C, Milner EC, Knitter-Jack N, Nepom GT. Mutational analysis of the HLA-DQ3.2 insulin-dependent diabetes mellitus susceptibility gene. Proc. Natl. Acad. Sci. U.S.A. 86: 1027-1030 (1989). *
Kwok WW, Nepom GT. Structural and functional constraints on HLA class II dimers implicated in susceptibility to insulin dependent diabetes mellitus. Baillieres Clin. Endocrinol. Metab. 5: 375-393 (1991).
Kwon H, Jun HS, Khil LY, Yoon JW. Role of CTLA-4 in the activation of single- and double-positive thymocytes. J. Immunol. 173: 6645-6653 (2004). *
Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res. Clin. Pract. 77 Suppl. 1: S228-S232 (2007).
Kwon OJ, Brautbar C, Weintrob N, Sprecher E, Saphirman C, Bloch K, Pinhas-Hamiel O, Assah S, Vardi P, Israel S. Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients. Hum. Immunol. 62: 85-91 (2001).
Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75: 504-507 (2004). *
La Nasa G, Carcassi C, Cirillo R, Mulargia M, Leone AL, Vacca A, Pizzati A, Boero R, Arras M, Porcella R, et al. Serological and molecular studies of HLA in insulin-dependent diabetes mellitus in Sardinia. Dis. Markers 8: 333-340 (1990).
Laadhar L, Ben Hariz M, Zitouni M, Sellami-Kallel M, Toumi A, Mehrezi A, Makni S. Prevalence of diabetes-related autoantibodies in celiac disease. Ann. Endocrinol. (Paris) 67: 588-590 (2006).
Laadhar L, Zitouni M, Kallel-Sellami M, Bouguerra R, Chaabouni H, Makni S. Spectrum of autoantibodies in Tunisian adult type 1 diabetes mellitus. Ann. N. Y. Acad. Sci. 1107: 356-362 (2007). *
Laban-Guceva N, Bogoev M, Antova M. Serum concentrations of interleukin (IL-)1alpha, 1beta, 6 and tumor necrosis factor (TNF) alpha in patients with thyroid eye disease (TED). Med. Arh. 61: 203-206 (2007).
Laberge G, Mailloux CM, Gowan K, Holland P, Bennett DC, Fain PR, Spritz RA. Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. Pigment Cell Res. 18: 300-305 (2005). *
Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 38: 1179-1184 (2007).
Lacson R, Pitzer E, Hinske C, Galante P, Ohno-Machado L. Evaluation of a large-scale biomedical data annotation initiative. BMC Bioinformatics 10 Suppl. 9: S10 (2009). *
Ladero JM. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr. Drug Metab. 9: 532-537 (2008).
Ladner MB, Bottini N, Valdes AM, Noble JA. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum. Immunol. 66: 60-64 (2005).
LaFemina J, Sokal SM, Chang Y, McGrath D, Berger DL. Effect of medical or surgical admission on outcome of patients with gallstone pancreatitis and common bile duct stones. J. Gastrointest. Surg. 12: 1554-1560 (2008).
Lafon M. Viral superantigens. Rev. Med. Interne. 21: 713-716 (2000).
Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, Rigina O, Hinsby AM, Tumer Z, Pociot F, Tommerup N, Moreau Y, Brunak S. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat. Biotechnol. 25: 309-316 (2007). *
Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation: current concepts concerning its role in immune function and inflammation. Cell. Immunol. 252: 139-145 (2008). *
Lagu B, Lebedev R, Pio B, Yang M, Pelton PD. Dihydro-[1H]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia. Bioorg. Med. Chem. Lett. 17: 3491-3496 (2007). *
Lagu B, Pio B, Lebedev R, Yang M, Pelton PD. RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia. Bioorg. Med. Chem. Lett. 17: 3497-3503 (2007). *
Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P, de Ledinghen V. The liver and methotrexate. Gastroenterol. Clin. Biol. 32: 134-142 (2008).
Lahiri S, Futerman AH. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64: 2270-2284 (2007). *
Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J. Gastroenterol. 15: 5121-5128 (2009). *
Lai CC, Huang WC, Cheng SN. Successful treatment of refractory Langerhans cell histiocytosis by allogeneic peripheral blood stem cell transplantation. Pediatr. Transplant. 12: 99-104 (2008). *
Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43: 1295-1302 (2006). *
Laine AP, Nejentsev S, Veijola R, Korpinen E, Sjoroos M, Simell O, Knip M, Akerblom HK, Ilonen J. A linkage study of 12 IDDM susceptibility loci in the Finnish population. Diabetes Metab. Res. Rev. 20: 144-149 (2004).
Laine AP, Turpeinen H, Veijola R, Hermann R, Simell O, Knip M, Ilonen J. Evidence for linkage to and association with type 1 diabetes at the 3q21 region in the Finnish population. Genes Immun. 7: 69-72 (2006). *
Lajer M, Tarnow L, Jorsal A, Parving HH. Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrol. Dial. Transplant. 22: 3235-3239 (2007). *
Laki J, Kiszel P, Vatay A, Blasko B, Kovacs M, Korner A, Madacsy L, Blatniczky L, Almassy Z, Szalai C, Rajczy K, Pozsonyi E, Karadi I, Fazakas A, Hosszufalusi N, Panczel P, Arason GJ, Wu YL, Zhou B, Yang Y, Yu CY, Fust G. The HLA 8.1 ancestral haplotype is strongly linked to the C allele of -429T>C promoter polymorphism of receptor of the advanced glycation end product (RAGE) gene. Haplotype-independent association of the -429C allele with high hemoglobin(A1C) levels � Mol. Immunol. 44: 648-655 (2007). *
Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB, Xu J, Bowden DW, Herrington DM. The association between innate immunity gene (IRAK1) and C-reactive protein in the Diabetes Heart Study. Exp. Mol. Pathol. 82: 280-283 (2007). *
Lalazar G, Preston S, Zigmond E, Ben Ya'acov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem. 6: 1249-1253 (2006).
Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55: 1605-1613 (2006). *
Lally S, Owens D, Tomkin GH. The different effect of pioglitazone as compared to insulin on expression of hepatic and intestinal genes regulating post-prandial lipoproteins in diabetes. Atherosclerosis 193: 343-351 (2007).
Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann. Hepatol. 8 Suppl. 1: S51-S59 (2009). *
Lamb MM, Yin X, Barriga K, Hoffman MR, Baron AE, Eisenbarth GS, Rewers M, Norris JM. Dietary glycemic index, development of islet autoimmunity, and subsequent progression to type 1 diabetes in young children. J. Clin. Endocrinol. Metab. 93: 3936-3942 (2008). *
Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, Bingley PJ. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J. Clin. Endocrinol. Metab. 89: 4037-4043 (2004). *
Lamberts SW, Uitterlinden AG. Genetic testing in clinical practice. Annu. Rev. Med. 60: 431-442 (2009). *
Lambova SN, Muller-Ladner U. The specificity of capillaroscopic pattern in connective autoimmune diseases. A comparison with microvascular changes in diseases of social importance: arterial hypertension and diabetes mellitus. Mod. Rheumatol. Sep 25 [Epub ahead of print] (2009). *
Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, Alsheadat S, Liou HC, Chen YH. Transcriptional regulation of type I diabetes by NF-kappa B. J. Immunol. 171: 4886-4892 (2003). *
Lammer C, Weimann E. Early onset of type I diabetes mellitus, Hashimoto's thyroiditis and celiac disease in a 7-yr-old boy with Down's syndrome. Pediatr. Diabetes 9: 423-425 (2008).
Lammert F, Sauerbruch T. Genetics of gallstone disease. Falk Symposium 156. XIII Falk Liver Week (Part II). GENETICS IN LIVER DISEASES, Freiburg (Germany), October 8-9, 2006, p. 16-18 (2006). *
Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in type 1 diabetes? Med. Sci. Monit. 11: RA63-RA69 (2005). *
Lampasona V, Belloni C, Piquer S, Bonicchio S, Furlan R, Bonifacio E. Radiobinding assay for detecting autoantibodies to single epitopes. J. Immunol. Methods 336: 127-134 (2008). *
Lampasona V, Petrone A, Tiberti C, Capizzi M, Spoletini M, di Pietro S, Sondini M, Bonicchio S, Giorgino F, Bonifacio E, Bosi E, Bozzetti R; for the NIRAD Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: NIRAD 4. Diabetes Care Oct 6 [Epub ahead of print] (2009).
Lan RY, Ansari AA, Lian ZX, Gershwin ME. Regulatory T cells: development, function and role in autoimmunity. Autoimmun. Rev. 4: 351-363 (2005).
Landa Garrido L, Huaman Munnte J, Valencia Caballero V, Lozano Miranda Z, Nago Nago A. Hereditary hemochromatosis. Rev. Gastroenterol. Peru 23: 302-306 (2003).
Landman N, Jeong SY, Shin SY, Voronov SV, Serban G, Kang MS, Park MK, Di Paolo G, Chung S, Kim TW. Presenilin mutations linked to familial Alzheimer's disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism. Proc. Natl. Acad. Sci. U.S.A. 103: 19524-19529 (2006). *
Lane JS, Magno CP, Lane KT, Chan T, Hoyt DB, Greenfield S. Nutrition impacts the prevalence of peripheral arterial disease in the United States. J. Vasc. Surg. 48: 897-904 (2008).
Lang F, Gorlach A. Heterocyclic indazole derivatives as SGK1 inhibitors, WO2008138448. Expert Opin. Ther. Pat. 20: 129-135 (2010).
Lang JA, Kominski D, Bellgrau D, Scheinman RI. Partial activation precedes apoptotic death in T cells harboring an IAN gene mutation. Eur. J. Immunol. 34: 2396-2406 (2004). *
Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA, Uematsu S, Akira S, Hengartner H, Zinkernagel RM. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 11: 138-145 (2005). *
Lang L. IBD legislation introduced. Gastroenterology 132: 1215 (2007). *
Lango H, Weedon MN. What will whole genome searches for susceptibility genes for common complex disease offer to clinical practice? J. Intern. Med. 263: 16-27 (2008). *
Lankinen M, Schwab U, Gopalacharyulu PV, Seppanen-Laakso T, Yetukuri L, Sysi-Aho M, Kallio P, Suortti T, Laaksonen DE, Gylling H, Poutanen K, Kolehmainen M, Oresic M. Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. Jun 22 [Epub ahead of print] (2009).
Lankisch TO, Jaeckel E, Strassburg CP, Manns MP. Autoimmune polyglandular syndromes. Internist (Berl.) 46: 750-758 (2005).
Lantz KA, Vatamaniuk MZ, Brestelli JE, Friedman JR, Matschinsky FM, Kaestner KH. Foxa2 regulates multiple pathways of insulin secretion. J. Clin. Invest. 114: 512-520 (2004). *
Lapcevic M. Autoimmune thyroid disease and associated diseases. Srp. Arh. Celok. Lek. 133 Suppl. 1: 84-87 (2005).
Lapolla A, Dalfra MG, Fedele D. Diabetes related autoimmunity in gestational diabetes mellitus: is it important? Nutr. Metab. Cardiovasc. Dis. 19: 674-682 (2009).
Lara LF, Levy MJ. Idiopathic recurrent acute pancreatitis. MedGenMed. 6: 10 (2004). *
Lara LP, Chari ST. Autoimmune pancreatitis. Curr. Gastroenterol. Rep. 7: 101-106 (2005).
Laramie JM, Wilk JB, Williamson SL, Nagle MW, Latourelle JC, Tobin JE, Province MA, Borecki IB, Myers RH. Polymorphisms near EXOC4 and LRGUK on chromosome 7q32 are associated with type 2 diabetes and fasting glucose; the NHLBI Family Heart Study. BMC Med. Genet. 9: 46 (2008). *
Larbi A, Fulop T, Pawelec G. Immune receptor signaling, aging and autoimmunity. Adv. Exp. Med. Biol. 640: 312-324 (2008). *
Laroni A, Calabrese M, Perini P, Albergoni MP, Ranzato F, Tiberio M, Battistin L, Gallo P. Multiple sclerosis and autoimmune diseases epidemiology and HLA-DR association in North-east Italy. J. Neurol. 253: 636-639 (2006). *
Larsen CE, Alper CA. The genetics of HLA-associated disease. Curr. Opin. Immunol. 16: 660-667 (2004).
Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses J, Seifert B, Mandrup-Poulsen T, Donath M. Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes. Ugeskr. Laeger. 169: 3868-3871 (2007).
Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sorensen SJ, Hansen LH, Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5: e9085 (2010). *
Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone. Eur. J. Pharmacol. 596: 173-179 (2008).
Larsen ZM, Kristiansen OP, Mato E, Johannesen J, Puig-Domingo M, de Leiva A, Nerup J, Pociot F. IDDM12 (CTLA4) on 2q33 and IDDM13 on 2q34 in genetic susceptibility to type 1 diabetes (insulin-dependent). Autoimmunity 31: 35-42 (1999).
Larsson HE, Hansson G, Carlsson A, Cederwall E, Jonsson B, Jonsson B, Larsson K, Lynch K, Neiderud J, Lernmark A, Ivarsson SA; for the DiPiS Study Group. Children developing type 1 diabetes before 6 years of age have increased linear growth independent of HLA genotypes. Diabetologia 51: 1623-1630 (2008). *
Larsson K, Carlsson A, Cederwall E, Jonsson B, Neiderud J, Jonsson B, Lernmark A, Ivarsson SA; on behalf of the Skane Study Group. Annual screening detects celiac disease in children with type 1 diabetes. Pediatr. Diabetes 9: 354-359 (2008).
Larsson SC, Giovannucci E, Wolk A. Methionine and vitamin B6 intake and risk of pancreatic cancer: a prospective study of Swedish women and men. Gastroenterology 132: 113-118 (2007). *
Latini G, Loredana Marcovecchio M, Del Vecchio A, Gallo F, Bertino E, Chiarelli F. Influence of environment on insulin sensitivity. Environ. Int. 35: 987-993 (2009).
Lau C, Toft U, Tetens I, Carstensen B, Jorgensen T, Pedersen O, Borch-Johnsen K. Dietary patterns predict changes in two-hour post-oral glucose tolerance test plasma glucose concentrations in middle-aged adults. J. Nutr. 139: 588-593 (2009). *
Lauer K. Divergent risk of multiple sclerosis in two anabaptist communities in America. Med. Hypotheses 67: 969-974 (2006).
Laughlin E, Burke G, Pugliese A, Falk B, Nepom G. Recurrence of autoreactive antigen-specific CD4+ T cells in autoimmune diabetes after pancreas transplantation. Clin. Immunol. 128: 23-30 (2008). *
Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M; Finnish Diabetes Prevention Study Group. Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J. Clin. Endocrinol. Metab. 89: 6286-6290 (2004). *
Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes. Metab. 11: 632-636 (2009).
Lauretani F, Maggio M, Pizzarelli F, Michelassi S, Ruggiero C, Ceda GP, Bandinelli S, Ferrucci L. Omega-3 and renal function in older adults. Curr. Pharm. Des. 15: 4149-4156 (2009).
Lavant EH, Carlson JA. A new automated human leukocyte antigen genotyping strategy to identify DR-DQ risk alleles for celiac disease and type 1 diabetes mellitus. Clin. Chem. Lab. Med. 47: 1489-1495 (2009). *
Lawler A. Diabetes research. Broad-Novartis venture promises a no-strings, public gene database. Science 306: 795 (2004). *
Lawless MW, Mankan AK, Norris S. Hereditary hemochromatosis should be considered a conformational disorder. Med. Hypotheses 70: 783-784 (2008).
Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RD, Peakman M, Tree TI. Increased resistance to CD4CD25 regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154: 353-359 (2008). *
Lazar A, Zimmermann T, Koch W, Grundemann D, Schomig A, Kastrati A, Schomig E. Lower prevalence of the OCT2 Ser270 allele in patients with essential hypertension. Clin. Exp. Hypertens. 28: 645-653 (2006).
Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D, Phillip M, Josefsberg Z. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab. Res. Rev. 23: 286-291 (2007).
Lazar MA. How obesity causes diabetes: not a tall tale. Science 307: 373-355 (2005). *
Lazar MA. East meets West: an herbal tea finds a receptor. J. Clin. Invest. 113: 23-25 (2004). *
Lazarus JH, Premawardhana LD. BEST PRACTICE NO 184. Screening for thyroid disease in pregnancy. J. Clin. Pathol. 58: 449-452 (2005). *
Le Bail B, Bioulac-Sage P, Senuita R, Quinton A, Saric J, Balabaud C. Fine structure of hepatic sinusoids and sinusoidal cells in disease. J. Electron Microsc. Tech. 14: 257-282 (1990).
Le Campion A, Gagnerault MC, Auffray C, Becourt C, Poitrasson-Riviere M, Lallemand E, Bienvenu B, Martin B, Lepault F, Lucas B. Lymphopenia-induced spontaneous T-cell proliferation as a cofactor for autoimmune disease development. Blood 114: 1784-1793 (2009). *
Le Lay J, Kaestner KH. The Fox genes in the liver: from organogenesis to functional integration. Physiol. Rev. 90: 1-22 (2010). *
Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis. Curr. Diab. Rep. 9: 215-220 (2009).
Leak TS, Keene KL, Langefeld CD, Gallagher CJ, Mychaleckyj JC, Freedman BI, Bowden DW, Rich SS, Sale MM. Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab. 92: 145-150 (2007). *
Lebovitz H. Diabetes: assessing the pipeline. Atheroscler. Suppl. 7: 43-49 (2006).
Lebovitz HE. Treating hyperglycemia in type 2 diabetes: new goals and strategies. Cleve. Clin. J. Med. 69: 809-820 (2002).
Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes. Metab. 8: 237-249 (2006).
Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J. Hepatol. 47: 142-156 (2007). *
Lee AS, Gibson DL, Zhang Y, Sham HP, Vallance BA, Dutz JP. Gut barrier disruption by an enteric bacterial pathogen accelerates insulitis in NOD mice. Diabetologia Dec 14 [Epub ahead of print] (2009). *
Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci. Lett. 410: 141-145 (2006). *
Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc. Natl. Acad. Sci. U.S.A. 103: 2434-2439 (2006). *
Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl. Acad. Sci. U.S.A. 103: 3444-3449 (2006). *
Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH. Foxa2 is required for the differentiation of pancreatic alpha-cells. Dev. Biol. 278: 484-495 (2005). *
Lee CS, Sund NJ, Vatamaniuk MZ, Matschinsky FM, Stoffers DA, Kaestner KH. Foxa2 controls Pdx1 gene expression in pancreatic beta-cells in vivo. Diabetes 51: 2546-2551 (2002). *
Lee CT, Adler AI, Forouhi NG, Luben R, Welch A, Khaw KT, Bingham S, Wareham NJ. Cross-sectional association between fish consumption and albuminuria: the European prospective investigation of Cancer-Norfolk study. Am. J. Kidney Dis. 52: 876-886 (2008).
Lee DD, Grossman E, Chong AS. Cellular therapies for type 1 diabetes. Horm. Metab. Res. 40: 147-154 (2008).
Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 31: 572-580 (2006). *
Lee G, Shamma FN, Diamond MP, Lee JT. HLA-DQ beta 57 in Hispanic patients with insulin-dependent diabetes mellitus. Am. J. Obstet. Gynecol. 167: 1565-1570 (1992).
Lee HC, Ikegami H, Fujisawa T, Ogihara T, Park SW, Chung YS, Park JO, Lee EJ, Lim SK, Kim KR, Huh KB, Kim YS, Lee DS, Kim DH. Role of HLA class II alleles in Korean patients with IDDM. Diabetes Res. Clin. Pract. 31: 9-15 (1996).
Lee HK, Lee BH, Park SA, Kim CW. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis. Proteomics 6: 1223-1229 (2006). *
Lee HS, Park H, Yang S, Kim D, Park Y. STAT4 polymorphism is associated with early-onset type 1 diabetes, but not with late-onset type 1 diabetes. Ann. N. Y. Acad. Sci. 1150: 93-98 (2008). *
Lee IF, Qin H, Priatel JJ, Tan R. Critical role for IFN-gamma in natural killer cell-mediated protection from diabetes. Eur. J. Immunol. 38: 82-89 (2008). *
Lee IK, Lee JH, Yun BS. Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis. Bioorg. Med. Chem. Lett. 18: 4566-4568 (2008). *
Lee J, Jung E, Lee J, Kim S, Huh S, Kim Y, Kim Y, Byun SY, Kim YS, Park D. Isorhamnetin represses adipogenesis in 3T3-L1 cells. Obesity (Silver Spring) 17: 226-232 (2009). *
Lee J, Wen J, Park JY, Kim SA, Lee EJ, Song SY. Reversal of diabetes in rats using GLP-1-expressing adult pancreatic duct-like precursor cells transformed from acinar to ductal cells. Stem Cells Dev. 18: 991-1002 (2009).
Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann. Clin. Lab. Sci. 38: 361-367 (2008).
Lee JL, Naguwa SM, Cheema G, Gershwin ME. Recognizing calcific uremic arteriolopathy in autoimmune disease: an emerging mimicker of vasculitis. Autoimmun. Rev. 7: 638-643 (2008).
Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. J. Int. Med. Res. 37: 1803-1812 (2009).
Lee K, Berthiaume F, Stephanopoulos GN, Yarmush ML. Profiling of dynamic changes in hypermetabolic livers. Biotechnol. Bioeng. 83: 400-415 (2003). *
Lee M, Park H, Youn J, Oh ET, Ko K, Kim S, Park Y. Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes. Ann. N. Y. Acad. Sci. 1079: 313-319 (2006). *
Lee S, Lee J, Lee SK, Lee JW. Activating signal cointegrator-2 is an essential adaptor to recruit histone H3 lysine 4 methyltransferases MLL3 and MLL4 to the liver X receptors. Mol. Endocrinol. 22: 1312-1319 (2008). *
Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 87: 983-991 (2009).
Lee SH, Kwon HS, Yoo SJ, Ahn YB, Yoon KH, Cha BY, Lee KW, Son HY. Identifying latent autoimmune diabetes in adults in Korea: the role of C-peptide and metabolic syndrome. Diabetes Res. Clin. Pract. 83: e62-e65 (2009).
Lee SJ, Choi MG. Association of manganese superoxide dismutase gene polymorphism (V16A) with diabetic macular edema in Korean type 2 diabetic patients. Metabolism 55: 1681-1688 (2006). *
Lee SJ, Choi MG, Kim DS, Kim TW. Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients. Metabolism 55: 1-7 (2006). *
Lee TA, Pickard AS, Bartle B, Weiss KB. Osteoarthritis: a comorbid marker for longer life? Ann. Epidemiol. 17: 380-384 (2007).
Lee WT, Jiang J. The resurgence of the importance of vitamin D in bone health. Asia Pac. J. Clin. Nutr. 17 Suppl. 1: 138-142 (2008).
Lee Y, Thompson JT, de Lera AR, Vanden Heuvel JP. Isomer-specific effects of conjugated linoleic acid on gene expression in RAW 264.7. J. Nutr. Biochem. 20: 848-859.e1-e5 (2009). *
Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab. Rep. 5: 70-75 (2005).
Lee YJ, Huang FY, Lo FS, Wang WC, Hsu CH, Kao HA, Yang TY, Chang JG. Association of CTLA4 gene A-G polymorphism with type 1 diabetes in Chinese children. Clin. Endocrinol. (Oxf.) 52: 153-157 (2000). *
Lee YS, Cho YK, Pae JC, Oh SY, Kang MS, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Lee WY, Oh KW, Yun EJ, Oh ES. The relationship between serum adiponectin level and serum alanine aminotransferase elevation in Korean male with nonalcoholic fatty liver disease. Korean J. Hepatol. 12: 221-229 (2006).
Leech MD, Chung CY, Culshaw A, Anderton SM. Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur. J. Immunol. 37: 3576-3581 (2007). *
Leelayuwat C, Townend DC, Degli-Esposti MA, Abraham LJ, Dawkins RL. A new polymorphic and multicopy MHC gene family related to nonmammalian class I. Immunogenetics 40: 339-351 (1994).
Lefebvre DE, Powell KL, Strom A, Scott FW. Dietary proteins as environmental modifiers of type 1 diabetes mellitus. Annu. Rev. Nutr. 26: 175-202 (2006). *
Lefebvre P. Molecular basis for designing selective modulators of retinoic acid receptor transcriptional activities. Curr. Drug Targets Immune Endocr. Metabol. Disord. 1: 153-164 (2001).
Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89: 147-191 (2009). *
Lefkowitch JH. Liver histopathology. Clin. Liver Dis. 6: xv-xix (2002). *
Lefkowitch JH. Morphology of alcoholic liver disease. Clin. Liver Dis. 9: 37-53 (2005).
Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).
Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G, Manduchi E, Grant GR, Lazar MA. Cell-specific determinants of PPARgamma function in adipocytes and macrophages. Mol. Cell. Biol. Feb 22 [Epub ahead of print] (2010). *
Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, Cristancho A, Feng D, Zhuo D, Stoeckert CJ Jr, Liu XS, Lazar MA. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22: 2941-2952 (2008). *
Leger J, Velasquez A, Garel C, Hassan M, Czernichow P. Thickened pituitary stalk on magnetic resonance imaging in children with central diabetes insipidus. J. Clin. Endocrinol. Metab. 84: 1954-1960 (1999). *
Lehman DM, Richardson DK, Jenkinson CP, Hunt KJ, Dyer TD, Leach RJ, Arya R, Abboud HE, Blangero J, Duggirala R, Stern MP. P2 promoter variants of the hepatocyte nuclear factor 4alpha gene are associated with type 2 diabetes in Mexican Americans. Diabetes 56: 513-517 (2007). *
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270: 12953-12956 (1995). *
Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, Wilson JM, Lazar MA. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRalpha. Cell. Metab. 1: 297-308 (2005). *
Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J. Am. Coll. Cardiol. 49: 442-449 (2007).
Lehrke M, Pascual G, Glass CK, Lazar MA. Gaining weight: the Keystone Symposium on PPAR and LXR. Genes Dev. 19: 1737-1742 (2005). *
Lei XG, Cheng WH, McClung JP. Metabolic regulation and function of glutathione peroxidase-1. Annu. Rev. Nutr. 27: 41-61 (2007). *
Leibbrandt A, Penninger JM. ESCI award lecture: from a little mouse to rationale medicine for bone loss. Eur. J. Clin. Invest. 39: 842-850 (2009).
Leibowitz MD, Ardecky RJ, Boehm MF, Broderick CL, Carfagna MA, Crombie DL, D'Arrigo J, Etgen GJ, Faul MM, Grese TA, Havel H, Hein NI, Heyman RA, Jolley D, Klausing K, Liu S, Mais DE, Mapes CM, Marschke KB, Michellys PY, Montrose-Rafizadeh C, et al. Biological characterization of a heterodimer selective RXR modulator: potential benefits for the treatment of type 2 diabetes. Endocrinology 147: 1044-1053 (2006). *
Leiter EH. The NOD mouse: a model for insulin-dependent diabetes mellitus. Curr. Protoc. Immunol. Chapter 15: Unit 15.9 (2001).
Leiter EH, Reifsnyder P, Driver J, Kamdar S, Choisy-Rossi C, Serreze DV, Hara M, Chervonsky A. Unexpected functional consequences of xenogeneic transgene expression in beta-cells of NOD mice. Diabetes Obes. Metab. 9: 14-22 (2007).
Leitinger N. The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell. Biochem. 49: 325-350 (2008).
Leitzmann C. Vegetarian diets: what are the advantages? Forum Nutr. 57: 147-156 (2005).
Lek N, Acerini CL. Cystic fibrosis related diabetes mellitus - diagnostic and management challenges. Curr. Diabetes Rev. Dec 23 [Epub ahead of print] (2009).
Lelievre V, Favrais G, Abad C, Adle-Biassette H, Lu Y, Germano PM, Cheung-Lau G, Pisegna JR, Gressens P, Lawson G, Waschek JA. Gastrointestinal dysfunction in mice with a targeted mutation in the gene encoding vasoactive intestinal polypeptide: a model for the study of intestinal ileus and Hirschsprung's disease. Peptides 28: 1688-1699 (2007). *
Lemos ET, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Silva GC, Teixeira N, Silva AS, Carvalho L, Teixeira F, Das UN. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 25: 330-339 (2009). *
Lemos MC, Coutinho E, Gomes L, Bastos M, Fagulha A, Barros L, Carrilho F, Geraldes E, Regateiro FJ, Carvalheiro M. The CTLA4 +49 A/G polymorphism is not associated with susceptibility to type 1 diabetes mellitus in the Portuguese population. Int. J. Immunogenet. 36: 193-195 (2009). *
Lemos MC, Fagulha A, Coutinho E, Gomes L, Bastos M, Barros L, Carrilho F, Geraldes E, Regateiro FJ, Carvalheiro M. Lack of association of vitamin D receptor gene polymorphisms with susceptibility to type 1 diabetes mellitus in the Portuguese population. Hum. Immunol. 69: 134-138 (2008).
Lempainen J, Vaarala O, Makela M, Veijola R, Simell O, Knip M, Hermann R, Ilonen J. Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes. J. Autoimmun. 33: 155-164 (2009).
Leng Q, Nie Y, Zou Y, Chen J. Elevated CXCL12 expression in the bone marrow of NOD mice is associated with altered T cell and stem cell trafficking and diabetes development. BMC Immunol. 9: 51 (2008). *
Lengeling A. From man to mice - from mice to man. Gene Funct. Dis. 3: 67-68 (2002). *
Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Receptors Channels 7: 249-258 (2001).
Lennon GP, Bettini M, Burton AR, Vincent E, Arnold PY, Santamaria P, Vignali DA. T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event. Immunity 31: 643-653 (2009).
Lennon R, Welsh GI, Singh A, Satchell SC, Coward RJ, Tavare JM, Mathieson PW, Saleem MA. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1. Diabetologia 52: 1944-1952 (2009). *
Leonard BE. Inflammation, depression and dementia: are they connected? Neurochem. Res. 32: 1749-1756 (2007). *
Leone JE, Gray KA, Massie JE, Rossi JM. Celiac disease symptoms in a female collegiate tennis player: a case report. J. Athl. Train. 40: 365-369 (2005).
Leong GM, Kee AJ, Millard SM, Martel N, Eriksson N, Turner N, Cooney GJ, Hardeman EC, Muscat GE. The Ski proto-oncogene regulates body composition and suppresses lipogenesis. Int. J. Obes. (Lond.) Dec 22 [Epub ahead of print] (2009). *
Lerner SM. Kidney and pancreas transplantation in type 1 diabetes mellitus. Mt. Sinai J. Med. 75: 372-384 (2008). *
Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol. 26: 608-612 (2005). *
Lernmark B, Lynch K, Lernmark AK. Cord blood islet autoantibodies are related to stress in the mother during pregnancy. Ann. N. Y. Acad. Sci. 1079: 345-349 (2006). *
Leslie RD. Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes 59: 330-331 (2010).
Leslie RD, Hawa M. Twin studies in auto-immune disease. Acta Genet. Med. Gemellol. (Roma) 43: 71-81 (1994).
Leslie RD, Kolb H, Schloot NC, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum W, Williams R, Pozzilli P. Diabetes classification: grey zones, sound and smoke: action LADA 1. Diabetes Metab. Res. Rev. 24: 511-519 (2008).
Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, de Andrade M, Henley JR, Rocca WA, Ahlskog JE, Maraganore DM. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 3: e98 (2007). *
Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. Hum. Mol. Genet. 17: R116-R121 (2008). *
Leu JD, Lin IF, Sun YF, Chen SM, Liu CC, Lee YJ. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J. Gastroenterol. 15: 5592-5597 (2009). *
Leung PS. The physiology of a local renin-angiotensin system in the pancreas. J. Physiol. 580: 31-37 (2007). *
Lever M, George PM, Slow S, Elmslie JL, Scott RS, Richards AM, Fink JN, Chambers ST. Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc. Drugs Ther. 23: 395-401 (2009).
Levin L, Ban Y, Concepcion E, Davies TF, Greenberg DA, Tomer Y. Analysis of HLA genes in families with autoimmune diabetes and thyroiditis. Hum. Immunol. 65: 640-647 (2004).
Levin L, Tomer Y. The etiology of autoimmune diabetes and thyroiditis: evidence for common genetic susceptibility. Autoimmun. Rev. 2: 377-386 (2003).
Levin MC, Lee SM, Kalume F, Morcos Y, Dohan FC Jr, Hasty KA, Callaway JC, Zunt J, Desiderio D, Stuart JM. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat. Med. 8: 509-513 (2002). *
Levinthal GN, Tavill AS. Liver disease and diabetes mellitus. Clinical Diabetes 17: 73 (1999). *
Levisetti MG, Lewis DM, Suri A, Unanue ER. Weak proinsulin peptide-major histocompatibility complexes are targeted in autoimmune diabetes in mice. Diabetes 57: 1852-1860 (2008). *
Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition and pathophysiology. Antioxid. Redox Signal. Nov 4 [Epub ahead of print] (2009).
Levitt N. Diabetes in Africa: epidemiology, management and healthcare challenges. Heart 94: 1376-1382 (2008).
Levy A, Asleh R, Blum S, Levy N, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul F, Asaf R, Farbstein D, Pollak M, Soloveichik Y, Strauss M, Alshiek J, Livshits A, Schwartz A, Awad H, Jad K, Goldenstein H. Haptoglobin: basic and clinical aspects. Antioxid. Redox Signal. Aug 6 [Epub ahead of print] (2009).
Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV; Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40: 1984-1990 (2002). *
Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).
Levy E. The metabolic syndrome: can nutrition influence rebellious organs? Bull. Acad. Natl. Med. 193: 1271-1278 (2009).
Levy E, Lalonde G, Delvin E, Elchebly M, Precourt LP, Seidah NG, Spahis S, Rabasa-Lhoret R, Ziv E. Intestinal and hepatic cholesterol carriers in diabetic Psammomys obesus. Endocrinology Feb 3 [Epub ahead of print] (2010).
Levy E, Spahis S, Ziv E, Marette A, Elchebly M, Lambert M, Delvin E. Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids. Diabetologia 49: 1937-1945 (2006). *
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, Marotta P, Boillot O, Muehlbacher F, Klintmalm G; LIS2T Study Group. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 77: 1632-1638 (2004).
Levy P, Barthet M, Mollard BR, Amouretti M, Marion-Audibert AM, Dyard F. Estimation of the prevalence and incidence of chronic pancreatitis and its complications. Gastroenterol. Clin. Biol. 30: 838-844 (2006).
Lewandowski KC, Marcinkowska M, Skowronska-Jozwiak E, Makarewicz J, Lewinski A. New onset Graves' disease as a cause of an adrenal crisis in an individual with panhypopituitarism: brief report. Thyroid Res. 1: 7 (2008). *
Lewis EC, Dinarello CA. Responses of IL-18- and IL-18 receptor-deficient pancreatic islets with convergence of positive and negative signals for the IL-18 receptor. Proc. Natl. Acad. Sci. U.S.A. 103: 16852-16857 (2006). *
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology 134: 688-695 (2008). *
Lewis JH. Drug-induced liver disease. Curr. Opin. Gastroenterol. 18: 307-313 (2002).
Lewis JR, Te HS, Gehlbach B, Oto A, Chennat J, Mohanty SR. A case of biliopleural fistula in a patient with hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 6: 248-251 (2009). *
Lewis SN, Bassaganya-Riera J, Bevan DR. Virtual screening as a technique for PPAR modulator discovery. PPAR Res. 2010: 861238 (2010). *
Lewy H, Hampe CS, Kordonouri O, Haberland H, Landin-Olsson M, Torn C, Laron Z. Seasonality of month of birth differs between type 1 diabetes patients with pronounced beta-cell autoimmunity and individuals with lesser or no beta-cell autoimmunity. Pediatr. Diabetes 9: 46-52 (2008). *
Lewy H, Meirson H, Laron Z. Seasonality of birth month of children with celiac disease differs from that in the general population and between sexes and is linked to family history and environmental factors. J. Pediatr. Gastroenterol. Nutr. 48: 181-185 (2009). *
Leyvraz C, Suter M, Verdumo C, Calmes JM, Paroz A, Darimont C, Gaillard RC, Pralong FP, Giusti V. Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation. Diabetes Obes. Metab. Nov 5 [Epub ahead of print] (2009).
Li A, Chen J, Hattori M, Franco E, Zuppan C, Ojogho O, Iwaki Y, Escher A. A therapeutic DNA vaccination strategy for autoimmunity and transplantation. Vaccine 28: 1897-1904 (2010).
Li C, Xu M, Gu Q. ATP binding cassette transporter G1 gene expression is reduced in type 2 diabetic patients. Endocr. J. 56: 313 (2009). *
Li D, Wu Y, Zhang AZ, Wahlqvist ML. Omega-3 PUFA status in type 2 diabetes mellitus patients, a case-control study. Asia Pac. J. Clin. Nutr. 14: S101 (2005).
Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488 (2009). *
Li D, Zhu SW, Liu DJ, Liu GL, Shan ZY. Expression of monocyte chemoattractant protein-1 in the pancreas of mice. Chin. Med. J. (Engl.) 118: 1269-1273 (2005).
Li DS, Warnock GL, Tu HJ, Ao Z, He Z, Dai LJ. Do immunotherapy and ss cell replacement play a synergistic role in the treatment of type 1 diabetes? Life Sci. 85: 549-556 (2009). *
Li H, Huang G, Zhang S, Wang X, Jin HL, Zhou ZG. Diagnostic value of protein tyrosine phosphatase-2beta antibody (IA-2betaA) in type 1 diabetes. Zhonghua Yi Xue Za Zhi 88: 939-942 (2008).
Li J, Wang JJ, Chen D, Mott R, Yu Q, Ma JX, Zhang SX. Systemic administration of HMG CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes. Exp. Eye Res. 89: 71-78 (2009).
Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29: 300-304 (2006).
Li L, He Q, Garland A, Yi Z, Aybar LT, Kepler TB, Frelinger JA, Wang B, Tisch R. beta Cell-specific CD4+ T cell clonotypes in peripheral blood and the pancreatic islets are distinct. J. Immunol. 183: 7585-7591 (2009).
Li L, Soetandyo N, Wang Q, Ye Y. The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta 1793: 346-353 (2009). *
Li L, Wang B, Frelinger JA, Tisch R. T cell promiscuity in autoimmune diabetes. Diabetes 57: 2099-2106 (2008). *
Li L, Yi Z, Tisch R, Wang B. Immunotherapy of type 1 diabetes. Arch. Immunol. Ther. Exp. (Warsz.) 56: 227-236 (2008).
Li L, Yi Z, Wang B, Tisch R. Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination. J. Immunol. 183: 4809-4816 (2009).
Li LL, Kang XL, Ran XJ, Wang Y, Wang CH, Huang L, Ren J, Luo X, Mao XM. Associations between 45T/G polymorphism of the adiponectin gene and plasma adiponectin levels with type 2 diabetes. Clin. Exp. Pharmacol. Physiol. 34: 1287-1290 (2007). *
Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).
Li M, Guo D, Isales CM, Eizirik DL, Atkinson M, She JX, Wang CY. SUMO wrestling with type 1 diabetes. J. Mol. Med. 83: 504-513 (2005). *
Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D. Heme oxygenase-1/p21(WAF1) mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells. FEBS J. Feb 13 [Epub ahead of print] (2010). *
Li M, Zheng DJ, Field LL, Bonnevie-Nielsen V. Murine pancreatic beta TC3 cells show greater 2', 5'-oligoadenylate synthetase (2'5'AS) antiviral enzyme activity and apoptosis following IFN-alpha or poly(I:C) treatment than pancreatic alpha TC3 cells. Exp. Diabetes Res. 2009: 631026 (2009).
Li M, Zhou Y, Feng G, Su SB. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr. Mol. Med. 9: 365-374 (2009).
Li MZ, Yu DM, Yu P, Liu DM, Wang K, Tang XZ. Mitochondrial gene mutations and type 2 diabetes in Chinese families. Chin. Med. J. (Engl.) 121: 682-686 (2008).
Li N, Zhao D, Kirschbaum M, Zhang C, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl. Acad. Sci. U.S.A. 105: 4796-4801 (2008). *
Li RJ, Qiu SD, Chen HX, Tian H, Wang HX. The immunotherapeutic effects of Astragalus polysaccharide in type 1 diabetic mice. Biol. Pharm. Bull. 30: 470-476 (2007). *
Li S, Sun Y, Liang CP, Thorp EB, Han S, Jehle AW, Saraswathi V, Pridgen B, Kanter JE, Li R, Welch CL, Hasty AH, Bornfeldt KE, Breslow JL, Tabas I, Tall AR. Defective phagocytosis of apoptotic cells by macrophages in atherosclerotic lesions of ob/ob mice and reversal by a fish oil diet. Circ. Res. 105: 1072-1082 (2009).
Li T, Kong X, Owsley E, Ellis E, Strom S, Chiang JY. Insulin regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes: roles of forkhead box O1 and sterol regulatory element binding protein 1c. J. Biol. Chem. 281: 28745-28754 (2006). *
Li T, Ma H, Chiang JY. TGFbeta1, TNFalpha, and insulin signaling crosstalk in regulation of the rat cholesterol 7alpha-hydroxylase gene expression. J. Lipid Res. 49: 1981-1989 (2008). *
Li W, Ji F, Zhang Y, Wang Y, Yang N, Ge H, Wang F. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide. Acta Biochim. Biophys. Sin. (Shanghai) 40: 381-390 (2008).
Li WJ, Zhen YS, Sun K, Xue H, Song XD, Wang YB, Fan XH, Han YF, Hui RT. Ghrelin receptor gene polymorphisms are associated with female metabolic syndrome in Chinese population. Chin. Med. J. (Engl.) 121: 1666-1669 (2008).
Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor-gamma (PPARgamma) and retinoic acid X receptors (RXR). J. Biol. Chem. 280: 38317-38327 (2005). *
Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 25: 411-416 (2009).
Li X, Song F, Jiang H, Zhang M, Lin J, Bao W, Yao P, Yang X, Hao L, Liu L. A genetic variation in the fat mass- and obesity-associated gene is associated with obesity and newly diagnosed type 2 diabetes in a Chinese population. Diabetes Metab. Res. Rev. Feb 23 [Epub ahead of print] (2010). *
Li X, Zhou Z, Huang G, Su H, Yan X, Yang L. Metabolic syndrome in adult-onset latent autoimmune diabetes. Metab. Syndr. Relat. Disord. 3: 174-180 (2005).
Li Y, Fisher E, Klapper M, Boeing H, Pfeiffer A, Hampe J, Schreiber S, Burwinkel B, Schrezenmeir J, Doring F. Association between functional FABP2 promoter haplotype and type 2 diabetes. Horm. Metab. Res. 38: 300-307 (2006).
Li Y, Qi Y, Huang TH, Yamahara J, Roufogalis BD. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. Diabetes Obes. Metab. 10: 10-17 (2008).
Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren B, Natarajan R. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kB dependent inflammatory genes: relevance to diabetes and inflammation. J. Biol. Chem. 283: 26771-26781 (2008). *
Li YC. Vitamin D and diabetic nephropathy. Curr. Diab. Rep. 8: 464-469 (2008).
Li Z, Diehl AM. Innate immunity in the liver. Curr. Opin. Gastroenterol. 19: 565-571 (2003).
Li Z, Liao C, Ko BC, Shan S, Tong EH, Yin Z, Pan D, Wong VK, Shi L, Ning ZQ, Hu W, Zhou J, Chung SS, Lu XP. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators. Bioorg. Med. Chem. Lett. 14: 3507-3511 (2004). *
Li Z, White P, Tuteja G, Rubins N, Sackett S, Kaestner KH. Foxa1 and Foxa2 regulate bile duct development in mice. J. Clin. Invest. 119: 1537-1545 (2009). *
Li Z, Zhang Q, Peng X, Wu Y, Xia Y, Liu X. The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes Obes. Metab. 10: 794-802 (2008). *
Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, Zhen Y, Fan M, Wu Z. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. Br. J. Pharmacol. 158: 1865-1873 (2009). *
Liang H, Ward WF. PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ. 30: 145-151 (2006). *
Liang H, Yagi K, Asano A, Kobayashi J, Mabuchi H. Association between CTLA-4 +49 A/G polymorphism and type 1B diabetes in Japanese population. Endocrine 25: 105-110 (2004).
Liang HJ, Suk FM, Wang CK, Hung LF, Liu DZ, Chen NQ, Chen YC, Chang CC, Liang YC. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice. Chem. Biol. Interact. 181: 309-315 (2009). *
Liang HL, Ouyang Q. A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis. Zhonghua Nei Ke Za Zhi 45: 548-551 (2006).
Liang TJ. Hepatitis B: the virus and disease. Hepatology 49: S13-S21 (2009).
Liangpunsakul S, Chalasani N. Treatment of nonalcoholic fatty liver disease. Curr. Treat. Options Gastroenterol. 6: 455-463 (2003).
Liao C, Liu B, Shi L, Zhou J, Lu XP. Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators. Eur. J. Med. Chem. 40: 632-640 (2005). *
Liao KP, Gunnarsson M, Kallberg H, Ding B, Plenge RM, Padyukov L, Karlson EW, Klareskog L, Askling J, Alfredsson L. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum. 60: 653-660 (2009). *
Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, Hu PJ. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment. Pharmacol. Ther. 23: 289-294 (2006). *
Liao YF, Chen LL, Zeng TS, Zheng J, Li HQ. Association of the +33371 A/G polymorphism in adiponectin receptor 2 gene with type 2 diabetes in the Chinese population. J. Endocrinol. Invest. 30: 860-864 (2007).
Liao YF, Zeng TS, Chen LL, Li YM, Yu F, Hu LJ, Yue L. Association of a functional polymorphism (C59038T) in GTP cyclohydrolase 1 gene and type 2 diabetic macrovascular disease in the Chinese population. J. Diabetes Complications Jun 8 [Epub ahead of print] (2009).
Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am. J. Cardiol. 99: 27-40 (2007).
Liblau RS, Caillat-Zucman S, Fischer AM, Bach JF, Boitard C. The prevalence of selective IgA deficiency in type 1 diabetes mellitus. APMIS 100: 709-712 (1992).
Libman IM, Sun K, Foley TP, Becker DJ. Thyroid autoimmunity in children with features of both type 1 and type 2 diabetes. Pediatr. Diabetes 9: 266-271 (2008).
Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J. Clin. Pathol. 59: 211-215 (2006). *
Licata A. Osteoporosis in men: suspect secondary disease first. Cleve. Clin. J. Med. 70: 247-254 (2003).
Lich JD, Jayne JA, Zhou D, Elliott JF, Blum JS. Editing of an immunodominant epitope of glutamate decarboxylase by HLA-DM. J. Immunol. 171: 853-859 (2003). *
Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional and physiologic regulation. Annu. Rev. Nutr. 29: 153-176 (2009). *
Lidar M, Rachmani R, Half E, Ravid M. Insulin autoimmune syndrome after therapy with imipenem. Diabetes Care 22: 524-525 (1999).
Lie BA, Sollid LM, Ascher H, Ek J, Akselsen HE, Ronningen KS, Thorsby E, Undlien DE. A gene telomeric of the HLA class I region is involved in predisposition to both type 1 diabetes and coeliac disease. Tissue Antigens 54: 162-168 (1999). *
Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr. Opin. Immunol. 17: 526-531 (2005).
Lie BA, Todd JA, Pociot F, Nerup J, Akselsen HE, Joner G, Dahl-Jorgensen K, Ronningen KS, Thorsby E, Undlien DE. The predisposition to type 1 diabetes linked to the human leukocyte antigen complex includes at least one non-class II gene. Am. J. Hum. Genet. 64: 793-800 (1999). *
Lie BA, Viken MK, Akselsen HE, Flam ST, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE. Association analysis in type 1 diabetes of the PRSS16 gene encoding a thymus-specific serine protease. Hum. Immunol. 68: 592-598 (2007).
Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 36: 511-529 (2004). *
Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM. Model of nonalcoholic steatohepatitis. Am. J. Clin. Nutr. 79: 502-509 (2004). *
Lien E, Zipris D. The role of Toll-like receptor pathways in the mechanism of type 1 diabetes. Curr. Mol. Med. 9: 52-68 (2009).
Liepa GU, Basu H. C-reactive proteins and chronic disease: what role does nutrition play? Nutr. Clin. Pract. 18: 227-233 (2003).
Liepa GU, Sengupta A, Karsies D. Polycystic ovary syndrome (PCOS) and other androgen excess-related conditions: can changes in dietary intake make a difference? Nutr. Clin. Pract. 23: 63-71 (2008). *
Lietz G, Hesketh J. A network approach to mic